clopidogrel has been researched along with Hemorrhage in 1289 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (0.54) | 18.2507 |
| 2000's | 252 (19.55) | 29.6817 |
| 2010's | 740 (57.41) | 24.3611 |
| 2020's | 290 (22.50) | 2.80 |
| Authors | Studies |
|---|---|
| Anil Kumar, KS; Bajaj, K; Barthwal, MK; Dikshit, DK; Dikshit, M; Jain, M; Misra, A; Shandilya, S; Shukla, P; Srivastava, S | 1 |
| Angiolillo, DJ; Baber, U; Beerkens, F; Cao, D; Capodanno, D; Chang, K; Chiarito, M; Dangas, G; Hermanides, RS; Kini, AS; Mehran, R; Nardin, M; Nicolas, J; Pivato, CA; Sartori, S; Sharma, SK; Tavenier, AH; Ten Berg, JM; Valgimigli, M; van 't Hof, AWJ | 1 |
| Bae, JW; Cho, BR; Cho, DK; Cho, JH; Choi, JH; Choi, JW; Choi, SH; Choi, WG; Chun, WJ; Gwon, HC; Hahn, JY; Im, ES; Jang, WJ; Jeong, JO; Kim, DB; Kim, HY; Koh, YY; Lee, JM; Lee, JY; Lee, SH; Lee, SU; Lee, WS; Oh, JH; Oh, SK; Park, TK; Park, YH; Rha, SW; Roh, JW; Song, YB; Yang, JH; Yoon, HJ; Yun, KH | 1 |
| Benit, E; Diletti, R; Ferrario, M; Hamm, C; Heg, D; Huber, K; Janssens, L; Jüni, P; Mc Fadden, EP; Odutayo, A; Onuma, Y; Räber, L; Serruys, PW; Steg, PG; Valgimigli, M; Vranckx, P; Windecker, S | 1 |
| Amano, T; Ikari, Y; Inohara, T; Ishii, H; Kohsaka, S; Nishida, H; Noma, S; Shimoji, K; Tanaka, N; Ueno, K; Yamaji, K; Yashima, F | 1 |
| Ahn, Y; Chang, K; Choi, YS; Choo, EH; Hwang, BH; Jeon, DS; Jeong, MH; Jeong, YH; Kim, CJ; Kim, HY; Kim, MC; Lee, KY; Park, MW; Seung, KB; Shin, ES; Yim, HW; Yoo, KD | 1 |
| Lyu, SQ; Shao, XH; Wang, J; Wu, S; Yang, YM; Zhang, H; Zhu, J | 1 |
| Ahmad, H; Aronow, WS; Briasoulis, A; Gupta, R; Guthier, DG; Joshi, AM; Kluck, B; Malik, AH; Patel, NC; Popli, T; Vyas, AV | 1 |
| Abbas, KS; Abdelazeem, B; Adhikari, G; Baral, N; El-Shahat, NA; Hassan, M; Khan, H; Shehata, J | 1 |
| Chen, X; Cui, YK; Dong, JZ; Du, X; Feng, L; He, L; Hu, R; Jia, CQ; Li, X; Long, DY; Lv, WH; Ma, CS; Ning, M; Sang, CH; Tang, RB | 1 |
| Ahn, Y; Choi, DH; Gwon, HC; Hwang, JY; Jeong, MH; Ki, YJ; Kim, HK; Kim, HS; Kim, SS; Koh, YY; Park, KH; Rha, SW | 1 |
| Luijkx, J; van 't Hof, A; Winkler, P | 1 |
| Alaamri, S; Dalbhi, SA | 1 |
| Hvas, AM; Nissen, PH; Pedersen, TF; Schultz-Lebahn, A; Tang, M | 1 |
| Huang, Z; Yang, Y; Zhang, X | 1 |
| Go, YI; Kim, GW | 1 |
| Bath, PM; Jiang, Y; Jing, J; Johnston, SC; Li, H; Li, Y; Li, Z; Lin, J; Liu, J; Liu, L; Meng, X; Tian, X; Wang, A; Wang, F; Wang, Y; Xie, X; Zhao, X; Zuo, Y | 1 |
| Arrot, X; Beygui, F; Bignon, M; Lecoq, G; Malcor, G; Potier, B; Rebouh, I; Roule, V; Roupie, E; Trotel, J | 1 |
| Ferro, A; Passacquale, G; Perera, D; Sharma, P | 1 |
| Ahn, TH; Ahn, Y; Cha, KS; Chae, JK; Chae, SC; Cho, MC; Choi, DJ; Gwon, HC; Hur, SH; Hwang, JY; Jeong, MH; Joo, SJ; Ki, YJ; Kim, CJ; Kim, DI; Kim, HK; Kim, HS; Kim, SS; Kook, HY; Oh, SK; Park, JS; Park, KH; Rha, SW; Seong, IW; Seung, KB; Yoon, JH | 1 |
| Abu-Assi, E; Bruno, F; Cerrato, E; Chieffo, A; Conrotto, F; D'Ascenzo, F; De Ferrari, GM; De Filippo, O; Dominguez-Rodriguez, A; Elia, E; Gallone, G; Henriques, JPS; Iannaccone, M; Kinnaird, T; Leonardi, S; Liebetrau, C; Manzano-Fernández, S; Omedè, P; Patti, G; Piroli, F; Raposeiras-Roubin, S; Wańha, W | 1 |
| Chen, S; Han, Y; Li, J; Li, X; Li, Y; Ma, S; Na, K; Qi, Z; Qiu, M | 1 |
| Atassi, B; Baumann Kreuziger, L; Berger, JS; Berry, S; Bochicchio, G; Cheng, Y; Cushman, M; de Oliveira Antunes, M; Farkouh, ME; Gong, MN; Greenstein, Y; Hade, EM; Hochman, JS; Hudock, K; Hyzy, R; Khatri, P; Kim, KS; Kindzelski, A; Kirwan, BA; Kornblith, LZ; Lawler, PR; Leifer, E; Lopes, RD; Lopez-Sendon Moreno, J; Lopez-Sendon, J; Luther, JF; McVerry, BJ; Neal, MD; Nigro Maia, L; Quigley, J; Reynolds, HR; Sherwin, R; Wahid, L; Wilson, J | 1 |
| Chen, S; Han, Y; Jiang, Z; Li, J; Li, Y; Ma, S; Na, K; Qi, Z; Qiu, M | 1 |
| Abu-Assi, E; Bianco, M; Bo, M; Breviario, S; Bruno, F; Conrotto, F; D'Ascenzo, F; De Ferrari, GM; de Filippo, O; Elia, E; Iannaccone, M; Manai, R; Patti, G; Raposeiras-Roubin, S; Wańha, W | 1 |
| Bai, N; Ma, Y; Niu, Y; Shang, YS; Wang, ZL; Zhong, PY | 2 |
| Bergh, N; Myredal, A; Nivedahl, P; Petzold, M; Wallerstedt, SM; Wartenberg, C; Zarin, S | 1 |
| Akin, I; Bernlochner, I; Cassese, S; Gewalt, S; Hemetsberger, R; Ibrahim, T; Joner, M; Kastrati, A; Kufner, S; Lahu, S; Laugwitz, KL; Mayer, K; Menichelli, M; Ndrepepa, G; Neumann, FJ; Richardt, G; Sager, HB; Schunkert, H; Schüpke, S; Valina, C; Witzenbichler, B; Wöhrle, J; Xhepa, E | 1 |
| Abe, M; Ando, K; Domei, T; Furukawa, Y; Hibi, K; Ikari, Y; Isawa, T; Kadota, K; Kawai, K; Kimura, T; Mori, H; Morimoto, T; Morino, Y; Nakagawa, Y; Nakao, K; Natsuaki, M; Nishikura, T; Obayashi, Y; Ogita, M; Ohya, M; Sakamoto, H; Suwa, S; Suzuki, H; Tada, T; Tanabe, K; Tatsushima, S; Tokuyama, H; Wakabayashi, K; Watanabe, H; Yamaji, K; Yamamoto, K | 1 |
| Ip, A; Lau, KK; Ng, AK; Ng, PY; Siu, CW | 1 |
| Buzzetti, R; Cavallari, I; Grigioni, F; Maddaloni, E; Mangiacapra, F; Patti, G; Ricottini, E; Ussia, GP; Veneziano, F | 1 |
| Fan, H; Li, J; Li, X; Li, Y; Liu, T; Niu, X; Ren, J; Wang, Y; Wu, X; Zhang, K | 1 |
| Alkhalil, M; Bhatt, DL; Džavík, V; Mehran, R; Mehta, SR | 1 |
| Cui, Y; Gong, Y; Jiang, J; Liu, Z; Ma, L; Mu, G; Xiang, Q; Xie, Q; Zhang, Z; Zhou, S | 1 |
| Alraies, MC; Cuisset, T; Faisaluddin, M; Fischman, DL; Khalil, F; Pasha, AK; Rao, SV; Sabouret, P; Sandhyavenu, H; Savage, MP; Ullah, W; Zahid, S | 1 |
| Angelini, F; Baldetti, L; Bocchino, PP; Chieffo, A; Conrotto, F; D'Ascenzo, F; de Ferrari, GM; DE Filippo, O; DE Lio, G; Melillo, F; Montefusco, A; Omedè, P; Piroli, F; Saglietto, A | 1 |
| Azhar, AZ; Baibhav, B; Cheung, JW; Rao, M; Tan, BE; Thakkar, S; Wong, PY | 1 |
| Jung, YS; Park, DI; Park, JH; Park, SH; Park, SK; Sohn, CI; Yang, HJ | 1 |
| Ali, ZO; Arabi, A; Arafa, S; Awaisu, A; Bader, L; Cavallari, L; Elewa, H; Langaee, T; Mohammed, S; Mraiche, F; Rizk, N; Shahin, MH | 1 |
| An, HJ; He, YY; Li, S; Sheng, XY; Ye, YF; Zhao, JL | 1 |
| Ding, H; Guo, L; Huang, R; Meng, S; Wang, J; Wu, S; Ye, Z | 1 |
| Bernasek, TL; Engel, CC; Gill, MK; Maxfield, DG | 1 |
| Doundoulakis, I; Farmakis, IT; Giannakoulas, G; Karagiannidis, E; Karvounis, H; Kassimis, G; Michalis, LK; Moysidis, DV; Pagiantza, A; Stalikas, N; Zafeiropoulos, S | 1 |
| França, ACW; Macedo, LSDN; Magliano, CADS; Meirelles, I; Piccin Padilla, M; Santos, MDS | 1 |
| Grisafi, L; Mennuni, M; Patti, G; Rognoni, A; Spinoni, EG | 1 |
| Gong, Y; Han, Y; Jiang, H; Kang, Y; Lai, X; Li, J; Li, Y; Liu, B; Liu, Y; Ma, S; Qi, Z; Ren, L; Sun, H; Tang, C; Tang, Y; Zhao, X; Zheng, M | 1 |
| D Tangonan, R; Guterman, L; Kass-Hout, O; Kass-Hout, T; Morsi, RZ; Stern, J; Thind, S | 1 |
| Ahn, CM; Cho, JY; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Lee, YJ; Yun, KH | 1 |
| Chilbert, MR; Denny, O; Mills, K; Woodruff, AE | 1 |
| Averkov, O; Berwanger, O; Brass, N; Cantor, WJ; Damiani, LP; Dehghani, P; Goodman, SG; Granger, CB; Lavi, S; Lopes, RD; Lutchmedial, S; Malaga, G; Moia, DDF; Nicholls, SJ; Nicolau, JC; Parkhomenko, A; Piegas, LS; Tajer, CD; Tan, M; White, HD | 1 |
| Diener, HC; Kyriakoulis, IG; Ntaios, G; Sagris, D; Tasoudis, PT | 1 |
| Dou, KF; Gao, R; Guan, C; Huang, Y; Qiao, S; Wang, HY; Wu, Y; Xie, L; Xu, B; Yang, W; Yang, Y; Zhang, R | 1 |
| Amos, D; Brieger, D; Chew, DP; Hou, M; Hyun, K; Kritharides, L | 1 |
| Fang, JY; Gong, W; Nie, SP; Wang, X; Yan, Y | 1 |
| Kamouchi, M; Kimura, K; Kitazono, T; Koyama, N; Matsumaru, Y; Matsuo, H; Nakamura, M; Tsutsumi, J; Umemura, K | 1 |
| Hu, F; Qi, G; Wang, P; Xing, Y; Yang, J; Zhang, X | 1 |
| Chanfreau-Coffinier, C; Dong, OM; Friede, KA; Voora, D | 1 |
| Gersh, BJ; Holmes, DR; Kandlakunta, H; Kochar, A; Kuchkuntla, AR; Murad, MH; Patlolla, SH; Rab, ST; Vallabhajosyula, S; Wang, Z; West, CP; Zhao, DX | 1 |
| Bai, C; Chen, Z; Ding, Y; Ilagan, R; Ji, X; Meng, R; Wu, X | 1 |
| Abbott, JD; Farkouh, ME; Goodman, SG; Lennon, R; MacDougall, AM; Madan, M; McLaughlin, MA; Murthy, V; Pereira, NL; Rihal, C; Saw, J; So, DYF | 1 |
| Agala, CB; Browder, SE; Caruso, DM; Curcio, J; Duchesneau, E; Kibbe, MR; Kindell, DG; Marulanda, K; McGinigle, K; Patel, S | 1 |
| Lin, J; Qin, Q; Xie, C; Zhu, J | 1 |
| Liu, J; Liu, X; Suo, M; Wang, Y; Wang, Z; Wu, X; Yang, N; Zhang, X; Zhao, D | 1 |
| Bath, PM; Cheng, J; Jiang, Y; Jin, A; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Pan, Y; Wang, Y; Wang, Z; Xie, X; Yang, H; Zhao, X | 1 |
| Cheng, J; Deng, X; Li, H; Ma, Y; Shi, T; Wang, X; Wu, Y; Zhang, Z; Zhu, Q | 1 |
| Hoshino, H; Kimura, K; Kitagawa, K; Minematsu, K; Okamura, S; Omae, K; Toyoda, K; Uchiyama, S; Yamaguchi, T | 1 |
| Peng, F; Xu, B; Xuan, M; Yan, L; Yu, Z; Zhou, Y | 1 |
| Fujii, S; Fujita, K; Hirai, S; Ishikawa, M; Karakama, J; Miki, K; Nemoto, S; Sumita, K; Yamaoka, H; Yoshimura, M | 1 |
| Adar, A; Akbay, E; Akıncı, S; Çoner, A; Müderrisoğlu, H | 1 |
| Kozieł-Siołkowska, M; Lip, GY; Shantsila, E | 1 |
| Antonicelli, R; Bongioanni, S; Bossi, I; Cacucci, M; Cavallini, C; Cesana, BM; Corrada, E; De Luca, G; De Luca, L; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Murena, E; Ottani, F; Petronio, AS; Piatti, L; Ravera, A; Savonitto, S; Sganzerla, P; Tondi, S; Tortorella, G; Toso, A; Verdoia, M; Vitrella, G | 1 |
| Abe, M; Akao, M; Ando, K; Domei, T; Furukawa, Y; Hata, Y; Ikari, Y; Inada, T; Isawa, T; Kadota, K; Kawai, K; Kimura, T; Morimoto, T; Morino, Y; Morishima, I; Nakagawa, Y; Nakao, K; Natsuaki, M; Obayashi, Y; Okayama, H; Sakamoto, H; Suematsu, N; Suwa, S; Suzuki, H; Tamura, T; Tanabe, K; Tokuyama, H; Wakabayashi, K; Watanabe, H; Yagi, M; Yamaji, K; Yamamoto, K; Yoshida, R | 1 |
| Bhatt, DL; Butt, JH; Christensen, MK; Fosbøl, EL; Gislason, G; Godtfredsen, SJ; Jørgensen, SH; Kragholm, KH; Køber, L; Leutscher, P; Pareek, M; Sessa, M; Torp-Pedersen, C | 1 |
| Harris, J; Johnson, TW; Lasserson, D; Loke, YK; Mahadevan, K; Mumford, A; Pouwels, K; Pufulete, M; Reeves, BC | 1 |
| Chen, B; Chen, J; Chen, Y; Chen, Z; Liang, J; Liu, X; Tang, L; Tu, S; Xia, J | 1 |
| Chen, Y; Gao, H; Han, P; Li, C; Lian, K; Liang, Y; Liu, Y; Tan, Z; Tao, F; Wang, Q; Wang, Z; Xu, S; Yang, L; Zhang, A; Zhang, Y; Zhao, S; Zhu, B | 1 |
| de Borst, GJ; Hannink, G; Kramers, K; Maas, DPMSM; Mees, BME; Reijnen, MMPJ; Riksen, NP; Ten Cate, H; van der Vijver-Coppen, RJ; Warlé, MC; Willems, LH; Zeebregts, CJ | 1 |
| Calderone, D; Capodanno, D; Scalia, L | 1 |
| Amarenco, P; Bereczki, D; Czlonkowska, A; Diener, HC; Donovan, M; Endres, M; Gailani, D; Hankey, GJ; Kahl, A; Kasner, SE; Li, D; Lutsep, HL; Molina, CA; Ntaios, G; Perera, V; Sharma, M; Shuaib, A; Toyoda, K; Tsivgoulis, G | 1 |
| Gao, R; Gao, Y; Guo, T; Li, J; Qiu, H; Qiu, Z; Wang, Y; Xi, Z; Zheng, J | 1 |
| Cheung, KS; Guo, CG; Leung, WK; Li, YK; Liu, KSH | 1 |
| Beohar, N; Escolar, E; Gazzhal, A; Gjergjindreaj, M; Ibrahim, M; Lacy, SC; Perez, J; Saint Croix, G; Shehadeh, M; Torres, C; Vedantam, K | 1 |
| Boytsov, SA; Erlikh, AD; Kukava, NG; Pevsner, DV; Rytova, YK; Shakhnovich, RM; Tereschenko, SN | 1 |
| Moustafa, B; Testai, FD | 1 |
| Chen, W; Jiang, T; Li, C; Ling, L; Liu, M | 1 |
| Al Kindi, DI; Al-Mashdali, A; Alamin, MA; Elshaikh, EA; Othman, F | 1 |
| Cheng, Y; Li, D; Liu, H; Shao, T; Wang, H; Yang, T; Zhang, J; Zhang, T | 1 |
| Chen, M; Cheng, K; Ge, J; Huang, J; Lan, J; Li, G; Qian, J; Wang, X; Wang, Y; Wei, G; Wu, H; Xu, L; Zhang, C; Zhang, H; Zhao, X | 1 |
| Bae, JW; Han, JK; Hur, SH; Hwang, D; Kang, J; Kim, HS; Koo, BK; Lee, H; Lee, NH; Park, KW; Rha, SW; Shin, ES; Yang, HM | 1 |
| Aulinger, BA; Lange, CM; Mayerle, J; Saner, FH; Stark, K | 1 |
| Ahn, Y; Chang, K; Choi, IJ; Choo, EH; Hwang, BH; Jeon, DS; Kim, CJ; Kim, HY; Kim, MC; Lee, KY; Lim, S; Moon, D; Park, MW; Seok Choi, Y; Yoo, KD | 1 |
| Li, X; Lin, Y; Peng, W; Zhang, Y | 1 |
| Fonarow, GC; Ge, J; Han, Y; Hao, Y; Huo, Y; Liu, J; Ma, C; Morgan, L; Smith, JSC; Yang, N; Zhao, D | 1 |
| Farley, JF; Kumar, A; Lutsey, PL; Rajpurohit, A; Schommer, JC; St Peter, WL; Van't Hof, JR | 1 |
| Bath, PM; Jiang, Y; Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Wang, A; Wang, Y; Xie, X; Xu, Q; Zhao, X | 1 |
| Banach, M; Biondi-Zoccai, G; Costabel, JP; De Rosa, S; Fischman, D; Galli, M; Gulati, M; Sabouret, P; Savage, MP; Spadafora, L; Ullah, W; Zeitouni, M | 1 |
| Ando, K; Domei, T; Fujii, S; Hayashi, F; Isawa, T; Ishii, M; Kimura, T; Komiyama, K; Mori, H; Morimoto, T; Natsuaki, M; Nikaido, A; Nishikura, T; Obayashi, Y; Ogita, M; Ohya, M; Shigematsu, T; Suematsu, N; Suwa, S; Suzuki, H; Tada, T; Tatsushima, S; Watanabe, H; Watanabe, N; Yamaji, K; Yamamoto, K | 1 |
| Barreau, X; Berge, J; Cagnazzo, F; Collemiche, FL; Costalat, V; Dargazanli, C; Derraz, I; Ferreira, I; Gariel, F; Gascou, G; Lefevre, PH; Marnat, G; Papaxanthos, J; Radu, RA; Riquelme, C | 1 |
| Endo, S; Fujii, T; Ikari, Y; Kasai, S; Kawamura, Y; Nagamatsu, H; Tsuchiya, R; Yoshimachi, F | 1 |
| Dangas, G; Dasgupta, S; Feng, Y; Giustino, G; Hooda, A; Khera, S; Kini, AS; Koshy, AN; Krishnamoorthy-Melarcode, P; Kumar, KR; Mehran, R; Sartori, S; Serrao, GW; Sharma, R; Sharma, SK; Snyder, C; Sweeny, J | 1 |
| Amarenco, P; Bath, PM; Chen, W; Gao, Y; Han, S; Jing, J; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, T; Wang, Y; Yang, Y; Zhao, X | 1 |
| Bae, JW; Bong, JM; Chun, KJ; Han, JK; Hwang, D; Kang, HJ; Kang, J; Kim, HS; Kim, SY; Koo, BK; Lee, BK; Lee, KS; Lee, NH; Lim, HS; Lim, YH; Park, K; Park, KH; Park, KW; Rha, SW; Rhew, JY; Shin, WY; Yang, HM | 1 |
| Asif, M; Aziz, A; Aziz, M; Gangwani, MK; Ghaffar, U; Hart, B; Javaid, T; Lee-Smith, W; Nawras, A; Patel, A; Priyanka, F; Weissman, S | 1 |
| Hoshino, H; Houkin, K; Kimura, K; Matsumoto, M; Minematsu, K; Naritomi, H; Nishiyama, Y; Okada, Y; Origasa, H; Otsuka, T; Sakai, N; Terayama, Y; Tomimoto, H; Tominaga, T; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T; Yasuda, S | 1 |
| Azzahhafi, J; Mani, N; Ten Berg, JM; van den Broek, WWA | 1 |
| Jing, J; Li, H; Li, Z; Liu, H; Meng, X; Wang, A; Wang, Y; Xu, Q | 1 |
| Asada, K; Fukuyama, M; Hayashi, A; Higo, Y; Hira, D; Isono, T; Kodama, K; Kohyama, S; Morita, SY; Nakagawa, Y; Ozawa, T; Sakai, H; Sawayama, Y; Shioyama, W; Tomita, Y; Yagi, N; Yamamoto, T | 1 |
| Landi, A | 1 |
| Atar, D; Gurvich, ML; Marciniak, TA; Serebruany, VL; Tanguay, JF | 1 |
| Chen, BL; Dai, W; Mo, ZZ; Peng, YY; Tang, J; Wang, G; Yuan, Z; Zhang, W; Zhou, WL | 1 |
| Chen, X; Jiang, L; Liu, C; Su, J; Zheng, N; Zhong, J | 1 |
| Aboyans, V; Angiolillo, D; Atar, D; Capodanno, D; Fox, KAA; Halvorsen, S; James, S; Jüni, P; Kunadian, V; Landi, A; Leonardi, S; Mehran, R; Montalescot, G; Navarese, EP; Niebauer, J; Oliva, A; Piccolo, R; Price, S; Storey, RF; Valgimigli, M; Völler, H; Vranckx, P; Windecker, S | 1 |
| Aradi, D; Chang, K; Choo, EH; Chung, J; Claassens, DMF; Han, JK; Hwang, D; Kang, HJ; Kang, J; Kim, HS; Koo, BK; Massberg, S; Park, KW; Rizas, KD; Sibbing, D; Ten Berg, JM; van den Broek, W; Yang, HM | 1 |
| Arnous, S; Cusack, R; Kiernan, T; O'Connor, C; Soh, BWT; Waters, M | 1 |
| Berteotti, M; Ciardetti, N; Di Mario, C; Fortini, A; Giusti, B; Gori, AM; Grossi, G; Lotti, E; Marchionni, N; Marcucci, R; Migliorini, A; Valenti, R | 1 |
| Fujii, T | 1 |
| Gong, Y; Li, J; Wang, X; Wang, Y; Zhou, T | 1 |
| Bae, HJ; Cha, JK; Cho, KH; Cho, YJ; Choi, JC; Choi, JK; Choi, KH; Gorelick, PB; Gwak, DS; Han, MK; Hong, JH; Hong, KS; Jeong, HB; Kang, CH; Kang, J; Kang, K; Kim, BJ; Kim, C; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Kim, JY; Kim, WJ; Kim, YS; Kwon, DH; Kwon, JH; Lee, BC; Lee, J; Lee, K; Lee, M; Lee, SH; Lee, SJ; Norrving, B; Oh, MS; Park, H; Park, HK; Park, JM; Park, KY; Park, MS; Park, SS; Park, TH; Shin, DI; Sohn, SI; Yu, KH; Yum, KS | 1 |
| Baralis, G; Bianco, M; Cerrato, E; Cinconze, S; Giordana, F; Mottola, FF; Musumeci, G; Rossini, R; Verra, A | 1 |
| An, L; Lei, M; Li, C; Li, Y; Sun, X; Wang, J; Xue, Z; Yang, Y; Zhao, Z | 1 |
| Antono, D; Nugroho, P; Rinaldi, I; Rusdi, L; Shatri, H; Wahyudi, W; Wijaya, IP; Yunir, E | 1 |
| Aradi, D; Gross, L; Hadamitzky, M; Hein-Rothweiler, R; Komócsi, A; Massberg, S; Merkely, B; Rizas, KD; Sibbing, D; Trenk, D | 1 |
| Jia, S; Wu, H | 1 |
| de Havenon, A; Easton, JD; Furie, KL; Henninger, N; Johnston, SC; Kim, A; Lang, AE; Mac Grory, B; Shu, L; Yaghi, S | 1 |
| Iijima, R | 1 |
| Alsbrook, DL; Bhatia, K; Carr, KH; Di Napoli, M; Divani, AA; Hinduja, A; Hosseini Farahabadi, M; Jafarli, A; Ladd, LM; McCullough, LD; Ortiz Garcia, JG; Sabbagh, SY; Saver, JL | 1 |
| Han, JK; Jun, EJ; Kang, J; Kim, B; Kim, HS; Koo, BK; Park, KW; Rhee, TM; Shin, ES; Won, KB; Yang, HM | 1 |
| Bae, JW; Chae, IH; Han, JK; Hur, SH; Jeong, MH; Kang, J; Kim, DK; Kim, HS; Kim, YH; Koo, BK; Kwak, SH; Lee, H; Lee, NH; Oh, JH; Park, KW; Rha, SW; Rhee, TM; Shin, ES; Shin, WY; Yang, HM; Yoon, J | 1 |
| Bae, JH; Bailey, K; Baudhuin, LM; Bell, MR; Farkouh, ME; Fu, YP; Geller, N; Goodman, SG; Hasan, A; Ingraham, BS; Iturriaga, E; Jeong, MH; Lennon, RJ; Lerman, A; Mathew, V; Pereira, NL; Rihal, C; Rosenberg, Y; So, D; Tanguay, JF; Welsh, RC | 1 |
| Brown, JD; Cavallari, LH; Thomas, CD; Wang, Y; Winterstein, AG | 1 |
| Chen, Y; Li, D; Liu, S; Ma, X; Zhong, P | 1 |
| He, X; Li, J; Ma, S; Qiu, M; Qu, X; Wang, Q; Wang, X; Wu, C; Zhang, L | 1 |
| Blackburn, SL; Ciavarra, B; Guttenberg, KB; Kole, MJ; Li, W; McIntyre, T; Yao, W | 1 |
| Angiolillo, DJ; Bhatt, DL; Franchi, F; Giordano, S; Ortega-Paz, L; Pollack, CV; Rollini, F | 1 |
| Ito, Y; Kimata, M; Koseki, T; Sekido, K; Tanaka, J; Yamada, S | 1 |
| Bai, J; Chen, Y; Dong, P; Gong, X; Hua, R; Ke, Y; Li, C; Liu, K; Wang, Q; Wang, X; Wu, T; Xiao, J; Ying, L; Zhang, B; Zhang, J; Zhang, W; Zhang, X; Zhu, L | 1 |
| Leon, SJ; Shah, AH; Tangri, N; Whitlock, R; Wiens, EJ | 1 |
| Mantri, N; McNulty, E; Mutyala, R; Sachdeva, A; Solomon, M; Zhu, S | 1 |
| Alfredsson, J; Erlinge, D; James, S; Jernberg, T; Lindahl, B; Mohammad, MA; Omerovic, E; Szummer, K; Tjerkaski, J; Venetsanos, D | 1 |
| Bath, PM; Jiang, Y; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, Y; Xie, X; Xu, A; Xu, Q; Zhao, X | 1 |
| Briasoulis, A; Fujisaki, T; Kuno, T; Latib, A; Misumida, N; Takagi, H | 1 |
| Asano, T; Fukushima, K; Harada, J; Hiraga, T; Ishio, N; Kanda, J; Kitahara, H; Kobayashi, T; Kobayashi, Y; Kuriyama, N; Matsumoto, T; Miyahara, H; Ohno, Y; Okino, S; Sakamoto, N; Sano, M; Sato, T; Suzuki, S; Uchiyama, R; Yamamoto, M; Yamashita, D; Yamazaki, T | 1 |
| Charlot, MG; Engstrøm, T; Freeman, P; Glinge, C; Grove, EL; Holmvang, L; Jabbari, R; Jacobsen, MR; Kelbæk, H; Køber, L; Maeng, M; Pedersen, F; Sørensen, R; Torp-Pedersen, C; Veien, K | 1 |
| An, L; Hau, WK; Lei, M; Li, Y; Nie, S; Wang, J; Wang, X; Xue, Z; Yang, Y; Zhao, Z; Zhou, H | 1 |
| Han, Y; Li, J; Li, P; Li, Y; Liu, H; Na, K; Qi, Z; Qiu, M; Wang, B; Xu, K; Zhou, H | 1 |
| Jiang, Y; Jing, J; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Tian, X; Wang, A; Wang, Y; Xie, X; Zhang, J; Zhao, X | 1 |
| Chan, CC; Chan, YH; Chu, PH; Lee, KT; Tung, YC | 1 |
| Appleton, JP; Bath, PM; Christensen, H; Dineen, RA; England, TJ; James, M; Krishnan, K; Montgomery, AA; Ranta, A; Robinson, TG; Sprigg, N; Woodhouse, LJ | 1 |
| Denda, M; Goda, M; Hamano, H; Higashionna, T; Ishizawa, K; Lin, TJ; Miyata, K; Nawa, H; Neishi, M; Niimura, T; Yagi, K; Zamami, Y | 1 |
| Al-Roub, NM; Almarzooq, ZI; Kinlay, S | 1 |
| Berdibekov, BS; Bulaeva, NI; Golukhova, EZ; Kubova, MC; Ruzina, EV | 1 |
| Ge, P; Guo, Y; Li, Z; Xiao, J; Xie, L | 1 |
| Bath, PM; Claiborne Johnston, S; Jiang, Y; Jing, J; Li, H; Li, Z; Liu, L; Meng, X; Wang, A; Wang, Y; Xie, X; Xu, Q; Zhao, X | 1 |
| Ge, F; Li, M; Lin, H; Shi, J; Yang, Q; Zhang, X | 1 |
| Ahn, SG; Ahn, Y; Chang, K; Cho, KH; Hong, YJ; Jeon, DS; Jeong, MH; Jeong, YH; Kim, HY; Kim, JH; Kim, MC; Lee, JW; Shin, ES; Sim, DS; Yoo, KD; Youn, YJ | 1 |
| Ahn, JM; Cha, SJ; Jang, MH; Kang, DY; Kim, AR; Kim, JH; Kim, S; Kim, T; Kim, TO; Lee, J; Lee, JH; Lee, PH; Lee, YJ; Oh, HJ; Park, DW; Park, SJ | 1 |
| Ahn, HS; Cha, KS; Choi, HH; Han, JK; Hur, SH; Hwang, D; Jo, SH; Kang, J; Kim, HS; Koo, BK; Lee, NH; Park, KW; Ryu, JK; Shin, ES; Suh, IW; Woo, SI; Yang, HM; Yang, S | 1 |
| Ahmad, FS; Anderson, RD; Benziger, CP; Effron, MB; Farrehi, P; Girotra, S; Gupta, K; Harrington, RA; Hernandez, AF; Jain, SK; Jones, WS; Kripalani, S; Marquis-Gravel, G; Muñoz, D; Polonsky, TS; Roe, MT; Rothman, RL; Stebbins, A; Whittle, J; Wruck, L | 1 |
| Bao, D; Cui, M; Deng, J; Feng, J; Gao, W; Han, Y; Han, YL; He, C; Huang, YH; Jia, SB; Jiang, CM; Jiang, MN; Jiang, X; Li, JX; Li, Y; Li, ZS; Liao, Z; Ma, SC; Ma, SR; Ma, YT; Qiu, MH; Qu, P; Ru, LS; Sheng, JQ; Stone, GW; Tao, L; Wang, BM; Wang, JH; Wang, XY; Wang, XZ; Yang, K; Yang, SQ; Yang, YL; Zhang, WJ; Zhao, XX | 1 |
| Liu, C; Ma, L | 1 |
| Cayla, G; Lattuca, B | 1 |
| Resnick, MJ | 1 |
| Aradi, D; Hille, L; Leggewie, S; Nührenberg, TG; Schrör, K; Sibbing, D; Stratz, C; Trenk, D | 1 |
| Asselbergs, FW; Barbato, E; Bergmeijer, TO; Boersma, C; Claassens, DMF; de Boer, A; Deneer, VHM; Dewilde, WJM; Hermanides, RS; Herrman, JR; Janssen, PWA; Kelder, JC; Morisco, C; Mosterd, A; Postma, MJ; Ten Berg, JM; Tjon Joe Gin, RM; van 't Hof, AWJ; van der Harst, P; Vos, GJA | 1 |
| Cao, X; Li, JL; Liu, XJ; Xin, YG | 1 |
| Abe, M; Ando, K; Doi, M; Domei, T; Furukawa, Y; Hanaoka, KI; Hata, Y; Hibi, K; Ikari, Y; Kadota, K; Kawai, K; Kimura, T; Kozuma, K; Morimoto, T; Morino, Y; Nakagawa, Y; Nakao, K; Nanasato, M; Natsuaki, M; Noda, T; Ohya, M; Okayama, H; Sakamoto, H; Seino, Y; Shiomi, H; Suematsu, N; Suwa, S; Tada, T; Takagi, K; Takamisawa, I; Tanabe, K; Toyota, T; Watanabe, H; Yagi, M; Yokomatsu, T | 2 |
| Jiang, J; Li, C; Shen, X; Sun, Y; Tao, M; Wang, DW; Wang, Y; Yan, J; Ye, H; Yu, B; Yu, T; Zeng, H; Zhang, L | 1 |
| Baumgartner, I; Berger, JS; Blomster, JI; Fowkes, FG; Hiatt, WR; Huang, Z; Jones, WS; Kansal, A; Katona, B; Mahaffey, KW; Norgren, L; Patel, MR; Rockhold, FW | 1 |
| Abu-Assi, E; Alexopoulos, D; Ariza-Solé, A; Autelli, M; Biolè, C; Blanco, PF; Boccuzzi, G; Cequier, A; Correia, L; D'Amico, M; D'Ascenzo, F; Dominguez-Rodriguez, A; Durante, A; Fabrizio, U; Fernández, MC; Fujii, T; Gallo, D; Garay, A; Gili, S; González-Juanatey, JR; Grosso, A; Grossomarra, W; Henriques, JPS; Huczek, Z; Iñiguez-Romo, A; Kawaji, T; Kawashiri, MA; Kinnaird, T; Liebetrau, C; Lopez-Cuenca, A; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Nie, SP; Nuñez-Gil, I; Paz, RC; Peyracchia, M; Pousa, IM; Quadri, G; Queija, BC; Raposeiras-Roubin, S; Rinaldi, M; Rognoni, A; Saglietto, A; Taha, S; Usmiani, T; Velicki, L; Wilton, SB; Xanthopoulou, I | 1 |
| Akita, K; Amano, T; Inohara, T; Ishii, H; Kadota, K; Kohsaka, S; Maekawa, Y; Nakamura, M; Numasawa, Y; Yamaji, K | 1 |
| Akbari, A; Barry, JP; Gravenor, MB; Halcox, JP; Harris, DE; Jenkins, GH; Lacey, A; Obaid, DR; Smith, DA | 1 |
| Aw, JWX; Goh, LL; Ho, HK; Liu, J; Ong, HY; Tan, DS; Wee, E; Winther, M | 1 |
| Tan, WK | 1 |
| Kimura, T; Watanabe, H | 1 |
| Aoki, K; Fujimura, S; Ishibashi, T; Kaku, S; Kan, I; Karagiozov, K; Kato, N; Kodama, T; Murayama, Y; Nishimura, K; Sakuta, K; Sasaki, Y; Yuki, I | 1 |
| Abdel-Wahab, M; Arnold, M; Balan, P; Blanke, P; Dangas, GD; De Backer, O; Guimarães, AHC; Jeger, RV; Jilaihawi, H; Kim, WK; Kini, AS; Kofoed, KF; Leipsic, JA; Makkar, R; Mathiassen, ON; Mehran, R; Nørgaard, BL; Søndergaard, L; Terkelsen, CJ; Van Mieghem, N; Veien, KT; Windecker, S | 1 |
| Baldus, S; Dangas, GD; De Backer, O; Gilard, M; Giustino, G; Guimarães, AHC; Gullestad, L; Herrmann, HC; Kini, A; Mack, M; Makkar, RR; Mehran, R; Möllmann, H; Moreno, R; Schäfer, U; Seeger, J; Søndergaard, L; Tchétché, D; Thomitzek, K; Tijssen, JGP; Valgimigli, M; van Amsterdam, RGM; Volkl, AA; von Lewinski, D; Vranckx, P; Welsh, RC; Wildgoose, P; Windecker, S; Wöhrle, J; Zazula, A | 1 |
| Bolognese, L; Cantor, WJ; Cequier, Á; Chettibi, M; Collet, JP; Diallo, A; Ecollan, P; Fabris, E; Goodman, SG; Hamm, CW; Hammett, CJ; Hermanides, RS; Huber, K; Janzon, M; Lapostolle, F; Lassen, JF; Merkely, B; Montalescot, G; Silvain, J; Storey, RF; Tavenier, AH; Ten Berg, JM; van 't Hof, AWJ; Vicaut, E; Willems, FF; Zeymer, U | 1 |
| Airaksinen, J; Hasvold, P; Khanfir, H; Kytö, V; Prami, T; Reissell, E | 1 |
| Ayari, A; Barra, N; Billé, J; Joly, P; Maillard, L; Peycher, P; Sévilla, J; Silvestri, M; Tavildari, A; Vochelet, F | 1 |
| Baumgartner, I; Berger, JS; Blomster, JI; Fowkes, FGR; Hiatt, WR; Huang, Z; Jones, WS; Katona, BG; Mahaffey, KW; Mehta, R; Norgren, L; Patel, MR; Povsic, TJ; Rockhold, FW; Vemulapalli, S; Ward, R | 1 |
| Bhatt, DL; Cannon, CP; de Veer, A; Hohnloser, SH; Jansky, P; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Seung, KB; Steg, PG; Ten Berg, JM; Zateyshchikov, DA | 1 |
| Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Maeng, M; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Abu-Assi, E; Alexopoulos, D; Ariza-Solé, A; Autelli, M; Biolè, C; Biondi-Zoccai, G; Blanco, PF; Boccuzzi, G; Bongiovanni, F; Cequier, A; Cerrato, E; Conrotto, F; Correia, L; D'Ascenzo, F; De Ferrari, GM; Dominguez-Rodriguez, A; Durante, A; Fabrizio, U; Fernández, MC; Fujii, T; Gaido, F; Gallo, D; Garay, A; Gili, S; González-Juanatey, JR; Grosso, A; Henriques, JPS; Huczek, Z; Iñiguez-Romo, A; Kawaji, T; Kawashiri, MA; Kinnaird, T; Liebetrau, C; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Nie, SP; Nuñez-Gil, I; Omedè, P; Paz, RC; Pousa, IM; Quadri, G; Queija, BC; Raposeiras-Roubin, S; Rettegno, S; Rognoni, A; Song, X; Stone, GW; Taha, S; Templin, C; Valdés, M; Velicki, L; Wilton, SB; Xanthopoulou, I | 1 |
| Liao, YWB; Wang, TKM | 1 |
| Caballero-Jambrina, I; Diarte-de Miguel, JA; Fuertes-Ferre, G; Jimeno-Sánchez, J; Ortas-Nadal, MR; Ruiz-Aranjuelo, A | 1 |
| Dalén, M | 1 |
| Ahn, JH; Ahn, Y; Hong, YJ; Hur, SH; Hwang, JY; Jeong, MH; Kim, JH; Kim, MC; Oh, SK; Seong, IW; Sim, DS; Yoon, JH | 1 |
| Del Aguila, M; Girotra, S; Hu, B; Ince, B; Jeng, JS; Kutluk, K; Liu, L; Lou, M; Min Han, J; Paciaroni, M; Paek, D; Parfenov, V; Wong, KSL; Zamani, B | 1 |
| Bhatt, DL; Cannon, CP; de Veer, A; Hohnloser, SH; Kimura, T; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Ben-Yehuda, O; Claessen, BE; Crowley, A; Faggioni, M; Farhan, S; Généreux, P; Kirtane, AJ; Maehara, A; Mastoris, I; Mehran, R; Redfors, B; Stone, GW; Weisz, G; Witzenbichler, B | 1 |
| Graham, MM; Har, B; James, MT; Koshman, SL; Turgeon, RD; Wilton, SB; Youngson, E | 1 |
| Li, H; Li, J; Lin, J; Liu, L; Wang, A; Wang, Y; Zhao, X; Zuo, Z | 1 |
| Gao, L; Geng, L; Guo, W; Li, H; Li, J; Wan, Q; Wang, X; Wang, Y; You, J; Zhang, Q | 1 |
| Colombo, A; Gallo, F; Giannini, F; Khokhar, AA; Laricchia, A; Mangieri, A; Sticchi, A | 1 |
| Bliden, K; Gurbel, PA; Rout, A; Tantry, US; Timilsina, S | 1 |
| Han, Y; Jiang, Z; Li, Y; Li, Z; Ma, S; Song, H; Yu, P | 1 |
| Cao, X; Gu, J; Li, X; Liu, P; Miao, Y; Sun, D; Xu, Z; Zhang, J | 1 |
| Álvarez-Antón, S; Carballeira, D; Concepción, R; Dejuán-Bitriá, C; Del Castillo, H; Delgado-Calva, FA; López-Soberón, E; Marschall, A; Martí, D; Morales, MJ; Palazuelos, J; Pérez-Guzmán, J | 1 |
| Ferlini, M; Galvani, M; Visconti, LO | 1 |
| Dishy, V; Kobayashi, F; Kochan, J; Limsakun, T; McPhillips, P; Mendell, J; Orihashi, Y; Pav, J; Pizzagalli, F; Rambaran, C; Vandell, AG; Warren, V; Zhou, J | 1 |
| Antonicelli, R; Bongioanni, S; Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Luca, G; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Grosseto, D; Mariani, M; Morici, N; Murena, E; Petronio, AS; Piatti, L; Ravera, A; Rogacka, R; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A; Verdoia, M; Vitrella, G | 1 |
| Cui, CS; Hou, AJ; Luan, B; Luo, DF; Meng, QK; Tao, J; Wang, CF; Wang, Y; Zhang, XJ; Zhao, HW; Zhu, Y | 1 |
| Bergmeijer, TO; Claassens, DMF; Deneer, VHM; Hermanides, RS; Hinrichs, DL; Tavenier, AH; Ten Berg, JM; van 't Hof, AWJ; Vos, GJA | 1 |
| Chai, M; Liang, J; Liu, W; Liu, X; Xi, Z; Yu, Y; Zhao, Y; Zhou, Y | 1 |
| Bell, JS; Farinola, N; Hauta-Aho, M; Huupponen, R; Johns, S; Korhonen, MJ; Shakib, S; Teperi, S | 1 |
| Butala, NM; Faridi, KF; Garratt, KN; Kennedy, KF; Maddox, TM; Secemsky, EA; Yeh, RW | 1 |
| Si, LY; Su, Y; Wang, Z; Xu, Q; Zhou, DY | 1 |
| Antman, EM; Bergmark, BA; Bonaca, MP; Braunwald, E; Morrow, DA; Murphy, SA; Sabatine, MS; Scirica, BM; Wiviott, SD | 1 |
| Abe, K; Ikeda, Y; Kitagawa, K; Kitazono, T; Nanto, S; Nishikawa, M; Ogawa, A; Toyoda, K | 1 |
| Feit, F | 1 |
| Baan, J; Brouwer, J; Buysschaert, I; Chan Pin Yin, DRPP; De Bruyne, B; Delewi, R; Dubois, CLF; Ferdinande, B; Frambach, P; Hermanides, RS; Holvoet, W; Kelder, JC; Nijenhuis, VJ; Peper, J; Rensing, BJWM; Roosen, J; Schotborgh, CE; Stella, PR; Swaans, MJ; Ten Berg, JM; Thielen, FWF; Timmers, L; Toušek, P; van 't Hof, AWJ; van der Harst, P; Van Der Heyden, JAS; van der Kley, F; van Houwelingen, GK; Veenstra, L | 2 |
| Fukuda, K; Heidenreich, PA; Ikemura, N; Kohsaka, S; Numasawa, Y; Sandhu, AT; Sawano, M; Shiraishi, Y; Shoji, S; Suzuki, M; Ueno, K | 1 |
| Berry, NC; Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Mauri, L; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Byun, JK; Cha, J; Choi, BG; Choi, CU; Choi, JY; Choi, SY; Jang, WY; Jeong, MH; Kang, DO; Kim, EJ; Kim, JS; Kim, W; Na, JO; Oh, DJ; Park, CG; Park, Y; Rha, SW; Roh, SY; Seo, HS | 1 |
| Ben-Dor, I; Chen, Y; Gajanana, D; Iantorno, M; Khalid, N; Khan, JM; Kolm, P; Musallam, A; Rogers, T; Satler, LF; Shlofmitz, E; Torguson, R; Waksman, R; Weintraub, WS; Zhang, C | 1 |
| Bolognese, L; Cimminiello, C; Micieli, G; Patti, G | 1 |
| Cheng, Y; Liu, F; Liu, X; Ma, Y; Sun, Y; Zhang, D; Zhao, Y; Zhou, Y | 1 |
| Baldetti, L; Beneduce, A; Calvo, F; Capodanno, D; Cappelletti, AM; D'Ascenzo, F; De Ferrari, GM; Gallone, G; Godino, C; Gramegna, M; Melillo, F; Moroni, F; Pagnesi, M; Venuti, A | 1 |
| Allou, N; Allyn, J; Brulliard, C; Caron, M; Charpentier, T; Cordier, C; Emery, M; Ferdynus, C; Lair, T; Valance, D | 1 |
| Cannata, F; Cao, D; Chiarito, M; Condorelli, G; De Caterina, R; Ferrante, G; Godino, C; Panico, C; Regazzoli, D; Reimers, B; Sanz-Sánchez, J; Stefanini, GG; Sturla, M | 1 |
| Chen, S; Qu, J; Rao, C; Zhang, D; Zhang, H; Zhao, Y; Zheng, Z | 1 |
| Bonello, L; Burtey, S; Canault, M; Cayla, G; Laine, M; Lemesle, G; Paganelli, F; Pankert, M; Puymirat, E; Quaino, G; Range, G | 1 |
| De Luca, G; Khedi, E; Suryapranata, H; Verdoia, M | 1 |
| Abe, K; Ikeda, Y; Kitagawa, K; Kitazono, T; Matsumoto, M; Minematsu, K; Nagao, T; Nagata, I; Nanto, S; Nishikawa, M; Ogawa, A; Shirai, T; Tanahashi, N; Toyoda, K; Uchiyama, S; Yamagami, H | 1 |
| Aradi, D; Baquet, M; Gschwendtner, S; Hochholzer, W; Hoffmann, E; Jochheim, D; Kastrati, A; Mansmann, U; Massberg, S; Mayer, K; Mehilli, J; Neumann, FJ; Schüpke, S; Sibbing, D; Tesche, C; Thienel, M; Xu, Y; Zadrozny, M | 1 |
| Murphy, SA; O'Donoghue, ML; Sabatine, MS | 1 |
| Antonucci, E; Calabrò, P; Cavallari, I; Cesaro, A; Cirillo, P; Gaudio, C; Gragnano, F; Gresele, P; Ielasi, A; Marcucci, R; Moscarella, E; Pafundi, PC; Palareti, G; Patti, G; Pelliccia, F; Pengo, V; Pignatelli, P; Sasso, FC | 1 |
| Chen, R; Chen, Y; Li, J; Liu, C; Sheng, Z; Song, L; Yan, H; Zhao, H; Zhou, J; Zhou, P | 1 |
| Ferraris, VA | 1 |
| Berghold, A; Mahla, E; Pregartner, G; Schoerghuber, M; Seitelberger, R; Toller, W; Voetsch, A | 1 |
| Akilesh, R; Krishnan, B; Madhan, B; Mote, NP; Prasad, GA; Saravanan, R | 1 |
| Feng, W; Song, Y; Tiemuerniyazi, X; Xu, F; Yan, H | 1 |
| Chen, H; Jing, J; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, Y; Xu, Y; Yan, H; Zhao, X; Zong, L | 1 |
| Hu, Z; Jing, Y; Li, X; Lv, Q; Seybert, A; Wang, J; Wu, H; Xie, X; Xue, Y | 1 |
| Darius, H | 1 |
| Chierico, S; Klersy, C; Lovotti, M; Marazzi, G; Marone, EM; Palmieri, P; Rinaldi, LF | 1 |
| AbdElghany, M; El-Abhar, HS; Mohareb, MW; Zaki, HF | 1 |
| Asada, K; Fukuyama, M; Hira, D; Horie, M; Isono, T; Miyamoto, A; Nakagawa, Y; Ozawa, T; Sakai, H; Sawayama, Y; Terada, T; Tomita, Y; Yagi, N; Yamamoto, T | 1 |
| Angiolillo, DJ; Chen, S; Han, Y; Jing, Q; Li, J; Li, Y; Qiao, S; Wang, B; Wang, X | 1 |
| Balusson, F; Bouget, J; Lacut, K; Oger, E; Pavageau, L; Roy, PM; Viglino, D | 1 |
| Chang, CJ; Chang, SH; Kuo, CT; Liu, JR; See, LC; Tung, YC | 1 |
| De Servi, S; Landi, A; Savonitto, S | 1 |
| Abbott, JD; Bae, JH; Bailey, K; Baudhuin, L; Bell, M; Cagin, C; Chavez, I; Farkouh, ME; Fu, YP; Geller, N; Goodman, SG; Gordon, P; Hasan, A; Iturriaga, E; Jeong, MH; Lennon, R; Lerman, A; Mathew, V; Pereira, NL; Rihal, C; Rosenberg, Y; Sidhu, M; So, D; Tanguay, JF; Wang, L; Weinshilboum, R; Welsh, R | 1 |
| Boccuzzi, G; Brscic, E; Casu, G; Colombo, A; Golino, P; Mangieri, A; Pagnotta, PA; Pasceri, V; Patti, G; Rapacciuolo, A; Russo, V; Sticchi, A; Verolino, G; Vizzi, V | 1 |
| Casula, M; Fabris, F; Ferlini, M; Fortuni, F; Leonardi, S; Oltrona Visconti, L | 1 |
| Angiolillo, DJ; Beitelshees, AL; Cavallari, LH; Chen, Y; Cook, KJ; Coons, JC; Dillon, C; Duarte, JD; Empey, PE; Franchi, F; Giri, J; Gong, Y; Johnson, JA; Kreutz, RP; Lee, CR; Lee, JC; Limdi, NA; McDonough, CW; Skaar, TC; Stevenson, JM; Stouffer, GA; Thomas, CD; Tuteja, S; Weck, KE | 1 |
| Elgendy, IY | 1 |
| Kelsey, MD; Newby, LK | 1 |
| Gower, MN; Gustafson, C; Lee, CR; Pauley, E; Stouffer, GA; Weck, KE; Williams, AK | 1 |
| Gao, R; Guo, T; Li, J; Li, Y; Qiao, S; Qiu, H; Tang, Y; Wang, Y; Xu, B; Yan, L; Yang, Y; Zheng, J | 1 |
| Baumgartner, I; Berger, JS; Blomster, JI; Fowkes, FGR; Gutierrez, JA; Heizer, GM; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Norgren, L; Patel, MR; Rockhold, FW | 1 |
| Bath, PM; Xiong, Y | 1 |
| Abdul Rahman, L; Almallouhi, E; Chimowitz, MI; Cotsonis, G; Holmstedt, CA; Turan, TN | 1 |
| Biswas, M; Biswas, TK; Ibrahim, B; Rahaman, S | 1 |
| Ahmed, SH; Benitez, RM; Hartzell, SA; Kalich, BA; Lusk, KA | 1 |
| Bikdeli, B; Cho, J; Gupta, A; Hripcsak, G; Kim, J; Krumholz, HM; Londhe, A; Madigan, D; Park, J; Park, RW; Reich, CG; Rho, Y; Ryan, PB; Schuemie, M; Siapos, A; Suchard, MA; Weaver, J; You, SC | 1 |
| Bondarenco, M; Enghelberg, S; Fox, B; Natif, N; Perl, S; Shpirer, Y | 1 |
| Hyodo, A; Nagaishi, M; Suzuki, K; Suzuki, R; Takano, I; Takigawa, T | 1 |
| Kargiotis, O; Tsivgoulis, G | 1 |
| Duong, K; Eadon, MT; Fekete, K; Kenneally, A; Milway, E; Nguyen, KA; Oh, H; Schleyer, TK; Whipple, EC; Yoo, R | 1 |
| Bhatt, DL; Cannon, CP; Costa, F; Hohnloser, SH; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM; Valgimigli, M | 1 |
| Cai, ZX; Dou, KF; Song, WH; Wang, HY; Yang, YJ; Yin, D | 1 |
| Greason, KL; Nei, SD; Scott, R; Wieruszewski, PM | 1 |
| Birlea, M; Hassell, KL; Hughes, HN; Schofield, JR | 1 |
| Ahmad, B; Alraies, MC; Biswas, S; Fichman, DL; Goldsweig, AM; Pacha, HM; Prasad, A; Sattar, Y; Ullah, W; Velagapudi, P; Zaher, N; Zghouzi, M | 1 |
| Byeon, JS; Choe, J; Hwang, SW; Kim, GU; Lee, S; Myung, SJ; Park, SH; Yang, DH; Yang, SK; Ye, BD | 1 |
| Guan, Y; Huang, J; Lin, X; Wang, L; Wang, S | 1 |
| Akao, M; Ako, J; Hagiwara, N; Hirayama, A; Kaikita, K; Kimura, K; Matoba, T; Matsui, K; Miyauchi, K; Nakamura, M; Ogawa, H; Yasuda, S | 1 |
| Beasley, M; Brown, TM; Cai, A; Clarkson, SA; Dillon, C; Heindl, B; Limdi, N | 1 |
| Alfredsson, J; Desta, L; Erlinge, D; Hagström, E; Jernberg, T; Lindahl, B; Mellbin, L; Nilsson, J; Omerovic, E; Szummer, KE; Träff, E; Venetsanos, D; Zwackman, S | 1 |
| Fajar, JK; Heriansyah, T; Ilmawan, M; Mahdi, BA; Mahendra, AI; Mazen, M; Pikir, BS; Purnamasari, Y; Rohman, MS; Tamara, F; Yamin, M | 1 |
| Ben-Dor, I; Case, BC; Forrestal, BJ; Mintz, GS; Rogers, T; Satler, LF; Waksman, R; Yerasi, C | 1 |
| Chen, L; Devi Shamloll, Y; Jiang, Z; Jin, J; Xiao, M; Zhuo, X | 1 |
| Chang, SH; Chen, SW; Huang, YT; Kuo, CC; Kuo, CF; Tu, HT; Wang, CL; Wen, MS; Wu, VC | 1 |
| Aggarwal, S; Ali, T; Ding, WY; Elamin, A; Fisher, M; Grainger, R; Hasara, J; Heseltine, T; Kasolo, Y; Khand, A; Kirmani, BH; Meah, MN; Mullen, L; Obeidat, M; Patel, B; Rashid, M; Shahzad, A; Shaw, M; Thatchil, J | 1 |
| Bilker, WB; Brensinger, CM; Hennessy, S; Leonard, CE; Pham Nguyen, TP | 1 |
| Biocina, B; Gasparovic, H; Goerlinger, K; Golubic Cepulic, B; Pasalic, M; Petricevic, M; Raos, M; Rotim, K; Vasicek, V | 1 |
| Dhaliwal, S; Dowlatshahi, D; Hutton, B; Lun, R; Roy, DC; Shorr, R; Zitikyte, G | 1 |
| Angiolillo, DJ; Capodanno, D; Cavallari, LH; Crea, F; Franchi, F; Galli, M; Rollini, F | 1 |
| Clemmensen, P; Desch, S; Dudek, D; Feistritzer, HJ; Freund, A; Fuernau, G; Geisler, T; Haller, P; Hausleiter, J; Huber, K; Kleeberger, J; Massberg, S; Montalescot, G; Neumer, A; Noc, M; Orban, M; Ouarrak, T; Schneider, S; Thiele, H; Zeymer, U | 1 |
| Bae, JW; Cho, DK; Choi, SH; Gwon, HC; Hahn, JY; Jeong, JO; Oh, JH; Park, YH; Rha, SW; Song, PS; Song, YB | 1 |
| Hsieh, KP; Hwang, SJ; Li, YS; Wang, SH; Yang, YH | 1 |
| Chang, W; Li, L; Lin, F; Liu, H; Yin, J; Zhang, H; Zhao, Y | 1 |
| Adlbrecht, C; Cuhaj, C; Delle-Karth, G; Grabenwöger, M; Hasan, W; Mach, M; Poschner, T; Strouhal, A; Szalkiewicz, P; Watzal, V; Winkler, B | 1 |
| Ali, S; Badillo, R; DaVee, RT; Guha, S; Haddad, PG; Hermann, A; Kannadath, BS; Meriwether, M; Munjal, A; Patil, P; Ramireddy, S; Rashtak, S; Thosani, N; Yoon, ED | 1 |
| Li, H; Sun, L; Wang, F; Wang, T; Yu, L | 1 |
| Kengkla, K; Kumtep, W; Saokaew, S; Senthong, V; Ungsriwong, S; Wongsalap, Y | 1 |
| Egashira, Y; Enomoto, Y; Iwama, T; Kinoshita, T; Mizutani, D; Shoda, K | 1 |
| Abu-Assi, E; Alexopoulos, D; Ariza-Solè, A; Bianco, M; Biolè, CA; Boccuzzi, G; Careggio, A; Cerrato, E; Correia, L; D'Ascenzo, F; De Ferrari, GM; Destefanis, P; Dominguez-Rodriguez, A; Durante, A; Fujii, T; Gonzàlez Juanatey, JR; Henriques, JPS; Huczek, Z; Kawaji, T; Kawashiri, MA; Kinnaird, T; Liebetrau, C; Luciano, A; Manzano-Fernàndez, S; Montagna, L; Morbiducci, U; Nie, SP; Nunez-Gil, I; Quadri, G; Quiros, A; Raposeiras-Roubin, S; Rognoni, A; Song, X; Spirito, A; Templin, C; Ugo, F; Varbella, F; Velicki, L; Wilton, SB | 1 |
| Case, BC; Doros, G; Medranda, GA; Waksman, R; Weintraub, WS; Yerasi, C; Zhang, C | 1 |
| Flahive, J; Fraielli, K; Gill, K; Servati, N | 1 |
| Bálint, A; Eitmann, S; Garami, A; Hanák, L; Hegyi, P; Komócsi, A; Márta, K; Rumbus, Z; Solymár, M; Szakács, Z | 1 |
| Al-Rawaf, S; Diab, K; Soriano, R | 1 |
| Bai, H; Li, H; Li, Y; Liu, W; Sun, L; Wang, T; Wu, J; Yu, A; Yu, L; Zhu, W | 1 |
| Abusnina, W; Al-Abdouh, A; Alshebani, Y; Bizanti, A; Dahal, K; Gill, G; Houssien, A; Kanmanthareddy, A | 1 |
| Han, J; Li, W; Lin, B; Lin, Y; Peng, W; Shi, X; Wang, Y; Yan, J; Zhang, Y; Zheng, Z | 1 |
| Ambler, GK; Behrendt, CA; Nordanstig, J; Twine, CP | 1 |
| Ardissino, D; Bahit, MC; Bode, C; Bueno, H; Claeys, MJ; Cornel, JH; Gibson, CM; Goto, S; Güray, Ü; Husted, S; James, SK; Kiss, RG; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Park, DW; Plotnikov, A; Povsic, TJ; Rockhold, F; Roe, MT; Steg, PG; Strony, J; Sun, X; Tendera, M; Welsh, RC; White, J | 1 |
| Bacchi-Reggiani, ML; Bordoni, B; Calabrò, P; Dallago, M; Di Pasquale, G; Franco, N; Leone, AM; Maggiolini, S; Magnavacchi, P; Mameli, S; Nicolino, A; Palmieri, C; Piccalò, G; Piovaccari, G; Rubboli, A; Saia, F; Sciahbasi, A; Steffanon, L; Vignali, L | 1 |
| Berti, S; Bolognese, L; D'Ascenzo, F; De Luca, L; De Servi, S; Marchese, A; Musumeci, G; Parodi, G; Saia, F; Varbella, F | 1 |
| Dong, Y; He, H; Lu, J; Ma, X; Meng, T; Xie, J; Zhai, Y | 1 |
| Alfredsson, J; Armstrong, PW; Bhatt, DL; Cornel, JH; Fox, KA; Goodman, SG; Mahaffey, KW; Neely, B; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Tricoci, P; White, HD; Winters, KJ | 1 |
| Belmin, J; Jarzebowski, W; Lafuente-Lafuente, C; Melkonian, M; Pautas, E; Siguret, V | 1 |
| Becker, RC; Cannon, CP; Hagström, E; Himmelmann, A; James, SK; Katus, HA; Lindholm, D; López-Sendón, JL; Maurer, G; Siegbahn, A; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Dixon, SR; Gurm, HS; Khandelwal, A; LaLonde, TA; Seth, M; Sukul, D | 1 |
| Bi, Q; Fu, P; Guo, F; Qiao, M; Song, Z; Wang, Y | 1 |
| Boyd, A; Chambers, A; Chanas, T; Coons, JC; Eckardt, J; Ensor, CR; Iasella, CJ; Lemon, LS; Lyons, J; Merkel, A; Rihtarchik, L; Smith, R; Wang, N; Williams, K | 1 |
| Arima, Y; Hokimoto, S; Ishii, M; Ito, M; Iwashita, S; Kaikita, K; Kojima, S; Mitsuse, T; Oimatsu, Y; Sueta, D; Takahashi, A; Tsujita, K; Yamamoto, E | 1 |
| Anstrom, KJ; Bagai, A; Cohen, DJ; Effron, MB; Henry, TD; McCoy, LA; Peterson, ED; Schulte, PJ; Stone, GW; Wang, TY; Zettler, ME | 1 |
| Becker, RC; Budaj, A; Cannon, CP; Cornel, JH; Ducrocq, G; Held, C; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Schulte, PJ; Sorbets, E; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Jang, HJ; Kang, WC; Kim, TH; Kwon, SW; Lee, K; Moon, J; Oh, PC; Park, HW; Park, SD; Suh, J | 1 |
| Alexopoulos, D; Davlouros, P; Deftereos, S; Goudevenos, J; Hamilos, M; Kanakakis, I; Lekakis, J; Sitafidis, G; Vavouranakis, M; Xanthopoulou, I | 1 |
| Apruzzese, PK; Cutlip, DE; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW | 1 |
| Bhatt, DL; Grove, EL; Kristensen, SD; Pareek, M; Ten Berg, JM | 1 |
| Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Cuisset, T; Deffarges, S; Deharo, P; Fourcade, L; Johnson, TW; Lambert, M; Morange, PE; Mouret, JP; Quilici, J; Verdier, V | 1 |
| Armstrong, PW; Gershlick, A; Halvorsen, S; Huber, K; Shavadia, J; Steg, PG; Van de Werf, F; Welsh, R; Zheng, Y | 1 |
| Al-Qoofi, F; Chamandi, C; Côté, M; Dumont, E; Garcia Del Blanco, B; Généreux, P; Maluenda, G; Masson, JB; Paradis, JM; Pelletier, M; Rodés-Cabau, J; Serra, V; Thoenes, M; Webb, JG; Welsh, RC | 1 |
| Ahn, JM; Choi, HI; Kang, SH; Kang, SJ; Kim, YH; Lee, CW; Lee, PH; Lee, SW; Park, DW; Park, SJ; Park, SW | 1 |
| Godier, A; Houssany-Pissot, S; Martin, AC; Taylor, G; Zlotnik, D | 1 |
| Chiswell, K; Doll, JA; Kosiborod, M; Li, S; Roe, MT; Scirica, BM; Wang, TY | 1 |
| Giedraitiene, A; Kupstyte, N; Lesauskaite, V; Tatarunas, V; Zaliunas, R | 1 |
| Ariotti, S; Baldo, A; Franzone, A; Gargiulo, G; Moschovitis, A; Piccolo, R; Santucci, A; Tumscitz, C; Valgimigli, M; Windecker, S | 1 |
| Chang, S; Chang, Y; Lu, S; Sun, Q; Zhang, Y | 1 |
| Chen, Q; Geng, G; Han, W; Hao, Y; Hao, Z; Jia, K; Liu, H; Liu, L; Liu, Y; Wang, D; Zhou, Y | 1 |
| Huang, C; Wang, Y; Wu, Y; Xu, W; Yan, H; Zhang, L; Zhou, Y; Zhu, J; Zhu, W | 1 |
| Bertoldi Franco, J; Buhatem Medeiros, F; Gallottini, M; Itagiba Neves, IL; Ortega, KL; Pepe Medeiros de Rezende, N; Porrio de Andrade, AC; Timerman, L | 1 |
| Adlbrecht, C; Eber, B; Egger, F; Hajos, J; Helmreich, W; Huber, K; Machata, M; Michael, N; Neumayr, M; Rohla, M; Suppan, M; Tscharre, M; Weiss, TW; Zweiker, R | 1 |
| Ako, J; Ando, K; Anzai, H; Hamasaki, T; Iijima, R; Inoue, K; Ishiwata, S; Ito, Y; Kadotani, M; Kawaguchi, K; Morita, T; Nakamura, M; Niinuma, H; Nishida, Y; Ochiai, M; Ohira, H; Okada, H; Omiya, K; Shinke, T; Takiuchi, S; Tanaka, H; Ueda, Y; Yasaka, Y; Yokoi, H; Zen, K | 1 |
| Armengaud, J; Barragan, P; Ben Amer, H; Berlan, J; Blanchard, D; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Didier, R; Druelles, P; Dupouy, P; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J | 1 |
| Bachelot-Loza, C; Belleville-Rolland, T; Gaussem, P; Godier, A; Helley, D; Martin, AC | 1 |
| Huang, RC; Yuan, C; Zhong, L | 1 |
| Ahn, TH; Cha, KS; Chae, JK; Chae, SC; Choi, DJ; Gwon, HC; Hwang, KK; Jeong, MH; Kim, HK; Kim, HS; Kim, KB; Kim, YJ; Oh, DJ; Oh, SK; Park, KH; Seong, IW; Seung, KB | 1 |
| Jiang, M; You, JHS | 1 |
| Ait Hamou, Z; Baillard, C; Chilot, F; Eyraud, V; Pailleret, C; Rosencher, N; Samama, CM | 1 |
| Borse, MS; Dong, OM; Farley, JF; Lee, CR; Polasek, MJ; Stouffer, GA | 1 |
| Aquino, M; Baber, U; Baker, BA; Chandrasekhar, J; Dangas, G; DeFranco, A; Effron, MB; Faggioni, M; Farhan, S; Henry, TD; Kapadia, S; Keller, S; Kini, AS; Mehran, R; Muhlestein, JB; Pocock, S; Rao, S; Sartori, S; Strauss, C; Toma, C; Vogel, B; Weintraub, W; Weiss, S | 1 |
| Ben-Yehuda, O; Brodie, BR; Cox, DA; Duffy, PL; Généreux, P; Gurbel, PA; Henry, TD; Kirtane, AJ; Litherland, C; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Rinaldi, MJ; Simonton, CA; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B | 1 |
| Adriaenssens, T; Bernlochner, I; Byrne, RA; Colleran, R; Emmer, R; Fischer, M; Giacoppo, D; Han, Y; Harada, Y; Ibrahim, T; Jacobshagen, C; Kastrati, A; Kufner, S; Lahmann, AL; Laugwitz, KL; Lohaus, R; Maeng, M; Mayer, K; Mehilli, J; Michel, J; Morath, T; Neumann, FJ; Schulz-Schüpke, S; Schunkert, H; Seyfarth, M; Ten Berg, JM; Tölg, R; Wöhrle, J; Wolk, A; Zrenner, B | 1 |
| Baschin, M; Greinacher, A; Kohlmann, T; Schroeder, HW; Selleng, S; Thiele, T; Westphal, A; Zeden, JP | 1 |
| Alexopoulos, D; Goudevenos, J; Hamilos, M; Kanakakis, J; Kochiadakis, G; Lekakis, J; Petousis, S; Sitafidis, G; Skalidis, E; Vardas, PE; Vavouranakis, M; Xanthopoulou, I | 1 |
| Bhatt, DL; Cannon, CP; Ellis, SG; Gropper, S; Harper, R; Hohnloser, SH; Januzzi, JL; Kimura, T; Kleine, E; Lip, GYH; Maeng, M; Manassie, J; Merkely, B; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM; Zeymer, U | 1 |
| Aradi, D; Dézsi, CA; Felix, SB; Geisler, T; Gross, L; Hadamitzky, M; Holdt, L; Huber, K; Huczek, Z; Jacobshagen, C; Kiss, RG; Klopotowski, M; Koltowski, L; Komócsi, A; Massberg, S; Mehilli, J; Merkely, B; Neumann, FJ; Orban, M; Parma, R; Rieber, J; Schwinger, RHG; Sibbing, D; Trenk, D | 1 |
| Fairley, S; Harding, SA; Holley, A; Larsen, PD; Simmonds, M; Wilkins, B | 1 |
| Agrifoglio, M; Benedetto, U; Bianco, M; Colombo, A; Conrotto, F; D'Amico, M; D'Ascenzo, F; D'Onofrio, A; Moretti, C; Ribichini, F; Rinaldi, M; Salizzoni, S; Tarantini, G | 1 |
| Almaghrabi, TS; Cai, C; Chang, TR; Choi, HA; Grotta, JC; Lee, K; McDonald, MM; Rahbar, MH; Saenz, DM | 1 |
| Fu, WX; He, RX; Jing, QM; Liu, HW; Liu, YJ; Wang, XZ; Yuan, WJ; Zhang, L; Zhou, TN | 1 |
| Ahn, S; Cho, MJ; Cho, S; Ha, J; Kim, SY; Lee, J; Min, SI; Min, SK | 1 |
| Dong, Y; Gui, L; Jing, J; Li, H; Li, S; Li, Z; Liu, LP; Meng, X; Wang, A; Wang, D; Wang, G; Wang, YJ; Wang, YL; Zhao, XQ; Zheng, H | 1 |
| Atanasov, DT; Dinkova, AS; Vladimirova-Kitova, LG | 1 |
| Baker, BA; Effron, MB; Fonarow, GC; Henry, TD; McCoy, LA; Peterson, ED; Wang, TY; Zettler, ME | 1 |
| Amiel, J; Chevallier, D; De Broca, B; Durand, M; Prader, R | 1 |
| Chao, TH; Chen, JY; Cheng, CL; Kao Yang, YH; Lee, CH; Li, YH | 1 |
| He, B; Lin, H; Tobe, RG; Wu, B; Zhang, L | 1 |
| Bossard, M; Faxon, DP; Fox, KAA; Gao, P; Granger, CB; Jolly, SS; Mehta, SR; Montalescot, G; Natarajan, MK; Niemela, K; Steg, PG; Tanguay, JF; Widimsky, P; Yusuf, S | 1 |
| Albaladejo, P; Kamphuisen, P; Llau, JV | 1 |
| Athanasiou, A; Damaskos, C; Moris, D; Politou, M; Spartalis, E; Spartalis, M; Tzatzaki, E | 1 |
| Carugo, S; Castini, D; Cazzaniga, S; Centola, M; Ferrante, G; Lucreziotti, S; Persampieri, S; Salerno-Uriarte, D; Sponzilli, C | 1 |
| de Man, FHAF; Doggen, CJM; Hartmann, M; Knottnerus, IL; Kok, MM; Linssen, GCM; Louwerenburg, JW; Löwik, MM; Stoel, MG; van der Heijden, LC; van Houwelingen, KG; von Birgelen, C; Zocca, P | 1 |
| Becher, PM; Blankenberg, S; Fluschnik, N; Schnabel, R; Westermann, D | 1 |
| Alexopoulos, D; Lekakis, J; Pappas, C; Sfantou, D | 1 |
| Landmesser, U; Stähli, BE | 1 |
| Bellesini, M; Donadini, MP; Middeldorp, S; Squizzato, A; Takeda, A | 1 |
| He, X; Hou, J; Li, B; Li, C; Liu, Z; Wu, H; Yang, M; Zhang, Q; Zhao, P; Zhong, M; Zhong, W; Zhong, Z | 1 |
| Antonijevic, N; Kusic-Tisma, J; Matic, D; Novkovic, M; Radojkovic, D; Rakicevic, L | 1 |
| Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Camoin-Jau, L; Cuisset, T; Deharo, P; Fernandez, M; Fourcade, L; Ibrahim, M; Johnson, TW; Morange, PE; Quilici, J; Suchon, P; Verdier, V | 1 |
| Bonello, L; Camoin-Jau, L; Gaubert, M; Laine, M; Paganelli, F; Resseguier, N | 1 |
| Appleton, JP; Bath, PM; Beridze, M; Christensen, H; Dineen, RA; Duley, L; England, TJ; Flaherty, K; Havard, D; Heptinstall, S; James, M; Krishnan, K; Markus, HS; Montgomery, AA; Pocock, SJ; Randall, M; Ranta, A; Robinson, TG; Scutt, P; Sprigg, N; Venables, GS; Woodhouse, LJ | 1 |
| Benavente, OR; Bhatt, DL; Connolly, SJ; Doros, G; Elmariah, S; Hsieh, WH; Liu, Y; Mauri, L; Steinhubl, SR; Yeh, RW; Yusuf, S | 1 |
| Åkerblom, A; Aukrust, P; Becker, RC; Bertilsson, M; Ghukasyan, T; Himmelmann, A; James, SK; Kontny, F; Michelsen, AE; Siegbahn, A; Storey, RF; Ueland, T; Wallentin, L | 1 |
| Cooper, R; Curzen, N; Kemp, I; Khanna, V; Mars, C; Shahzad, A; Shaw, M; Stables, RH; Wilson, K | 1 |
| Czub, P; Fojt, A; Grygier, M; Hendzel, P; Kapłon-Cieślicka, A; Karolczak, N; Kochman, J; Lodziński, P; Maksym, J; Marchel, M; Mazurek, T; Opolski, G; Piątkowski, R; Wilimski, R | 1 |
| de Belder, MA; Freeman, P; Johnson, T; Kontopantelis, E; Kwok, CS; Ludman, P; Mamas, MA; Sirker, A; Zaman, A | 1 |
| Ajjan, RA; Bertilsson, M; Gabrysch, K; Himmelmann, A; James, SK; Siegbahn, A; Storey, RF; Sumaya, W; Wallentin, L | 1 |
| Bologna, F; Bordignon, S; Chen, S; Chun, KRJ; Konstantinou, A; Nagase, T; Perrotta, L; Schmidt, B; Weise, FK | 1 |
| Abdel-Latif, A; Aoi, S; Kim, SM; Misumida, N; Ziada, KM | 1 |
| Fujimoto, W; Kawai, H; Miyata, T; Oishi, S; Onishi, T; Osue, T; Sawada, T; Shimane, A; Takahashi, Y; Takaya, T; Taniguchi, Y; Toba, T; Yasaka, Y | 1 |
| Ayhan, A; Dannenberg, L; Helten, C; Hohlfeld, T; Kelm, M; Levkau, B; Naguib, D; Pöhl, M; Polzin, A; Zeus, T | 1 |
| Banerjee, K; Garg, A; Goel, S; Hollander, G; Kapadia, S; Krishnaswamy, A; Mick, S; Raheja, H; Shani, J; White, J | 1 |
| Baschera, D; Grubhofer, F; Oberle, J; Schmid, SL | 1 |
| Averkov, O; Berwanger, O; Candido, CT; Carvalho, AC; Damiani, LP; de Barros E Silva, PGM; De Luca, FA; Fonseca, FA; Goodman, SG; Granger, CB; Guimaraes, HP; Jiang, L; Lasagno, CMR; Lopes, RD; Malaga, G; Moia, DDF; Nicholls, SJ; Nicolau, JC; Paisani, DM; Parkhomenko, A; Piegas, LS; Saraiva, JFK; Tajer, C; Valeis, N; White, HD | 1 |
| Gach, O; Lancellotti, P; Magne, J; Nyssen, A; Oury, C; Pirlet, C | 1 |
| Austin, PC; Chong, A; de Melo, JF; Jackevicius, CA; Ko, DT; Koh, M; Krumholz, HM; Stukel, TA; Tu, JV | 1 |
| Abad-Santos, F; Bárcena, E; Belmonte, C; Caniego, JL; Koller, D; Romero-Palacián, D; Saiz-Rodríguez, M; Talegón, M; Villalobos-Vilda, C | 1 |
| Adams, G; Ansel, G; Baumgartner, I; Grosso, M; Jaff, M; Lin, M; Mercur, MF; Minar, E; Moll, F; Nwachuku, C; Rundback, J; Tangelder, M; Zeller, T | 1 |
| Carrero, JJ; Edfors, R; Evans, M; James, SK; Jernberg, T; Lagerqvist, B; Renlund, H; Sahlén, A; Spaak, J; Szummer, K; Varenhorst, C | 1 |
| Fonarow, GC; Ge, J; Han, Y; Hao, Y; Huo, Y; Liu, J; Ma, C; Morgan, L; Nie, S; Smith, SC; Taubert, KA; Wang, X; Zhao, D; Zhao, G; Zhou, M | 1 |
| Alexopoulos, D; Bona, RD; Bongo, AS; Capodanno, D; Gaudio, G; Guasti, L; Lupi, A; Meliga, E; Porto, I; Schaffer, A; Valgimigli, M | 1 |
| Angiolillo, DJ; Bhatt, DL; Deliargyris, EN; Gibson, CM; Groves, EM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Armstrong, PW; Cyr, DD; Fox, KAA; Goodman, SG; Neely, M; Ohman, EM; Prabhakaran, D; Roe, MT; White, H; Yan, AT | 1 |
| Bath, PM; Heptinstall, S; May, J | 1 |
| Bode, C; Brachmann, J; Darius, H; Duerschmied, D; Frey, N; Katus, HA; Rottbauer, W; Schäfer, A; Thiele, H; Zeymer, U | 1 |
| Bundhun, PK; Huang, F | 1 |
| Amin, AP; Bhatt, DL; Fan, W; Généreux, P; Gibson, CM; Harrington, RA; Kirtane, AJ; Pinto, DS; Stone, GW; Tamez, H; White, HD; Yeh, RW | 1 |
| Billinger, M; Blöchlinger, S; Heg, D; Hunziker, L; Karagiannis, A; Koskinas, KC; Moro, C; Moschovitis, A; Pilgrim, T; Praz, F; Räber, L; Räsänen, M; Seiler, C; Stortecky, S; Temperli, F; Valgimigli, M; Windecker, S; Zanchin, C; Zanchin, T | 1 |
| Ahn, TH; Cha, KS; Chae, JK; Chae, SC; Cho, MC; Choi, DJ; Gwon, HC; Hur, SH; Hwang, JY; Jeong, MH; Joo, SJ; Kim, CJ; Kim, DI; Kim, HS; Oh, SK; Park, JS; Rha, SW; Seong, IW; Seung, KB; Sim, DS; Yoon, JH | 2 |
| Alexopoulos, D; Andreou, I; Briasoulis, A; Ikonomidis, I; Pappas, C | 1 |
| Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY | 1 |
| Gibler, WB | 1 |
| Chai, DY; Chen, SL; Gao, XF; Ge, Z; Kong, XQ; Lu, S; Wang, F; Wang, ZM; Zhang, JJ; Zuo, GF | 1 |
| de Man, FHAF; Doggen, CJM; Hartmann, M; Knottnerus, IL; Kok, MM; Linssen, GCM; Louwerenburg, JHW; Stoel, MG; van der Heijden, LC; van Houwelingen, KG; von Birgelen, C; Zocca, P | 1 |
| Ding, L; Peng, B | 1 |
| Chen, JY; Deng, CY; Fu, YH; Han, YL; Lei, HP; Li, XH; Lin, YB; Sheng, WS; Tang, QJ; Wu, H; Zhong, SL | 1 |
| Averkov, O; Berwanger, O; Candido, CT; Carvalho, AC; Damiani, LP; de Barros E Silva, PGM; Fonseca, F; Goodman, S; Granger, CB; Guimaraes, HP; Jiang, L; Kerr Saraiva, JF; Lasagno, CMR; Lopes, RD; Malaga, G; Moia, DDF; Nicholls, SJ; Nicolau, JC; Paisani, DM; Parkhomenko, A; Piegas, LS; Tajer, C; Valeis, N; White, H | 1 |
| Aradi, D; Baylacher, M; Felix, SB; Geisler, T; Gross, L; Hadamitzky, M; Hausleiter, J; Huber, K; Huczek, Z; Jacobshagen, C; Kiss, RG; Koltowski, L; Komócsi, A; Massberg, S; Mehilli, J; Merkely, B; Neumann, FJ; Parma, R; Sibbing, D; Trenk, D | 1 |
| Gao, Y; Hu, C; Liu, Y; Luo, Y; Wang, X; Zhang, X; Zhao, X; Zhou, H | 1 |
| Huang, J; Liu, L; Tang, X; Zhang, X | 1 |
| Abdalla, A; Ahmed, S; Bachuwa, G; Barbarawi, M; Bhatt, DL; Hassan, M; Haykal, T; Hicks, M; Kheiri, B; Osman, M; Zayed, Y | 1 |
| Antonicelli, R; Cecchini, S; Di Pillo, R; Galeazzi, R; Giovagnetti, S; Malatesta, G; Montesanto, A; Olivieri, F; Rose, G; Spazzafumo, L | 1 |
| Alderson, P; Lewis, SR; Pritchard, MW; Schofield-Robinson, OJ; Smith, AF | 1 |
| Bellesini, M; Donadini, MP; Squizzato, A | 1 |
| Abe, K; Ikeda, Y; Kitazono, T; Nishikawa, M; Ogawa, A; Yoshiba, S | 1 |
| Daimon, S | 1 |
| Jiang, WJ; Li, C; Liu, AF; Qiu, H; Wang, K; Wu, Z; Zhang, Y; Zhou, J | 1 |
| Han, YL; Li, J; Li, Y; Wang, HY; Xu, XM | 1 |
| Chen, J; Fan, Y; Ji, Y; Kong, D; Li, C; Li, J; Meng, H; Xu, K; Ye, S; Zhang, J; Zhu, T | 1 |
| Calnan, MW; Crawford, AN | 1 |
| Alfredsson, J; Erlinge, D; James, S; Jernberg, T; Omerovic, E; Persson, J; Ravn-Fischer, A; Svennblad, B; Tornvall, P; Ueda, P; Varenhorst, C | 1 |
| Ben-Dor, I; Buchanan, KD; Gajanana, D; Iantorno, M; Okubagzi, PG; Pichard, AD; Rogers, T; Satler, LF; Thourani, VH; Torguson, R; Waksman, R; Weintraub, WS | 1 |
| Carrillo-Alemán, L; Esteve-Pastor, MA; Lozano, T; Macías-Villanego, MJ; Marín, F; Martínez-Martínez, JG; Orenes-Piñero, E; Pernias-Escrig, V; Rivera-Caravaca, JM; Ruiz-Nodar, JM; Tello-Montoliu, A; Véliz-Martínez, A; Vicente-Ibarra, N | 1 |
| Allocco, DJ; Christen, T; Dauerman, HL; Kereiakes, DJ; Kirtane, AJ; Mauri, L; Meredith, IT; Price, MJ; Windecker, S; Yeh, RW | 1 |
| Ahn, J; Cha, KS; Choe, JC; Choi, JH; Hong, TJ; Jeong, MH; Lee, HC; Lee, HW; Oh, JH; Park, JS | 1 |
| Fan, CJ; Hu, HY; Li, XY; Su, GH; Wang, GX | 1 |
| Aradi, D; Bonello, L; Burtey, S; Dabry, T; Frere, C; Laine, M; Lemesle, G; Mancini, J; Paganelli, F; Puymirat, E; Sibbing, D; Thuny, F | 1 |
| Berger, JS; Gislason, GH; Lamberts, M; Lock Hansen, M; Nissen Bonde, A; Olesen, JB; Pallisgaard, JL; Sindet-Pedersen, C; Staerk, L; Torp-Pedersen, C | 1 |
| Andreotti, F; Calò, L; Crea, F; D'Amario, D; Della Bona, R; Galli, M; Porto, I; Savarese, G; Vergallo, R | 1 |
| Baccar, H; Boughalleb, M; Charfi, R; Gorgi, Y; Hammami, N; Hosni, H; Kharrat, M; Klouz, A; Kouidhi, S; Limam, M; Mrabet, A; Mzoughi, K; Sfar, I; Trabelsi, S; Zaïri, I; Zedini, C | 1 |
| Hoppe, UC; Jung, C; Lauten, A; Lichtenauer, M; Navarese, EP; Wernly, B | 1 |
| Brener, SJ; Brodie, BR; Cox, DA; Duffy, PL; Gurbel, PA; Henry, TD; Kirtane, AJ; Mazzaferri, EL; McAndrew, T; Mehran, R; Metzger, DC; Neumann, FJ; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B | 1 |
| Jing, J; Johnston, SC; Li, H; Liu, H; Liu, L; Pan, Y; Wang, D; Wang, Y; Wang, Z; Zhao, X; Zhu, B | 1 |
| Chen, M; Hu, X; Wang, Y; Yang, FY; Zhang, Y | 1 |
| Desai, RJ; Gagne, JJ; Lewey, JJ; Patorno, E; Schneeweiss, S; Spoendlin, J | 1 |
| Hirata, KI; Konishi, A; Nishio, R; Otake, H; Shinke, T; Tahara, N | 1 |
| Abellán-Huerta, J; Jurado-Román, A; López-Lluva, MT; Lozano-Ruiz Poveda, F; Piqueras-Flores, J; Sánchez-Pérez, I | 1 |
| Chang, CC; Chen, SM; Chen, YC; Cheng, SM; Chuang, CL; Lin, FY; Lin, RH; Lin, YW; Sheu, JS; Tsai, CS | 1 |
| Cui, XR; Jia, M; Li, RB; Wang, D; Yang, XH; Zhang, JD | 1 |
| Abdalla, A; Ahmed, S; Al Qasmi, M; Bachuwa, G; Bhatt, DL; Chahine, A; Hassan, M; Haykal, T; Kheiri, B; Osman, M; Swaid, B | 1 |
| Cho, YR; Choi, SY; Kim, MH; Min Lee, K; Park, TH; Sung Park, J; Yun, SC | 1 |
| Michaud, G; Zouk, AN | 1 |
| Foroutan, F; Guyatt, G; Hao, Q; O'Donnell, M; Siemieniuk, RA; Tampi, M | 1 |
| Banerjee, S; Baskar, A; Chauhan, S; Cui, Z; Dargham, BB; Sum-Ping, J; Tejani, I; Weideman, RA | 1 |
| Argyriou, C; Georgakarakos, EI; Georgiadis, GS; Koutsoumpelis, A; Tasopoulou, KM | 1 |
| Du, L; Du, X; Lai, J; Lai, Q; Tu, B; Wan, Z; Xu, B; Zhang, F; Zhao, M; Zhou, Y | 1 |
| Baber, U; Chieffo, A; Cohen, DJ; Colombo, A; Dangas, G; Gibson, CM; Henry, TD; Kini, A; Krucoff, M; Leisman, DE; Mehran, R; Moliterno, D; Pocock, SJ; Sartori, S; Steg, PG; Witzenbichler, B | 1 |
| Candela-Sanchez, E; Carrillo-Aleman, L; Esteve-Pastor, MA; Lozano, T; Macías, M; Marín, F; Martínez-Martínez, JG; Orenes-Piñero, E; Pernias-Escrig, V; Quintana-Giner, M; Rivera-Caravaca, JM; Ruiz-Nodar, JM; Sandín-Rollan, M; Veliz, A; Vicente-Ibarra, N | 1 |
| Claessen, BE; Collet, JP; Dangas, GD; Guedeney, P; Mehran, R; Ten Berg, J | 1 |
| Bolognese, L; Bovenzi, FM; Cacucci, M; Crimi, G; De Carlo, M; De Luca, G; De Servi, S; Elia, LR; Ferrario, M; Ferri, LA; Grosseto, D; Mandurino Mirizzi, A; Morici, N; Piatti, L; Piscione, F; Savonitto, S; Toso, A; Trimarco, B | 1 |
| Aquino, M; Baber, U; Baker, B; Bansilal, S; Chandrasekhar, J; Claessen, B; Defranco, A; Effron, M; Faggioni, M; Ge, Z; Henry, TD; Kapadia, S; Keller, S; Kini, A; Mehran, R; Muhlestein, B; Pocock, S; Poddar, KL; Rao, SV; Sartori, S; Snyder, C; Strauss, C; Toma, C; Vogel, B; Weintraub, W; Weiss, S | 1 |
| Benichou, J; Blin, P; Bonello, L; Dallongeville, J; Danchin, N; Droz, C; Dureau-Pournin, C; Falissard, B; Jové, J; Lassalle, R; Moore, N; Thomas-Delecourt, F | 1 |
| Aboyans, V; Anand, SS; Bauersachs, R; Bosch, J; Debus, ES; Eikelboom, JW; Mazzolai, L; Nehler, M; Nikol, S; Pastori, D; Patel, MR; Ricco, JB; Tanguay, JF; Verhamme, P; Violi, F | 1 |
| Abou-Ali, A; Fahmy, AI; Mekkawy, MA | 1 |
| Aradi, D; Filipiak, KJ; Gori, T; Gross, L; Hadamitzky, M; Huber, K; Huczek, Z; Jacobshagen, C; Klopotowski, M; Koltowski, L; Komosa, A; Kowara, M; Lesiak, M; Massberg, S; Opolski, G; Parma, R; Rymuza, B; Sibbing, D; Tomaniak, M; Witkowski, A | 1 |
| Cheng, CI; Chung, WJ; Hsueh, SK; Lee, CH; Lin, CJ; Tsai, TH | 1 |
| Åkerblom, A; Asselbergs, FW; Becker, RC; Bernlochner, I; Bopp, R; Byrne, RA; Erdmann, J; Eriksson, N; James, S; Kastrati, A; Katus, HA; Kessler, T; Koenig, W; Kofink, D; Laugwitz, KL; Mahmoodi, BK; Mayer, K; Munz, M; Nordio, F; O'Donoghue, ML; Rai, H; Sager, HB; Schunkert, H; Sibbing, D; Solakov, L; Storey, RF; Ten Berg, JM; Tragante, V; Wallentin, L; Wobst, J; Wolf, B | 1 |
| Ahn, CM; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, C; Kim, DS; Kim, JS; Ko, YG; Lee, H; Oh, SK; Park, J; Shin, DH | 1 |
| Klein, MD; Lee, CR; Martin, J; Rossi, JS; Stouffer, GA; Weck, KE; Williams, AK | 1 |
| Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| King, A; Levi, C; Madigan, J; Markus, HS; Norris, J | 1 |
| Bernlochner, I; Fiedler, KA; Goedel, A; Hoppmann, P; Kastrati, A; Laugwitz, KL; Maeng, M; Massberg, S; Mayer, K; Mehilli, J; Sarafoff, N; Schunkert, H; Schüpke, S; Sibbing, D; von Olshausen, G | 1 |
| Albertsson, P; Angerås, O; Dworeck, C; Erlinge, D; Haraldsson, I; Ioanes, D; Koul, S; Odenstedt, J; Omerovic, E; Persson, J; Petursson, P; Råmunddal, T; Redfors, B; Völz, S | 1 |
| Abtan, J; Bhatt, DL; Deliargyris, EN; Ducrocq, G; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Bilotta, F; Campo, G; Parodi, G; Pavasini, R; Serenelli, M; Tonet, E; Vitali, F | 1 |
| Hicks, GL | 1 |
| Chen, S; Cui, Y; Gong, Y; Hu, K; Jiang, J; Liu, Z; Mu, G; Wang, Z; Xiang, Q; Xie, Q; Zhou, S | 1 |
| Coons, JC; Huang, L; Iasella, CJ; Kreider, MS; Stevenson, JM | 1 |
| Baber, U; Baker, BA; Chandiramani, R; Chandrasekhar, J; Claessen, BE; Dangas, G; DeFranco, A; Effron, MB; Ge, Z; Henry, TD; Kapadia, S; Keller, S; Kini, AS; Li, SX; Mehran, R; Muhlestein, B; Pocock, S; Rao, SV; Sartori, S; Strauss, C; Toma, C; Weiss, S | 1 |
| Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kreuzer, J; Lip, GYH; Mauri, L; Miede, C; Montalescot, G; Nordaby, M; Oldgren, J; Ozkor, M; Steg, PG; Ten Berg, JM; Vardas, P | 1 |
| Fujimoto, Y; Fukushima, KI; Himi, T; Kitahara, H; Kobayashi, Y; Nakayama, T; Nameki, M; Shiba, T; Shikama, N; Tokimasa, S | 1 |
| Benatti, G; Bosi, D; Cattabiani, MA; Cozza, F; Guidorossi, A; Lina, D; Menozzi, A; Vignali, L | 1 |
| Angiolillo, DJ; Chan, KT; Del Aguila, M; Girotra, S; Han, Y; Huang, WC; Paek, D; Patti, G; Sibbing, D; Yakovlev, A | 1 |
| Azzalini, L; Li, L; Li, Y; Mao, Q; Tian, J; Tong, W; Xie, L; Zhao, X; Zheng, W; Zhou, D | 1 |
| Barsan, W; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY; Tillman, H | 1 |
| Liu, R; Nie, S; Qin, X; Shaqdan, A; Wang, C; Wang, X; Yuan, L; Zhao, X; Zheng, W | 1 |
| Carrillo-Alemán, L; Esteve-Pastor, MA; Lozano, T; Macías-Villanego, MJ; Marín, F; Martínez, J; Orenes-Piñero, E; Pernías-Escrig, V; Quintana-Giner, M; Rivera-Caravaca, JM; Ruiz-Nodar, JM; Sandín-Rollán, M; Tello-Montoliú, A; Veliz-Martínez, A; Vicente-Ibarra, N | 1 |
| Bo, WL; Feng, W; He, MJ; Li, S; Li, Y; Liu, GZ; Liu, YY; Shi, J; Sun, DH; Wang, WN; Wang, ZH; Zhang, CY; Zhang, S; Zheng, LQ | 1 |
| Coutts, SB; Hill, MD; Tse, D | 1 |
| Honda, T; Horie, K; Inoue, N; Isawa, T; Kato, S; Matsumoto, T; Mizutani, Y; Ootomo, T; Osai, N; Tada, N; Taguri, M | 1 |
| Ao, H; Liu, X | 1 |
| Belletrutti, PJ; Lamonaca, L; Repici, A | 1 |
| Honkoop, P; Sonneveld, MJ; Ter Borg, PCJ | 1 |
| Mogavero, G; Paggi, S; Radaelli, F | 1 |
| Chen, S; Gao, X; Ge, Z; Kong, X; Wang, F; Wang, Z; Zhang, J; Zuo, G | 1 |
| Åkerblom, A; Becker, RC; Cannon, CP; de Souza Brito, F; Himmelmann, A; James, SK; Katus, HA; Lopes, RD; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
| Hu, L; Jiang, HY; Li, ZZ; Xue, J; Yue, YH; Zhang, XG; Zhu, XQ | 1 |
| Audrone, V; Jurgaityte, J; Kupstyte-Kristapone, N; Lesauskaite, V; Norvilaite, R; Skipskis, V; Stuoka, M; Tamakauskas, V; Tatarunas, V | 1 |
| Abad-Santos, F; Bárcena, E; Belmonte, C; Caniego, JL; Eugene, AR; Koller, D; Ochoa, D; Romero-Palacián, D; Saiz-Rodríguez, M; Zubiaur, P | 1 |
| Bode, C; Cornel, JH; Gibson, CM; James, S; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Plotnikov, AN; Povsic, TJ; Rockhold, FW; Roe, MT; Steg, PG; Welsh, RC; White, J | 1 |
| Ding, J; Xu, GM; Yuan, J | 1 |
| Benedetto, U; Doble, B; Harris, J; Johnson, TW; Lasserson, D; Loke, Y; Mumford, A; Pithara, C; Pufulete, M; Redwood, S; Reeves, BC; Rogers, CA; Sterne, JAC; Wordsworth, S | 1 |
| Bergmeijer, TO; Breet, NJ; Deneer, VHM; Godschalk, TC; Hackeng, CM; Janssen, PWA; Kelder, JC; Qaderdan, K; Ten Berg, JM; Vos, GA | 1 |
| Asaumi, Y; Honda, S; Kimura, K; Kojima, S; Kosuge, M; Nishihira, K; Ogawa, H; Sakata, Y; Sumiyoshi, T; Suzuki, M; Takahashi, J; Takayama, M; Takegami, M; Yasuda, S | 1 |
| Hao, Z; Xiang, L; Yang, C; Zheng, L | 1 |
| Aradi, D; Dézsi, CA; Geisler, T; Gross, L; Hadamitzky, M; Holdt, L; Huber, K; Huczek, Z; Kiss, RG; Koltowski, L; Komócsi, A; Massberg, S; May, AE; Merkely, B; Mügge, A; Neumann, FJ; Rizas, KD; Ruzsa, Z; Sibbing, D; Trenk, D; Ungi, I; Zeiher, AM | 1 |
| Bae, JW; Cho, BR; Cho, DK; Cho, JH; Choi, JH; Choi, JW; Choi, SH; Choi, WG; Chun, WJ; Gwon, HC; Hahn, JY; Im, ES; Jang, WJ; Jeong, JO; Koh, YY; Lee, JM; Lee, JY; Lee, SH; Lee, SU; Lee, WS; Oh, JH; Oh, SK; Park, TK; Park, YH; Rha, SW; Song, YB; Yang, JH; Yoon, HJ; Yun, KH | 1 |
| Albers, GW; Barsan, WG; Cucchiara, BL; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Kleindorfer, DO; Lindblad, AS; Lutsep, HL; Palesch, YY; Pearson, C; Sethi, P; Vora, N; Zurita, KG | 1 |
| Cai, JJ; Lu, Y; Sun, X; Wang, B; Wu, JR; Wu, QY; Xu, P; Yin, SH; Yuan, H; Zhou, ML | 1 |
| Chan, FKL; Kyaw, MH | 1 |
| Atwell, TD; Kashyap, R; Kern, RM; Mullon, JJ; Nelson, DR; Patel, PP; Singh, S | 1 |
| Cho, MS; Kim, S; Kim, YJ; Nam, GB; Park, DW; Park, JJ; Park, K; Yun, JE | 1 |
| Cavallari, LH; Lee, CR | 1 |
| Adriaenssens, T; De Smet, BJ; Dewilde, WJ; Heestermans, AA; Herrman, JP; Kelder, JC; Oirbans, T; ten Berg, JM; Tijsen, JG; van 't Hof, AW; Verheugt, FW; Vis, MM; Vrolix, M | 1 |
| Abtan, J; Barthélémy, O; Beygui, F; Brugier, D; Cayla, G; Collet, JP; Kerneis, M; Martin, R; Montalescot, G; O'Connor, SA; Silvain, J; Vignalou, JB | 1 |
| Carrie, D; Cattan, S; Cayla, G; Eltchaninoff, H; Furber, A; Georges, JL; Helft, G; Le Feuvre, C; Leclercq, F; Metzger, JP; Prunier, F; Sebagh, L; Vicaut, E | 1 |
| Boyanova, D; Dandekar, T; Dittrich, M; Geiger, J; Hubertus, K; Mischnik, M; Philippi, N; Timmer, J; Wangorsch, G | 1 |
| Angiolillo, DJ; Bhatt, DL; Bramucci, E; Gallup, D; Généreux, P; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Liu, T; Mahaffey, KW; McLaurin, BT; Prats, J; Price, MJ; Radke, PW; Skerjanec, S; Spriggs, D; Steg, PG; Stone, GW; Tauth, J; Todd, M; Tousek, F; White, HD; Widimský, P | 1 |
| Arystanova, AZh; Balli, M; Batyraliev, TA; Fettser, DV; Kagliian, KÉ; Samko, AN; Serchelik, A; Sidorenko, BA; Tekin, K; Turkmen, S | 1 |
| Hossain, FS; Koch, L; Rambani, R; Ribee, H | 1 |
| Bhatt, DL | 3 |
| Chaput, CD; Patel, KV; Probe, RA; Wallace, HC | 1 |
| Dean, A; Novitskaya, E; Rene, C | 1 |
| Wang, H; Wang, WE; Wang, X; Zeng, C | 1 |
| Devys, JM; Osinski, D; Taylor, G; Thevenin, A | 1 |
| Bonzi, M; Fiorelli, EM | 1 |
| Oprea, AD; Popescu, WM | 1 |
| Bach, T; Brüning, M; Gabuev, A; Gross, AJ; Herrmann, TR; Netsch, C; Stoehrer, M | 1 |
| Berglund, U; Janzon, M; Nilsson, L | 1 |
| Ali, K; Cheng, J; Kram, B; Short, S; Taylor, S; Vasquez, D | 1 |
| de Lemos, JA; Diercks, DB; Hollander, JE; Holmes, DN; Kontos, MC; Mumma, BE; Saucedo, JF; Wiviott, S | 1 |
| Campo, G; De Palma, R; Guastaroba, P; Guiducci, V; Magnavacchi, P; Manari, A; Marino, M; Marzocchi, A; Saia, F; Sangiorgio, P; Taglieri, N; Tondi, S; Valgimigli, M; Varani, E | 1 |
| Wheatcroft, S | 1 |
| Conde, D; Elissamburu, P; Lalor, N; Rodriguez, L; Trivi, M | 1 |
| Abdel-Wahab, M; Akin, I; El-Mawardy, M; Geist, V; Richardt, G; Seivani, Y; Sulimov, DS; Toelg, R | 1 |
| Berger, F; Dähnert, I; Fontecave, S; Li, JS; Newburger, JW; Rakhit, A; Wessel, DL | 1 |
| Cui, L; Dong, Q; Jia, J; Johnston, SC; Li, H; Li, Y; Liu, L; Meng, X; Wang, C; Wang, D; Wang, Y; Wang, Z; Xia, H; Xu, A; Zeng, J; Zhao, X | 1 |
| Altamirano, AV; Callender, RA; Cattano, D; Mukalel, J; Pivalizza, EG | 1 |
| Hu, B; Huang, Y; Li, JY; Li, M; Mao, L; Xia, YP | 1 |
| Ardissino, D; Armstrong, PW; Aylward, PE; Bassand, JP; Boden, WE; Dalby, AJ; Fox, KA; Goodman, SG; Gottlieb, S; Hochman, JS; Martinez, F; McGuire, DK; Ohman, EM; Prabhakaran, D; Roe, MT; Stevens, SR; White, HD; Winters, KJ | 1 |
| Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L | 1 |
| Han, YL; Kang, J; Li, Y; Liang, ZY; Yan, CH; Zhang, XL | 1 |
| Cea Soriano, L; García Rodríguez, LA; Johansson, S | 1 |
| Adena, M; Aylward, P; Chim, L; De Abreu Lourenço, R; Liew, D | 1 |
| Biondi-Zoccai, G; Chatterjee, S; D'Ascenzo, F; DiNicolantonio, JJ; Niazi, AK; Tomek, A | 1 |
| Choi, DJ; Kang, HJ; Kim, HS; Kim, MA; Koo, BK; Lee, HY; Lee, S; Oh, BH; Park, KW | 1 |
| Chang, K; Choi, YS; Chung, WS; Her, SH; Jeon, DS; Kim, CJ; Kim, DB; Kim, HS; Kim, HY; Kim, PJ; Koh, YS; Lee, JM; Park, CS; Park, HJ; Park, MW; Seo, SM; Seung, KB; Shin, DI; Shin, JG; Yoo, KD | 1 |
| Darvish-Kazem, S; Douketis, JD; Gandhi, M; Marcucci, M | 1 |
| Post, S; Wilhelm, TJ | 1 |
| Alessi, MC; Beguin, S; Bonnet, JL; Camoin, L; Cuisset, T; Grosdidier, C; Lambert, M; Loosveld, M; Loundou, AD; Morange, PE; Pankert, M; Quilici, J | 1 |
| Gross, L; Massberg, S; Orban, M; Sibbing, D | 1 |
| Ahn, T; Choi, H; Choi, IS; Han, SH; Kang, WC; Lee, K; Moon, CI; Oh, PC; Shin, EK; Suh, SY | 1 |
| Alexopoulos, D; Angelidis, C; Deftereos, S; Goudevenos, JA; Hahalis, G; Hamilos, M; Kanakakis, I; Ntalas, IV; Parissis, H; Petousis, S; Sitafidis, G; Stefanadis, C; Vavuranakis, M; Xanthopoulou, I | 1 |
| Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G | 1 |
| Al Khudairy, A; Al-Hadeedi, O; Galvin, R; Quinlan, JF; Sayana, MK | 1 |
| Chang, SC; Chiang, FT; Hsin, HT; Hwang, JJ; Kuo, CT; Lai, WT; Li, AH; Lin, TH; Wang, CL | 1 |
| Cha, KS; Chae, IH; Hwang, KK; Jeon, HK; Jeong, MH; Kang, HJ; Kang, SH; Kim, HS; Kim, S; Koo, BK; Kwon, HM; Lee, SY; Moon, KW; Oh, JH; Park, BE; Park, JJ; Park, KW; Park, TH; Rhew, JY; Shin, ES; Yang, HM; Yoon, JH | 1 |
| Aradi, D; Bonello, L; Collet, JP; Gulba, D; Huber, K; Husted, S; Kiss, RG; Komócsi, A; Sibbing, D; Storey, RF; Trenk, D | 1 |
| Chen, Y; Huang, X; Tang, Y; Xie, Y; Zhang, Y | 1 |
| Curkovic, I; Egbring, M; Kullak-Ublick, GA | 1 |
| Harris, NS; Karon, BS; Kristensen, SR; Montalescot, G; Price, MJ | 1 |
| Holm, L; Loikas, D; Malmström, RE; Mejyr, S; Rydberg, DM; Schenck-Gustafsson, K; von Euler, M; Wettermark, B | 1 |
| Ahn, JM; Chae, JK; Cheong, SS; Choi, YS; Han, S; Hur, SH; Jang, JS; Jeon, DS; Jeong, MH; Kang, SJ; Kim, HS; Kim, KS; Kim, YH; Lee, BK; Lee, CW; Lee, K; Lee, NH; Lee, SG; Lee, SU; Lee, SW; Lim, DS; Nah, DY; Park, DW; Park, HS; Park, SJ; Park, SW; Rha, SW; Seong, IW; Seung, KB; Suh, IW; Yang, JY; Yoon, JH | 1 |
| Limbruno, U; Musumeci, G | 1 |
| Hasvold, P; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Sundström, A; Varenhorst, C | 1 |
| Donovan, JL; Kanaan, AO; Malloy, RJ; Silva, MA | 1 |
| Baek, YH; Cho, DS; Chung, WT; Han, SY; Kang, SH; Lee, SW; Park, IC | 1 |
| Damman, P; Eriksson, P; Erlinge, D; James, SK; Koul, S; Lagerqvist, B; Varenhorst, C | 1 |
| Abizaid, A; Abizaid, AS; Bhatt, DL; Botelho, RV; Castello, HJ; Costa, JR; Costa, RA; de Castro, JP; de Paula, JE; Devito, FS; Feres, F; Gusmão, M; King, SB; Labrunie, A; Leon, MB; Liu, M; Mangione, JA; Marin-Neto, JA; Meireles, GX; Negoita, M; Nicolela, EL; Perin, MA; Salvadori, D; Staico, R | 1 |
| Kichikawa, K; Nakagawa, H; Nakagawa, I; Nakase, H; Nishimura, F; Park, HS; Wada, T; Yamada, S | 1 |
| Guidoni, CM; Obreli-Neto, PR; Pereira, LR | 1 |
| Araki, T; Enomoto, Y; Hara, H; Hori, M; Iijima, R; Itaya, H; Ito, N; Nagashima, Y; Nakamura, M; Shiba, M; Sugi, K; Tokue, M; Utsunomiya, M; Yamazaki, K | 1 |
| Arntz, HR; Boudriot, E; Garlichs, C; Helms, TM; Hoffmann, S; Ince, H; Klingenheben, T; Schäfer, A; Silber, S; Weil, J; Zugck, C | 1 |
| Espinosa, EV; Karim, ZA; Khasawneh, FT; Lin, OA; Vemana, HP | 1 |
| Gislason, GH; Hansen, ML; Køber, L; Lamberts, M; Lassen, JF; Lip, GY; Mikkelsen, AP; Olesen, JB; Sørensen, R; Torp-Pedersen, C | 1 |
| Gilchrist, IC; Kunselman, AR; Lippe, CM; Reineck, EA | 1 |
| Aradi, D; Faluközy, J; Horváth, IG; Komócsi, A; Kónyi, A; Magyari, B; Pintér, T; Tornyos, A; Veress, G; Vorobcsuk, A | 1 |
| Alcocer, F; Combs, BR; Jordan, WD; Lowman, B; Mujib, M; Novak, Z; Passman, MA | 1 |
| Bohn, RL; Choudhry, NK; Daniel, GW; Gagne, JJ; Liu, J; Patrick, AR; Rassen, JA; Schneeweiss, S; Sridhar, G | 1 |
| Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ | 1 |
| Aoki, S; Hosomi, N; Ito, H; Kataoka, S; Kohriyama, T; Matsumoto, M; Mihara, C; Mukai, T; Nezu, T; Noda, K; Nomura, E; Ohtsuki, T; Ota, T; Takamatsu, K; Takeda, I; Torii, T; Yamada, A; Yokoyama, T | 1 |
| Ho, PM; Magid, D; Raebel, MA; Shetterly, S; Tsai, TT; Xu, S | 1 |
| Gao, RL; Han, YL; Jing, QM; Li, Y; Ma, YY; Wang, G; Wang, XZ; Xu, B; Zhang, L | 1 |
| Kleiman, NS | 1 |
| Sabouret, P; Taiel-Sartral, M | 1 |
| Delzor, F; Nanau, RM; Neuman, MG | 1 |
| Abbate, R; Antoniucci, D; Bellandi, B; Carrabba, N; Comito, V; De Luca, G; Gensini, GF; Marcucci, R; Migliorini, A; Parodi, G; Ramazzotti, RN; Valenti, R | 1 |
| Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D | 1 |
| Byrne, RA; Kastrati, A; Laugwitz, KL; Ndrepepa, G; Neumann, FJ; Pache, J; Pöhler, A; Richardt, G; Schulz, S | 1 |
| Bernlochner, I; Braun, S; Hausleiter, J; Kastrati, A; Laugwitz, KL; Massberg, S; Mayer, K; Morath, T; Schulz, S; Schunkert, H; Sibbing, D | 1 |
| Boothroyd, DB; Dudley, RA; Garber, AM; Hlatky, MA; Kazi, DS; Mell, MW; Moshkevich, S; Owens, DK; Rhee, C; Shah, RU | 1 |
| Cannon, CP; Cornel, JH; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Lindholm, D; Maya, J; Steg, PG; Stevens, SR; Storey, RF; Varenhorst, C; Wallentin, L | 1 |
| Delemos, J; Peng, SA; Peterson, ED; Roe, MT; Sherwood, MW; Wang, TY; Wiviott, SD | 1 |
| Biscaglia, S; Leonardi, S; Mehran, R; Parrinello, G; Rao, SV; Tebaldi, M; Valgimigli, M; Vranckx, P | 1 |
| Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H | 1 |
| Alexopoulos, D; Goudevenos, J; Xanthopoulou, I | 1 |
| Albert, F; Barbou, F; Belle, L; Berthier, R; Beygui, F; Brunel, P; Cazaux, P; Chassaing, S; Claudel, JP; Collet, JP; De Poli, F; Decomis, MP; Delarche, N; Dupouy, P; Köning, R; Montalescot, G; Rangé, G; Richard, P; Teiger, E; Thuaire, C; Yayehd, K | 1 |
| De Servi, S; Goedicke, J; Schirmer, A; Widimsky, P | 1 |
| Becker, RC; Emanuelsson, H; Hiatt, WR; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Patel, MR; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
| Angiolillo, DJ; Antonelli, M; Biglioli, F; Boni, L; Bovenzi, F; Bozzani, A; Bramucci, E; Buffoli, F; Capodanno, D; Castiglioni, B; Comel, A; Cremonesi, A; Crescini, C; D'Angelo, F; De Servi, S; Dionigi, G; Droghetti, A; Francetti, L; Gadda, F; Guagliumi, G; Lettieri, C; Lettino, M; Lorini, L; Musumeci, G; Parolari, A; Piccaluga, E; Ravelli, P; Rossini, R; Salvi, L; Savonitto, S; Scarone, P; Setacci, C; Staurenghi, G; Trabattoni, D; Valdatta, L; Visconti, LO | 1 |
| Han, H; Li, Y; Liang, J; Liu, W; Liu, Y; Shi, D; Wang, Z; Yang, L; Zhang, L; Zhao, Y; Zhou, Y | 1 |
| Barbato, E; Boland, J; Chenu, P; Claeys, MJ; Cuisset, T; Dens, J; Gach, O; Legrand, V; Magne, J; Martinez, C; Vrolix, M; Wijns, W | 1 |
| Izuhara, C; Takayama, S; Takeuchi, K | 1 |
| Delle Karth, G; Siller-Matula, JM | 1 |
| Costigan, T; Iqbal, K; Lopez-Sendon, J; Ramos, Y; Widimsky, P; Wilcox, R | 1 |
| Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z | 2 |
| Abendschein, D; Broekman, MJ; Chen, R; Drosopoulos, JH; Jeong, SS; Marcus, AJ; Moeckel, D; Nguyen, A; Robson, SC; Sun, X | 1 |
| Chen, S; He, L; Li, H; Li, M; Li, Y; Peng, Y; Shen, Q; Tang, Y | 1 |
| Blicher, TM; Hommel, K; Kamper, AL; Kristensen, SL; Madsen, M; Olesen, JB; Torp-Pedersen, C | 1 |
| Anderson, DC; Benavente, OR; Coffey, CS; Connolly, SJ; Hart, RG; Palacio, S; Pearce, LA; Sharma, M | 1 |
| Baradat, C; Bolognese, L; Cantor, WJ; Cequier, A; Chettibi, M; Collet, JP; Ecollan, P; Goodman, SG; Hamm, CW; Hammett, CJ; Heutz, WM; Huber, K; Janzon, M; Lapostolle, F; Lassen, JF; Licour, M; Merkely, B; Montalescot, G; Silvain, J; Stibbe, O; Storey, RF; Swahn, E; Tsatsaris, A; van 't Hof, AW; Vicaut, E; Willems, FF; Zeymer, U | 1 |
| Van de Werf, F | 1 |
| Clemmensen, P; Danchin, N; Goedicke, J; Goldstein, P; Grieco, N; Ince, H; Ramos, Y; Schmitt, J | 1 |
| Bernlochner, I; Braun, S; Hadamitzky, M; Hausleiter, J; Hoppmann, P; Kastrati, A; Laugwitz, KL; Massberg, S; Mayer, K; Mehilli, J; Morath, T; Orban, M; Schulz, S; Schunkert, H; Sibbing, D; Tiroch, K | 1 |
| Chen, J; Gao, RL; Gao, Z; Ma, YL; Meng, XM; Song, L; Tang, XF; Wang, J; Wu, Y; Xu, B; Yao, Y; Yuan, JQ; Zhang, JH; Zhang, Y | 1 |
| Gislason, GH; Hansen, PR; Kristensen, KE; Markowitz, JS; Rasmussen, HB; Torp-Pedersen, C; Wang, X; Zhu, HJ | 1 |
| Gawaz, M; Huber, K; Kristensen, SD; Schrör, K; Siller-Matula, JM; Storey, RF; Trenk, D | 1 |
| Thompson, PL; Verheugt, FW | 1 |
| Aryal, MR; Badal, M; Fortuin, FD; Hakim, F; Karmacharya, P; Mahmood, M; Mainali, NR; Pandit, A; Pathak, R; Ukaigwe, A | 1 |
| Becker, RC; Cannon, CP; Ducrocq, G; Harrington, RA; Held, C; Himmelmann, A; Lassila, R; Schulte, PJ; Sorbets, E; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Almendro-Delia, M; Blanco Ponce, E; Caballero-Garcia, A; Cruz-Fernandez, MJ; Garcia-Rubira, JC; Gomez-Domínguez, R; Gonzalez-Matos, C; Hidalgo-Urbano, R; Lobo-Gonzalez, M | 1 |
| Angiolillo, DJ; Calabria, P; Capodanno, D; Gavazzi, A; Guagliumi, G; Inashvili, A; Lettieri, C; Limbruno, U; Musumeci, G; Romano, M; Rossini, R; Russo, N; Senni, M; Sirbu, V; Tarantini, G; Valsecchi, O | 1 |
| Blevins, A; El Accaoui, R; Karrowni, W; Vyas, A | 1 |
| Bliden, KP; Gesheff, M; Gurbel, PA; Liu, F; Tantry, US | 1 |
| Ikeda, Y; Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H | 1 |
| Bacchi-Reggiani, ML; Bolognese, L; Briguori, C; Calabrò, P; Carosio, G; Di Pasquale, G; Galvani, M; Imperadore, F; La Vecchia, L; Maggioni, AP; Palmieri, C; Rizzi, A; Rubboli, A; Saia, F; Sangiorgi, GM; Sciahbasi, A; Steffanon, L; Steffenino, G; Valgimigli, M | 1 |
| Braunwald, E; Cohen, DJ; Cutlip, DE; Dauerman, HL; Driscoll-Shempp, P; Garratt, KN; Hermiller, J; Holmes, DR; Kandzari, DE; Kereiakes, DJ; Krucoff, MW; Lee, DP; Massaro, JM; Mauri, L; Normand, SL; Pow, TK; Rinaldi, MJ; Simon, DI; Steg, PG; Ver Lee, P; Wiviott, SD; Yeh, RW | 1 |
| Alber, H; Bonetti, PO; Eberli, F; Erne, P; Galatius, S; Jeger, RV; Kaiser, CA; Pedrazzini, G; Pfisterer, ME; Rickli, H; Sørensen, R; von Felten, S | 1 |
| Armstrong, PW; Aylward, PE; Chen, E; Cornel, JH; Harrington, RA; Held, C; Huang, Z; Jennings, LK; Lokhnygina, Y; Mahaffey, KW; Moliterno, DJ; Strony, J; Tricoci, P; Van de Werf, F; Wallentin, L; White, HD | 1 |
| Armengaud, J; Barragan, P; Benamer, H; Berland, J; Blanchard, D; Boschat, J; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Druelles, P; Dupouy, P; Endresen, K; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J | 1 |
| Geersing, GJ; Kappelle, LJ; Verheugt, FW | 1 |
| Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H | 1 |
| González-Pérez, A; Johansson, S; Nagy, P; Rodríguez, LA; Sáez, ME | 1 |
| Chen, L; Fu, C; Lu, W; Ma, G; Wang, Y; Yao, Y; Zuo, P | 1 |
| Andell, P; Björnsson, S; Erlinge, D; Götberg, M; Harnek, J; Koul, S; Martinsson, A; Norström, E; Scherstén, F; Smith, JG | 1 |
| Cohen, DJ; Généreux, P; Hahn, R; Kodali, SK; Leon, MB; Mack, M; Parvataneni, R; Rodes-Cabau, J; Webb, JG; Xu, K; Yadav, M | 1 |
| Kazi, DS | 1 |
| Bolanos, MD; Ferraris, VA | 1 |
| Li, J; Li, Y; Shang, X; Wang, C; Yan, C; Zhang, L; Zhang, Q; Zheng, M | 1 |
| Abdel-Wahab, M; Adriaenssens, T; Angiolillo, DJ; Bernlochner, I; Byrne, RA; Desmet, W; Feuchtenberger, A; Fischer, M; Han, Y; Hengstenberg, C; Ibrahim, T; Jacobshagen, C; Janssen, PW; Kastrati, A; Kufner, S; Laugwitz, KL; Li, Y; Maeng, M; Mehilli, J; Morath, T; Mudra, H; Neumann, FJ; Rifatov, N; Schömig, A; Schulz-Schüpke, S; Schunkert, H; Seyfarth, M; Ten Berg, JM; Tiroch, K; Tölg, R; Valina, C; von Hodenberg, E; von Merzljak, B; Wöhrle, J; Zrenner, B | 1 |
| Cohen, DJ; Galper, BZ; Garg, P; Mauri, L; Yeh, RW | 1 |
| Agnihotri, A; Aranki, S; Cannon, CP; Guo, J; Kumar, A; Maree, AO; McLean, DS; Reed, GW; Rosenfield, K; Shekar, P | 1 |
| Akinosoglou, K; Alexopoulos, D; Barampoutis, N; Hahalis, G; Karvounis, H; Koniari, I; Panagiotidis, T; Patsilinakos, S; Perperis, A; Xanthopoulou, I; Ziakas, A | 1 |
| Bultas, J | 1 |
| Cutlip, DE; Dauerman, HL; Kereiakes, DJ; Mauri, L; Stoler, R | 1 |
| Bhatt, DL; Cortese, B; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Liu, T; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD; Wilensky, M | 1 |
| Ando, G; Calabro, P; Costa, F; Leonardi, S; Moscarella, E; Oreto, G; Valgimigli, M; Vranckx, P; Zijlstra, F | 1 |
| Kereiakes, DJ; Mauri, L; Yeh, RW | 1 |
| Airoldi, F; Briguori, C; Campo, G; Colangelo, S; de Cesare, N; Dellavalle, A; Ferlini, M; Gabriel, HM; Garbo, R; Liistro, F; McFadden, E; Meliga, E; Menozzi, A; Patialiakas, A; Roffi, M; Tebaldi, M; Testa, L; Thury, A; Tondi, S; Ungi, I; Valgimigli, M; Vranckx, P | 1 |
| Kandzari, DE | 1 |
| Bourdakis, A; Charmpas, C; Christogiannis, Z; Dimoulis, N; Draganigos, A; Efthimiadis, I; Giannakoulas, G; Giatrakos, I; Giogiakas, V; Goudevenos, JA; Goumas, G; Hatziathanasiou, G; Kalantzi, KI; Kazakos, E; Kipouridis, N; Konstantinou, S; Nikolopoulos, D; Ntalas, IV; Panagiotakos, DB; Peltekis, L; Prokopakis, N; Sinteles, I; Stroumbis, CS; Terzoudi, K; Thoma, M; Tselepis, AD; Tsilias, K; Tsoumani, ME; Vakalis, JN; Vardakis, K; Vasilakopoulos, V; Vemmos, KN; Voukelatou, M; Xaraktsis, I | 1 |
| Auer, R; Carballo, D; Gencer, B; Heg, D; Jaguszewski, M; Jakob, P; Jüni, P; Klingenberg, R; Landmesser, U; Lüscher, TF; Mach, F; Maier, W; Matter, CM; Meier, B; Nanchen, D; Räber, L; Rodondi, N; Roffi, M; Stähli, BE; Stefanini, GG; Templin, C; Vogt, P; Windecker, S | 1 |
| Ballocca, F; Bangalore, S; Barbero, U; Capodanno, D; Cerrato, E; Conrotto, F; D'Ascenzo, F; Dewilde, W; DiNicolantonio, J; Fernández, S; Gaita, F; Giordana, F; Grossomarra, W; Lamberts, M; Meier, P; Meynet, I; Moretti, C; Omedè, P; Persson, J; Quadri, G; Reed, M; Rubboli, A; Taha, S; Zoccai, G | 1 |
| Adams, G; Ansel, G; Baumgartner, I; Duggal, A; Grosso, M; Jaff, M; Mercuri, M; Minar, E; Moll, FL; Nwachuku, CE; Shi, M; Tangelder, MJ | 1 |
| Angoulvant, D; Bejan-Angoulvant, T; Fauchier, L; Ivanes, F; Lip, GYH; Saint Etienne, C; Villejoubert, O | 1 |
| Cai, TQ; Chintala, M; Forrest, M; Handt, L; Michener, MS; Raubertas, R; Seiffert, D; Sitko, G; Wickham, LA | 1 |
| Gurbel, PA; Liu, F; Tantry, US | 1 |
| Chen, YF; Lin, CH; Lin, L; Lin, WW; Wang, CL; Wang, H | 1 |
| Chae, IH; Cho, YS; Choi, DJ; Kim, HS; Kim, SH; Lee, SA; Park, JJ; Suh, JW; Yoon, CH; Youn, TJ | 1 |
| Chen, K; Chu, H; Jia, M; Li, L; Li, Z | 1 |
| Angiolillo, DJ; Aradi, D; Bonello, L; Cuisset, T; Freynhofer, MK; Gurbel, PA; Huber, K; Janssen, P; Kastrati, A; Kirtane, A; Mangiacapra, F; Marcucci, R; Morel, O; Palmerini, T; Patti, G; Price, MJ; Sibbing, D; Siller-Matula, JM; Stone, GW; Tantry, US; ten Berg, J; Valgimigli, M | 1 |
| Adamo, M; Costa, F; Garcia-Garcia, HM; Leonardi, S; Navarese, EP; Valgimigli, M; Vranckx, P | 1 |
| Aledort, L; Binder, A | 1 |
| Baan, J; Barbanti, M; Blanchard, D; Delewi, R; Durand, E; Eltchaninoff, H; Hassell, ME; Hildick-Smith, D; Kikkert, WJ; Piek, JJ; Poliacikova, P; Rubino, P; Sharma, S; Stabile, E; Tamburino, C; Ussia, GP; Wiegerinck, EM | 1 |
| Barbieri, L; De Luca, G; Suryapranata, H; Verdoia, M | 1 |
| Bono, J; Nandi, S; Shubert, D | 1 |
| Calabrò, P; Rubboli, A; Saia, F; Sciahbasi, A | 1 |
| Gao, F; Liu, XL; Shen, H; Wang, ZJ; Yang, SW; Zhou, YJ | 1 |
| Filipiak, KJ; Grabowski, M; Grygier, M; Huczek, Z; Kochman, J; Lesiak, M; Mazurek, T; Ochala, A; Olasinska-Wisniewska, A; Opolski, G; Parma, R; Scislo, P; Sibbing, D; Wilimski, R | 1 |
| Ajani, AE; Andrianopoulos, N; Brennan, A; Clark, DJ; Duffy, SJ; Eccleston, D; Farouque, O; Reid, C; Yudi, MB | 1 |
| Becker, RC; Clare, RM; Gao, R; Held, C; Himmelmann, A; James, SK; Kang, HJ; Lim, ST; Santoso, A; Wallentin, L; Yu, CM | 1 |
| Chen, HB; Huang, BY; Liang, HB; Liu, XW; Xiu, J; Zhang, XL; Zhang, XY | 1 |
| Amerena, J; Aylward, PE; Gunasekara, A; Harding, SA; Mussap, CJ; Schrale, R; Van Gaal, WJ | 1 |
| Serebruany, VL | 6 |
| Fletcher, J; Gruen, R; Koh, TL; Ong, WL; Royce, P | 1 |
| Folch, E; Oh, S; Peters, JI | 1 |
| Braunitzer, G; Dézsi, BB; Dézsi, CA; Hangyási, DB; Koritsánszky, L | 1 |
| Auer, R; Baumbach, A; Carballo, D; Engstrøm, T; Gencer, B; Heg, D; Jüni, P; Kelbæk, H; Klingenberg, R; Lüscher, TF; Mach, F; Matter, CM; Meier, B; Moschovitis, A; Ostojic, M; Räber, L; Rodondi, N; Roffi, M; Stefanini, GG; Tüller, D; von Birgelen, C; Windecker, S; Zanchin, T | 1 |
| Guimarães, PO; Tricoci, P | 1 |
| Armstrong, PW; Clemmensen, P; Cornel, JH; Fox, KA; Hafley, G; Melloni, C; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; White, HD; Zamoryakhin, D | 1 |
| Afzal, S; Balzer, J; Kelm, M; Polzin, A; Rassaf, T; Zeus, T | 1 |
| Chen, J; Ding, L; Hong, H; Huang, X; Ma, H; Tan, S; Xiao, X; Xu, R; Yang, S; Yu, S; Zhang, Z | 1 |
| Khatri, S; Pierce, T | 1 |
| Grove, EL; Kristensen, SD; Thomas, MR; Würtz, M | 1 |
| Gomi, M; Hashimoto, T; Ishibashi, R; Ishii, A; Kira, J; Kouge, J; Matsumoto, S; Miyata, H; Nagata, I; Nakahara, I; Nishi, H; Ohta, T; Okata, T; Sadamasa, N; Saka, M; Sonoda, K; Watanabe, S | 1 |
| Conde, D; Cura, F; Elissamburu, P; Filipini, E; Lalor, N; Nau, G; Rodríguez, L; Trivi, M | 1 |
| Emanuelsson, H; Goto, S; Huang, CH; Kimura, T; Park, SJ | 1 |
| Arif, SA; D'Souza, J; Gil, M; Gim, S | 1 |
| Bhatt, DL; Blankenship, JC; Deliargyris, EN; Généreux, P; Gibson, CM; Gutierrez, JA; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Ding, SL; Fang, D; Fang, Q; Gan, XD; Li, KY; Peng, S; Wan, J; Wei, BZ | 1 |
| Akins, S; Bhal, V; Dixon, M; Herr, MJ; Hord, E; Jennings, LK; Kotha, J; Seiffert, D; White, MM | 1 |
| Bundhun, PK; Chen, MH; Qin, T | 1 |
| Andell, P; Cannon, CP; Cyr, DD; Erlinge, D; Himmelmann, A; Husted, S; James, SK; Keltai, M; Koul, S; Santoso, A; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Chandrasekhar, J; Froeschl, M; Hibbert, B; May, ML; Mehran, R; So, D | 1 |
| Kim, MH; Pokov, AN; Serebruany, VL; Tomek, A | 1 |
| Auffret, V; Avez, B; Bacquelin, R; Bedossa, M; Boulanger, B; Boulmier, D; Castellant, P; Coudert, I; Druelles, P; Filippi, E; Gilard, M; Hacot, JP; Le Breton, H; Le Guellec, M; Leurent, G; Moquet, B; Oger, E; Rialan, A; Rouault, G; Treuil, J | 1 |
| Giusti, B; Grifoni, E; Marcucci, R | 1 |
| Ikeda, Y; Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Tanaka, Y; Yokoi, H | 1 |
| Dhillon, SS; Harris, K; Karnyski, J; Kumar, A | 1 |
| Dannenberg, L; Kelm, M; Polzin, A; Sophia Popp, V; Zeus, T | 1 |
| Ahn, MS; Ahn, SG; Choi, E; Hung, OY; Kim, J; Kim, JY; Lee, JH; Lee, JW; Lee, SH; Samady, H; Yoo, BS; Yoo, SY; Yoon, J; Youn, YJ | 1 |
| Dobesh, PP; Oliphant, CS; Trevarrow, BJ | 1 |
| Armstrong, PW; Beaven, AW; Blackwell, KL; Cyr, DD; Eckart, D; Fox, KA; Houterloot, L; Morse, MA; Ohman, EM; Onken, JE; Prabhakaran, D; Ready, NE; Roe, MT; Schulte, PJ; Strickler, JH; White, HD; Winters, KJ; Wiviott, SD; Zafar, SY; Zamoryakhin, D | 1 |
| Andò, G; Ariotti, S; Costa, F; De Palma, R; Giatti, S; Guastaroba, P; Moscarella, E; Oreto, G; Tijssen, JG; Valgimigli, M; Zijlstra, F | 1 |
| Carlson, ML; Driscoll, CL; Haynes, DS; Hunter, JB; Sweeney, AD; Tombers, NM; Wanna, GB | 1 |
| Huang, F; Liu, Y; Wu, Q; Yang, J; Zhang, J; Zhou, Y; Zhu, E; Zou, Y | 1 |
| Baker, BA; Cohen, DJ; Effron, M; Jackson, LR; Ju, C; Messenger, JC; Peterson, ED; Stone, GW; Wang, TY; Zettler, M | 1 |
| Bai, J; Han, Q; Huang, XH; Liu, C; Shen, DL; Wang, B; Zhang, JY | 1 |
| Brodie, BR; Cox, DA; Duffy, PL; Généreux, P; Henry, TD; Kirtane, AJ; Maehara, A; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Parikh, PB; Parvataneni, R; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B; Xu, K | 1 |
| Abunassar, J; Chong, AY; Dick, A; Froeschl, M; Fu, A; Glover, C; Hibbert, B; Labinaz, M; Le May, M; Malhotra, N; Marquis, JF; Singh, K; So, DY | 1 |
| Cavallari, I; De Luca, L; Patti, G; Ricottini, E | 1 |
| Ahn, JH; Choi, YM; Gurbel, PA; Hwang, JY; Hwang, SJ; Jeong, YH; Kim, KH; Koh, JS; Kwak, CH; Kwon, TJ; Park, JR; Park, Y; Smith, SC; Tantry, US | 1 |
| Bauters, C; Caudmont, S; Ketelers, R; Lamblin, N; Lemaire, N; Lemesle, G; Meurice, T; Philias, A; Schurtz, G; Tricot, O | 1 |
| Bernat, I; Dragounová, E; Hromádka, M; Jirouš, Š; Pechman, V; Rokyta, R; Seidlerová, J; Tůmová, P | 1 |
| Gao, P; Hu, Y; Qian, J; Tang, X; Yang, C | 1 |
| Parker, WA; Storey, RF | 1 |
| Ajani, AE; Andrianopoulos, N; Brennan, A; Clark, DJ; Duffy, SJ; Eccleston, D; Farouque, O; Lefkovits, J; Oqueli, E; Ramchand, J; Reid, CM; Yip, T; Yudi, MB | 1 |
| Choi, SY; Guo, LZ; Jin, E; Kim, MH; Kim, TH; Park, JS; Serebruany, VL; Shim, CH | 1 |
| Bae, SK; Kim, GJ; Kim, JH; Lee, J; Lee, S; Lim, HS; Noh, Y; Oh, E; Shin, S | 1 |
| Conrad, MF; Cronenwett, JL; Goodney, PP; Jones, DW; Nolan, BW; Powell, RJ; Rzucidlo, EM; Stone, DH | 1 |
| Guo, ZN; Jin, H; Niu, PP; Xing, YQ; Yang, Y | 1 |
| Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Yang, X; Zhang, C; Zhao, X | 1 |
| Jing, Q; Li, R; Liu, P; Liu, Y; Tang, X; Wang, Q; Zhang, P | 1 |
| Armstrong, PW; Boden, WE; Chin, CT; Corbalán, R; Dalby, AJ; Fox, KA; Gottlieb, S; Leiva-Pons, JL; Neely, B; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Schiele, F; White, HD; Winters, KJ | 1 |
| Kataoka, Y; Nakagawa, A; Otoshi, T; Otsuka, K; Tomii, K | 1 |
| de la Salle, H; El Mdawar, MB; Gachet, C; Hechler, B; Heim, V; Magnenat, S; Maître, B | 1 |
| Ariti, C; Baber, U; Chieffo, A; Cohen, DJ; Colombo, A; Dangas, G; Gibson, CM; Giustino, G; Henry, TD; Kini, AS; Kirtane, AJ; Krucoff, MW; Litherland, C; Mehran, R; Moliterno, DJ; Pocock, S; Sartori, S; Steg, PG; Stone, GW; Weisz, G; Witzenbichler, B | 1 |
| Benezet, JF; Cayla, G; Cornillet, L; de La Coussaye, JE; Fabbro-Peray, P; Lattuca, B; Leclercq, F; Ledermann, B; Macia, JC; Messner-Pellenc, P; Schmutz, L | 1 |
| Bourdakis, A; Charmpas, C; Christogiannis, Z; Dimoulis, N; Draganigos, A; Efthimiadis, I; Giannakoulas, G; Giatrakos, I; Giogiakas, V; Goudevenos, JA; Goumas, G; Hatziathanasiou, G; Kalantzi, KI; Kazakos, E; Kipouridis, N; Konstantinou, S; Milionis, H; Nikolopoulos, D; Ntalas, IV; Panagiotakos, DB; Peltekis, L; Prokopakis, N; Sinteles, I; Stroumbis, C; Terzoudi, K; Thoma, M; Tselepis, AD; Tsilias, K; Tsoumani, ME; Vakalis, I; Vardakis, K; Vasilakopoulos, V; Vemmos, K; Voukelatou, M; Xaraktsis, I | 1 |
| Barry, AR; Basaraba, JE | 1 |
| Aquino, M; Baber, U; Chandrasekhar, J; Dangas, G; Kini, A; Mehran, R; Sartori, S; Sharma, S; Shlofmitz, RA; Skurk, C; Witzenbichler, B; Yu, J | 1 |
| Fu, ZH; Han, BS; Li, DY; Ren, YH; Song, YQ; Xue, Q; Yi, J; Zhou, CF | 1 |
| Ahn, TH; Ahn, Y; Cha, KS; Chae, JK; Chae, SC; Choi, DJ; Gwon, HC; Hwang, KK; Jeong, MH; Kim, HS; Kim, KB; Kim, YJ; Oh, DJ; Oh, SK; Park, KH; Seong, IW; Seung, KB | 1 |
| Bekbossynova, M; Kim, MH; Pya, Y; Serebruany, VL; Tomek, A | 1 |
| Baber, U; Brodie, BR; Cox, DA; Dangas, GD; Duffy, PL; Francese, DP; Généreux, P; Giustino, G; Gurbel, PA; Henry, TD; Kirtane, AJ; Maehara, A; Mazzaferri, EL; Mehran, R; Metzger, C; Neumann, FJ; Ozan, O; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B | 1 |
| Cong, H; Li, X; Li, Z; Wang, Z; Zhang, F; Zhang, L | 1 |
| Du, M; Ma, G; Shi, Y; Zhang, D | 1 |
| Arora, V; Kapoor, D; Omar, A; Pillai, A; Poommipanit, P; Shah, RR; Zhao, J | 1 |
| Choi, D; Her, AY; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Shin, DH | 1 |
| Agarwal, S; Barakat, AF; Chaudhury, P; Ellis, SG; Faza, NN; Kapadia, SR; Mentias, A; Murat Tuzcu, E; Parashar, A; Wayangankar, S | 1 |
| Bash, LD; Davies, G; Du, M; Oguz, M; Ozer-Stillman, I; Whalen, JD | 1 |
| Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD | 1 |
| Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; Vaduganathan, M; White, HD | 1 |
| Gao, P; Hu, YH; Tang, X; Wei, CL; Yang, C; Zhang, YQ | 1 |
| Tokgözoğlu, L | 1 |
| Göktekin, O; Yamaç, AH | 1 |
| French, JK; Gupta, R; Holmes, LE; Juergens, CP; Luu, J; Rajendran, S | 1 |
| Guo, L; Han, Y; Li, Y; Liu, X; Wang, X; Wang, Y; Xu, K; Zang, H; Zhao, W | 1 |
| Johnston, SC; Li, H; Lin, J; Lin, Y; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Xu, J; Zhao, X | 1 |
| Brener, SJ; Brodie, BR; Cox, DA; Duffy, PL; Henry, TD; Kirtane, AJ; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Parvataneni, R; Rinaldi, MJ; Stone, GW; Stuckey, TD; Witzenbichler, B | 1 |
| Abu-Assi, E; Alexopoulos, D; Alfonso, E; Ariza-Sole, A; Chen, Y; Correia, L; D'Ascenzo, F; Fan, JY; Filipiak, K; Fujii, T; Gaita, F; Garay, A; García-Acuña, JM; Giordana, F; González-Juanatey, JR; Henriques, JP; Huczek, Z; Ikari, Y; Kalpak, O; Kawaji, T; Kawashiri, MA; Kedev, S; Kikkert, WJ; Kowara, M; Liebetrau, C; Möllmann, H; Montefusco, A; Moretti, C; Nakahayshi, T; Nie, SP; Nuñez-Gil, I; Osman, N; Raposeiras-Roubín, S; Sakata, K; Saucedo, J; Scarano, S; Shiomi, H; Song, X; Southern, D; Terol, B; Wang, X; Wilton, SB; Xanthopoulou, I; Yamagishi, M; Yan, Y; Zhang, D | 1 |
| Aonuma, K; Gosho, M; Hoshi, T; Nogami, A; Sato, A | 1 |
| Dong, T; Jin, L; Liao, H; Yan, H; Yu, H; Zhang, B; Zou, X | 1 |
| Gearman, DJ; Ingimarsson, JP; Krambeck, AE; Scales, J; Sharma, V; Westerman, ME | 1 |
| Armstrong, PW; Bhatt, DL; Corbalán, R; Cyr, DD; Fox, KA; Jackson, LR; Lopes, RD; Lüscher, TF; Magnus Ohman, E; Martinez, F; Neely, ML; Piccini, JP; Prabhakaran, D; Roe, MT; White, HD; Winters, KJ | 1 |
| Abouzgheib, W; Bartter, T; Boujaoude, Z; Meena, N; Patolia, S; Rosenheck, J | 1 |
| Chang, CY; Chen, YC; Lin, SY; Tsai, CH; Tsai, JR | 1 |
| Barbieri, L; Brouwer, MA; Camaro, C; Damen, SA; de Boer, MJ; De Luca, G; Kedhi, E; Lee, SW; Ligtenberg, E; Rognoni, A; Suryapranata, H; van T Hof, AW; Verdoia, M | 1 |
| Ariotti, S; Baldo, A; Esposito, G; Franzone, A; Gargiulo, G; Magnani, G; Marino, M; Piccolo, R; Santucci, A; Valgimigli, M; Windecker, S | 1 |
| Bhat, A; Pang, M; Wu, Y; Zhang, H; Zhang, Y; Zhao, Y; Zhuang, K | 1 |
| Lee, JH; Park, TK; Shin, SJ | 1 |
| Adriaenssens, T; Bernlochner, I; Byrne, RA; Fischer, M; Han, Y; Ibrahim, T; Jacobshagen, C; Kastrati, A; Kufner, S; Lahmann, AL; Laugwitz, KL; Lohaus, R; Maeng, M; Mayer, K; Mehilli, J; Michel, J; Morath, T; Neumann, FJ; Schulz-Schüpke, S; Schunkert, H; Seyfarth, M; Ten Berg, JM; Tölg, R; Wöhrle, J; Wolk, A; Zrenner, B | 1 |
| Ge, H; He, H; Jiang, Y; Jin, H; Li, Y; Liu, P; Lv, X; Ren, H | 1 |
| Wang, CH; Wang, YQ; Zhang, JH | 1 |
| Aquino, M; Ariti, C; Baber, U; Bansilal, S; Chandrasekhar, J; Chieffo, A; Cohen, D; Colombo, A; Dangas, G; Faggioni, M; Farhan, S; Gabriel Steg, P; Giustino, G; Henry, T; Kini, A; Mehran, R; Michael Gibson, C; Moliterno, D; Pocock, S; Saporito, R; Sartori, S; Stuckey, T; Vogel, B; Witzenbichler, B | 1 |
| Aradi, D; Baylacher, M; Dézsi, CA; Felix, SB; Geisler, T; Gori, T; Gross, L; Hadamitzky, M; Hausleiter, J; Holdt, L; Horstkotte, J; Huber, K; Huczek, Z; Ince, H; Jacobshagen, C; Kiss, RG; Koltowski, L; Komócsi, A; Löw, A; Malek, L; Massberg, S; Mehilli, J; Merkely, B; Mudra, H; Neumann, FJ; Orban, M; Parma, R; Rieber, J; Schwinger, R; Sibbing, D; Teupser, D; Thalmeier, A; Trenk, D | 1 |
| Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Aribogan, A; Bali, C; Ergenoglu, P; Ozmete, O; Suner, HI | 1 |
| Gershlick, AH; Gunarathne, A; Hussain, S | 1 |
| Barbieri, L; De Luca, G; Schaffer, A; Suryapranata, H; Verdoia, M | 1 |
| Bernick, J; Chong, AY; Dick, A; Froeschl, M; Glover, C; Hibbert, B; Labinaz, M; Le May, MR; Lugomirski, P; Marquis, JF; Maze, R; Pourdjabbar, A; Ramirez, FD; Simard, T; So, DY; Wells, G | 1 |
| Baker, BA; Cohen, DJ; Effron, MB; Faries, DE; Jackson, LR; Ju, C; McCoy, LA; Messenger, JC; Peterson, ED; Wang, TY; Zettler, M | 1 |
| Ardissino, D; Armstrong, PW; Bhatt, DL; Cornel, JH; Erlinge, D; Fox, KA; Gurbel, PA; Jakubowski, JA; Neely, B; Ohman, EM; Prabhakaran, D; Roe, MT; Tantry, US; White, HD | 1 |
| Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A | 1 |
| Cheema, AN; Cieza, T; Dehghani, P; Déry, JP; Fisher, HN; Goodman, SG; Henderson, MA; Kokis, A; Lavi, S; Lutchmedial, S; Mehta, SR; Siega, AJ; Welsh, RC; Wong, BY; Zhang, X; Zhu, YE | 1 |
| Bode, C; Gibson, CM; James, S; Ohman, EM; Povsic, TJ; Roe, MT; Steg, PG; Welsh, RC | 1 |
| Cho, K; Do, JM; Dufour, AB; Faxon, DP; Gagnon, DR; Kinlay, S; Ly, S; Michael Gaziano, J; Ostrowski, S; Quach, L; Wimmer, NJ | 1 |
| Carrero, JJ; Evans, M; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Spaak, J; Szummer, K; Varenhorst, C | 1 |
| Douglass-Molloy, H; Hennessey, DB; Jack, G; Kinnear, N | 1 |
| Atwell, T; Knudsen, J; McBane, R; McMenomy, B; Pieper, M; Schmitz, J; Wennberg, P | 1 |
| Bhatt, DL; Deliargyris, EN; Elkin, S; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Menozzi, A; Prats, J; Price, MJ; Steg, PG; Stone, GW; Vaduganathan, M; White, HD | 1 |
| Cho, DK; Choi, JH; Choi, SH; Doh, JH; Gwon, HC; Hahn, JY; Kim, SH; Lee, JB; Lee, JM; Lee, SH; Oh, JH; Park, TK; Song, YB; Yang, JH | 1 |
| Bekta, P; Chmielak, Z; Debski, A; Jamiolkowski, J; Klopotowski, M; Kukula, K; Kunicki, PK; Polanska-Skrzypczyk, M; Witkowski, A | 1 |
| Baumgartner, I; Berger, JS; Blomster, J; Fowkes, FG; Heizer, G; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Millegård, M; Norgren, L; Patel, MR; Reist, C | 1 |
| Anstrom, KJ; Baker, BA; Cohen, DJ; Effron, MB; Henry, TD; McCoy, LA; Messenger, JC; Peterson, ED; Wang, TY; Zettler, ME | 1 |
| Bekta, P; Chmielak, Z; Debski, A; Jamiolkowski, J; Klopotowski, M; Kukula, K; Kunicki, P; Witkowski, A | 1 |
| Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD | 1 |
| Dai, H; He, P; Li, W; Lin, H; Ping, Y; Xu, H | 1 |
| Ariotti, S; Franzone, A; Gargiulo, G; Heg, D; Magnani, G; Marino, M; Piccolo, R; Santucci, A; Tebaldi, M; Valgimigli, M; Windecker, S | 1 |
| Combes, N; Dinet, ML; Iriart, X; Jalal, Z; Pillois, X; Renou, P; Sibon, I; Thambo, JB | 1 |
| Dong, AQ; Liu, H; Liu, JQ; Su, N; Wu, HJ; Zuo, FT | 1 |
| Abizaid, A; Angelini, GD; Bacchi Reggiani, L; Benedetto, U; Bhatt, DL; Biondi-Zoccai, G; Chieffo, A; Colombo, A; Della Riva, D; Feres, F; Généreux, P; Gilard, M; Hong, MK; Jang, Y; Kim, BK; Kim, HS; Morice, MC; Palmerini, T; Park, KW; Pufulete, M; Sangiorgi, D; Stone, GW; Valgimigli, M; White, J | 1 |
| Beauloye, C; Claeys, MJ; Pourbaix, S; Sinnaeve, PR | 1 |
| Benzeroual, D; Elharda, CA; Hattaoui, ME; Oualim, S | 1 |
| Hansen, RA; Rahman, MM; Scalese, MJ | 1 |
| Chao, PW; Chen, HT; Chen, YT; Hsu, CY; Kuo, SC; Ou, SM; Shih, CJ | 1 |
| Baber, U; Ben-Yehuda, O; Brodie, BR; Cox, DA; Duffy, PL; Henry, TD; Kirtane, AJ; Maehara, A; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Ooi, SY; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B; Xu, K; Yu, J | 1 |
| Bruno, V; Egger, F; Freynhofer, MK; Huber, K; Hübl, W; Iliev, L; Rohla, M; Weiss, TW; Willheim, M; Wojta, J | 1 |
| Cabrera-Fuentes, HA; Cho, YR; Kim, MH; Kim, YD; Lee, K; Park, K; Park, TH; Serebruany, VL; Yoon, SC | 1 |
| Abizaid, A; Costa, JR; Costa, R; Feres, F; Mangione, JA; Piva E Mattos, LA; Siqueira, D; Sousa, A; Staico, R; Zuliani Mauro, MF | 1 |
| Bae, JW; Hur, SH; Jeon, DW; Kim, BS; Kim, HS; Koo, BK; Lee, H; Lee, JH; Lee, NH; Lim, SW; Oh, SK; Park, KW; Park, TH; Rha, SW; Shin, ES | 1 |
| Chase, M; Davies, G; Du, M; Oguz, M | 1 |
| Ben-Yehuda, O; Brodie, BR; Gupta, R; Kirtane, AJ; Mehran, R; Metzger, DC; Ozan, MO; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B | 1 |
| Kichikawa, K; Motoyama, Y; Nakagawa, I; Nakase, H; Park, HS; Wada, T; Yamada, S; Yokoyama, S | 1 |
| Bhatt, DL; Colombo, A; Costa, F; Feres, F; Heg, D; Hong, MK; James, S; Kim, HS; Palmerini, T; Pilgrim, T; Räber, L; Steg, PG; Steyerberg, EW; Stone, GW; Valgimigli, M; van Klaveren, D; Wallentin, L; Windecker, S; Zanchin, T | 1 |
| Amarshi, N; Sullivan, J | 1 |
| Alberts, MJ; Hanley, DF; Serebruany, VL | 1 |
| Brandt, JT; Farid, NA; Jakubowski, JA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ | 1 |
| Boshoff, D; Eyskens, B; Gewillig, M; Mertens, L | 1 |
| Bauersachs, J; Eigenthaler, M; Schäfer, A | 1 |
| Cambronero, F; Caro, C; Garrido, IP; Lip, GYH; Manzano-Fernández, S; Marín, F; Pascual-Figal, DA; Pastor, FJ; Pinar, E; Valdés, M | 1 |
| Antman, EM; Braunwald, E; Huber, K; Lopez-Sendon, J; McCabe, CH; Morocutti, G; Murphy, SA; Weerakkody, G; Wiviott, SD | 1 |
| Bandyopadhyay, D; Ghosh, S | 1 |
| Berger, PB; Blankenship, JC; Büttner, HJ; Byrne, RA; Dirschinger, J; Graf, I; Iijima, R; Kastrati, A; Khattab, AA; Mehilli, J; Minners, J; Neumann, FJ; Pache, J; Richardt, G; Schömig, A; Schulz, S; Seyfarth, M; Skelding, KA | 1 |
| Kent, DM; Thaler, DE | 1 |
| Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S | 1 |
| Alexander, D; Brown, DL; Cannon, CP; Fintel, DJ; Gibler, WB; Ohman, EM; Ou, FS; Peterson, ED; Pollack, CV; Roe, MT | 1 |
| Avezum, A; Fox, KA; Gersh, BJ; Haladyn, K; Jolly, SS; Mehta, SR; Peters, RJ; Pogue, J; Rupprecht, HJ; Yusuf, S | 1 |
| Behlouli, H; Cox, J; Demers, V; Jackevicius, CA; Johansen, H; Kalavrouziotis, D; Melo, M; Newman, A; Pilote, L; Rinfret, S; Tu, JV | 1 |
| Halperin, JL; Rubboli, A | 1 |
| Marín, F; Roldán, V | 1 |
| Graw, J; Schwenk, W; Volk, T | 1 |
| Barragan, P; Bonello, L; Paganelli, F | 1 |
| Satler, LF | 1 |
| Brener, M; Carroll, JD; Cox, DA; Cristea, E; Garcia, E; Grines, CL; Guagliumi, G; Lansky, AJ; Leon, MB; Mehran, R; Moses, J; Pietras, C; Rutherford, BD; Stone, GW; Stuckey, T; Tcheng, JE; Tsuchiya, Y; Turco, M | 1 |
| Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S | 1 |
| Bonello, L; de Labriolle, A; Kaneshige, K; Kent, KM; Lemesle, G; Lindsay, J; Pichard, AD; Roy, P; Satler, LF; Slottow, TL; Steinberg, DH; Suddath, WO; Torguson, R; Waksman, R; Xue, Z | 1 |
| Angiolillo, DJ; Bass, TA; Della Rovere, F; Gavazzi, A; Lettieri, C; Mantovani, P; Mihalcsik, L; Molfese, M; Musumeci, G; Rossini, R; Sirbu, V | 1 |
| Bauer, T; Gitt, AK; Heer, T; Juenger, C; Senges, J; Towae, F; Zahn, R; Zeymer, U | 1 |
| Beckerman, P; Ben-Artzi, M; Ben-Yehuda, A; Haber, G; Levin, A; Muszkat, M; Varon, D | 1 |
| De Servi, S; Mariani, G; Mariani, M | 1 |
| Blais, N; Boudreault, D; Girard, F; Hardy, JF; Lortie, E; Mansour, S; Ruel, M | 1 |
| Kopyleva, O; Serebruany, V; Shalito, I | 1 |
| Calatzis, A | 1 |
| Curzen, N; Hobson, A | 1 |
| Crain, EJ; Hua, J; Rehfuss, R; Schumacher, WA; Watson, CA; Wong, PC | 1 |
| Lane, DA; Lip, GY; Tay, KH | 1 |
| de Boer, A; Klungel, OH; Schalekamp, T; Souverein, PC | 1 |
| Price, MJ | 1 |
| Andrea, R; Freixa, X; Guasch, E; Heras, M; Loma-Osorio, P; Reverter, JC; Sionis, A | 1 |
| Ezban, M; Lauritzen, B; Tranholm, M | 1 |
| Aronow, HD; Berger, PB; Brennan, DM; Steinhubl, SR; Topol, EJ | 1 |
| Andrésson, T; Bjarnadottir, M; Bjornsson, JM; Fabre, JE; Gurney, ME; Hategen, G; Kiselyov, A; Magnusson, O; Mishra, R; Onua, E; Polozov, A; Ramírez, JL; Sigthorsson, G; Singh, J; Stefansson, K; Thorsteinsdottir, M; Yu, P; Zeller, W; Zembower, D; Zhang, J; Zhou, N | 1 |
| Mohler, ER | 1 |
| Bhatt, DL; Fox, KA; Haffner, SM; Hamm, CW; Hankey, GJ; Johnston, SC; Mak, KH; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ | 1 |
| Stone, GW | 1 |
| Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Murphy, SA; Wiviott, SD | 1 |
| Antonino, MJ; Gurbel, PA; Mahla, E; Tantry, US | 1 |
| Kala, P; Motovska, Z | 1 |
| Colombo, A; Merlini, P | 1 |
| Berger, PB; Bhatt, DL; Brennan, DM; Eikelboom, JW; Hankey, GJ; Montalescot, G; Steinhubl, SR; Topol, EJ | 1 |
| Furlan, AJ | 1 |
| Mazloum, Y; Zibaeenezhad, MJ | 1 |
| Pollack, CV; Slattery, D | 1 |
| Bhatt, DL; Easton, JD; Fox, KA; Hankey, GJ; Mak, KH; Shao, M; Topol, EJ | 1 |
| Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Mitchell, P; Storey, RF | 1 |
| Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S | 1 |
| Brahin, E; Dessain, S; Ezekowitz, MD; Gracely, E; Nagarakanti, R; Notaro, LA; Usman, MH | 1 |
| Chua, D; Ignaszewski, A | 1 |
| Argüello Viudez, L | 1 |
| Biller, J | 1 |
| Gibler, WB; Harrington, RA; Ohman, EM; Ou, FS; Peterson, ED; Roe, MT; Wang, TY | 1 |
| Diodati, JG; Lordkipanidzé, M; Pharand, C | 1 |
| Jähne, J; Schirren, J | 1 |
| Marzot, F; Pengo, V | 1 |
| Katus, HA; Rottbauer, W | 1 |
| Bölükbas, S; Jähne, J; Schirren, J | 1 |
| Alfonso, F; Angel, J; Bueno, H; Fernández-Avilés, F; Ferreira-González, I; García-Dorado, D; López-Minguez, JR; Mainar, V; Maristany, J; Prendergast, B; Rodríguez, O; Sambola, A; San Román, A; Tornos, P; Zueco, J | 1 |
| Haverich, A; Martens, A | 1 |
| Ball, J | 1 |
| Gurbel, PA; Kereiakes, DJ | 1 |
| Aleil, B; Cazenave, JP; Collet, JP; De Poli, F; Dickele, MC; Gachet, C; Jacquemin, L; Monassier, JP; Montalescot, G; Zaehringer, M | 1 |
| Bertrand, ME; Chew, D; Cox, DA; Desmet, W; Feit, F; Lincoff, AM; Manoukian, SV; Mehran, R; Ohman, EM; Pollack, CV; Steinhubl, SR; Stone, GW; Ware, JH | 1 |
| Buller, C; Densem, C; Fox, R; Fung, A; Jokhi, P; Mancini, GB; Ricci, D; Saw, J; Starovoytov, A; Walsh, S; Wong, G | 1 |
| Alessi, MC; Bali, L; Bonnet, JL; Cuisset, T; Frere, C; Lambert, M; Morange, PE; Moro, PJ; Mouret, JP; Quilici, J | 1 |
| Choe, KS; Jani, AB; Liauw, SL | 1 |
| Alexander, JH; Becker, RC; Bhatt, DL; Cools, F; Crea, F; Dellborg, M; Fox, KA; Goodman, SG; Harrington, RA; Huber, K; Husted, S; Lewis, BS; Lopez-Sendon, J; Mohan, P; Montalescot, G; Ruda, M; Ruzyllo, W; Verheugt, F; Wallentin, L | 1 |
| Makarov, LM; Serebruany, VL | 1 |
| Spinler, SA | 1 |
| Kereiakes, DJ | 1 |
| Colombo, A; Moussa, ID | 1 |
| Kittisupamongkol, W | 1 |
| De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW | 1 |
| Carrel, T; Englberger, L | 1 |
| Becker, RC; Budaj, A; Cannon, CP; Emanuelsson, H; Freij, A; Harrington, RA; Held, C; Horrow, J; Husted, S; James, S; Katus, H; Mahaffey, KW; Scirica, BM; Skene, A; Steg, PG; Storey, RF; Thorsén, M; Wallentin, L | 1 |
| Collet, JP; Montalescot, G | 1 |
| Alessi, MC; Bali, L; Bonnet, JL; Cayla, G; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Poyet, R; Quilici, J | 1 |
| Almaroof, B; Castillo-Sang, M; Cireddu, J; Engoren, M; Kasper, G; Sferra, J; Tsang, AW; Zelenock, GB | 1 |
| Bagur, R; Bertrand, OF; Costerousse, O; Larochellière, RD; Larose, E; Nguyen, CM; Noel, B; Poirier, P; Rinfret, S; Rodés-Cabau, J; Roy, L | 1 |
| Borderías Clau, L; Caballero, G; Garrapiz López, J | 1 |
| Aranki, SF; Body, SC | 1 |
| Goldstein, LB | 1 |
| Butaffuoco, F; Richard, T; Vanhaeverbeek, M | 1 |
| Hessen, SE; Joy, PS; Karalis, DG; Nkonde, C; Watson, PD | 1 |
| Bagur, R; Bertrand, OF; Costerousse, O; De Larochellière, R; Gleeton, O; Larose, E; Proulx, G; Rinfret, S; Rodés-Cabau, J; Roy, L | 1 |
| Badreldin, A; Hekmat, K; Kamiya, H; Kroener, A; Lichtenberg, A | 1 |
| Atar, D; Donovan, JL; Goto, S; Kannan, AO; Makarov, L; Rao, SV; Serebruany, V; Silva, MA | 1 |
| Helft, G | 1 |
| Healey, JS | 1 |
| Apostolakis, S; Lane, DA; Lip, GY; Shantsila, E | 1 |
| Abu-Fadel, M; Norgard, NB | 1 |
| Amine, M; Angiolillo, DJ; Becker, RC; Bhatt, DL; Chew, DP; French, WJ; Gibson, CM; Goodman, SG; Harrington, RA; Kleiman, NS; Leisch, F; Lincoff, AM; Mahaffey, KW; McNulty, S; Montalescot, G; Parikh, KH; Pollack, CV; Skerjanec, S; Stone, GW; White, HD | 1 |
| Berger, JS; Berger, PB; Bhatt, DL; Fox, KA; Hacke, W; Lincoff, AM; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ | 2 |
| Braun, S; Kastrati, A; Mehilli, J; Morath, T; Schömig, A; Schulz, S; Sibbing, D; Stegherr, J; von Beckerath, N | 1 |
| Banach, M; Hannam, S; Kowalczyk, M; Mikhailidis, DP; Rysz, J | 1 |
| Lazar, LD; Lincoff, AM | 1 |
| Gilchrist, IC | 2 |
| Bittira, B; Brister, S; Eikelboom, J; Fitchett, D; Fremes, S; Graham, J; Gupta, M; Karkouti, K; Lee, A; Love, M; Mazer, D; McArthur, R; Peterson, M; Singh, S; Verma, S; Yau, T | 1 |
| Grove, EL; Storey, RF | 1 |
| Abildstrom, SZ; Andersson, C; Gislason, GH; Hansen, ML; Hansen, PR; Hvelplund, A; Jørgensen, C; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C | 1 |
| Demirtas, MM; Gunay, R; Kayacioglu, I; Sensoz, Y | 1 |
| Guerra, DR; Tcheng, JE | 1 |
| Antman, E; Arnold, SV; Braunwald, E; Cohen, DJ; Mahoney, EM; Proskorovsky, I; Wang, K; Wiviott, S | 1 |
| Bhatt, DL; Chhatriwalla, AK | 1 |
| Colombo, A; Gerber, RT | 1 |
| Froeschl, M; Glover, CA; Jadhav, S; Kass, M; Labinaz, M; Le May, MR; Marquis, JF; O'Brien, ER; So, DY; Thomas, A; Turek, M; Wells, GA | 1 |
| Aberg, C; Bojestig, M; Carlhed, R; Garmo, H; Lindahl, B; Peterson, A | 1 |
| Avsar, O; Batyraliev, TA; Fettser, DV; Islek, M; Preobrazhenskiĭ, DV; Sidorenko, BA; Vural, A | 1 |
| Cattaneo, M | 3 |
| Lotfi, A; Rothberg, M; Wartak, SA | 1 |
| Badimon, JJ; Choi, BG; Ibáñez, B; Jin, X; Piñero, A; Sharma, RK; Vorchheimer, DA; Zafar, MU | 1 |
| Braun, S; Gebhard, D; Kastrati, A; Koch, W; Morath, T; Schömig, A; Schuster, T; Sibbing, D; Stegherr, J; von Beckerath, N | 1 |
| Carrie, D; Galinier, M; Lapeyre-Mestre, M; Montastruc, JL; Pathak, A; Tavassoli, N; Voisin, S | 1 |
| Abla, AA; Killory, BD; Nakaji, P; Spetzler, RF; Starke, RM; Wait, SD | 1 |
| Hayashi, F; Iijima, R; Nakamura, M; Sugi, K | 1 |
| Armero, S; Barragan, P; Bonello, C; Bonello, L; Camoin-Jau, L; Dignat-George, F; Lemesle, G; Mancini, J; Mokhtar, OA; Paganelli, F; Tahirou, I | 1 |
| Bolliger, D; Levy, JH; Rumph, B; Szlam, F; Tanaka, KA | 1 |
| Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD | 1 |
| Ebina, T; Hashiba, K; Hibi, K; Iwahashi, N; Kimura, K; Kosuge, M; Maejima, N; Morita, S; Nakachi, T; Ohtsuka, F; Okuda, J; Sugano, T; Tahara, Y; Tsukahara, K; Umemura, S | 1 |
| Gao, F; Jia, de A; Liu, XL; Nie, B; Shen, H; Wang, ZJ; Yan, ZX; Yang, SW; Yu, M; Zhou, YJ | 1 |
| Anstrom, KJ; Barron, JJ; Califf, RM; Curtis, LH; Cziraky, MJ; Eisenstein, EL; Hammill, BG; Krucoff, MW; Petersen, JL; Schulman, KA; Wahl, PM | 1 |
| Banning, AP; Bedogni, F; Bhindi, R; Biondi Zoccai, GG; Brambilla, N; Lanotte, S; Latini, RA; Laudisa, ML; Pizzocri, S; Testa, L; Valgimigli, M; Van Gaal, WJ | 1 |
| Doraiswamy, VA | 1 |
| Islam, AM; Patel, PM | 1 |
| Azuma, J; Maegdefessel, L; Tsao, PS | 1 |
| Dumont, LA; Gangloff, D; Garrido-Stowhas, I; Rongières, M; Tchénio, P | 1 |
| Fareed, J; Jeske, WP; Mousa, SA | 1 |
| Buchan, AM; Chandratheva, A; Geraghty, OC; Kennedy, J; Marquardt, L; Rothwell, PM | 1 |
| Ackman, ML; Pickett, AM; Taylor, DA | 1 |
| Stiefelhagen, P | 1 |
| Ben-Dor, I; Collins, SD; Delhaye, C; Gaglia, MA; Gonzalez, MA; Kaneshige, K; Kent, KM; Li, Y; Maluenda, G; Pichard, AD; Satler, LF; Scheinowitz, M; Suddath, WO; Syed, AI; Torguson, R; Wakabayashi, K; Waksman, R; Xue, Z | 1 |
| Bauters, C; Bonello, L; Delhaye, C; Lablanche, JM; Lemesle, G; Maluenda, G; Sudre, A | 1 |
| Fukushima, K; Iwata, Y; Kitahara, H; Kobayashi, Y; Komuro, I; Kuroda, N; Nomura, F; Ooyama, M | 1 |
| Berger, PB; Bhatt, DL; Brennan, DM; Fox, KA; Fuster, V; Hacke, W; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ | 1 |
| Ambrosio, G; Bertrand, ME; Gresele, P; Lincoff, AM; Mehran, R; Moses, JW; Ohman, EM; Steinhubl, S; Stone, GW; Tritto, I; White, HD; Zuchi, C | 1 |
| Bathina, JD; Daher, IN; Durand, JB; Iliescu, C; Yusuf, SW | 1 |
| Burdess, A; Dawson, AR; Fox, KA; Garden, OJ; Murie, JA; Newby, DE; Nimmo, AF | 1 |
| Bhatt, DL; Boden, WE; Flather, MD | 1 |
| Givol, N; Halkin, A | 1 |
| Hanke, A; Posch, A; Schöchl, H; Solomon, C; Voelckel, W | 1 |
| Kastrati, A; Schömig, A; Schulz, S; Sibbing, D; Steinhubl, SR | 1 |
| Aboyans, V; Lacroix, P; Le Guyader, A | 1 |
| Frolova, NS; Mazurov, AV; Pevzner, DV; Ruda, MY; Samko, AN; Staroverov, II | 1 |
| Pakhomov, IaM | 1 |
| Bachelot-Loza, C; Dizier, B; Emmerich, J; Gaussem, P; Godier, A; Grelac, F; Hindy-François, C; Le Bonniec, B; Samama, CM | 1 |
| Tebaldi, M; Valgimigli, M | 1 |
| Baumgartner, I; Becquemin, JP; Belch, JJ; Bergqvist, D; Biasi, BM; Biasi, GM; Cairols, M; Clement, D; Diehm, C; Dormandy, J; Eikelboom, B; Golledge, J; Hiatt, WR; Jawien, A; Leizorovicz, A; Lepäntalo, M; Matyas, L; Minar, E; Norgren, L; Stonebridge, P; Vermassen, F | 1 |
| Budaj, A; Chrolavicius, S; Connolly, SJ; De Caterina, R; Morais, J; Pogue, J; Renda, G; Yusuf, S | 1 |
| Marín, F; Merino, A; Roldán, I; Worner, F | 1 |
| Aïssaoui, N; Danchin, N | 1 |
| Alfonso, F; Baz, JA; Brugaletta, S; Capote, ML; Cárdenas, M; Casanova, J; Cascant, P; De La Torre, JM; Ferreira-González, I; García-Del Blanco, B; García-Dorado, D; González-Béjar, O; Iñiguez, A; Marsal, JR; Martí, G; Martín-Yuste, V; Permanyer-Miralda, G; Pujol, B; Ribera, A; Ruíz-Lera, M; Sabaté, M; Sánchez-Gila, J; Sanmiguel, D; Trillo, R | 1 |
| Christ, G; Herkner, H; Huber, K; Jilma, B; Kubica, J; Schrör, K; Siller-Matula, JM | 1 |
| Angiolillo, DJ; Cornel, JH; Erlinge, D; Husted, S; James, S; Kontny, F; Maya, J; Nicolau, JC; Spinar, J; Stevens, SR; Storey, RF; Wallentin, L | 1 |
| Aylward, P; Buck, KK; Budaj, A; Cannon, CP; Cornel, JH; Harrington, RA; Horrow, J; James, S; Katus, H; Keltai, M; Lewis, BS; Parikh, K; Storey, RF; Szummer, K; Wallentin, L; Wojdyla, D | 1 |
| Black, C; Crosby, JR; Gao, D; Levi, M; Löwenberg, EC; MacLeod, AR; Meijers, JC; Monia, BP; Revenko, AS; Stroes, ES; Zhang, H; Zhao, C | 1 |
| Fuster, V | 1 |
| Afzal, R; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KA; Granger, CB; Jolly, S; Joyner, CD; Mehta, SR; Pogue, J; Rupprecht, HJ; Widimsky, P; Yusuf, S | 1 |
| Batyraliev, TA; Besnili, F; Fettser, DV; Niiazova-Karben, ZA; Preobrazhenskiĭ, DV; Sidorenko, BA | 1 |
| Abildstrøm, SZ; Andersen, SS; Clausen, MT; Fog-Petersen, ML; Folke, F; Gadsbøll, N; Gislason, GH; Hansen, ML; Køber, L; Poulsen, HE; Raunsø, J; Schramm, TK; Sørensen, R; Torp-Pedersen, C | 1 |
| Hwang, JY; Hwang, SJ; Jeong, YH; Kang, MK; Kim, IS; Kwak, CH; Park, Y; Yun, SE | 1 |
| Bakaeen, F; Chu, D | 1 |
| Bergman, G; Feldman, DN; Minutello, RM; Moussa, I; Wong, SC | 1 |
| Schlitt, A | 1 |
| Anand, SS; Bhatt, DL; Connolly, SJ; Eikelboom, JW; Fox, KA; Hirsh, J; Mehta, SR; Paré, G; Simonsen, K; Yusuf, S | 1 |
| Ardissino, D; Becker, RC; Cannon, CP; Emanuelsson, H; Finkelstein, A; Harrington, RA; Husted, S; James, S; Katus, H; Kilhamn, J; Olofsson, S; Steg, PG; Storey, RF; Wallentin, L; Weaver, WD | 1 |
| Pollack, CV | 1 |
| Kleiman, NS; Mangalpally, KK | 1 |
| Brieger, D; Eagle, KA; Fox, KA; Goodman, SG; Gore, JM; Huang, W; Montalescot, G; Sibbald, M; Steg, PG; Yan, AT | 1 |
| Budnitz, DS; Kegler, SR; Shehab, N; Sperling, LS | 1 |
| Gendlin, GE; Storozhakov, GI; Tronina, OA | 1 |
| Cannon, C; Croce, K; Kirshenbaum, J; Manica, A; Marchini, J; Morrow, D; Resnic, F | 1 |
| Armani, AM | 1 |
| Delarochelliere, R; Kulik, A; Le May, MR; Mesana, TG; Naidoo, S; Ruel, M; Tardif, JC; Voisine, P; Wells, GA | 1 |
| Aboodi, MS; Delgado, JA; Fernandez, A; Granada, JF; Milewski, K; Rodríguez, A | 1 |
| Minarelli, M; Valgimigli, M | 1 |
| Rechner, AR | 1 |
| Frey, N; Ivandic, B | 1 |
| Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH | 1 |
| Arora, R; Bedi, U; Khosla, S; Molnar, J; Singh, M; Singh, PP | 1 |
| Bansal, V; Coimbra, R; Doucet, J; Fortlage, D; Lee, J; Potenza, B | 1 |
| Táborský, M; Václavík, J | 1 |
| Adam, M; Cadiou, G; Capet, C; Caussin, M; Doucet, J; Kadri, N; Landrin, I; Mariette, N; Mouton-Schleifer, D; Remy, E | 1 |
| Di Sciascio, G; Pasceri, V; Patti, G; Ricottini, E; Vizzi, V | 1 |
| Banya, W; Bigalke, B; Bischofs, C; Fateh-Moghadam, S; Flather, M; Gawaz, M; Geisler, T; Htun, P; May, AE; Müller, K; Stellos, K | 1 |
| Aydogdu, S; Balbay, Y; Cagirci, G; Cay, S; Demir, AD; Erbay, AR; Maden, O; Sen, N | 1 |
| Armstrong, PW; Braunwald, E; Califf, RM; Giugliano, RP; Harrington, RA; James, SK; Montalescot, G; Newby, LK; Tricoci, P; Van de Werf, F; Wang, TY; White, JA; Zeymer, U | 1 |
| Desilets, AR; Goodwin, MM; Willett, KC | 1 |
| Cruden, NL; Hilton, JD; Klinke, WP; Morch, K; Ofiesh, J; Wong, DR | 1 |
| Ahmed, S; Cannon, CP; Michael Gibson, C; Murphy, SA; Sabatine, MS | 1 |
| Lopes, RD | 1 |
| Suissa, S; Vaduganathan, M | 1 |
| Abildstrøm, SZ; Andersson, C; Charlot, M; Fosbøl, EL; Gislason, GH; Hansen, PR; Hvelplund, A; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C | 1 |
| Angiolillo, DJ; Aragon, JR; Berger, PB; Bertrand, OF; Cannon, CP; Garratt, KN; Kandzari, DE; Lee, MS; Manoukian, SV; Price, MJ; Puri, S; Robbins, M; Schork, NJ; Spriggs, D; Stillablower, ME; Stillabower, ME; Stinis, CT; Tanguay, JF; Teirstein, PS; Topol, EJ | 1 |
| Aout, M; Barthelemy, O; Bellemain-Appaix, A; Beygui, F; Cayla, G; Collet, JP; Connor, S'; Montalescot, G; Payot, L; Silvain, J; Vicaut, E | 1 |
| Arntz, HR; Boudriot, E; Garlichs, C; Helms, TM; Hoffmann, S; Ince, H; Klingenheben, T; Silber, S; Steiger, H; Weil, J; Zugck, C | 1 |
| Davila, RE; Feagins, LA; Harford, WV; Spechler, SJ; Uddin, FS | 1 |
| Fujishiro, M | 1 |
| Scharf, RE | 1 |
| Bellemain, A; Collet, JP; Ecollan, P; Montalescot, G; Silvain, J | 1 |
| Hofman-Bang, C; Lagerqvist, B; Lindbäck, J; Persson, J; Samnegard, A; Stenestrand, U | 1 |
| Green, A; Sauder, M; Ziegelstein, RC | 1 |
| Guthrie, R | 1 |
| Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L | 1 |
| Ardissino, D; Demola, MA; Magnani, G; Mantovani, F; Patti, G | 1 |
| Castriota, F; De Luca, G; De Servi, S; Kozinski, M; Kubica, J; Navarese, EP; Schaffer, A; Suriano, P; Verdoia, M | 1 |
| Moliterno, DJ | 1 |
| Antman, EM; Braunwald, E; Contant, CF; Dalby, AJ; Giugliano, RP; Guo, J; Hochholzer, W; Montalescot, G; Wiviott, SD | 1 |
| Athanasiou, T; Malik, IS; Nijjer, SS; Watson, G | 1 |
| Bowling, R; Cohen, MG; Dupont, AG; Gabriel, D; Garbarino, J; Motsinger-Reif, AA; Rossi, JS; Schuler, C | 1 |
| Eikelboom, JW; Fitchett, DH; Goodman, SG; Mehta, SR; Quinlan, DJ; Théroux, P; Welsh, RC | 1 |
| Martin, MT; Nutescu, EA; Spinler, SA | 1 |
| Amin, AP; Berger, P; Cohen, DJ; Kennedy, KF; Kleiman, N; Lopez, J; Pencina, M; Piana, RN | 1 |
| Brugada, R; Elosua, R; Lluis-Ganella, C; Lucas, G; Marrugat, J; Masiá, R; Sala, J; Subirana, I; Tomás, M; Zabalza, M | 1 |
| Di Sciascio, G; Pasceri, V; Patti, G | 2 |
| Airaksinen, KE; Biancari, F; Lip, GY | 1 |
| Erlinge, D; James, S; Koul, S; Lagerqvist, B; Scherstén, F; Smith, JG | 1 |
| Aïssaoui, N; Bataille, V; Blanchard, D; Carrié, D; Coste, P; Danchin, N; Dentan, G; Drouet, E; Mulak, G; Puymirat, E; Simon, T | 1 |
| Banerjee, A; Bhala, N; Rajasekhar, P; Taggar, JS | 1 |
| Karkouti, K; Levy, JH | 1 |
| Bakaeen, FG; Chu, D | 1 |
| Alber, HF; Frick, M; Huber, K; Pachinger, O | 1 |
| Ajani, AE; Andrianopoulos, N; Brennan, AL; Clark, DJ; Duffy, SJ; Loane, P; Reid, CM; Yan, BP | 1 |
| Ahn, SW; Kwak, YL; Lee, JS; Shim, JK; Song, JW; Yoo, KJ | 1 |
| Alessi, MC; Bonnet, JL; Cuisset, T; Fourcade, L; Gaborit, B; Grosdidier, C; Molines, L; Morange, PE; Pankert, M; Quilici, J | 1 |
| Abu-Yousef, MM; Kuehn, DM; Laroia, AT; Larson, JH; Wu, AS | 1 |
| Al Suwaidi, J; Alsheikh-Ali, AA; Anderson, FA; Awad, HH; Goldberg, RJ; Gore, JM; Zubaid, M | 1 |
| Hobson, AR; Qureshi, Z | 1 |
| Carr, ME; Gabriel, D; Khutoryansky, NM; Pusateri, AE; Shenouda, M; Skolnick, BE | 1 |
| Demkow, M; Kalinczuk, L; Lubiszewska, B | 1 |
| Dasgupta, K; Labos, C; Nedjar, H; Rahme, E; Turecki, G | 1 |
| Dalén, M; Ivert, T; Lindvall, G; van der Linden, J | 1 |
| Arkebauer, MR; Chawla, N; Gomes, SB; Mangla, D; Nielsen, VG; Sadacharam, K; Vosseller, K; Wasko, KA | 1 |
| Banach, M; Beghi, C; Borsani, P; Bruno, VD; Cottini, M; Dominici, C; Mariscalco, G; Piffaretti, G; Sala, A | 1 |
| Connolly, SJ; de Caterina, R; Eikelboom, JW; Hart, RG; Hirsh, J; Hohnloser, S; Ng, J; Pogue, J; Yusuf, S | 1 |
| Cayla, G; Collet, JP; Montalescot, G; O'Connor, SA; Silvain, J | 1 |
| Blais, D; Burcham, P; Firstenberg, MS | 1 |
| Bassand, JP; Becker, RC; Budaj, A; Cornel, JH; French, J; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Lassila, R; Lopez-Sendon, J; Mahaffey, KW; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
| Basra, SS; Lakkis, NM; Tsai, P | 1 |
| Brilakis, ES; de Lemos, JA | 1 |
| Angiolillo, DJ; Capodanno, D; Gavazzi, A; Guagliumi, G; Lettieri, C; Musumeci, G; Romano, M; Rosiello, R; Rossini, R; Valsecchi, O | 1 |
| Barakoti, M; Neupane, P; Pant, S; Ramesh, KC | 1 |
| Hu, YF; Li, Y; Tang, HL; Xie, HG | 1 |
| Comin, J; Kallmes, D | 1 |
| Barthélémy, O; Bellemain-Appaix, A; Beygui, F; Brieger, D; Collet, JP; Costagliola, D; Lancar, R; Mercadier, A; Montalescot, G; Silvain, J | 1 |
| Ahn, T; Chae, IH; Choi, JH; Choi, SH; Choi, YJ; Chung, WY; Gwon, HC; Hahn, JY; Han, KR; Hong, TJ; Hur, SH; Jang, Y; Jeon, DW; Jeon, HK; Jeong, MH; Kang, HJ; Kim, BO; Kim, HS; Koo, BK; Kwon, HM; Lee, NH; Lim, DS; Park, KW; Park, SH; Song, YB; Yoon, JH | 1 |
| Collet, JP; De Luca, L; Wouter Jukema, J | 1 |
| Arntz, HR; Darius, H; Dill, T; Diller, F; Fichtlscherer, S; Huber, K; Mark, B; Schöller, R; Werner, G; Zahn, R; Zeymer, U | 1 |
| Casas, JP; Hingorani, AD; Holmes, MV; Perel, P; Shah, T | 1 |
| Nissen, SE | 1 |
| Davies, JE; Francis, DP; Nijjer, SS | 1 |
| Delle-Karth, G; Grzybowski, T; Huber, K; Jilma, B; Kozinski, M; Kubica, J; Lang, IM; Linkowska, K; Maurer, G; Neunteufl, T; Siller-Matula, JM | 1 |
| Ho, PM; Magid, D; Powers, D; Raebel, MA; Shetterly, S; Tsai, TT; Xu, S | 1 |
| Chee, A; MacEachern, P; Stather, DR; Tremblay, A | 1 |
| Eckman, MH; Fang, MC; Go, AS; Halperin, JL; Howard, PA; Hughes, M; Hylek, EM; Lane, DA; Lip, GYH; Manning, WJ; Schulman, S; Singer, DE; Spencer, FA; You, JJ | 1 |
| Mackay, SM; Tcheng, JE | 1 |
| He, J; Lu, J; Qin, YY; Wei, X; Wu, MJ; Xu, JF; Ye, XF; Zhou, YH | 1 |
| Becker, RC; Berger, JS; Frye, CB; Harshaw, Q; Herout, PM; Steinhubl, SR | 1 |
| Lopez, J; Luzardo, H; Molero, T; Perera, M; Suarez, A | 1 |
| Dambrink, JH; Gosselink, AT; Hamm, C; Hermanides, RS; Ottervanger, JP; Stella, PR; ten Berg, JM; van 't Hof, AW; van Houwelingen, G | 1 |
| Bell, K; Gdovin, J; Graham, J; Jing, Y; Johnston, SS | 1 |
| Acheré, C; Boulé, S; Brigadeau, F; Goéminne-Boulé, C; Guédon-Moreau, L; Kacet, S; Klug, D; Kouakam, C; Lacroix, D; Marquié, C; Vanesson-Bricout, C | 1 |
| Askari, AT; Stephens, JC | 1 |
| Berger, PB; Bhakta, N; Bhatt, DL; Cacoub, P; Creager, MA; Eikelboom, JW; Emison, ES; Flather, MD; Fox, KA; Hacke, W; Kottke-Marchant, K; Lincoff, AM; Mak, KH; Mehta, SR; Montalescot, G; Murugesan, G; Paré, G; Simonsen, KL; Steg, PG; Steinhubl, SR; Topol, EJ | 1 |
| Renzulli, A; Rossi, M; Serraino, GF; Spadafora, A | 1 |
| Beitelshees, AL; Daniel Mullins, C; Onukwugha, E; Reese, ES | 1 |
| Verheugt, FW | 2 |
| Alexander, KP; Fosbol, EL; Klaskala, W; Li, S; Lopes, RD; Mills, RM; Peterson, ED; Piccini, JP; Roe, MT; Shah, B; Thomas, L; Wang, TY | 1 |
| Polasek, TM; Sorich, MJ; Wiese, MD | 1 |
| Nusca, A; Patti, G | 1 |
| Ghosn, S; Sheikh-Taha, M | 1 |
| Lyseng-Williamson, KA | 1 |
| Mustonen, P; Puurunen, M | 1 |
| Halperin, JL; Varughese, CJ | 1 |
| Abe, M; Araki, M; Byrne, RA; Ehara, N; Eizawa, H; Fujiwara, H; Furukawa, Y; Inada, T; Iwabuchi, M; Kaburagi, S; Kadota, K; Kastrati, A; Kimura, T; Kita, T; Mitsudo, K; Mitsuoka, H; Mizoguchi, T; Morimoto, T; Nakagawa, Y; Nakano, A; Natsuaki, M; Nobuyoshi, M; Nohara, R; Shiomi, H; Shizuta, S; Suwa, S; Tada, T; Takizawa, A; Taniguchi, R; Tazaki, J | 1 |
| Chen, L; Coyle, D; Moertl, D; Steiner, S; Wells, GA | 1 |
| Goodnough, LT; Lenarz, LA; Levy, JH; Poston, RS; Short, MA; Smith, PK; Weerakkody, GJ | 1 |
| Angiolillo, DJ; Berdan, LG; Bhatt, DL; French, WJ; Gibson, CM; Gretler, DD; Gurbel, PA; Harrington, RA; Huber, K; Kochman, J; Leonardi, S; Madan, M; McClure, MW; Paynter, G; Rao, SV; Thompson, VP; Welsh, RC; Zeymer, U | 1 |
| Faxon, DP; Gaziano, M; Kinlay, S; Lawler, E; Young, M | 1 |
| De Smet, PA; Kramers, C; Lamfers, EJ; Pop, GA; Roukens, M; Warlé-Van Herwaarden, MF | 1 |
| Igarashi, K; Ikari, Y; Isshiki, T; Kimura, T; Kobayashi, M; Nakamura, M; Ueno, T; Yokoi, H | 1 |
| Chen, H; Dai, ZL; Wu, XY | 1 |
| Byrne, RA; Sarafoff, N; Sibbing, D | 1 |
| Ahmad, S; Storey, RF | 1 |
| Bessereau, J; Bonello, L; Camoin-Jau, L; Laine, M; Paganelli, F; Sébastien, A | 1 |
| Bhatt, DL; Kar, S | 1 |
| Alexander, KP; Foody, JM; Funk, M; Granger, CB; Li, L; Lopes, RD; Peterson, ED; Wang, TY | 1 |
| Ahlehoff, O; Charlot, M; Gislason, GH; Hansen, ML; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Nielsen, LH; Olsen, AM; Torp-Pedersen, C | 1 |
| Angiolillo, DJ; Rollini, F; Tello-Montoliu, A | 1 |
| Darnborough, S | 1 |
| Benavente, OR; Hart, RG; Palacio, S; Pearce, LA | 1 |
| Deng, J; Geng, DF; Jin, DM; Liu, M; Wang, JF; Wu, W | 1 |
| Kanorskiĭ, SG; Shevelev, VI | 1 |
| Limper, U; Lynch, J | 1 |
| Kadoyama, K; Okuno, Y; Sakaeda, T; Tamura, T | 1 |
| Gislason, GH; Hansen, CM; Hansen, ML; Karasoy, D; Kristensen, SL; Køber, L; Lamberts, M; Olesen, JB; Ruwald, MH; Torp-Pedersen, C | 1 |
| Rao, SV; Vavalle, JP | 1 |
| Biocina, B; Djuric, Z; Gasparovic, H; Kopjar, T; Petricevic, M; Svetina, L | 1 |
| Burgess, S; Juergens, CP; Mallard, TA | 1 |
| Benavente, OR; Coffey, CS; Hart, RG; McClure, LA; Pearce, LA; Szychowski, JM | 1 |
| El Mallah, W; Moliterno, DJ | 1 |
| Lincoff, AM; May, CH | 1 |
| Bach, RG; Becker, RC; Cannon, CP; Heras, M; Horrow, J; Husted, S; James, S; Katus, H; Lopes, RD; Mahaffey, KW; Morais, J; Storey, RF; Wallentin, L; Wojdyla, D | 1 |
| Einecke, D | 2 |
| Minematsu, K; Tanahashi, N; Uchiyama, S | 1 |
| DiNicolantonio, JJ; Serebruany, VL | 1 |
| Kastrati, A | 1 |
| Bennett, CL; Moore, TJ | 1 |
| Braun, OÖ; Koul, S; Lumsden, J; Ohman, J; Rydell, E; Scherstén, F; Smith, JG; Svensson, PJ; van der Pals, J; Wieloch, M | 1 |
| Arthur, AS; Hoit, DA; Jones, GM; Twilla, JD | 1 |
| Meyer, S | 1 |
| Berger, JS; Hochman, JS; Ladapo, JA; Lala, A; Scott Braithwaite, R; Sharma, G | 1 |
| Abdel Samie A, A; Sun, R; Theilmann, L; Vöhringer, U | 1 |
| Bechara, RI; Berkowitz, DM; Parks, C; Zalt, MB | 1 |
| Cohen, DJ; Jones, PG; Li, Y; Salisbury, AC; Spertus, JA; Wang, K | 1 |
| Chatterjee, S; Frankel, R; Ghose, A; Guha, G; Mukherjee, D; Sharma, A | 1 |
| Hanna, EB | 1 |
| Fusari, M | 1 |
| Ahn, JM; Kang, SJ; Kim, WJ; Kim, YH; Lee, CW; Lee, JY; Lee, SW; Park, DW; Park, SJ; Park, SW; Song, HG; Yun, SC | 1 |
| Kanorsky, SG; Shevelev, VI | 1 |
| Barthélémy, O; Bellemain-Appaix, A; Bernasconi, F; Beygui, F; Collet, JP; Cucherat, M; Jacq, L; Montalescot, G; O'Connor, SA; Silvain, J | 1 |
| Fareed, J; Jeske, W; Thethi, I | 1 |
| Azoulay, L; Dell'Aniello, S; Renoux, C; Simon, T; Suissa, S | 1 |
| Diener, HC; Weber, R | 1 |
| Alessi, MC; Beguin, S; Bonnet, JL; Camoin, L; Cohen, W; Cuisset, T; Gaborit, B; Grosdidier, C; Lambert, M; Loosveld, M; Morange, PE; Moro, PJ; Pankert, M; Quilici, J; Saut, N | 1 |
| Chen, YD; Jin, ZN; Liu, H; Liu, X; Lü, SZ; Song, XT | 1 |
| Lloyd, FR; Sare, GM; Stower, MJ | 1 |
| Turpie, AG | 1 |
| Budaj, A; Chrolavicius, S; Fox, KA; Franzosi, MG; Hunt, D; Keltai, M; Mehta, SR; Tognoni, G; Yusuf, S; Zhao, F | 1 |
| Alpert, JS; Antman, EM; Beasley, JW; Braunwald, E; Califf, RM; Cheitlin, MD; Faxon, DP; Fuster, V; Gibbons, RJ; Gregoratos, G; Hiratzka, LF; Hochman, JS; Jacobs, AK; Jones, RH; Kereiakes, D; Kupersmith, J; Levin, TN; Pepine, CJ; Schaeffer, JW; Smith, EE; Smith, SC; Steward, DE; Theroux, P | 1 |
| Berger, PB; Steinhubl, S | 1 |
| Alberts, MJ; Easton, JD | 1 |
| Blumenthal, M; Budaj, A; Commerford, PJ; Fox, KA; Gersh, BJ; Mehta, SR; Wittlinger, T; Yusuf, S; Zhao, F | 1 |
| Meyer, BJ | 1 |
| Tsakiris, DA | 1 |
| Mychaskiw, G; Vaughn, C | 1 |
| McConn Walsh, R; Watters, K | 1 |
| Bhatt, DL; Gerschutz, GP | 1 |
| Dahm, M; Ehrlich, A; Eimermacher, A; Peetz, D; Rupprecht, HJ; Schlitt, A; von Bardeleben, RS | 1 |
| Gandhi, PJ; Schroeder, WS | 1 |
| Alberio, L; Friess, D; Lämmle, B | 1 |
| Berger, PB; Brennan, D; Kereiakes, DJ; Saw, J; Serebruany, VL; Steinhubl, SR; Topol, EJ | 1 |
| Commerford, PJ; Diaz, R; Fox, KA; Kopecky, SL; Lewis, BS; Mehta, SR; Peters, RJ; Valentin, V; Yusuf, S; Zhao, F | 1 |
| Pieper, JA; Wodlinger, AM | 1 |
| Helenius, I; Remes, V | 1 |
| Robb-Nicholson, C | 1 |
| Blankenship, JC; Cohen, EA; Dauerman, HL; Exaire, JE; Moliterno, DJ; Raymond, RE; Topol, EJ; Wolski, K | 1 |
| Becker, RC; Spencer, FA | 1 |
| Berger, PB; Burger, K; Fasseas, P; Holmes, DR; Melby, S; Orford, JL; Steinhubl, SR | 1 |
| Ankri, A; Beygui, F; Choussat, R; Collet, JP; Drobinski, G; Golmard, JL; Montalescot, G; Tanguy, ML; Thomas, D; Vignolles, N | 1 |
| Ankri, A; Beygui, F; Choussat, R; Collet, JP; Dumaine, R; Gallois, V; Montalescot, G; Payot, L; Tanguy, ML; Thomas, D | 1 |
| Brener, SJ; Lincoff, AM; Moliterno, DJ; Steinhubl, SR; Topol, EJ; Wolski, KE | 1 |
| Fox, KA; Gersh, BJ; Lakkis, N; Mehta, SR; Peters, R; Yusuf, S; Zhao, F | 1 |
| Moore, M; Power, M | 1 |
| Kerr, JL; Oppelt, TF; Rowen, RC | 1 |
| Betriu, A; DeSmet, W; Kleiman, NS; Lincoff, AM; Rutsch, W; Saw, J; Topol, EJ; Wilcox, RG; Wolski, K | 1 |
| Erdmann, E | 1 |
| Griffin, S; Hawkins, N; Henderson, R; Jones, L; Main, C; Orton, V; Palmer, S; Riemsma, R; Sculpher, M; Sudlow, C | 1 |
| Bogousslavsky, J | 1 |
| Mattle, HP | 1 |
| Davis, KE; Denardo, SJ; Tcheng, JE | 1 |
| Heidenreich, PA; Schleinitz, MD | 1 |
| Alberti, PF; Del Soldato, P; Gresele, P; Minuz, P; Momi, S; Pitchford, SC | 1 |
| Antman, EM; Leopold, JA | 1 |
| Braunwald, E; Cannon, CP; Claeys, MJ; Cools, F; Gibson, CM; Hill, KA; López-Sendón, JL; McCabe, CH; Montalescot, G; Sabatine, MS; Skene, AM; Theroux, P | 1 |
| Becker, HD; Ernst, A; Feller-Kopman, D; Garland, R; Herth, F; Wahidi, MM | 1 |
| Grubitzsch, H; Sander, M; Schoenfeld, H; Spies, C; von Heymann, C; Ziemer, S | 1 |
| Buresly, K; Eisenberg, MJ; Pilote, L; Zhang, X | 1 |
| Madi-Jebara, S; Rkeiby-Kassabian, N; Yazigi, A | 1 |
| Antman, EM; Behounek, BD; Braunwald, E; Carney, RJ; Lazzam, C; McCabe, CH; McKay, RG; Murphy, SA; Weerakkody, G; Winters, KJ; Wiviott, SD | 1 |
| Antoniucci, D; Memisha, G; Migliorini, A; Moschi, G; Parodi, G; Pupi, A; Sciagrà, R; Valenti, R | 1 |
| Berthold, HK; Müller-Oerlinghausen, B; Tiaden, JD; Wenzel, E | 1 |
| Kannan, S | 1 |
| Arab, D; Cho, L; Joyal, D; Lewis, B; Leya, F; Steen, L | 1 |
| Hartung, HP; Nitschmann, S; Siebler, M | 1 |
| Gill, SS | 1 |
| Antman, EM; Braunwald, E; Cannon, CP; Dellborg, M; Gibson, CM; Keltai, M; Leiva-Pons, JL; McCabe, CH; Montalescot, G; Morrow, DA; Murphy, SA; Sabatine, MS | 1 |
| Bezerra, DC; Bogousslavsky, J | 1 |
| Iwata, M; Kimura, Y; Nakamura, T; Uchiyama, S; Yamazaki, M | 1 |
| Leschke, M; Sauer, H | 1 |
| Berger, PB; Bhatt, DL; Black, HR; Boden, WE; Booth, J; Brennan, DM; Cacoub, P; Cohen, EA; Creager, MA; Easton, JD; Fabry-Ribaudo, L; Flather, MD; Fox, KA; Hacke, W; Haffner, SM; Hamm, CW; Hankey, GJ; Johnston, SC; Mak, KH; Mas, JL; Montalescot, G; Pearson, TA; Steg, PG; Steinhubl, SR; Topol, EJ; Weber, MA | 1 |
| Bafi, AS; Boyce, SW; Corso, PJ; Dullum, MK; Haile, E; Hill, PC; Kapetanakis, EI; Medlam, DA; Petro, KR | 1 |
| Calvet, D; Mas, JL; Touzé, E | 1 |
| Bergman, G; Chou, E; Hong, MK; Khurram, Z; Minutello, R; Naidu, S; Parikh, M; Wong, SC | 1 |
| Adgey, JA; McClelland, AJ; Walsh, SJ | 1 |
| Lutsep, HL | 1 |
| Arayawichanont, A; Kongsaengdao, S | 1 |
| Kamalesh, M | 1 |
| Galor, A; Hoffman, GS; Lee, MS; Smith, SD | 1 |
| Kristensen, SD | 1 |
| Kjaer, J; Larsen, CH; Mickley, H; Møller, JE; Poulsen, TS | 1 |
| Bromberg-Marin, G; Canto, JG; Marin-Neto, JA; Parsons, LS; Rogers, WJ | 1 |
| Lindvall, G; Sartipy, U; van der Linden, J | 1 |
| Poston, R | 1 |
| Adgey, J; Cannon, CP; Lambert, Y; Lapostolle, F; Montalescot, G; Sabatine, MS; Soulat, L; Verheugt, FW | 1 |
| Gudín-Uriel, M; Ridocci-Soriano, F; Sánchez-Torrijos, J | 1 |
| Campbell, ME; Dery, JP; Gibson, CM; Harrington, RA; Madan, M; Mathias, J; O'Shea, JC; Pieper, KS; Tcheng, JE; Tolleson, TR | 1 |
| Cannon, CP; Guo, W; McCabe, CH; McLean, DS; Sabatine, MS | 1 |
| Crain, EJ; Knabb, RM; Lam, PY; Quan, ML; Watson, CA; Wexler, RR; Wong, PC | 1 |
| Liao, JK | 1 |
| Hawken, S; Keltai, M; Lewis, BS; Mann, JF; Mehta, SR; Sitkei, E; Tonelli, M; Yusuf, S | 1 |
| Fitzgerald, DJ; Maree, AO | 1 |
| Andrel, J; Chervoneva, I; DeCaro, M; DeEugenio, D; Duong, P; Greenspon, A; Kolman, L; Lam, L; Lee, G; McGowan, C; Ruggiero, N; Singhal, S | 1 |
| Al Askar, A; Al Shimemeri, A; Arabi, Y; Cherfan, A | 1 |
| Ackerstaff, RG; de Borst, GJ; de Vries, JP; Hilgevoord, AA; Moll, FL; van de Pavoordt, HD; van der Mee, M | 1 |
| Jackson, AJ; Orr, DJ; Teenan, RP | 1 |
| Macdonald, S | 1 |
| Chow, G; Ziegelstein, RC | 1 |
| Collins, JS; Gurm, HS | 1 |
| Meinertz, T | 1 |
| Anand, S; Budaj, A; Cina, C; Crowell, R; Eikelboom, J; Gosselin, G; Guzman, R; Keltai, M; Liu, L; Pogue, J; Sussex, B; Xie, C; Yusuf, S | 1 |
| Chassot, PG; Delabays, A; Spahn, DR | 1 |
| Bhatt, DL; Brennan, DM; Fox, K; Mak, KH; Saw, J; Steinhubl, SR; Topol, EJ | 1 |
| Bhatt, DL; Boden, WE; Brennan, DM; Flather, MD; Fox, KA; Hacke, W; Mak, KH; Montalescot, G; Pearson, TA; Steg, PG; Steinhubl, SR; Topol, EJ; Wang, TH | 1 |
| Bavry, AA; Bhatt, DL; Duggal, S; Helton, TJ; Kumbhani, DJ; Roukoz, H | 1 |
| Rivkin, A | 1 |
| Badimon, L; Casaní, L; Vilahur, G | 1 |
| Cannon, CP | 1 |
| Bergeron, S; Brulotte, S; Lemieux, A; Magne, J; Nguyen, CM; Poirier, P; Sénéchal, M | 1 |
| Eagle, KA; Froehlich, J; Gurm, HS; Li, J; Moscucci, M; Motivala, AA; Rogers, EK; Saab, F; Tamhane, U | 1 |
| Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Peters, G; Scirica, BM; Storey, RF | 1 |
| Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD | 1 |
| Berger, PB; Bruskina, O; Dirschinger, J; Dotzer, F; Iijima, R; Kastrati, A; Mehilli, J; Ndrepepa, G; Neumann, FJ; Schömig, A; Schulz, S; ten Berg, J | 1 |
| Dawley, CA; Fletcher, SF; Walker, CW | 1 |
| Berezny, KY; Bokesch, PM; Bonnet, D; Ewert, P; Graham, TP; Jennings, LK; Li, JS; Michelson, AD; Sanders, SP; Sidi, D; Takahashi, M; Yow, E | 1 |
| Delate, T; Johnson, SG; Rogers, K; Witt, DM | 1 |
| Bauer, T; Gitt, A; Gottwik, M; Heer, T; Jünger, C; Koeth, O; Mark, B; Senges, J; Zahn, R; Zeymer, U | 1 |
| Jakubczyk, M; Jakubczyk, P; Popławski, C | 1 |
| Kwa, AT; Rogers, JH | 1 |
| Foley, P | 1 |
| Dorsch, MP; Reaume, KT; Regal, RE | 1 |
| Schaerlig, E | 1 |
| Gawaz, M; Geisler, T; May, AE | 1 |
| Bonaca, M; Giugliano, R; Hoekstra, JW; Lefebvre, CW | 1 |
| Serebruany, V | 1 |
| Hollander, JE; Pollack, CV | 1 |
| Albers, GW; Schwartz, NE | 1 |
| Berger, PB; Best, PJ; Brennan, DM; Califf, RM; Dasgupta, A; Steinhubl, SR; Szczech, LA; Topol, EJ | 1 |
| Eikelboom, JW; Hankey, GJ; Langton, PE | 1 |
| Billett, HH | 1 |
| Brodie, BR | 1 |
| Kastrati, A; Mann, JF; Mehilli, J; Ndrepepa, G; Pinkau, T; Schömig, A; Schulz, S | 1 |
| Purushothaman, B | 1 |
| Hermosillo, AJ; Spinler, SA | 1 |
| Antman, EM; Braunwald, E; Chandna, H; Hasin, Y; Macias, W; McCabe, CH; Murphy, SA; Voitk, J; Widimsky, P; Wiviott, SD | 1 |
| Alvarez, W | 1 |
| Haber, SL; Riley, AB; Tafreshi, MJ | 1 |
| Topol, EJ | 1 |
| Collins, M; Colombo, A; Iyer, S; Kreps, E; Maida, R; Moses, JW; Moussa, I; Oetgen, M; Roubin, G; Wang, X | 1 |
| Marks, KR; McCullough, PA | 1 |
| Boysen, G | 1 |
| Boissel, JP; Gent, M; Harker, LA; Pilgrim, AJ | 1 |
| Fitzgerald, DJ; Quinn, MJ | 1 |
| Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ | 1 |
| Diener, HC | 1 |
| Chew, DP; Moliterno, DJ; Mukherjee, D; Raymond, RE; Robbins, M; Yadav, JS | 1 |
| Kilaru, PK; Kozman, HA; Schweiger, MJ; Weil, TR | 1 |
| Kurz, HI; Lasala, JM; Taniuchi, M | 1 |
| Chrolavicius, S; Fox, KK; Mehta, SR; Tognoni, G; Yusuf, S; Zhao, F | 1 |
| Ashley, SA; Bowley, DM; Chapman, TW; Lambert, AW; Walker, AJ; Wilkins, DC | 1 |
| Owen, A | 1 |
| Yende, S | 1 |
| Doggrell, SA | 1 |
| Taylor, R; Ward, DJ | 1 |
| Khot, UN; Nissen, SE | 1 |
296 review(s) available for clopidogrel and Hemorrhage
| Article | Year |
|---|---|
Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2022 |
Comparative Safety and Effectiveness of Loading Doses of P2Y12 Inhibitors in Patients Undergoing Elective PCI: a Network Meta-analysis.
Topics: Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke | 2023 |
De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome | 2022 |
Clopidogrel or ticagrelor alongside dabigatran in acute coronary syndrome and indication for NOAC: a study rationale.
Topics: Acute Coronary Syndrome; Anticoagulants; Clopidogrel; Dabigatran; Drug Therapy, Combination; Hemorrhage; Humans; Multicenter Studies as Topic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Randomized Controlled Trials as Topic; Ticagrelor; Warfarin | 2022 |
Risk of bleeding with ticagrelor in elderly patients over 75 years old: A systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Saudi Arabia; Ticagrelor; Treatment Outcome | 2021 |
Efficacy and safety of clopidogrel and/or aspirin for ischemic stroke/transient ischemic attack: An overview of systematic reviews and meta-analysis.
Topics: Aspirin; Brain Ischemia; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Meta-Analysis as Topic; Platelet Aggregation Inhibitors; Quality of Life; Secondary Prevention; Stroke; Systematic Reviews as Topic | 2021 |
Antiplatelet therapy in cardiovascular disease: Current status and future directions.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor | 2022 |
Comparison of Ticagrelor With Clopidogrel in East Asian Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Topics: Acute Coronary Syndrome; Asian People; Clopidogrel; Dyspnea; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Thrombosis; Ticagrelor; Treatment Outcome | 2022 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor as Part of Dual Antiplatelet Therapy in Acute Coronary Syndrome-A Systematic Review and Meta-analysis.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dyspnea; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thrombosis; Ticagrelor; Treatment Outcome | 2022 |
Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention.
Topics: Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2022 |
Effect of CYP2C19 genetic polymorphism on the pharmacodynamics and clinical outcomes for patients treated with ticagrelor: a systematic review with qualitative and quantitative meta-analysis.
Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prospective Studies; Ticagrelor; Treatment Outcome | 2022 |
Extended, standard, or De-escalation antiplatelet therapy for patients with coronary artery disease undergoing percutaneous coronary intervention? A trial-sequential, bivariate, influential, and network meta-analysis.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Hemorrhage; Humans; Network Meta-Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2022 |
Duration and kind of dual antiplatelet therapy for acute coronary syndrome patients: a network meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Middle Aged; Myocardial Infarction; Network Meta-Analysis; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Ticagrelor | 2023 |
Clopidogrel Vs Aspirin Monotherapy Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.
Topics: Aspirin; Clopidogrel; Death; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stroke; Treatment Outcome | 2023 |
High-Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta-Analysis of Randomized Trials.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Dyspnea; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome | 2022 |
Efficacy and Safety of De-escalation of Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Meta-Analysis of Randomized Clinical Trials.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2022 |
Comparative efficacy and safety of oral P2Y
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Network Meta-Analysis; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2022 |
Safety and Efficacy of Selective, Clopidogrel-Based Strategies in Acute Coronary Syndrome: A Study-Level Meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Treatment Outcome | 2022 |
Clopidogrel Monotherapy versus Aspirin Monotherapy in Patients with Established Cardiovascular Disease: Systematic Review and Meta-Analysis.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Stroke | 2022 |
Newer P2Y
Topics: Clopidogrel; Female; Heart Arrest; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Shock, Cardiogenic; Thrombosis; Treatment Outcome | 2022 |
Efficacy and Safety of Ticagrelor in East Asian Patients with Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
Topics: Acute Coronary Syndrome; Asian People; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome | 2022 |
P2Y12 inhibitor pretreatment in patients with nonST-segment elevation acute coronary syndrome: A meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2022 |
Antiplatelet agents and anticoagulants for hypertension.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; Middle Aged; Platelet Aggregation Inhibitors; Thromboembolism; Thrombosis; Warfarin | 2022 |
Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis.
Topics: Aspirin; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Network Meta-Analysis; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban; Ticagrelor; Vitamin K | 2022 |
Antiplatelet therapy after noncardioembolic ischemic stroke or transient ischemic attack.
Topics: Anticoagulants; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Factor XI; Fibrinolytic Agents; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Platelet Aggregation Inhibitors; Stroke; Ticagrelor | 2022 |
Dual Antiplatelet Therapy in Patients Aged 75 Years and Older with Coronary Artery Disease: A Meta-Analysis and Systematic Review.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Ticagrelor; Treatment Outcome | 2022 |
Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Ticlopidine | 2022 |
Platelet Aggregation Inhibitors and Anticoagulants in Gastroenterological and Visceral Surgical Procedures.
Topics: Anticoagulants; Clopidogrel; Gastroenterology; Hemorrhage; Humans; Platelet Aggregation Inhibitors | 2022 |
De-escalation of antiplatelet therapy in patients with coronary artery disease: Time to change our strategy?
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Treatment Outcome | 2023 |
Dual Antiplatelet Therapy Does Not Increase Bleeding Risk in Percutaneous Gastrostomy Tube Placement: Network Meta-Analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Gastrostomy; Hemorrhage; Humans; Network Meta-Analysis; Platelet Aggregation Inhibitors; Treatment Outcome | 2023 |
Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis.
Topics: Aspirin; Atherosclerosis; Bayes Theorem; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Ischemic Stroke; Myocardial Infarction; Network Meta-Analysis; Platelet Aggregation Inhibitors; Regression Analysis; Rivaroxaban; Stroke; Ticagrelor | 2023 |
Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Treatment Outcome | 2023 |
Efficacy and Safety of Clopidogrel in the Prevention of Primary Failure of Arteriovenous Fistula in Patients with End-Stage Renal Disease: A Systematic Review.
Topics: Arteriovenous Fistula; Arteriovenous Shunt, Surgical; Clopidogrel; Hemorrhage; Humans; Kidney Failure, Chronic; Randomized Controlled Trials as Topic; Renal Dialysis | 2023 |
Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines.
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke; Warfarin | 2023 |
Efficacy and Safety of Ticagrelor versus Aspirin and Clopidogrel for Stroke Prevention in Patients with Vascular Disease: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Ischemic Stroke; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2023 |
Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; East Asian People; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticagrelor; Treatment Outcome | 2023 |
Clinical and Pre-Clinical Pharmacokinetics and Pharmacodynamics of Bentracimab.
Topics: Acute Coronary Syndrome; Antibodies, Monoclonal; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2023 |
P2Y12 Inhibitors for Non-ST-Segment Elevation Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Network Meta-Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2023 |
Antithrombotic treatment following percutaneous coronary intervention in patients with high bleeding risk.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Treatment Outcome | 2023 |
Ticagrelor or Clopidogrel as Antiplatelet Agents in Patients with Chronic Kidney Disease and Cardiovascular Disease: A Meta-analysis.
Topics: Acute Coronary Syndrome; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Ticagrelor; Treatment Outcome | 2023 |
Ticagrelor plus aspirin in patients with minor ischemic stroke and transient ischemic attack: a network meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Network Meta-Analysis; Platelet Aggregation Inhibitors; Stroke; Ticagrelor | 2023 |
Comparison efficacy and safety of different antiplatelet or anticoagulation drugs in chronic coronary syndromes patients: A Bayesian network meta-analysis.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Bayes Theorem; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Rivaroxaban; Ticagrelor; Treatment Outcome | 2023 |
Antagonizing P2Y12 Receptor Inhibitors: Current and Future Options.
Topics: Administration, Oral; Antibodies, Monoclonal; Blood Platelets; Broadly Neutralizing Antibodies; Cardiology; Clopidogrel; Hemadsorption; Hemorrhage; Hemostasis; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk; Signal Transduction; Thrombosis; Ticagrelor | 2019 |
Antithrombotic regimen for patients with cardiac indication for dual antiplatelet therapy and anticoagulation: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Factor Xa Inhibitors; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Ticagrelor; Warfarin | 2020 |
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrence; Risk Assessment; Risk Factors; Secondary Prevention; Stroke; Time Factors; Treatment Outcome | 2019 |
Dual antiplatelet therapy in coronary artery disease: from the past to the future prospective.
Topics: Acute Coronary Syndrome; Anticoagulants; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Heart Diseases; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Ticagrelor | 2020 |
Assessing platelet reactivity after drug eluting stent implantation: state of the art.
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists | 2020 |
Efficacy and Safety of Potent Oral P2Y
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.
Topics: Aged; Aged, 80 and over; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2020 |
The Role of Clopidogrel in 2020: A Reappraisal.
Topics: Blood Platelets; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Secondary Prevention; Treatment Outcome | 2020 |
Meta-Analysis Comparing P2Y
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Clopidogrel; Graft Occlusion, Vascular; Hemorrhage; Humans; Myocardial Infarction; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Ticagrelor | 2020 |
Monotherapy with a P2Y
Topics: Aged; Aspirin; Atherosclerosis; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Secondary Prevention; Stroke; Ticagrelor; Ticlopidine | 2020 |
Very short dual antiplatelet therapy after PCI and new DES: a meta-analysis of 5 randomized trials.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Randomized Controlled Trials as Topic; Ticagrelor; Time Factors; Treatment Outcome | 2021 |
The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Percutaneous Coronary Intervention; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Withholding Treatment | 2020 |
Antiplatelet Therapy in Elderly Patients with Acute Coronary Syndromes: the Clopidogrel Revenge: Possible Reasons for a Bright Comeback.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Dual Anti-Platelet Therapy; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor | 2021 |
Meta-Analysis Comparing Potent Oral P2Y
Topics: Aged; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic | 2021 |
Antiplatelet Therapy for Transient Ischemic Attack and Minor Stroke.
Topics: Aspirin; Clopidogrel; Drug Resistance; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Platelet Aggregation Inhibitors; Risk Assessment; Secondary Prevention; Severity of Illness Index; Ticagrelor | 2020 |
Effects of the
Topics: Acute Coronary Syndrome; ATP Binding Cassette Transporter, Subfamily B; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide | 2020 |
The 2020 breakthroughs in early secondary prevention: dual antiplatelet therapy versus single antiplatelet therapy.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Early Medical Intervention; Hemorrhage; History, 21st Century; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke | 2021 |
Risk Factors for Bleeding and Clinical Ineffectiveness Associated With Clopidogrel Therapy: A Comprehensive Meta-Analysis.
Topics: Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Plaque, Atherosclerotic; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Thrombosis; Time Factors; Treatment Failure | 2021 |
Meta-Analysis Comparing the Safety and Efficacy of Single vs Dual Antiplatelet Therapy in Post Transcatheter Aortic Valve Implantation Patients.
Topics: Aortic Valve Stenosis; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemic Attack, Transient; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Postoperative Care; Stroke; Thrombosis; Transcatheter Aortic Valve Replacement | 2021 |
Aspirin Alone Versus Dual Antiplatelet Therapy after Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis.
Topics: Aortic Valve; Aspirin; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Stroke; Transcatheter Aortic Valve Replacement | 2022 |
Comparison of major bleeding in patients with acute coronary syndrome that underwent coronary artery bypass grafting treated with clopidogrel or ticagrelor: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Ticagrelor | 2020 |
Usefulness of Antiplatelet Therapy After Transcatheter Aortic Valve Implantation.
Topics: Aortic Valve Stenosis; Aspirin; Cause of Death; Clopidogrel; Dual Anti-Platelet Therapy; Endothelium; Evidence-Based Medicine; Hemorrhage; Humans; Mortality; Platelet Aggregation Inhibitors; Stroke; Thrombosis; Transcatheter Aortic Valve Replacement | 2021 |
Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: A meta-analysis.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Pyrazoles; Pyridones; Risk Factors | 2021 |
Ticagrelor vs Clopidogrel in addition to Aspirin in minor ischemic stroke/ transient ischemic attack-Protocol for a systematic review and network meta-analysis.
Topics: Aspirin; Bayes Theorem; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Network Meta-Analysis; Platelet Aggregation Inhibitors; Ticagrelor | 2021 |
Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations.
Topics: Clopidogrel; Genetic Testing; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Precision Medicine; Purinergic P2Y Receptor Antagonists; Thrombosis | 2021 |
Efficacy and Safety of Low-Dose Prasugrel Versus Clopidogrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2022 |
Meta-Analysis of Usefulness of Antiplatelet Therapy in Ischemic Stroke or Transient Ischemic Attack.
Topics: Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Early Medical Intervention; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Mortality; Platelet Aggregation Inhibitors; Proportional Hazards Models; Secondary Prevention; Ticagrelor | 2021 |
Increased risk of adverse events in patients with low-on clopidogrel platelet reactivity after percutaneous coronary intervention: A systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2023 |
Ischemic and Bleeding Outcomes of Potent P2Y12 Inhibitor Antiplatelet Agents Versus Clopidogrel in Elderly Patients With Acute Coronary Syndrome: A Meta-Analysis of Randomized Trials.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stroke; Ticagrelor; Treatment Outcome | 2022 |
Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease.
Topics: Aged; Aspirin; Clopidogrel; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Lower Extremity; Male; Middle Aged; Network Meta-Analysis; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Rivaroxaban; Treatment Outcome | 2021 |
Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease.
Topics: Asian People; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Coronary Artery Disease; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Risk Factors; Ticlopidine | 2017 |
Bleeding risk of antiplatelet drugs compared with oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk; Stroke; Ticlopidine; Treatment Outcome; Vitamin K; Warfarin | 2017 |
Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recurrence; Ticlopidine | 2017 |
[Management of the bleeding risk associated with antiplatelet agents].
Topics: Adenosine; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Ticlopidine | 2017 |
The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis.
Topics: Anticoagulants; Aspirin; Bayes Theorem; Cardiovascular Diseases; Clopidogrel; Dabigatran; Dipyridamole; Hemorrhage; Humans; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Thiazoles; Ticlopidine; Treatment Outcome; Warfarin | 2017 |
Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Drug Resistance; Drug Therapy, Combination; Hemorrhage; Humans; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Precision Medicine; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Risk Factors; Ticlopidine; Treatment Outcome | 2017 |
[Antiplatelet agents and transfusion].
Topics: Adenosine; Antidotes; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk; Ticagrelor; Ticlopidine | 2017 |
[Impact of different antithrombotic therapy strategy on prognosis in coronary heart disease patients combining with atrial fibrillation: a meta analysis].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Randomized Controlled Trials as Topic; Stroke; Ticlopidine; Warfarin | 2017 |
Ticagrelor versus clopidogrel in East-Asian patients with acute coronary syndromes: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Asia; Clopidogrel; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticagrelor; Treatment Outcome | 2018 |
The role of prasugrel in the management of acute coronary syndromes: a systematic review.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thrombosis; Ticlopidine | 2017 |
Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives.
Topics: Adenosine Monophosphate; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2018 |
Dual antiplatelet therapy after percutaneous coronary intervention for stable CAD or ACS : Redefining the optimal duration of treatment.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemorrhage; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stents; Ticagrelor | 2018 |
Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine | 2017 |
Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Neoplasms; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2018 |
Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome: Systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aged; Asia, Eastern; Asian People; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Ticagrelor; Treatment Outcome | 2018 |
Comparison of single versus dual antiplatelet therapy after TAVR: A systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Postoperative Complications; Risk Assessment; Risk Factors; Time Factors; Transcatheter Aortic Valve Replacement; Treatment Outcome | 2018 |
Clinical utility of remote platelet function measurement using P-selectin: assessment of aspirin, clopidogrel, and prasugrel and bleeding disorders.
Topics: Aspirin; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; P-Selectin; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Ticlopidine | 2018 |
Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clopidogrel; Drug Administration Schedule; Evidence-Based Medicine; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Treatment Outcome | 2018 |
Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis.
Topics: Administration, Oral; Aged; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2018 |
Ticagrelor Versus Clopidogrel as Part of Dual or Triple Antithrombotic Therapy: a Systematic Review and Meta-Analysis.
Topics: Administration, Oral; Anticoagulants; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Ticagrelor; Treatment Outcome | 2018 |
Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; DNA; Drug Therapy, Combination; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Histones; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban; Thrombosis; Warfarin | 2018 |
Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a systematic review and meta-analysis.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2018 |
Efficacy and safety of triple therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing coronary stenting: A meta-analysis.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Stents; Stroke; Thrombosis; Warfarin | 2018 |
Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials.
Topics: Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; ST Elevation Myocardial Infarction; Stroke; Survival Analysis; Thrombolytic Therapy; Ticagrelor | 2018 |
Continuation versus discontinuation of antiplatelet therapy for bleeding and ischaemic events in adults undergoing non-cardiac surgery.
Topics: Adult; Aspirin; Cause of Death; Clopidogrel; Elective Surgical Procedures; Hemorrhage; Humans; Ischemia; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine; Withholding Treatment | 2018 |
Meta-Analysis of Potent P2Y12-ADP Receptor Antagonist Therapy Compared to Clopidogrel Therapy in Acute Coronary Syndrome Patients with Chronic Kidney Disease.
Topics: Acute Coronary Syndrome; Administration, Oral; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; France; Hemorrhage; Humans; Odds Ratio; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Survival Analysis; Ticagrelor; Treatment Outcome | 2018 |
Dropping aspirin in patients with atrial fibrillation undergoing percutaneous coronary intervention: a jump with a weak parachute?
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Decision-Making; Clopidogrel; Evidence-Based Medicine; Fibrinolytic Agents; Hemorrhage; Humans; Meta-Analysis as Topic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2019 |
Triple therapy: worth the risk?
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Humans; Mortality; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Rivaroxaban; Stents; Stroke; Thrombophilia; Ticlopidine | 2018 |
Single versus Dual Antiplatelet Therapy after Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-Analysis.
Topics: Aortic Valve; Aspirin; Cerebrovascular Disorders; Clopidogrel; Drug Therapy, Combination; Heart Valve Prosthesis; Hemorrhage; Humans; Mortality; Platelet Aggregation Inhibitors; Risk Assessment; Thrombosis; Treatment Outcome | 2018 |
Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Dyspnea; Hemorrhage; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Ticagrelor; Treatment Outcome | 2018 |
Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Risk Factors; Secondary Prevention; Stroke; Time Factors; Treatment Outcome | 2019 |
Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Mortality; Platelet Aggregation Inhibitors; Recurrence; Secondary Prevention; Severity of Illness Index; Stroke | 2018 |
Novel Oral Anticoagulants in Peripheral Artery Disease: Current Evidence.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Hemorrhage; Humans; Peripheral Arterial Disease; Treatment Outcome | 2018 |
Antithrombotic Therapy After Transcatheter Aortic Valve Replacement.
Topics: Anticoagulants; Aortic Valve Stenosis; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Transcatheter Aortic Valve Replacement; Treatment Outcome | 2019 |
Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy.
Topics: Aged; Anticoagulants; Aspirin; Atherosclerosis; Cardiology; Cardiovascular Diseases; Carotid Arteries; Carotid Artery Diseases; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Revascularization; Platelet Aggregation Inhibitors; Risk; Rivaroxaban | 2019 |
Efficacy and safety of alternative oral administrations of P2Y12-receptor inhibitors: Systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Safety; Ticagrelor; Treatment Outcome | 2019 |
Effectiveness and Safety of Platelet ADP -P2Y12 Receptor Inhibitors Influenced by Smoking Status: A Systematic Review and Meta-Analysis.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Cigarette Smoking; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Treatment Outcome | 2019 |
De-escalation from ticagrelor to clopidogrel in acute coronary syndrome patients: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Hospitalization; Humans; Patient Discharge; Prevalence; Ticagrelor | 2019 |
Early Secondary Prevention in Transient Ischemic Attack (TIA) and Minor Stroke.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke | 2019 |
Clinical Outcomes of Antithrombotic Strategies for Patients with Atrial Fibrillation After Percutaneous Coronary Intervention.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Observational Studies as Topic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Vitamin K | 2019 |
Aspirin Versus Clopidogrel Monotherapy for the Treatment of Patients with Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke | 2019 |
Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Cerebral Revascularization; Clopidogrel; Cytochrome P-450 CYP2C19; Gene Expression; Genotype; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stroke; Survival Analysis; Thrombosis | 2019 |
Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug-Eluting Stents; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Thrombosis | 2019 |
A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly.
Topics: Adenosine; Cardiac Surgical Procedures; Clopidogrel; Hemorrhage; Humans; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Surgical Procedures, Operative; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review.
Topics: Aspirin; Bleeding Time; Clopidogrel; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticlopidine; Treatment Outcome | 2013 |
Perioperative management of antiplatelet therapy in patients with a coronary stent who need noncardiac surgery: a systematic review of clinical practice guidelines.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Elective Surgical Procedures; Hemorrhage; Humans; Metals; Perioperative Care; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Stents; Thromboembolism; Ticlopidine; Time Factors; Withholding Treatment | 2013 |
[The most important aspects of risk assessment].
Topics: Algorithms; Aspirin; Cardiovascular Diseases; Clopidogrel; Digestive System Surgical Procedures; Drug Substitution; Drug Therapy, Combination; Health Status Indicators; Hemorrhage; Heparin; Humans; Perioperative Period; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Assessment; Thromboembolism; Ticlopidine; Viscera | 2013 |
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Contraindications; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Secondary Prevention; Stents; Stroke; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2013 |
Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons.
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Tetrazoles; Ticlopidine; Treatment Outcome | 2014 |
[Thrombocyte aggregation inhibitors: what are the risks?].
Topics: Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis.
Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Precision Medicine; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention; Stroke; Ticlopidine | 2013 |
[Differentiated antiplatelet therapy for acute coronary syndromes].
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine | 2014 |
New antiplatelet agents in the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Thrombosis; Diabetes Complications; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Renal Insufficiency; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Efficacy and safety of prasugrel in acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2014 |
Effects of P2Y12 receptor inhibition in patients with ST-segment elevation myocardial infarction.
Topics: Administration, Oral; Aged; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug; Electrocardiography; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Ticlopidine; Treatment Outcome | 2014 |
[Dual platelet inhibitors in intensive care units].
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Germany; Guideline Adherence; Hemorrhage; Humans; Hypothermia, Induced; Intensive Care Units; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Risk Assessment; Shock, Cardiogenic; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Risk; Safety; Stroke; Ticlopidine | 2014 |
Decade in review--acute coronary syndromes: Successes and future objectives in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Hemorrhage; Humans; Myocardial Revascularization; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2014 |
How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors--is an algorithm the answer?
Topics: Algorithms; Animals; Blood Platelets; Clopidogrel; Coronary Thrombosis; Decision Support Techniques; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Pharmacogenetics; Platelet Aggregation Inhibitors; Platelet Function Tests; Precision Medicine; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Ticlopidine; Treatment Outcome | 2015 |
Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Ticlopidine; Vitamin K; Warfarin | 2014 |
Dual versus single antiplatelet therapy in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Ticlopidine; Time Factors; Transcatheter Aortic Valve Replacement | 2015 |
Outcome comparison of 600 mg versus 300 mg loading dose of clopidogrel for patients with ST-elevation myocardial infarction: a meta-analysis.
Topics: Aged; Clopidogrel; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine | 2014 |
Resistance to antiplatelet drugs: what progress has been made?
Topics: Aspirin; Clopidogrel; Graft Occlusion, Vascular; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Precision Medicine; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Stents; Thrombosis; Ticlopidine; Treatment Failure | 2014 |
[Added value of clopidogrel in cardiology and neurology].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Factors; Secondary Prevention; Stroke; Thrombosis; Ticlopidine | 2014 |
Use of antiplatelet drugs after cardiac operations.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Administration Schedule; Drug Therapy, Combination; Graft Occlusion, Vascular; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome; Vascular Patency | 2014 |
Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Recurrence; Secondary Prevention; Stroke; Ticlopidine | 2015 |
[Anticoagulant therapy in secondary prevention of coronary events].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Ticlopidine; Warfarin | 2014 |
Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention.
Topics: Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stents; Ticlopidine; Treatment Outcome | 2015 |
P2Y12 receptor inhibitors for secondary prevention of ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Secondary Prevention; Stroke; Ticlopidine | 2015 |
High maintenance dose of clopidogrel in patients with high on-treatment platelet reactivity after a percutaneous coronary intervention: a meta-analysis.
Topics: Cerebrovascular Disorders; Chi-Square Distribution; Clopidogrel; Drug Resistance; Heart Diseases; Hemorrhage; Humans; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Assessment; Risk Factors; Ticlopidine; Treatment Outcome | 2015 |
Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies.
Topics: Acute Coronary Syndrome; Administration, Oral; Clopidogrel; Evidence-Based Medicine; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk Factors; Stroke; Thrombosis; Ticlopidine | 2015 |
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention.
Topics: Aged; Clopidogrel; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Stents; Thrombosis; Ticlopidine | 2015 |
Antiplatelet therapy following transcatheter aortic valve implantation.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Cardiac Catheterization; Clopidogrel; Drug Therapy, Combination; Female; Heart Valve Prosthesis Implantation; Hemorrhage; Humans; Male; Odds Ratio; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Substitution; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Survival Analysis; Thrombosis; Ticlopidine; Treatment Outcome | 2016 |
Meta-Analysis of Randomized Controlled Trials Comparing Risk of Major Adverse Cardiac Events and Bleeding in Patients With Prasugrel Versus Clopidogrel.
Topics: Clopidogrel; Coronary Artery Disease; Global Health; Hemorrhage; Humans; Incidence; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine | 2015 |
Practical experience with ticagrelor: an Australian and New Zealand perspective.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
Topics: Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Clopidogrel and Aspirin versus Aspirin Alone for Stroke Prevention: A Meta-Analysis.
Topics: Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Stroke; Ticlopidine | 2015 |
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2015 |
Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
Topics: Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Half-Life; Hemorrhage; Humans; Lactones; Myocardial Infarction; Myocardial Ischemia; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Receptor, PAR-1; Secondary Prevention; Stroke; Thrombosis; Ticlopidine | 2015 |
Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stroke; Ticlopidine | 2015 |
Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Stents; Tetrazoles; Thrombosis; Ticlopidine | 2015 |
The impact of switching P2Y12 receptor inhibitor therapy during index hospitalization: a systematic review.
Topics: Cardiovascular Diseases; Clopidogrel; Hemorrhage; Hospitalization; Humans; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2016 |
Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Comparative Effectiveness Research; Glomerular Filtration Rate; Hemorrhage; Humans; Lactones; Patient Selection; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Renal Insufficiency; Ticagrelor; Ticlopidine | 2015 |
On-treatment platelet reactivity: State of the art and perspectives.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Hemorrhage; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Sex Factors; Stents; Thrombosis; Ticagrelor; Ticlopidine | 2016 |
Clopidogrel Response Variability: Review of the Literature and Practical Considerations.
Topics: Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Thrombosis; Ticlopidine; Treatment Failure | 2016 |
Safety and Efficacy of Switching From Clopidogrel to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: A Study-level Meta-analysis From 15 Studies.
Topics: Clopidogrel; Drug Substitution; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Ticlopidine | 2016 |
[Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack].
Topics: Aspirin; Clopidogrel; Databases, Factual; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Risk; Stroke; Ticlopidine; Treatment Outcome | 2015 |
Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Risk Factors; Secondary Prevention; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke; Tetrazoles; Ticlopidine | 2016 |
What is the optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation?
Topics: Aspirin; Clopidogrel; Drug Administration Schedule; Drug-Eluting Stents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Thrombosis; Ticlopidine; Time Factors | 2016 |
[Meta-analysis of the combination of warfarin and clopidogrel after coronary stenting in patients with indications for chronic oral anticoagulation].
Topics: Administration, Oral; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stents; Stroke; Ticlopidine; Warfarin | 2016 |
[Switching from clopidogrel to prasugrel: Efficacy and safety data].
Topics: Clopidogrel; Drug Substitution; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine | 2015 |
Association between CYP3A5 polymorphisms and the risk of adverse events in patients undergoing clopidogrel therapy: Meta-analysis.
Topics: Clopidogrel; Cytochrome P-450 CYP3A; Drug Resistance; Genetic Association Studies; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2016 |
Prasugrel hydrochloride for the treatment of acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thrombosis; Ticlopidine | 2016 |
Risk and Benefits of Triple Therapy in Patients Undergoing Coronary Stent Implantation Requiring Oral Anticoagulation: A Meta-Analysis of 16 Studies.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk; Stents; Ticlopidine; Warfarin | 2016 |
A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease.
Topics: Adenosine; Antithrombins; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; Factor Xa Inhibitors; Hemorrhage; History, 20th Century; History, 21st Century; History, Ancient; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Ticagrelor; Ticlopidine | 2016 |
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
Topics: Acute Coronary Syndrome; Analysis of Variance; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Artery Disease; Death, Sudden, Cardiac; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Stroke; Ticlopidine; Treatment Outcome | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Kaplan-Meier Estimate; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Stents; Ticlopidine; Treatment Outcome | 2017 |
Dual antiplatelet therapy with clopidogrel and aspirin.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Contraindications; Coronary Artery Bypass; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Polypharmacy; Ticlopidine | 2008 |
[Clopidogrel--clinical use and potential therapeutic problems].
Topics: Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Heart Diseases; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Stents; Thrombosis; Ticlopidine | 2008 |
Prasugrel development - claims and achievements.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Drug Administration Schedule; Drug Discovery; Drug Resistance; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Research Design; Risk Assessment; Stents; Thiophenes; Ticlopidine; Treatment Outcome | 2009 |
Monitoring platelet function to reduce the risk of ischemic and bleeding complications.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Ischemia; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Risk Factors; Sensitivity and Specificity; Ticlopidine; Treatment Outcome | 2009 |
Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Evidence-Based Medicine; Hemodynamics; Hemorrhage; Humans; Ischemia; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Risk Assessment; Thrombosis; Ticlopidine; Treatment Outcome | 2009 |
Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Hemorrhage; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Registries; Risk Assessment; Ticlopidine | 2008 |
Does timing matter? Upstream or downstream administration of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Algorithms; Aspirin; Clopidogrel; Coronary Angiography; Drug Administration Schedule; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Ticlopidine | 2009 |
Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble?
Topics: Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dipyridamole; Drug Combinations; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine; Treatment Outcome | 2009 |
Clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug-Eluting Stents; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2009 |
Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Confounding Factors, Epidemiologic; Decision Making; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; Evidence-Based Medicine; Female; Follow-Up Studies; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Multicenter Studies as Topic; Patient Selection; Platelet Aggregation Inhibitors; Research Design; Secondary Prevention; Ticlopidine | 2009 |
Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: a look at the clinical and pharmacological evidence.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Factors; Ticlopidine; Withholding Treatment | 2009 |
Prasugrel for the treatment of patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome | 2009 |
[Drug-eluting stents: implications for modern coronary revascularization].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Bias; Clopidogrel; Comorbidity; Coronary Artery Bypass; Coronary Restenosis; Drug Therapy, Combination; Drug-Eluting Stents; Guideline Adherence; Hemorrhage; Humans; Intraoperative Complications; Long-Term Care; Platelet Aggregation Inhibitors; Publication Bias; Reoperation; Substance Withdrawal Syndrome; Survival Rate; Ticlopidine; Treatment Outcome | 2009 |
Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Hemorrhage; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Thrombin; Ticlopidine; Treatment Outcome | 2008 |
Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Secondary Prevention; Ticlopidine | 2009 |
Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Chemotherapy, Adjuvant; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Heparin; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Risk Assessment; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Antiplatelet therapy discontinuation following drug-eluting stent placement: dangers, reasons, and management recommendations.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Health Knowledge, Attitudes, Practice; Hemorrhage; Humans; Medication Adherence; Oral Surgical Procedures; Patient Education as Topic; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Coronary bypass surgery in patients treated with clopidogrel. Is it safe?
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine; Treatment Outcome | 2009 |
Platelet function testing and implications for clinical practice.
Topics: Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Hemorrhage; Hemostasis; Humans; Ischemia; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Risk Assessment; Thrombosis; Ticlopidine; Treatment Outcome | 2009 |
[Long-term use of oral antiplatelet therapy: from studies to practice].
Topics: Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Combinations; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Ticlopidine | 2010 |
Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2009 |
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Prasugrel: Clinical development and therapeutic application.
Topics: Acute Coronary Syndrome; Angioplasty; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Thrombosis; Ticlopidine | 2009 |
[Thienopyridines in the treatment and prevention of cardiovascular diseases. III. therapeutic application of clopidogrel as monotherapy (without acetylsalicylic acid)].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Pyridines; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Ticlopidine; Ulcer | 2009 |
What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.
Topics: Clopidogrel; Drug Evaluation, Preclinical; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Risk Factors; Thiophenes; Ticlopidine | 2010 |
Preventing serious sequelae after an acute coronary syndrome: the consequences of thrombosis versus bleeding with antiplatelet therapy.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Thrombosis; Ticlopidine | 2010 |
Modern role for clopidogrel in management of atrial fibrillation and stroke reduction.
Topics: Age Factors; Atrial Fibrillation; Clopidogrel; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2010 |
Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase III as Topic; Clopidogrel; Drug Evaluation, Preclinical; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Kidney Failure, Chronic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2010 |
Prolonged infusion of eptifibatide as bridge therapy between bare-metal stent insertion and cardiovascular surgery: case report and review of the literature.
Topics: Angioplasty; Anticoagulants; Aspirin; Cardiovascular Surgical Procedures; Clopidogrel; Coronary Artery Bypass; Eptifibatide; Hemorrhage; Humans; Male; Metals; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Thrombosis; Ticlopidine | 2010 |
Dosing strategies for antiplatelet therapy in percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2010 |
Safety evaluation of tirofiban.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Double-Blind Method; Drug Resistance; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Incidence; Multicenter Studies as Topic; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Thrombocytopenia; Ticlopidine; Tirofiban; Tyrosine | 2010 |
[Reduction of haemorrhagic risk in acute coronary syndromes].
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine | 2011 |
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease Management; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Ticlopidine; Treatment Outcome | 2011 |
[Thienopyridines in the treatment and prevention of cardiovascular diseases. Part V. Combination of clopidogrel and acetylsalicylic acid in the treatment of stable patients with atherothrombotic cardiovascular diseases].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Circulation; Death, Sudden, Cardiac; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Sex Factors; Streptokinase; Stroke; Thrombosis; Ticlopidine; Time Factors | 2010 |
[New aspects on "triple therapy" after coronary stent implantation].
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cross-Sectional Studies; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Risk Factors; Stents; Stroke; Thrombosis; Ticlopidine; Vitamin K | 2010 |
The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects.
Topics: Adenosine; Adenosine Diphosphate; Animals; Blood Platelet Disorders; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; Mice; Mutation; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
The safety of clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purpura, Thrombotic Thrombocytopenic; Ticlopidine | 2011 |
[Antithrombotic therapy in patients with prosthetic heart valves].
Topics: Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Drug Monitoring; Heart Valve Diseases; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Hemorrhage; Humans; Monitoring, Physiologic; Platelet Aggregation Inhibitors; Prognosis; Thromboembolism; Ticlopidine; Warfarin | 2010 |
Prasugrel: an efficacy and safety review of a new antiplatelet therapy option.
Topics: Acute Coronary Syndrome; American Heart Association; Angioplasty, Balloon, Coronary; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Assessment; Thiophenes; Ticlopidine; Treatment Outcome; United States | 2010 |
Platelet function testing in clinical diagnostics.
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Hemorrhage; Humans; Intracranial Embolism; Intracranial Thrombosis; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Ticlopidine | 2011 |
[New approaches and indications for the analysis of platelet function in cardiology].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Patient Selection; Risk Assessment; Risk Factors; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome; Warfarin | 2011 |
Antiplatelet therapy in the perioperative period.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; Hemorrhage; Humans; Perioperative Period; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Stents; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Thienopyridines in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thienopyridines; Ticlopidine | 2011 |
Antiplatelet agents in cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine; Time Factors; United States | 2011 |
[Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?].
Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2011 |
Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Myocardial infarction: Role of new antiplatelet agents].
Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Disease Management; Drug Resistance; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Reperfusion; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine; Time Factors | 2011 |
Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Headache; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Recurrence; Risk Factors; Stroke; Ticlopidine | 2011 |
Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies.
Topics: Acute Coronary Syndrome; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Critical Care; Female; Hemorrhage; Humans; Length of Stay; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Preoperative Care; Reoperation; Research Design; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Treatment Outcome | 2011 |
Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2011 |
Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Genotype; Hemorrhage; Humans; Pharmacogenetics; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Risk Factors; Ticlopidine | 2012 |
Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies.
Topics: Blood Transfusion; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Drug Administration Schedule; Evidence-Based Medicine; Hemorrhage; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Reoperation; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Anticipating and managing bleeding complications in patients with coronary stents who are receiving dual antiplatelet treatment.
Topics: Blood Component Transfusion; Catheters, Indwelling; Clopidogrel; Coagulants; Coronary Artery Disease; Coronary Restenosis; Drug Interactions; Drug Therapy, Combination; Drug-Eluting Stents; Endoscopy, Gastrointestinal; Fibrinolytic Agents; Forecasting; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Proton Pump Inhibitors; Risk Factors; Stents; Ticlopidine; Treatment Outcome | 2011 |
Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Clopidogrel "resistance": where are we now?
Topics: Clopidogrel; Dose-Response Relationship, Drug; Drug Resistance; Drug Substitution; Hemorrhage; Humans; Medication Adherence; Percutaneous Coronary Intervention; Pharmacogenetics; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Risk Factors; Thrombosis; Ticlopidine; Treatment Failure | 2013 |
Antiplatelet options for secondary prevention in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Risk Factors; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Kidney Diseases; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine; Uremia | 2011 |
The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Genetic Predisposition to Disease; Genetic Variation; Hemorrhage; Humans; Odds Ratio; Phenotype; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Thrombosis; Ticlopidine; Treatment Outcome | 2012 |
Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel.
Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Hemorrhage; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Randomized Controlled Trials as Topic; Risk; Thrombosis; Ticlopidine | 2011 |
Quantitative comparison of clopidogrel 600 mg, prasugrel and ticagrelor, against clopidogrel 300 mg on major adverse cardiovascular events and bleeding in coronary stenting: synthesis of CURRENT-OASIS-7, TRITON-TIMI-38 and PLATO.
Topics: Adenosine; Animals; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.
Topics: Acute Coronary Syndrome; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Thiophenes; Ticlopidine | 2012 |
Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Stroke; Ticlopidine; Treatment Outcome | 2012 |
Acute coronary syndromes: identifying the appropriate patient for prasugrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Secondary Prevention; Thiophenes; Ticlopidine | 2012 |
What do you do with the antiplatelet agents in patients with drug eluting stents who then receive a mechanical valve?
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Aspirin; Benchmarking; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Evidence-Based Medicine; Female; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Hemorrhage; Humans; Male; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Prosthesis Design; Risk Assessment; Risk Factors; Sirolimus; Thrombosis; Ticlopidine; Treatment Outcome | 2012 |
Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding.
Topics: Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Genetic Association Studies; Genetic Predisposition to Disease; Genotype; Hemorrhage; Humans; Polymorphism, Genetic; Risk; Thrombosis; Ticlopidine | 2012 |
Platelet function and inhibition in ischemic heart disease.
Topics: Blood Platelets; Clopidogrel; Drug Resistance; Hemorrhage; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Thrombin; Ticlopidine | 2012 |
[New antithrombotic drugs].
Topics: Adenosine; Anticoagulants; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2012 |
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombolytic Therapy; Ticlopidine; Warfarin | 2012 |
Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Clinical use of clopidogrel.
Topics: Blood Platelets; Calcium Channel Blockers; Cardiovascular Diseases; Clopidogrel; Drug Design; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Patient Selection; Platelet Aggregation Inhibitors; Platelet Function Tests; Practice Guidelines as Topic; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticlopidine; Treatment Outcome | 2012 |
Development and clinical use of prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Design; Hemorrhage; Hemostasis; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Resistance; Genotype; Hemorrhage; Humans; Patient Selection; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Predictive Value of Tests; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Warfarin | 2012 |
Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Precision Medicine; Risk; Thrombosis; Ticlopidine | 2012 |
Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trials.
Topics: Adult; Aged; Aspirin; Cause of Death; Cerebral Hemorrhage; Clopidogrel; Data Interpretation, Statistical; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine; Treatment Outcome | 2012 |
Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.
Topics: Acute Coronary Syndrome; Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stents; Stroke; Tetrazoles; Ticlopidine; Treatment Outcome | 2012 |
Bleeding and the use of antiplatelet agents in the management of acute coronary syndromes and atrial fibrillation.
Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Hospital Mortality; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Risk Assessment; Ticlopidine | 2012 |
Review of ticagrelor in the management of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dyspnea; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2012 |
Safety profile and bleeding risk of ticagrelor compared with clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dyspnea; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine | 2012 |
New anti-platelet agents: the end of resistance?
Topics: Adenosine; Animals; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Design; Drug Resistance; Drug Therapy, Combination; Evidence-Based Medicine; Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the U.S. Food and Drug Administration: empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide from the Southern Network on Adverse Reactions (SONAR).
Topics: Adverse Drug Reaction Reporting Systems; Clopidogrel; Hemorrhage; Humans; Thalidomide; Thrombosis; Ticlopidine; United States; United States Food and Drug Administration; Warfarin | 2012 |
Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis.
Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; PubMed; Randomized Controlled Trials as Topic; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2013 |
Clopidogrel, aspirin and proton pump inhibition after percutaneous valve implants: an update.
Topics: Aspirin; Clopidogrel; Heart Valve Prosthesis Implantation; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Review Literature as Topic; Ticlopidine | 2013 |
Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Endpoint Determination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Preoperative Care; Randomized Controlled Trials as Topic; Registries; Stroke; Ticlopidine; Treatment Outcome | 2012 |
Metabolic differences of current thienopyridine antiplatelet agents.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Fibrinolytic Agents; Hemorrhage; Humans; Inactivation, Metabolic; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Thiophenes; Ticlopidine | 2013 |
State of the art--a journey through the world of antithrombotic therapy.
Topics: Ambulatory Care; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Coronary Disease; Fibrinolytic Agents; Heart Failure; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Orthopedic Procedures; Platelet Aggregation Inhibitors; Postoperative Complications; Practice Guidelines as Topic; Recurrence; Respiratory Insufficiency; Thromboembolism; Thrombolytic Therapy; Thrombophlebitis; Thrombosis; Ticlopidine | 2002 |
Emergency management of hemorrhagic complications in the era of glycoprotein IIb/IIIa receptor antagonists, clopidogrel, low molecular weight heparin, and third-generation fibrinolytic agents.
Topics: Acute Disease; Angina, Unstable; Clopidogrel; Emergency Medical Services; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Ticlopidine | 2003 |
The role of clopidogrel in the management of acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Drug Interactions; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2003 |
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Comorbidity; Coronary Restenosis; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Peptide Fragments; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Stents; Thrombophilia; Ticlopidine; Tirofiban; Tyrosine | 2004 |
Role of clopidogrel in unstable angina and non-ST-segment elevation myocardial infarction: from literature and guidelines to practice.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Hemorrhage; Humans; Middle Aged; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors; Ticlopidine | 2004 |
Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Delayed-Action Preparations; Diarrhea; Dipyridamole; Drug Costs; Drug Eruptions; Dyspepsia; Evidence-Based Medicine; Hemorrhage; Humans; Ischemia; Models, Econometric; Nausea; Platelet Aggregation Inhibitors; Research Design; Risk Factors; Ticlopidine; Treatment Outcome; Vascular Diseases; Vomiting | 2004 |
Antiplatelet therapy in anticoagulated patients requiring coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Factors; Stents; Thromboembolism; Ticlopidine; Warfarin | 2005 |
Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something?
Topics: Aspirin; Clopidogrel; Depressive Disorder; Drug Interactions; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Selective Serotonin Reuptake Inhibitors; Ticlopidine | 2006 |
[Adding aspirin to clopidogrel in secondary prevention of ischemic stroke: no significant benefits. Results of the Match study].
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Ischemic Attack, Transient; Multicenter Studies as Topic; Myocardial Infarction; Patient Selection; Placebos; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Ticlopidine; Time Factors | 2006 |
Clopidogrel in the treatment of ischaemic heart disease.
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine | 2006 |
MATCH results: implications for the internist.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Controlled Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Europe; Hemorrhage; Humans; Ischemic Attack, Transient; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Thrombosis; Ticlopidine; Treatment Failure; United States | 2006 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyridamole; Disease Susceptibility; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Hemorrhage; Humans; Ischemic Attack, Transient; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Stroke; Tetrazoles; Ticlopidine; Treatment Outcome; Vasodilator Agents | 2007 |
Variable platelet response to aspirin and clopidogrel in atherothrombotic disease.
Topics: Adenosine Diphosphate; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Biomarkers; Biotransformation; Blood Coagulation Tests; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Interactions; Drug Resistance; Hemorrhage; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Thrombosis; Thromboxane A2; Thromboxane B2; Ticlopidine; Treatment Failure | 2007 |
The role of clopidogrel in revascularized and nonrevascularized patients with acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Coronary Disease; Cost-Benefit Analysis; Guideline Adherence; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Ticlopidine | 2007 |
Perioperative use of anti-platelet drugs.
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Elective Surgical Procedures; Hemorrhage; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2007 |
Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Assessment; Stroke; Ticlopidine | 2007 |
Clopidogrel: who, when, and how?
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Ischemia; Patient Selection; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Assessment; Secondary Prevention; Syndrome; Ticlopidine; Treatment Outcome | 2007 |
Aspirin combined with clopidogrel (Plavix) decreases cardiovascular events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Disease; Evidence-Based Medicine; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Thrombosis; Ticlopidine | 2007 |
Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Enoxaparin; Eptifibatide; Fibrinolytic Agents; Heart Conduction System; Hemorrhage; Heparin; Hirudins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Risk Assessment; Risk Factors; Ticlopidine | 2008 |
Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Drug-Eluting Stents; Evidence-Based Medicine; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2008 |
Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding.
Topics: Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Coagulation; Clopidogrel; Drug Resistance; Evidence-Based Medicine; Fibrinolytic Agents; Hemorrhage; Humans; Patient Selection; Perioperative Care; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Stents; Thrombosis; Ticlopidine | 2008 |
Antiplatelet therapy in acute coronary syndromes: the emergency physician's perspective.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Dose-Response Relationship, Drug; Emergency Medicine; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine | 2008 |
Use of antiplatelet agents to prevent stroke: what is the role for combinations of medications?
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Assessment; Stroke; Ticlopidine | 2008 |
Will prasugrel supersede clopidogrel for acute coronary syndromes?
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine | 2008 |
Antiplatelet agents and arterial thrombosis.
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Primary Prevention; Randomized Controlled Trials as Topic; Thrombosis; Ticlopidine; Warfarin | 2008 |
Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Ticlopidine; Vascular Diseases; Warfarin | 2008 |
Prasugrel: a novel antiplatelet agent.
Topics: Acute Coronary Syndrome; Animals; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Thrombolytic Therapy; Ticlopidine | 2008 |
Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Cardiac Catheterization; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Heparin; Hirudin Therapy; Hirudins; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Research Design; Ticlopidine | 1998 |
Aspirin and ticlopidine after routine coronary stenting: the gold standard as of 1999.
Topics: Anemia, Aplastic; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Therapy, Combination; Health Policy; Hematologic Diseases; Hemorrhage; Humans; Multivariate Analysis; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Premedication; Purpura, Thrombotic Thrombocytopenic; Randomized Controlled Trials as Topic; Retrospective Studies; Risk; Stents; Ticlopidine; Treatment Outcome | 1999 |
Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit-risk analysis.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Risk; Ticlopidine; Treatment Outcome | 1999 |
Ticlopidine and clopidogrel.
Topics: Adenosine Diphosphate; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Angina, Unstable; Aspirin; Bone Marrow Diseases; Carbamazepine; Cardiovascular Diseases; Clopidogrel; Combined Modality Therapy; Coronary Disease; Drug Interactions; Hemorrhage; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Phenytoin; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Safety; Stents; Theophylline; Thrombolytic Therapy; Ticlopidine | 1999 |
Stroke prevention: antiplatelet and antithrombolytic therapy.
Topics: Anticoagulants; Aspirin; Brain Damage, Chronic; Carotid Stenosis; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endarterectomy, Carotid; Fibrinolytic Agents; Gastritis; Goals; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Ischemic Attack, Transient; Meta-Analysis as Topic; Multicenter Studies as Topic; Neutropenia; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Risk; Safety; Single-Blind Method; Stroke; Thrombolytic Therapy; Ticlopidine; Treatment Failure; Treatment Outcome | 2000 |
Is CURE a cure for acute coronary syndromes? Statistical versus clinical significance.
Topics: Acute Disease; Angina, Unstable; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk; Secondary Prevention; Ticlopidine | 2002 |
317 trial(s) available for clopidogrel and Hemorrhage
| Article | Year |
|---|---|
P2Y12 inhibitor monotherapy in complex percutaneous coronary intervention: A post-hoc analysis of SMART-CHOICE randomized clinical trial.
Topics: Clopidogrel; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2021 |
Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS Trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticagrelor | 2021 |
Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.
Topics: Aged; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Republic of Korea; Stroke; Ticagrelor; Treatment Outcome | 2021 |
Bleeding Risk of Dual Antiplatelet Therapy after Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Treatment Outcome | 2022 |
Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Clopidogrel; Comorbidity; COVID-19; COVID-19 Drug Treatment; Extracorporeal Membrane Oxygenation; Female; Hemorrhage; Heparin; Hospital Mortality; Humans; Inpatients; Male; Medical Futility; Middle Aged; Outcome Assessment, Health Care; Oxygen Inhalation Therapy; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Respiration, Artificial; Thrombosis; Ticagrelor; Time Factors; Treatment Outcome | 2022 |
Pre-admission antiplatelet therapy and treatment effect of ticagrelor vs. prasugrel in patients with acute coronary syndromes-a subgroup analysis of the ISAR-REACT 5 trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor | 2022 |
Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2022 |
Antiplatelet effect, safety, and pharmacokinetics of vicagrel in patients with coronary artery disease undergoing percutaneous coronary intervention.
Topics: Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2022 |
Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2022 |
Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: Insights from the TREAT trial.
Topics: Clopidogrel; Hemorrhage; Humans; Morphine; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Thrombolytic Therapy; Ticagrelor; Treatment Outcome | 2022 |
Efficacy and Safety of Prasugrel vs Clopidogrel in Thrombotic Stroke Patients With Risk Factors for Ischemic Stroke Recurrence: A Double-blind, Phase III Study (PRASTRO-III).
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Ischemic Stroke; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stroke; Thrombotic Stroke; Treatment Outcome | 2023 |
Sex-Specific Differences in Clinical Outcomes After Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Sex Factors; Treatment Outcome | 2022 |
In-hospital outcomes of Ticagrelor versus Clopidogrel in high bleeding risk patients with acute coronary syndrome: Findings from the CCC-ACS project.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Hospitals; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial.
Topics: Aged; Alleles; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Male; Middle Aged; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2022 |
Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial.
Topics: Aspirin; Cerebral Infarction; Cilostazol; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Stroke; Treatment Outcome | 2023 |
Impact of hemoglobin levels at admission on outcomes among elderly patients with acute coronary syndrome treated with low-dose Prasugrel or clopidogrel: A sub-study of the ELDERLY ACS 2 trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Hemorrhage; Hospitalization; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Treatment Outcome | 2022 |
Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a 'targe
Topics: Acute Coronary Syndrome; Adolescent; Aspirin; Clopidogrel; Cohort Studies; Dinucleoside Phosphates; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; ST Elevation Myocardial Infarction; Ticagrelor | 2022 |
Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Factor XIa; Fibrinolytic Agents; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke; Thromboembolism; Treatment Outcome | 2022 |
Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Ischemic Stroke; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thrombosis; Treatment Outcome; Troponin | 2023 |
Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thrombosis; Treatment Outcome | 2023 |
Prognosis and the Effect of De-Escalation of Antiplatelet Therapy After Nuisance Bleeding in Patients With Myocardial Infarction.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Ticagrelor; Treatment Outcome | 2022 |
In-hospital outcomes of ticagrelor versus clopidogrel in patients 75 years or older with acute coronary syndrome: findings from the Improving Care for Cardiovascular Disease in China (CCC)-Acute Coronary Syndrome Project.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; China; Clopidogrel; Hemorrhage; Hospitals; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quality Improvement; Ticagrelor | 2022 |
Genotype-Guided Dual Antiplatelet Use for Transient Ischemic Attack and Minor Stroke by Imaging Status: Subgroup Analysis of the CHANCE-2 Trial.
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Genotype; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2023 |
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention.
Topics: Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2023 |
Rationale and design of a randomised double-blind 2×2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclero
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Atorvastatin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Ischemic Stroke; Middle Aged; Platelet Aggregation Inhibitors; Stroke | 2023 |
Prasugrel dose de-escalation in diabetic patients with acute coronary syndrome receiving percutaneous coronary intervention: results from the HOST-REDUCE-POLYTECH-ACS trial.
Topics: Acute Coronary Syndrome; Brain Ischemia; Clopidogrel; Diabetes Mellitus; Hemorrhage; Humans; Ischemia; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke | 2023 |
Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Prospective Studies; Secondary Prevention; Stroke; Stroke, Lacunar | 2023 |
Stroke Recurrence and Antiplatelets in Posterior Versus Anterior Circulation Minor Stroke or Transient Ischemic Attack.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Infarction; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2023 |
Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority ra
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Gastrointestinal Diseases; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Randomized Controlled Trials as Topic; Rivaroxaban; Treatment Outcome | 2023 |
Dual antiplatelet Use for extended period taRgeted to AcuTe ischemic stroke with presumed atherosclerotic OrigiN (DURATION) trial: Rationale and design.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Prospective Studies; Stroke; Treatment Outcome | 2023 |
Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes-a substudy of the TROPICAL-ACS trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Ischemia; Overweight; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride | 2023 |
Subsequent ischemic stroke and tobacco smoking: A secondary analysis of the POINT trial.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Neoplasm Recurrence, Local; Platelet Aggregation Inhibitors; Smoking; Stroke; Tobacco Smoking | 2023 |
Aspirin vs Clopidogrel for Long-term Maintenance After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the HOST-EXAM Trial.
Topics: Aspirin; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies | 2023 |
Genetic-Guided Oral P2Y
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2023 |
Rationale and design of the optimal antithrombotic treatment for acute coronary syndrome patients with concomitant atrial fibrillation and implanted with new-generation drug-eluting stent: OPtimal management of anTIthroMbotic Agents (OPTIMA)-4 trial.
Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combination; Drug-Eluting Stents; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2023 |
Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; East Asian People; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Male; Middle Aged; Platelet Aggregation Inhibitors; Stroke; Ticagrelor | 2023 |
Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack.
Topics: Aspirin; Body Mass Index; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Obesity; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2023 |
Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia.
Topics: Acute Disease; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Platelet Aggregation Inhibitors; Prospective Studies; Quality of Life; Stroke | 2023 |
Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stroke; Treatment Outcome | 2023 |
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Ticlopidine | 2023 |
Progression of Gastrointestinal Injury During Antiplatelet Therapy After Percutaneous Coronary Intervention: A Secondary Analysis of the OPT-PEACE Randomized Clinical Trial.
Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ulcer | 2023 |
A Genotype-Guided Strategy for Oral P2Y
Topics: Administration, Oral; Aged; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Female; Genotype; Hemorrhage; Humans; Intention to Treat Analysis; Male; Middle Aged; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Single-Blind Method; ST Elevation Myocardial Infarction; Stents; Ticagrelor | 2019 |
Impact of Procedural Bleeding in Peripheral Artery Disease: An Analysis From EUCLID Trial.
Topics: Aged; Amputation, Surgical; Clopidogrel; Double-Blind Method; Endovascular Procedures; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Revascularization; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement.
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Four-Dimensional Computed Tomography; Heart Valve Prosthesis; Hemorrhage; Humans; Intention to Treat Analysis; Male; Platelet Aggregation Inhibitors; Rivaroxaban; Thromboembolism; Transcatheter Aortic Valve Replacement | 2020 |
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Heart Valve Prosthesis; Hemorrhage; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Platelet Aggregation Inhibitors; Rivaroxaban; Thromboembolism; Transcatheter Aortic Valve Replacement | 2020 |
Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial.
Topics: Aged; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; ST Elevation Myocardial Infarction; Survival Analysis; Thrombosis; Ticagrelor; Treatment Outcome | 2020 |
Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Incidence; Intention to Treat Analysis; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Residence Characteristics; Risk Factors; Ticagrelor; Time Factors | 2020 |
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Substitution; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Warfarin | 2019 |
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Diabetes Mellitus; Drug Substitution; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Warfarin | 2019 |
Homocysteine Level Predicts Response to Dual Antiplatelet in Women With Minor Stroke or Transient Ischemic Attack: Subanalysis of the CHANCE Trial.
Topics: Aged; Aspirin; Biomarkers; China; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Homocysteine; Humans; Hyperhomocysteinemia; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggregation Inhibitors; Recurrence; Risk Assessment; Risk Factors; Sex Factors; Stroke; Time Factors; Treatment Outcome | 2020 |
Platelet function testing guided antiplatelet therapy reduces cardiovascular events in Chinese patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The PATROL study.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; China; Clopidogrel; Drug Substitution; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Impact of body mass index on clinical outcome among elderly patients with acute coronary syndrome treated with percutaneous coronary intervention: Insights from the ELDERLY ACS 2 trial.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Body Mass Index; Cause of Death; Clopidogrel; Comorbidity; Female; Frail Elderly; Geriatric Assessment; Hemorrhage; Humans; Italy; Male; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Treatment Outcome | 2020 |
Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Death; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies | 2020 |
Safety and Efficacy of Prasugrel in Elderly/Low Body Weight Japanese Patients with Ischemic Stroke: Randomized PRASTRO-II.
Topics: Age Factors; Aged; Aged, 80 and over; Asian People; Body Weight; Brain Ischemia; Clopidogrel; Double-Blind Method; Female; Health Status; Hemorrhage; Humans; Incidence; Japan; Male; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2020 |
Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Incidence; Kaplan-Meier Estimate; Male; Platelet Aggregation Inhibitors; Transcatheter Aortic Valve Replacement | 2020 |
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Risk Assessment; Risk Factors; Stents; Thromboembolism; Ticagrelor; Time Factors; Treatment Outcome; Warfarin | 2020 |
TicagRelor Or Clopidogrel in severe or terminal chronic kidney patients Undergoing PERcutaneous coronary intervention for acute coronary syndrome: The TROUPER trial.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Secondary Prevention; Thrombosis; Ticagrelor; Young Adult | 2020 |
Efficacy and Safety of Prasugrel by Stroke Subtype: A Sub-Analysis of the PRASTRO-I Randomized Controlled Trial.
Topics: Arteries; Arteriosclerosis; Atherosclerosis; Clopidogrel; Drug Monitoring; Female; Hemorrhage; Humans; Ischemic Stroke; Male; Middle Aged; Organ Size; Outcome and Process Assessment, Health Care; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Treatment Outcome | 2021 |
Randomized Comparison of Intensified and Standard P2Y
Topics: Administration, Oral; Aged; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Assessment; Risk Factors; Stents; Stroke; Time Factors; Treatment Outcome | 2020 |
Cerebral small vessel disease or intracranial large vessel atherosclerosis may carry different risk for future strokes.
Topics: Aged; Cerebral Angiography; Cerebral Small Vessel Diseases; China; Clopidogrel; Diffusion Magnetic Resonance Imaging; Disability Evaluation; Double-Blind Method; Female; Hemorrhage; Humans; Intracranial Arteriosclerosis; Ischemic Attack, Transient; Magnetic Resonance Angiography; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Risk Assessment; Risk Factors; Stroke | 2020 |
Optimal duration of dual antiplatelet therapy following PTA of the superficial femoral artery: the DAPT-SFA protocol.
Topics: Angioplasty; Aspirin; Clopidogrel; Drug Administration Schedule; Femoral Artery; Hemorrhage; Humans; Italy; Multicenter Studies as Topic; Peripheral Arterial Disease; Pilot Projects; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stents; Time Factors; Treatment Outcome; Vascular Patency | 2020 |
Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Clopidogrel; Cytochrome P-450 CYP2C19; Diabetes Mellitus; Egypt; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Young Adult | 2020 |
Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the O
Topics: Acute Coronary Syndrome; Adult; Aspirin; Clopidogrel; Double-Blind Method; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Outcome and Process Assessment, Health Care; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Adjustment; Stroke | 2020 |
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Female; Genotype; Genotyping Techniques; Hemorrhage; Heterozygote; Humans; Loss of Function Mutation; Male; Middle Aged; Percutaneous Coronary Intervention; Point-of-Care Testing; Precision Medicine; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Platelet Aggregation Inhibitors; Postoperative Period; Thrombosis; Transcatheter Aortic Valve Replacement | 2020 |
Efficacy and safety of ticagrelor and clopidogrel in East Asian patients with coronary artery disease undergoing percutaneous coronary intervention.
Topics: Aged; Asian People; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Preoperative Care; Ticagrelor; Treatment Outcome | 2020 |
CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial.
Topics: Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Extremities; Female; Hemorrhage; Humans; Ischemia; Loss of Function Mutation; Male; Middle Aged; Outcome and Process Assessment, Health Care; Peripheral Arterial Disease; Pharmacogenomic Testing; Platelet Aggregation Inhibitors; Vascular Surgical Procedures | 2020 |
Dual Antiplatelet Therapy Beyond 90 days in Symptomatic Intracranial Stenosis in the SAMMPRIS Trial.
Topics: Aged; Angioplasty; Aspirin; Clopidogrel; Drug Administration Schedule; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Intracranial Arteriosclerosis; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Stents; Stroke; Time Factors; Treatment Outcome | 2020 |
Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Outcome and Process Assessment, Health Care; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Adjustment; Rivaroxaban; Stroke | 2021 |
Clopidogrel vs. prasugrel vs. ticagrelor in patients with acute myocardial infarction complicated by cardiogenic shock: a pooled IABP-SHOCK II and CULPRIT-SHOCK trial sub-analysis.
Topics: Aged; Aged, 80 and over; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Intra-Aortic Balloon Pumping; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Shock, Cardiogenic; Ticagrelor | 2021 |
P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor | 2021 |
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Bypass; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Global Health; Hemorrhage; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Ticlopidine; Time Factors | 2017 |
Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Growth Differentiation Factor 15; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Risk Assessment; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Up-Regulation | 2017 |
Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Risk Factors; Stents; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Tablets; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug Therapy, Combination; Early Termination of Clinical Trials; Europe; Female; Fibrinolytic Agents; Heart Valve Prosthesis; Hemorrhage; Humans; Ischemic Attack, Transient; Kaplan-Meier Estimate; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Prosthesis Design; Risk Factors; South America; Stroke; Thrombosis; Ticlopidine; Time Factors; Transcatheter Aortic Valve Replacement; Treatment Outcome | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Ticlopidine; Treatment Outcome | 2017 |
Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Diabetic Cardiomyopathies; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Safety; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2017 |
Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Intention to Treat Analysis; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymers; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; France; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents.
Topics: Aged; Aspirin; Clinical Decision-Making; Clopidogrel; Coronary Disease; Coronary Thrombosis; Decision Support Techniques; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Prosthesis Design; Reproducibility of Results; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk; Ticagrelor; Ticlopidine; Warfarin | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Stroke; Ticlopidine | 2017 |
SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial.
Topics: Amputation, Surgical; Aspirin; Clinical Protocols; Clopidogrel; Computed Tomography Angiography; Constriction, Pathologic; Drug Therapy, Combination; Endovascular Procedures; Femoral Artery; Hemorrhage; Humans; Limb Salvage; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Popliteal Artery; Prospective Studies; Recurrence; Republic of Korea; Research Design; Risk Factors; Succinates; Ticlopidine; Time Factors; Treatment Outcome; Vascular Patency | 2017 |
Dual antiplatelet therapy may increase the risk of non-intracranial haemorrhage in patients with minor strokes: a subgroup analysis of the CHANCE trial.
Topics: Aged; Aspirin; China; Clopidogrel; Double-Blind Method; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2016 |
Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aged; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Proportional Hazards Models; Recurrence; Risk Factors; Smoking; ST Elevation Myocardial Infarction; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Drug Monitoring; Drug Resistance; Drug Substitution; Drug Therapy, Combination; Female; France; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Stents; Ticagrelor; Time Factors; Treatment Outcome | 2017 |
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Clopidogrel; Denmark; Dipyridamole; Drug Therapy, Combination; Female; Georgia; Hemorrhage; Humans; Ischemia; Ischemic Attack, Transient; Male; Middle Aged; New Zealand; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Research Design; Risk Assessment; Stroke; Thrombolytic Therapy; Ticlopidine; Treatment Outcome; United Kingdom | 2018 |
Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Osteoprotegerin; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Up-Regulation | 2018 |
Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy.
Topics: Acute Coronary Syndrome; Aged; Blood Coagulation; Clopidogrel; Double-Blind Method; Female; Fibrin; Fibrin Clot Lysis Time; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2018 |
Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial.
Topics: Aged; Clopidogrel; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Ticagrelor | 2018 |
Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Endovascular Procedures; Europe; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Israel; Lower Extremity; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Proof of Concept Study; Prospective Studies; Pyridines; Recurrence; Risk Factors; Thiazoles; Thrombosis; Time Factors; Treatment Outcome; United States; Vascular Patency | 2018 |
Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study.
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Double-Blind Method; Drug Costs; Female; Hemorrhage; Hospital Costs; Hospital Mortality; Humans; Length of Stay; Male; Middle Aged; Models, Economic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Time Factors; Treatment Outcome; United States | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Ischemia; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk; Secondary Prevention; Stroke; Ticlopidine | 2018 |
High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor | 2018 |
Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial.
Topics: Adult; Aged; Anticoagulants; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Intention to Treat Analysis; Male; Middle Aged; Prospective Studies; Purinergic P2Y Receptor Antagonists; Research Design; Single-Blind Method; ST Elevation Myocardial Infarction; Ticagrelor | 2018 |
Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Blood Platelets; Clopidogrel; Europe; Female; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Proportional Hazards Models; Risk Assessment; Single-Blind Method; Stroke | 2018 |
Vasodilator-stimulated phosphoprotein-guided Clopidogrel maintenance therapy reduces cardiovascular events in atrial fibrillation patients requiring anticoagulation therapy and scheduled for percutaneous coronary intervention: a prospective cohort study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Biomarkers; Blood Coagulation; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Drug Monitoring; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2018 |
Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel.
Topics: Aged; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Practice Guidelines as Topic; Prasugrel Hydrochloride; Stroke; Ticlopidine | 2018 |
Clinical pharmacodynamics and long-term efficacy of Talcom vs. Plavix in patients undergoing coronary stent implantation: a randomized study with 5-year follow-up.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Stents; Treatment Outcome | 2018 |
Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention.
Topics: Aged; Aspirin; Brazil; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Eluting Stents; Europe; Female; Hemorrhage; Humans; Incidence; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Treatment Outcome; United States | 2018 |
Switching from ticagrelor to clopidogrel in patients with ST-segment elevation myocardial infarction undergoing successful percutaneous coronary intervention in real-world China: Occurrences, reasons, and long-term clinical outcomes.
Topics: Aged; China; Clopidogrel; Coronary Thrombosis; Drug Costs; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Readmission; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Risk Factors; ST Elevation Myocardial Infarction; Stroke; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan.
Topics: Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Diamines; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Single-Blind Method; Taiwan; Thiazoles; Ticagrelor | 2019 |
Time Course of Ischemic and Bleeding Burden in Elderly Patients With Acute Coronary Syndromes Randomized to Low-Dose Prasugrel or Clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Italy; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Single-Blind Method; Survival Rate; Time Factors | 2019 |
Guided de-escalation of DAPT in acute coronary syndrome patients undergoing percutaneous coronary intervention with BVS implantation: a post-hoc analysis from the randomized TROPICAL-ACS trial.
Topics: Absorbable Implants; Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Blood Vessel Prosthesis Implantation; Clopidogrel; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thrombosis; Tissue Scaffolds; Young Adult | 2019 |
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Elective Surgical Procedures; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Stroke; Ticagrelor; Warfarin | 2019 |
Antiplatelet Therapy vs Anticoagulation Therapy in Cervical Artery Dissection: The Cervical Artery Dissection in Stroke Study (CADISS) Randomized Clinical Trial Final Results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Carotid Artery, Internal, Dissection; Clopidogrel; Dipyridamole; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Mortality; Platelet Aggregation Inhibitors; Recurrence; Secondary Prevention; Stroke; Treatment Outcome; Vertebral Artery Dissection; Warfarin; Young Adult | 2019 |
Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Risk Assessment; Stroke; Thromboembolism; Ticagrelor; Warfarin | 2019 |
Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Hematuria; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Proportional Hazards Models; Secondary Prevention; Severity of Illness Index; Stroke | 2019 |
Half-dose ticagrelor versus high-dose clopidogrel in reducing platelet reactivity in acute coronary syndrome patients with high on-clopidogrel platelet reactivity (divide study).
Topics: Acute Coronary Syndrome; Aged; Asian People; Clopidogrel; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Treatment Outcome | 2019 |
Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Heart Failure; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Stroke; Ticagrelor | 2019 |
Personalised antiplatelet therapy based on pharmacogenomics in acute ischaemic minor stroke and transient ischaemic attack: study protocol for a randomised controlled trial.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Pharmacogenomic Testing; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke; Ticagrelor | 2019 |
P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Ticagrelor | 2019 |
Comprehensive ascertainment of bleeding in patients prescribed different combinations of dual antiplatelet therapy (DAPT) and triple therapy (TT) in the UK: study protocol for three population-based cohort studies emulating 'target trials' (the ADAPTT Stu
Topics: Acute Coronary Syndrome; Adult; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; United Kingdom | 2019 |
Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Case-Control Studies; Clopidogrel; Death; Drug Therapy, Combination; Female; Hemorrhage; Humans; Ischemia; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Risk Assessment; Stroke; Treatment Outcome | 2019 |
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists | 2019 |
Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists | 2019 |
Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke.
Topics: Acute Disease; Aspirin; Clinical Protocols; Clopidogrel; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Humans; Ischemia; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk; Risk Assessment; Stroke; Time Factors | 2019 |
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine | 2013 |
Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial.
Topics: Aspirin; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; France; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Design; Research Design; Stroke; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine | 2013 |
Incidence and outcome of high on-treatment platelet reactivity in patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] study).
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Angiography; Death, Sudden, Cardiac; Electrocardiography; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Italy; Male; Myocardial Infarction; Platelet Activation; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Stroke; Ticlopidine | 2013 |
Clopidogrel in infants with systemic-to-pulmonary-artery shunts.
Topics: Anastomosis, Surgical; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Heart Defects, Congenital; Hemorrhage; Humans; Infant; Infant, Newborn; Kaplan-Meier Estimate; Male; Platelet Aggregation Inhibitors; Pulmonary Artery; Thrombosis; Ticlopidine | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggregation Inhibitors; Proportional Hazards Models; Secondary Prevention; Stroke; Ticlopidine | 2013 |
Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Disease Management; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-center, randomized, double-blind, phase IV, non-inferiority clinical trial.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Nervous System Diseases; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine | 2013 |
Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Combined Modality Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practolol; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-plate
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Prosthesis Design; Republic of Korea; Risk Factors; Stroke; Tetrazoles; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Ticlopidine; Treatment Outcome | 2014 |
Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]).
Topics: Acute Coronary Syndrome; Aged; Cause of Death; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Survival Rate; Sweden; Thiophenes; Ticlopidine; Treatment Outcome | 2014 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk; Sirolimus; Stroke; Thrombosis; Ticlopidine | 2013 |
Pharmacoepidemiologic study of warfarin prescription in a Brazilian tertiary hospital.
Topics: Adult; Aged; Anticoagulants; Brazil; Clopidogrel; Cross-Sectional Studies; Databases, Factual; Dose-Response Relationship, Drug; Drug Incompatibility; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Pharmacoepidemiology; Prevalence; Socioeconomic Factors; Tertiary Care Centers; Ticlopidine; Warfarin | 2014 |
Switching from clopidogrel to prasugrel in patients having coronary stent implantation.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Sex Factors; Stents; Thiophenes; Thrombosis; Ticlopidine | 2014 |
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Sex Factors; Stents; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Epidemiologic Methods; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recurrence; Ticlopidine | 2014 |
Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage; Humans; Japan; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors | 2014 |
Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial.
Topics: Angina, Unstable; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome | 2014 |
Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention.
Topics: Aged; China; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Resistance; Drug-Eluting Stents; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Renal Insufficiency, Chronic; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
Topics: Aged; Angina, Stable; Aspirin; Belgium; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Risk Factors; Stents; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Stents; Stroke; Thiophenes; Ticlopidine | 2014 |
Predictors of mortality in patients with lacunar stroke in the secondary prevention of small subcortical strokes trial.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Proportional Hazards Models; Secondary Prevention; Stroke, Lacunar; Ticlopidine | 2014 |
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Emergency Medical Services; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time-to-Treatment | 2014 |
MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
Topics: Acute Coronary Syndrome; Aged; Antithrombins; Clopidogrel; Drug Therapy, Combination; Europe; Female; Hemorrhage; Hirudins; Humans; Internationality; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Recombinant Proteins; Ticlopidine; Treatment Outcome | 2015 |
Relationship between ABCB1 polymorphisms, thromboelastography and risk of bleeding events in clopidogrel-treated patients with ST-elevation myocardial infarction.
Topics: Aged; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Risk Factors; Thrombelastography; Ticlopidine | 2014 |
Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Predictive Value of Tests; Proportional Hazards Models; Risk Assessment; Risk Factors; Severity of Illness Index; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention.
Topics: Aged; Brain Ischemia; Clopidogrel; Combined Modality Therapy; Coronary Disease; Cytochrome P-450 CYP2C19; Double-Blind Method; Elective Surgical Procedures; Female; Follow-Up Studies; Gene Frequency; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine; Time Factors | 2014 |
Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations.
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Maintenance Chemotherapy; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Failure; Risk Assessment; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Electrocardiography; Female; Hemorrhage; Humans; Lactones; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Secondary Prevention; Stroke; Survival Analysis; Ticlopidine; Treatment Outcome | 2014 |
6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Drug-Eluting Stents; Early Termination of Clinical Trials; Europe; Everolimus; Female; Hemorrhage; Humans; Immunosuppressive Agents; Male; Middle Aged; Middle East; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Rationale and design of MANJUSRI trial: a randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS.
Topics: Adenosine; Adolescent; Adult; Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Research Design; Ticagrelor; Ticlopidine; Warfarin; Young Adult | 2015 |
Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Clopidogrel; Echocardiography; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Kaplan-Meier Estimate; Male; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Prognosis; Risk Assessment; Severity of Illness Index; Survival Rate; Ticlopidine; Transcatheter Aortic Valve Replacement | 2014 |
ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Failure; Stroke; Ticlopidine; Treatment Outcome | 2015 |
Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis.
Topics: Adenosine; Aged; Blood Platelets; Clopidogrel; Female; Fibrinolysis; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Prospective Studies; Ticagrelor; Ticlopidine | 2015 |
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
Topics: Adenosine Monophosphate; Aged; Anticoagulants; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Female; Hemorrhage; Hirudins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recombinant Proteins; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Hemorrhage; Humans; Hyperplasia; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Stents; Stroke; Ticlopidine; Tunica Intima | 2015 |
Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.
Topics: Aged; Aged, 80 and over; Aspirin; Biocompatible Materials; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Hemorrhage; Humans; Immunosuppressive Agents; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Risk Assessment; Risk Factors; Sirolimus; Ticlopidine; Treatment Outcome | 2015 |
Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.
Topics: Aged; Aged, 80 and over; Clopidogrel; Drugs, Generic; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke; Thrombosis; Ticlopidine; Treatment Outcome | 2015 |
Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.
Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Clopidogrel; Drug-Eluting Stents; Female; Guideline Adherence; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome; Young Adult | 2015 |
A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.
Topics: Aged; Angioplasty; Aspirin; Clopidogrel; Drug Therapy, Combination; Europe; Factor Xa Inhibitors; Female; Femoral Artery; Fibrinolytic Agents; Hemorrhage; Humans; Israel; Male; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Popliteal Artery; Pyridines; Research Design; Risk Factors; Stents; Thiazoles; Ticlopidine; Time Factors; Treatment Outcome; United States | 2015 |
Study design of the influence of SErotonin inhibition on patients with RENAl impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Diabetes Mellitus; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Hepatic Insufficiency; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Renal Insufficiency, Chronic; Republic of Korea; Research Design; Serotonin Antagonists; Succinates; Ticlopidine | 2015 |
Does smoking habit affect the randomized comparison of 6 versus 24-month dual antiplatelet therapy duration? Insights from the PRODIGY trial.
Topics: Aged; Clopidogrel; Coronary Disease; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Smoking; Stents; Ticlopidine; Time Factors | 2015 |
Rationale and design of the RT-AF study: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention.
Topics: Adenosine; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneous Coronary Intervention; Research Design; Rivaroxaban; Ticagrelor; Ticlopidine; Warfarin | 2015 |
Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Creatinine; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Renal Insufficiency, Chronic; Stroke; Ticlopidine; Treatment Outcome | 2016 |
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Republic of Korea; Risk Factors; Stroke; Taiwan; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Female; Femoral Artery; Graft Occlusion, Vascular; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Radial Artery; Stents; Ticlopidine; Treatment Outcome | 2016 |
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dyspnea; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Risk Assessment; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
Topics: Acute Coronary Syndrome; Aged; Alleles; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind Method; Female; Genotype; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine | 2016 |
Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Long-Term Care; Male; Neoplasms; Non-ST Elevated Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine; Treatment Outcome | 2016 |
Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Assessment; Stents; Ticlopidine | 2015 |
Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk Assessment; Risk Factors; Survival Rate; Ticlopidine; Time Factors; Treatment Outcome; United States | 2015 |
Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Aspirin; Chi-Square Distribution; China; Clopidogrel; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Recurrence; Risk Factors; Secondary Prevention; Severity of Illness Index; Stroke; Ticlopidine; Time Factors; Time-to-Treatment; Treatment Outcome | 2016 |
Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Topics: Adenosine; Aged; Chi-Square Distribution; China; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Risk Factors; ST Elevation Myocardial Infarction; Stroke; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Drug Compounding; Drugs, Generic; Female; Greece; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Secondary Prevention; Stroke; Therapeutic Equivalency; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Inferiority of ticagrelor in the PHILO trial: Play of chance in East Asians or nightmare confirmation of PLATO-USA?
Topics: Acute Coronary Syndrome; Adenosine; Asian People; Aspirin; Black People; Clopidogrel; Hemorrhage; Humans; Japan; Ticagrelor; Ticlopidine; Treatment Outcome; United States; White People | 2016 |
Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study.
Topics: Aged; Anemia; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Europe; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Risk Assessment; Risk Factors; Survival Rate; Ticlopidine; United States | 2016 |
6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.
Topics: Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Hemorrhage; Humans; Intention to Treat Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Design; Republic of Korea; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Tirofiban; Tyrosine | 2016 |
Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial.
Topics: Adenosine Monophosphate; Aged; Brazil; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Europe; Female; Hemorrhage; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; New Zealand; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk Factors; Thailand; Ticlopidine; Time Factors; Treatment Outcome; United States | 2016 |
[TRILOGY-ACS and ACCOAST trial from an expert's perspective].
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Prasugrel Hydrochloride; Ticlopidine | 2015 |
A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; New South Wales; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results.
Topics: Acute Coronary Syndrome; Aged; Aspirin; China; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Fatty Alcohols; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Follow-Up Studies; Gene Silencing; Genotype; Hemorrhage; Heterozygote; Humans; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
Topics: Aspirin; Atrial Fibrillation; Blood Transfusion; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Pyrazoles; Pyridones; Stroke; Ticlopidine | 2017 |
The Prognostic Value of ADP-Induced Platelet Aggregation for Bleeding Complications in Low - Intermediate Risk Patients with Acute Coronary Syndrome Taking Clopidogrel After Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Prognosis; Risk Factors; Ticlopidine | 2017 |
Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Linear Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Graft Occlusion, Vascular; Hemorrhage; Humans; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Humans; Italy; Male; Middle Aged; Myocardial Infarction; Neointima; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Assessment; Risk Factors; Sex Factors; Stents; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
High-dose clopidogrel versus ticagrelor for treatment of acute coronary syndromes after percutaneous coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective, randomized, open-label, single-centre trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; China; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Long Term Adverse Effects; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Testing; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug-Eluting Stents; Follow-Up Studies; Hemorrhage; Humans; Middle Aged; Ticlopidine; Time Factors | 2016 |
A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes
Topics: Acute Coronary Syndrome; Adult; Aged; Blood Platelets; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Research Design; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome; Young Adult | 2017 |
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Angina, Stable; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. The CAPITAL OPTI-CROSS Study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Cross-Over Studies; Drug Administration Schedule; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Ontario; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy, Combination; Early Medical Intervention; Female; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Patient Readmission; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Stroke; Ticlopidine; Treatment Outcome | 2016 |
Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials.
Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Survival Rate; Treatment Outcome; United States | 2017 |
Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy
Topics: Acute Coronary Syndrome; Adult; Aspirin; Clopidogrel; Drug Monitoring; Drug-Eluting Stents; Everolimus; Female; Hemorrhage; Humans; Immunosuppressive Agents; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Republic of Korea; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease.
Topics: Adenosine; Aged; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Intermittent Claudication; Ischemia; Kaplan-Meier Estimate; Leg; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2017 |
Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Thrombosis; Ticlopidine | 2017 |
The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese patients: A randomized and controlled trail.
Topics: Arterial Occlusive Diseases; Aspirin; China; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Intracranial Arterial Diseases; Male; Middle Aged; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke; Survival Analysis; Ticlopidine; Treatment Outcome | 2017 |
Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
Topics: Aspirin; Cilostazol; Clopidogrel; Comorbidity; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Neointima; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Sirolimus; Tetrazoles; Ticlopidine; Treatment Outcome | 2017 |
Efficacy of cilostazol-based dual antiplatelet treatment in patients undergoing carotid artery stenting.
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Stenosis; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Complications; Stents; Stroke; Tetrazoles; Ticlopidine | 2017 |
Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Hemorrhage; Humans; Ischemic Attack, Transient; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Secondary Prevention; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2008 |
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.
Topics: Adenosine Diphosphate; Adult; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Female; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2008 |
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2008 |
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Heparin; Hirudins; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Premedication; Recombinant Proteins; Recurrence; Risk; Stents; Thrombosis; Ticlopidine | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; Factor Analysis, Statistical; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk; Secondary Prevention; Stroke; Telmisartan; Ticlopidine; Vascular Diseases | 2008 |
Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Su
Topics: Aged; Aged, 80 and over; Angina, Unstable; Clopidogrel; Electrocardiography; Female; Hemorrhage; Hospital Mortality; Hospitalization; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Assessment; Ticlopidine; Treatment Outcome | 2008 |
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Death, Sudden, Cardiac; Double-Blind Method; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Stroke; Ticlopidine; Treatment Outcome | 2009 |
Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Stroke; Ticlopidine; Treatment Outcome | 2008 |
Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors | 2009 |
The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease.
Topics: Aged; Aspirin; Body Mass Index; Clopidogrel; Coronary Disease; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Thrombosis; Ticlopidine | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Endpoint Determination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
Heparin infusion after successful percutaneous coronary intervention: a prospective, randomized trial.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Female; Hemorrhage; Heparin; Humans; Incidence; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Ticlopidine; Time Factors | 2009 |
Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study.
Topics: Aged; Atherosclerosis; Cause of Death; Clopidogrel; Double-Blind Method; Ethnicity; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Risk Factors; Stroke; Ticlopidine; Time Factors; United States | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Embolism; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk; Stroke; Ticlopidine; Vascular Diseases; Vitamin K | 2009 |
Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Europe; Female; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Odds Ratio; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Risk Assessment; Stents; Ticlopidine; Time Factors | 2008 |
Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and U
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Coronary Angiography; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Risk Assessment; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome; Troponin; Young Adult | 2008 |
The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Eptifibatide; Female; Heart Diseases; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Necrosis; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Disease-Free Survival; Drug Resistance; Drug Therapy, Combination; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk Assessment; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Ticlopidine; Young Adult | 2009 |
Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Emergency Medical Services; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Stents; Thrombolytic Therapy; Ticlopidine; Tirofiban; Tyrosine | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiography; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine | 2009 |
Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Infusions, Parenteral; Injections; Length of Stay; Logistic Models; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Platelet Aggregation Inhibitors; Proportional Hazards Models; Radial Artery; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Creatine Kinase, MB Form; Female; Follow-Up Studies; Hematoma; Hemorrhage; Heparin; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Count; Premedication; Retreatment; Sex Factors; Stents; Ticlopidine; Troponin T; Whole Blood Coagulation Time | 2009 |
Platelet inhibition with cangrelor in patients undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Double-Blind Method; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retreatment; Ticlopidine; Treatment Failure | 2009 |
Smoking, clopidogrel, and mortality in patients with established cardiovascular disease.
Topics: Aged; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Smoking; Ticlopidine | 2009 |
Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Drug Administration Schedule; Drug Therapy, Combination; Eptifibatide; Female; Hemorrhage; Heparin; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Ontario; Peptides; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Risk Assessment; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study.
Topics: Administration, Oral; Adult; Bleeding Time; Clopidogrel; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine | 2010 |
High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Resistance; Drug-Eluting Stents; Female; Follow-Up Studies; France; Hemorrhage; Hospitals, University; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Regression Analysis; Risk; Stents; Ticlopidine; Treatment Outcome | 2010 |
Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Embolism; Feasibility Studies; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Ontario; Platelet Aggregation Inhibitors; Recurrence; Stroke; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome; Ultrasonography; Ventricular Dysfunction, Left; Warfarin | 2010 |
Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR
Topics: Aged; Aspirin; Clopidogrel; Disease Management; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Risk Factors; Survival Rate; Thrombosis; Ticlopidine; Vascular Diseases | 2010 |
Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Europe; Female; Hemorrhage; Hospitalization; Humans; Incidence; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; New Zealand; Odds Ratio; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome; United States | 2011 |
Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia.
Topics: Aged; Amputation, Surgical; Aspirin; Clopidogrel; Double-Blind Method; Female; Flow Cytometry; Hemorrhage; Humans; Ischemia; Leg; Male; Myocardial Infarction; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine; Troponin | 2010 |
[Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation].
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Electrocardiography; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Secondary Prevention; Thrombocytopenia; Ticlopidine; Treatment Outcome | 2010 |
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Distribution; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Kaplan-Meier Estimate; Lower Extremity; Male; Middle Aged; Peripheral Vascular Diseases; Placebo Effect; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Reoperation; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome; Vascular Patency; Veins | 2010 |
Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W.
Topics: Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Irbesartan; Kaplan-Meier Estimate; Platelet Aggregation Inhibitors; Risk Factors; Stroke; Tetrazoles; Ticlopidine; Treatment Outcome; Vitamin K | 2010 |
Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug-Eluting Stents; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Patient Readmission; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prospective Studies; Renal Insufficiency; Self Medication; Thrombosis; Ticlopidine | 2010 |
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Glucose; Clopidogrel; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glycated Hemoglobin; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Kidney Diseases; Male; Middle Aged; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Research Design; Stroke; Ticlopidine | 2010 |
Enhanced platelet inhibition by adjunctive cilostazol to dual antiplatelet therapy after drug-eluting stent implantation for complex lesions.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Stents; Tetrazoles; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Atrial Fibrillation; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Hemorrhage; Humans; Male; Middle Aged; Mutation; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Electrocardiography; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Hyperplasia; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Saphenous Vein; Ticlopidine; Treatment Outcome; Tunica Intima; Ultrasonography, Interventional | 2010 |
Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE study).
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2011 |
Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents; Aspirin; Carotid Arteries; Carotid Stenosis; Chi-Square Distribution; Cilostazol; Clopidogrel; Coronary Angiography; Disease Progression; Drug Therapy, Combination; Hemorrhage; Humans; Inflammation Mediators; Middle Aged; Phosphodiesterase 3 Inhibitors; Platelet Aggregation Inhibitors; Prospective Studies; Republic of Korea; Risk Assessment; Risk Factors; Single-Blind Method; Stents; Tetrazoles; Ticlopidine; Time Factors; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2011 |
Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study.
Topics: Acute Coronary Syndrome; Administration, Cutaneous; Age Factors; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Stents; Stroke; Thrombocytopenia; Ticlopidine; Treatment Outcome | 2011 |
Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (E
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Electrocardiography; Eptifibatide; Hemorrhage; Humans; Middle Aged; Multivariate Analysis; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Ticlopidine; Treatment Outcome | 2011 |
Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis.
Topics: Adolescent; Adult; Aged; Clopidogrel; Coronary Angiography; Female; Fibrinolysis; Glomerular Filtration Rate; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Ticlopidine | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk; Thrombosis; Ticlopidine | 2011 |
Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2011 |
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Ticlopidine; Treatment Outcome | 2011 |
A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab wi
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; United States | 2011 |
Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Thrombolytic Therapy; Ticlopidine | 2011 |
Insights into the inhibition of platelet activation by omega-3 polyunsaturated fatty acids: beyond aspirin and clopidogrel.
Topics: Adult; Aspirin; Bleeding Time; Blood Platelets; Chi-Square Distribution; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Hemorrhage; Humans; Male; Middle Aged; North Carolina; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Surface Properties; Ticlopidine; Time Factors | 2011 |
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Topics: Aged; Atherosclerosis; Cause of Death; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Global Health; Hemorrhage; Humans; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Thrombosis; Ticlopidine | 2011 |
Effect of hydroxyethyl starch 130/0.4 on blood loss and coagulation in patients with recent exposure to dual antiplatelet therapy undergoing off-pump coronary artery bypass graft surgery.
Topics: Aged; Aspirin; Blood Coagulation; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass, Off-Pump; Crystalloid Solutions; Female; Hemoglobins; Hemorrhage; Humans; Hydroxyethyl Starch Derivatives; Isotonic Solutions; Male; Middle Aged; Perioperative Care; Plasma Substitutes; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2011 |
Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study.
Topics: Adult; Biopsy; Clopidogrel; Double-Blind Method; Factor VIIa; Hemorrhage; Hemostasis; Hemostatics; Humans; Male; New Jersey; Placebo Effect; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Recombinant Proteins; Thrombelastography; Ticlopidine; Time Factors; Treatment Outcome; Young Adult | 2011 |
Optimal timing of discontinuation of clopidogrel and risk of blood transfusion after coronary surgery. Propensity score analysis.
Topics: Aged; Aspirin; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Preoperative Care; Risk Factors; Ticlopidine | 2011 |
Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Sensitivity and Specificity; Stroke; Ticlopidine; Vitamin K | 2011 |
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Ticlopidine; Treatment Outcome | 2012 |
Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Emergency Medical Services; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Time Factors | 2012 |
Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Bypass, Off-Pump; Female; Hemorrhage; Humans; Length of Stay; Logistic Models; Male; Middle Aged; Platelet Aggregation Inhibitors; Preoperative Care; Retrospective Studies; Risk Factors; Ticlopidine | 2012 |
Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Electrocardiography; Emergency Medical Services; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prevalence; Retrospective Studies; Risk Factors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2012 |
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.
Topics: Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Hemorrhage; Heterozygote; Humans; Ischemia; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Stroke; Thrombosis; Ticlopidine | 2012 |
Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Cause of Death; Chest Tubes; Clopidogrel; Cohort Studies; Combined Modality Therapy; Coronary Artery Bypass; Drug Administration Schedule; Drug Therapy, Combination; Erythrocyte Transfusion; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Retrospective Studies; Risk Adjustment; Thiophenes; Ticlopidine | 2012 |
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PC
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Canada; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Europe; Female; Heart Diseases; Hemorrhage; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Platelet Aggregation; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Stroke; Sulfonamides; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome; United States | 2012 |
Clopidogrel trial in patients with elective percutaneous coronary intervention for stable angina and old myocardial infarction (CLEAN).
Topics: Adult; Aged; Angina, Stable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Assessment; Ticlopidine; Treatment Outcome; Young Adult | 2012 |
Dual antiplatelet therapy in patients with aspirin resistance following coronary artery bypass grafting: study protocol for a randomized controlled trial [NCT01159639].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Bypass; Croatia; Drug Resistance; Drug Therapy, Combination; Hemorrhage; Humans; Patient Readmission; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Research Design; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Effects of clopidogrel added to aspirin in patients with recent lacunar stroke.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Recurrence; Stroke; Stroke, Lacunar; Ticlopidine | 2012 |
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribution; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Patient Safety; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Stents; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Clopidogrel two doses comparative 1-year assessment of safety and efficacy (COMPASS) study in Japanese patients with ischemic stroke.
Topics: Age Factors; Aged; Asian People; Body Weight; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Japan; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Risk Factors; Secondary Prevention; Stroke; Ticlopidine; Treatment Outcome | 2012 |
Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Models, Statistical; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Clopidogrel added to aspirin adds no benefit but bleeding risk in patients with recent lacunar stroke.
Topics: Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Stroke, Lacunar; Ticlopidine | 2013 |
Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups.
Topics: Acute Disease; Aged; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Ticlopidine; Treatment Outcome | 2002 |
Early and late effects of clopidogrel in patients with acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kinetics; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Risk Assessment; Secondary Prevention; Stroke; Syndrome; Ticlopidine; Treatment Outcome | 2003 |
The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Heart Failure; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Recurrence; Stents; Stroke; Thrombosis; Ticlopidine | 2003 |
Clopidogrel and aspirin in the prevention of thromboembolic complications after mechanical aortic valve replacement (CAPTA).
Topics: Administration, Oral; Adult; Aged; Aortic Valve; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Heart Valve Prosthesis; Hemorrhage; Humans; Male; Middle Aged; Phenprocoumon; Pilot Projects; Thromboembolism; Ticlopidine; Treatment Outcome | 2003 |
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Female; Hemorrhage; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Stroke; Ticlopidine; Treatment Outcome | 2003 |
Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Stroke; Syndrome; Ticlopidine; Treatment Outcome | 2003 |
Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Femoral Artery; Hemorrhage; Hemostasis, Surgical; Heparin; Humans; Male; Middle Aged; Patient Selection; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Suture Techniques; Ticlopidine | 2004 |
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheterization; Clopidogrel; Cohort Studies; Combined Modality Therapy; Creatine Kinase; Creatine Kinase, MB Form; Drug Therapy, Combination; Enoxaparin; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Isoenzymes; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Survival Analysis; Ticlopidine; Treatment Outcome; Troponin I | 2004 |
Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
Topics: Acute Disease; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Risk; Stroke; Ticlopidine; Treatment Outcome | 2004 |
Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Clopidogrel; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Hirudins; Humans; Male; Middle Aged; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Survival Analysis; Ticlopidine; Treatment Outcome | 2004 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Secondary Prevention; Thrombolytic Therapy; Ticlopidine; Vascular Patency | 2005 |
Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemorrhage; Humans; Incidence; Male; Membrane Proteins; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2005 |
A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agents; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Radionuclide Imaging; Recurrence; Stents; Survival Analysis; Ticlopidine; Treatment Failure | 2005 |
Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Secondary Prevention; Ticlopidine; Treatment Outcome; Vascular Patency | 2005 |
Antiplatelets in stroke prevention: the MATCH trial. Some answers, many questions and countless perspectives.
Topics: Age Factors; Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Secondary Prevention; Stroke; Ticlopidine; Treatment Outcome | 2005 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, Statistical; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Risk Factors; Stroke; Thrombosis; Ticlopidine | 2006 |
Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial.
Topics: Aged; Ambulances; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emergency Medical Services; Female; Fibrinolysis; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2007 |
Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Eptifibatide; Female; Hemorrhage; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyridines; Retrospective Studies; Risk Assessment; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2007 |
Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28.
Topics: Aged; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Perioperative Care; Premedication; Risk Assessment; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2007 |
Renal function and outcomes in acute coronary syndrome: impact of clopidogrel.
Topics: Aged; Angina, Unstable; Clopidogrel; Coronary Disease; Creatinine; Double-Blind Method; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Research Design; Risk Factors; Severity of Illness Index; Survival Analysis; Syndrome; Ticlopidine; Treatment Outcome | 2007 |
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyridamole; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Endarterectomy, Carotid; Female; Hemorrhage; Humans; Intracranial Embolism; Ischemic Attack, Transient; Male; Middle Aged; Middle Cerebral Artery; Pilot Projects; Platelet Aggregation Inhibitors; Postoperative Care; Prospective Studies; Stroke; Ticlopidine; Treatment Outcome; Ultrasonography, Doppler, Transcranial | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Ticlopidine; Warfarin | 2007 |
Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial.
Topics: Atorvastatin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Pyrroles; Ticlopidine | 2007 |
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Disease-Free Survival; Drug Therapy, Combination; Epidemiologic Methods; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Stroke; Thiophenes; Thrombosis; Ticlopidine | 2007 |
Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Antibodies, Monoclonal; Biomarkers; Cardiovascular Surgical Procedures; Clopidogrel; Electrocardiography; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Platelet Aggregation Inhibitors; Preoperative Care; Survival Analysis; Ticlopidine; Time Factors; Treatment Outcome; Troponin T | 2008 |
Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial.
Topics: Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Hemorrhage; Humans; Infant; Infant, Newborn; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2008 |
The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Stents; Ticlopidine; Treatment Outcome | 2008 |
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy, Combination; Hemorrhage; Humans; Kaplan-Meier Estimate; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Ticlopidine | 2008 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Myocardial Ischemia; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 1996 |
Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Thrombosis; Diarrhea; Drug Eruptions; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Neutropenia; Platelet Aggregation Inhibitors; Postoperative Complications; Safety; Stents; Ticlopidine; Treatment Outcome | 1999 |
Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Gastrointestinal Diseases; Hemorrhage; Humans; Myocardial Infarction; Neutropenia; Platelet Aggregation Inhibitors; Stroke; Thrombocytopenia; Ticlopidine; Time Factors; Treatment Outcome | 1999 |
Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators.
Topics: Aspirin; Brain Ischemia; Cause of Death; Clopidogrel; Confidence Intervals; Double-Blind Method; Female; Hemorrhage; Hospitalization; Humans; Incidence; Ischemia; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Probability; Prognosis; Proportional Hazards Models; Risk Assessment; Secondary Prevention; Survival Analysis; Ticlopidine | 2000 |
Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population.
Topics: Abciximab; Antibodies, Monoclonal; Clopidogrel; Coronary Disease; Coronary Thrombosis; Eptifibatide; Exanthema; Female; Gastrointestinal Diseases; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Neutropenia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Thrombocytopenia; Ticlopidine; Tirofiban; Tyrosine | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine | 2001 |
Clopidogrel: a CURE in acute coronary syndromes?
Topics: Acute Disease; Aged; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Ticlopidine; Treatment Outcome | 2002 |
676 other study(ies) available for clopidogrel and Hemorrhage
| Article | Year |
|---|---|
Synthesis and evaluation of dual antiplatelet activity of bispidine derivatives of N-substituted pyroglutamic acids.
Topics: Animals; Blood Coagulation; Blood Platelets; Bridged Bicyclo Compounds, Heterocyclic; Hemorrhage; Humans; Mice; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Pulmonary Embolism; Pyrrolidonecarboxylic Acid; Thrombosis | 2016 |
In-hospital Bleeding Outcomes of Oral Anticoagulant and Dual Antiplatelet Therapy During Percutaneous Coronary Intervention: An Analysis From the Japanese Nationwide Registry.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Dual Anti-Platelet Therapy; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Japan; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Registries; Retrospective Studies; Warfarin | 2021 |
Utility of a pharmacogenetic-driven algorithm in guiding dual antiplatelet therapy for patients undergoing coronary drug-eluting stent implantation in China.
Topics: Aged; Algorithms; Asian People; Aspirin; Cardiovascular Diseases; China; Clopidogrel; Comorbidity; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Health Behavior; Hemorrhage; Humans; Male; Middle Aged; Pharmacogenetics; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Sociodemographic Factors; Ticagrelor; Ticlopidine | 2022 |
Antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation and chronic coronary syndrome.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Factors; Stroke; Treatment Outcome | 2022 |
Clinical Outcomes of Ticagrelor in Korean Patients with Acute Myocardial Infarction without High Bleeding Risk.
Topics: Acute Disease; Aged; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Propensity Score; Purinergic P2Y Receptor Antagonists; Registries; Republic of Korea; Risk; Ticagrelor; Treatment Outcome | 2021 |
Platelet function assessed by ROTEM
Topics: Aspirin; Clopidogrel; Deamino Arginine Vasopressin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Ticlopidine; Vascular Surgical Procedures | 2022 |
Bilateral multifocal muscular hemorrhage in the triceps surae during antiplatelet therapy: a case report.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Hemorrhage; Humans; Leg; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2021 |
Effectiveness and Safety of P2Y12 Inhibitors Pretreatment in Primary Percutaneous Coronary Intervention with Long Transfer Times.
Topics: Aged; Clopidogrel; Female; Hemorrhage; Humans; Percutaneous Coronary Intervention; Registries; ST Elevation Myocardial Infarction | 2022 |
The current status and outcomes of in-hospital P2Y12 receptor inhibitor switching in Korean patients with acute myocardial infarction.
Topics: Clopidogrel; Hemorrhage; Hospitals; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2022 |
Safety and efficacy of different P2Y12 inhibitors in patients with acute coronary syndromes stratified by the PRAISE risk score: a multicentre study.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Treatment Outcome | 2022 |
Ticagrelor versus clopidogrel in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Predictors and long-term outcomes of in-hospital switching from clopidogrel to ticagrelor among patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Diabetes Mellitus, Type 2; Hemorrhage; Hospitals; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Net clinical benefit of different strategies of dual antiplatelet therapy in elderly patients: Data from the praise registry.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Registries; Ticagrelor; Treatment Outcome | 2022 |
Risk of ischaemic and haemorrhagic stroke in Chinese undergoing percutaneous coronary intervention treated with potent P2Y12 inhibitor versus clopidogrel.
Topics: Acute Coronary Syndrome; Brain Ischemia; China; Clopidogrel; Hemorrhage; Hemorrhagic Stroke; Humans; Intracranial Hemorrhages; Ischemic Stroke; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Stroke; Ticagrelor | 2022 |
Association Between Platelet Reactivity and Long-Term Bleeding Complications After Percutaneous Coronary Intervention According to Diabetes Status.
Topics: Aspirin; Clopidogrel; Diabetes Mellitus; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies | 2022 |
Dual versus mono antiplatelet therapy in mild-to-moderate stroke during hospitalization.
Topics: Aspirin; Clopidogrel; Cohort Studies; Hemorrhage; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Stroke; Platelet Aggregation Inhibitors; Retrospective Studies; Stroke | 2022 |
Risk of post-polypectomy bleeding after endoscopic mucosal resection in patients receiving antiplatelet medication: comparison between the continue and hold groups.
Topics: Aspirin; Clopidogrel; Colonic Polyps; Colonoscopy; Endoscopic Mucosal Resection; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors | 2022 |
Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation.
Topics: Arabs; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Stents; Treatment Outcome | 2022 |
Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in Elderly Patients Undergoing Percutaneous Coronary Intervention: A Cohort Study.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Is it Safe to Continue Clopidogrel in Elective Hip and Knee Arthroplasty?
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Clopidogrel; Elective Surgical Procedures; Hemorrhage; Humans; Length of Stay; Postoperative Complications; Retrospective Studies | 2022 |
Cost Utility of Prasugrel in Postangioplasty Diabetic Patients.
Topics: Clopidogrel; Diabetes Mellitus; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quality of Life; Ticlopidine | 2022 |
An alternative reduced dose regimen of ticagrelor for neuroendovascular patients.
Topics: Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Treatment Outcome | 2023 |
Comparison of Ischemic and Bleeding Events Between Short-Duration Versus Long-Duration Tirofiban Regimens in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
Topics: Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; ST Elevation Myocardial Infarction; Thrombosis; Ticagrelor; Tirofiban; Treatment Outcome | 2022 |
New Insights Into Long- Versus Short-Term Dual Antiplatelet Therapy Duration in Patients After Stenting for Left Main Coronary Artery Disease: Findings From a Prospective Observational Study.
Topics: Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stents; Treatment Outcome | 2022 |
Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population.
Topics: Acute Coronary Syndrome; Aspirin; Australia; Clopidogrel; Hemorrhage; Hospital Mortality; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2022 |
[Multimorbidity in elderly patients with acute coronary syndrome: insights from BleeMACS registry].
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Humans; Multimorbidity; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Treatment Outcome | 2022 |
Association between ticagrelor plasma concentration and bleeding events in Chinese patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; China; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2022 |
Cost-effectiveness of CYP2C19-guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Veterans | 2023 |
Safety and efficacy comparison between OACs plus single antiplatelet and dual antiplatelet therapy in patients with cerebral venous sinus stenosis poststenting.
Topics: Adult; Anticoagulants; Aspirin; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Thrombosis; Treatment Outcome | 2022 |
Increased long-term bleeding complications in females undergoing endovascular revascularization for peripheral arterial disease.
Topics: Aged; Anticoagulants; Cardiovascular Abnormalities; Clopidogrel; Endovascular Procedures; Female; Fibrinolytic Agents; Hematoma; Hemorrhage; Humans; Male; Medicare; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; United States | 2022 |
Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients.
Topics: Aspirin; Body Weight; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Platelet Aggregation Inhibitors; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Stroke; Ticlopidine; Treatment Outcome | 2022 |
P2Y12 reaction units and ischemic and bleeding events after neuro-endovascular treatment.
Topics: Aspirin; Clopidogrel; Endovascular Procedures; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Ticlopidine; Treatment Outcome | 2022 |
In-Hospital Bleeding and Mortality in Acute Coronary Syndrome Patients Treated with Tirofiban and Potent P2Y12 Inhibitors.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Hemorrhage; Hospitals; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Tirofiban; Treatment Outcome | 2022 |
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2022 |
Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based study.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2022 |
Ticagrelor versus Clopidogrel in Patients with Severe Renal Insufficiency Undergoing PCI for Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Renal Insufficiency; Retrospective Studies; Ticagrelor; Treatment Outcome | 2022 |
Comparative Effectiveness and Safety of Ticagrelor Versus Clopidogrel for Elderly Chinese Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Retrospective Cohort Study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; China; Cholesterol; Clopidogrel; Cohort Studies; Coronary Artery Disease; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Treatment Outcome | 2022 |
Clopidogrel versus ticagrelor in East Asian patients aged 75 years or older with acute coronary syndrome: observations from the GF-APT registry.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dimaprit; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Ticagrelor; Treatment Outcome | 2022 |
Risk of Postcolonoscopy Thromboembolic Events: A Real-World Cohort Study.
Topics: Anticoagulants; Clopidogrel; Cohort Studies; Colonoscopy; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Thromboembolism; Warfarin | 2023 |
Features of antiplatelet therapy with P2Y12 receptor inhibitors in patients with myocardial infarction according to the Russian Register of Acute Myocardial Infarction REGION-MI.
Topics: Anticoagulants; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2022 |
Comparison of ticagrelor and clopidogrel on platelet function and prognosis in unstable angina.
Topics: Angina, Unstable; Clopidogrel; Fatty Acid Binding Protein 3; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Ticagrelor; Treatment Outcome | 2022 |
Eptifibatide-induced acute profound thrombocytopenia: A case report.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Eptifibatide; Glycoproteins; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Thrombocytopenia | 2022 |
Comparison of Cilostazol versus Clopidogrel in Addition to Aspirin in Patients with Ischemic Stroke who Underwent Intracranial or Extracranial Artery Stent Implantation.
Topics: Arteries; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Stroke; Tetrazoles; Ticlopidine; Treatment Outcome | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Ticagrelor; Treatment Outcome | 2023 |
Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome After Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adolescent; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2023 |
Ticagrelor versus clopidogrel dual antiplatelet therapy for unruptured intracranial aneurysms treated with flowdiverter.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Intracranial Aneurysm; Platelet Aggregation Inhibitors; Retrospective Studies; Thromboembolism; Ticagrelor; Treatment Outcome | 2023 |
Estimation of adverse events associated with P2Y12 receptor inhibitors stratified by academic research consortium for high bleeding risk criteria in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Treatment Outcome | 2023 |
Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2023 |
CYP2C9 Polymorphisms and the Risk of Cardiovascular Events in Patients Treated with Clopidogrel: Combined Data from the POPular Genetics and POPular AGE Trials.
Topics: Clopidogrel; Cytochrome P-450 CYP2C9; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2023 |
Clopidogrel Use in CYP2C19 Loss-of-Function Carriers With High Bleeding Risk After Percutaneous Coronary Intervention.
Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention | 2023 |
Duration more than type of dual antiplatelet therapy matters in ACS patients with high bleeding risk.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2023 |
Time Course of Death After Acute Coronary Syndrome Treated With Dual Antiplatelet Therapy for 1 Year.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome | 2023 |
miR-6076 rs1463411 polymorphisms are associated with bleeding during clopidogrel treatment in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Hemorrhage; Humans; MicroRNAs; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2023 |
Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneou
Topics: Aspirin; Cardiology; Clopidogrel; Coronary Artery Disease; Fibrinolytic Agents; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Stroke; Ticagrelor | 2023 |
Post-percutaneous coronary intervention CYP2C19 genotyping in an Irish population: The potential role in identifying clopidogrel therapy-related bleeding risks.
Topics: Acute Coronary Syndrome; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C19; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2023 |
Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy.
Topics: Atrial Fibrillation; Clopidogrel; Cytochrome P-450 CYP2C19; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2023 |
Replay to "duration more than type of dual antiplatelet therapy matters in ACS patients with high bleeding risk".
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Treatment Outcome | 2023 |
Acute coronary syndrome in very elderly patients-a real-world experience.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2023 |
Effectiveness of dual antiplatelet de-escalation therapy on the prognosis of patients with ST segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Topics: Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Retrospective Studies; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2023 |
A Comparative Study on Ticagrelor and Clopidogrel in Patients With Acute Coronary Syndrome Treated With Primary Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Genotype-Guided Antiplatelet Therapy After Coronary Intervention in Patients With High Bleeding Risk - Never Judge a Book by Its Cover.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Heart; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2023 |
Association of Clinical Outcomes With Sex in Patients Receiving Chronic Maintenance Antiplatelet Monotherapy After Percutaneous Coronary Intervention: A Post Hoc Gender Analysis of the HOST-EXAM Study.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2023 |
Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; Ticagrelor | 2023 |
Antiplatelet and anticoagulation therapy and the risk of pituitary apoplexy in pituitary adenoma patients.
Topics: Adenoma; Anticoagulants; Clopidogrel; Hemorrhage; Hormones; Humans; Male; Pituitary Apoplexy; Pituitary Neoplasms; Retrospective Studies; Stroke | 2023 |
Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Eye; Hemorrhage; Humans; Japan; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Rivaroxaban; Warfarin | 2023 |
Ticagrelor as Compared to Clopidogrel Following Percutaneous Coronary Intervention for Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Canada; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Treatment Outcome | 2023 |
P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Treatment Outcome | 2023 |
Comparison between ticagrelor and clopidogrel in myocardial infarction patients with high bleeding risk.
Topics: Clopidogrel; Hemorrhage; Humans; Ischemia; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Ticagrelor | 2023 |
Dual antithrombotic therapy with oral anticoagulant and P2Y12 inhibitors in patients with atrial fibrillation after percutaneous coronary intervention.
Topics: Anticoagulants; Atrial Fibrillation; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Retrospective Studies | 2023 |
Bleeding risk and P2Y12 inhibitors in all-comer patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention: a single-centre cohort study.
Topics: Aged; Clopidogrel; Cohort Studies; Female; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Ticagrelor | 2023 |
A novel de-escalation antiplatelet therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Contemporary Use of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A GRACE Risk Score Stratification-Based Analysis in a Large-Scale, Real-World Study From China.
Topics: Acute Coronary Syndrome; China; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Risk Assessment; Risk Factors; Ticagrelor; Treatment Outcome | 2023 |
Clinical outcomes of generic versus brand-name clopidogrel for secondary prevention in patients with acute myocardial infarction: A nationwide cohort study.
Topics: Clopidogrel; Cohort Studies; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Secondary Prevention; Treatment Outcome | 2023 |
Structural characterization of the optical isomers esomeprazole and omeprazole using the JADER and FAERS databases.
Topics: Adverse Drug Reaction Reporting Systems; Cilostazol; Clopidogrel; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Esomeprazole; Hemorrhage; Humans; Omeprazole; Prasugrel Hydrochloride; United States | 2023 |
[Comparison of Various Regimens of Antithrombotic Therapy in Patients With Valvular Heart Disease and Coronary Artery Disease After Surgical and Interventional Interventions].
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Fibrinolytic Agents; Heart Valve Diseases; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thromboembolism; Treatment Outcome | 2023 |
Dual Antiplatelet Therapies and Causes in Minor Stroke or Transient Ischemic Attack: A Prespecified Analysis in the CHANCE-2 Trial.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2023 |
De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Age- and Sex-Specific Disparities in Outcomes After Ticagrelor Versus Clopidogrel in East Asian Patients.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; East Asian People; Female; Hemorrhage; Humans; Ischemia; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2023 |
De-escalation from potent P2Y12 inhibitors to clopidogrel: an alternative to short DAPT duration in HBR patients?
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2023 |
Re: Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2019 |
Efficacy and Safety of Different Antiplatelet Strategies in Survivors of Myocardial Infarction With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Survivors; Ticagrelor; Treatment Outcome | 2019 |
Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With High Bleeding Risk: Insight From the STOPDAPT-2 Trial.
Topics: Aged; Aspirin; Chromium Alloys; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Female; Hemorrhage; Humans; Incidence; Japan; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Proportional Hazards Models; Randomized Controlled Trials as Topic; Single-Blind Method; Stroke | 2019 |
Clinical outcomes after ticagrelor and clopidogrel in Chinese post-stented patients.
Topics: Acute Coronary Syndrome; Aged; Asian People; China; Clopidogrel; Coronary Thrombosis; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Risk Assessment; Risk Factors; Stents; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries.
Topics: Acute Coronary Syndrome; Clopidogrel; Europe; Female; Hemorrhage; Humans; Male; Medication Therapy Management; Middle Aged; Mortality; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Registries; Risk Adjustment; Therapeutic Equivalency; Ticagrelor | 2020 |
Impact of reduced-dose prasugrel vs. standard-dose clopidogrel on in-hospital outcomes of percutaneous coronary intervention in 62 737 patients with acute coronary syndromes: a nationwide registry study in Japan.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Coronary Thrombosis; Databases, Factual; Female; Hemorrhage; Hospital Mortality; Hospitalization; Humans; Incidence; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Prospective Studies; Registries; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Treatment Outcome | 2020 |
Early Discontinuation of P2Y
Topics: Age Factors; Aged; Aged, 80 and over; Clopidogrel; Cohort Studies; Drug Prescriptions; Female; Hemorrhage; Humans; Hypertension; Male; Medication Adherence; Middle Aged; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Retreatment; Retrospective Studies; Stroke; Thromboembolism; Wales | 2019 |
CYP2C19 phenotype in South-East Asian Acute Coronary Syndrome patients and impact on major adverse cardiovascular events.
Topics: Acute Coronary Syndrome; Aged; Asian People; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies | 2020 |
One vs 12 Months of Dual Antiplatelet Therapy for Patients After Percutaneous Coronary Intervention.
Topics: Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine | 2019 |
1 vs 12 Months of Dual Antiplatelet Therapy for Patients After Percutaneous Coronary Intervention-Reply.
Topics: Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine | 2019 |
Preoperative Light Transmission Aggregometry Values Predict for Thromboembolic Complications After Stent-Assisted Coil Embolization.
Topics: Aspirin; Clopidogrel; Embolization, Therapeutic; Endovascular Procedures; Female; Hematoma; Hemorrhage; Humans; Intracranial Aneurysm; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Retrospective Studies; Risk Assessment; Stents; Thromboembolism | 2020 |
Concomitant use of drugs known to cause interactions with oral antiplatelets-polypharmacy in acute coronary syndrome outpatients in Finland.
Topics: Acute Coronary Syndrome; Administration, Oral; Adult; Aged; Clopidogrel; Cohort Studies; Drug Interactions; Female; Finland; Hemorrhage; Humans; Male; Middle Aged; Outpatients; Platelet Aggregation Inhibitors; Polypharmacy; Prasugrel Hydrochloride; Retrospective Studies; Ticagrelor | 2020 |
MAPT (Mono Antiplatelet Therapy) as Regular Regimen After COBRA PzF™ NanoCoated Coronary Stent (NCS) Implantation.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Chromium Alloys; Clopidogrel; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Thrombosis; Female; Hemorrhage; Humans; Male; Organophosphorus Compounds; Platelet Aggregation Inhibitors; Polymers; Prospective Studies; Prosthesis Design; Registries; Risk Assessment; Risk Factors; Stents; Time Factors; Treatment Outcome | 2020 |
Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Humans; Ischemia; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Recurrence; Registries; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors | 2020 |
Sex-specific differences in antithrombotic therapy and prognosis in patients with acute coronary syndrome treated with stent.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Practice Patterns, Physicians'; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Sex Factors; Stents; Ticagrelor; Ticlopidine | 2019 |
Reply.
Topics: Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Ticagrelor | 2020 |
Ticagrelor versus clopidogrel in acute myocardial infarction patients with multivessel disease; From Korea Acute Myocardial Infarction Registry-National Institute of Health.
Topics: Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Republic of Korea; Thrombolytic Therapy; Ticagrelor; Treatment Outcome | 2020 |
Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percut
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Stroke; Thromboembolism; Ticagrelor; Treatment Outcome; Warfarin | 2020 |
Comparison of Age (<75 Years Vs ≥75 Years) and Platelet Reactivity to the Risk of Thrombotic and Bleeding Events After Successful Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study).
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug-Eluting Stents; Graft Occlusion, Vascular; Hemorrhage; Humans; Middle Aged; Mortality; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Recurrence; Thrombosis; Young Adult | 2020 |
Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Clopidogrel; Dyspnea; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Treatment Outcome | 2020 |
A Pharmacodynamic Study of CN-218, a Novel Antiplatelet and Antithrombotic Agent Primarily Targeting the P2Y
Topics: Animals; Blood Coagulation; Blood Platelets; Carrageenan; Clopidogrel; Cyclic AMP; Disease Models, Animal; Fibrinolytic Agents; Hemorrhage; Male; Mice; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Rats, Wistar; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis | 2020 |
Impact of Anemia on the Risk of Bleeding Following Percutaneous Coronary Interventions in Patients ≥75 Years of Age.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anemia; Angina, Unstable; Anticoagulants; Antithrombins; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Artery Disease; Drug-Eluting Stents; Female; Gastrointestinal Hemorrhage; Hemorrhage; Heparin; Hirudins; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Hemorrhage; Prasugrel Hydrochloride; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Risk Assessment; Stents; Ticagrelor; Urologic Diseases | 2020 |
[The ISAR-REACT 5 trial: is there a winner between prasugrel and ticagrelor in acute coronary syndromes?]
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clinical Trials, Phase IV as Topic; Clopidogrel; Hemorrhage; Humans; Multicenter Studies as Topic; Non-ST Elevated Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2020 |
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clopidogrel; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; Healthy Volunteers; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Stroke; Venous Thromboembolism; Young Adult | 2020 |
Efficacy and safety of standard and low dose ticagrelor versus clopidogrel in east AsianPatients with chronic total occlusion undergoing percutaneous coronary intervention: a single center retrospective study.
Topics: Aged; Asian People; China; Chronic Disease; Clopidogrel; Coronary Occlusion; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Reloading When Switching From Ticagrelor or Prasugrel to Clopidogrel Within 7 Days After STEMI.
Topics: Clinical Decision-Making; Clopidogrel; Coronary Thrombosis; Drug Substitution; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Stents; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Frailty and Co-Prescribing of Potentially Interacting Drugs in New Users of Warfarin.
Topics: Acetaminophen; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Clopidogrel; Drug Interactions; Drug Prescriptions; Drug Utilization Review; Female; Frail Elderly; Frailty; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Warfarin | 2020 |
Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.
Topics: Aged; Cardiologists; Cardiology Service, Hospital; Clopidogrel; Drug Utilization; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Retrospective Studies; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors; Treatment Outcome; United States | 2020 |
How Un-POPular Is Bleeding in Patients with TAVI?
Topics: Anticoagulants; Aortic Valve Stenosis; Clopidogrel; Hemorrhage; Humans; Transcatheter Aortic Valve Replacement | 2020 |
Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Death; Drug Therapy, Combination; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Registries; Renal Insufficiency, Chronic; Retrospective Studies; Risk Assessment; Stroke | 2020 |
Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Topics: Aged; Asian People; Aspirin; Cilostazol; Clopidogrel; Databases, Factual; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Ischemic Versus Bleeding Outcomes After Percutaneous Coronary Interventions in Patients With High Bleeding Risk.
Topics: Aged; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Artery Disease; Dual Anti-Platelet Therapy; Female; Gastrointestinal Hemorrhage; Heart Failure; Hemorrhage; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prevalence; Renal Insufficiency; Risk; Risk Assessment; Stents; Thrombosis | 2020 |
Risk Factors for Postoperative Events in Patients on Antiplatelet Therapy Undergoing Off-Pump Coronary Artery Bypass Grafting Surgery.
Topics: Aged; Aged, 80 and over; Aspirin; Beijing; Clopidogrel; Coronary Artery Bypass, Off-Pump; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2020 |
Bleeding risk of ticagrelor compared to clopidogrel in intensive care unit patients with acute coronary syndrome: A propensity-score matching analysis.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Intensive Care Units; Male; Middle Aged; Patient Discharge; Propensity Score; Risk Factors; Ticagrelor; Treatment Outcome | 2020 |
Preoperative clopidogrel and outcomes in patients with acute coronary syndrome undergoing coronary artery bypass surgery.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Bypass; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Preoperative Care; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2022 |
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cause of Death; Clopidogrel; Female; Hemorrhage; Humans; Italy; Male; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Risk; Ticagrelor | 2021 |
Ticagrelor versus clopidogrel in patients with ST-elevation myocardial infarction: postdischarge mild bleeding and its clinical impacts.
Topics: Aged; China; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Prospective Studies; ST Elevation Myocardial Infarction; Ticagrelor | 2021 |
Adenosine Diphosphate Receptor Inhibitors: Balancing Perioperative Bleeding and Protection From Adverse Coronary Events.
Topics: Adenosine Diphosphate; Clopidogrel; Hemorrhage; Humans; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2021 |
How Do Type of Preoperative P2Y
Topics: Aged; Clopidogrel; Coronary Artery Bypass; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Preoperative Period; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Time Factors; Withholding Treatment | 2021 |
Post-extraction bleeding complications in patients on uninterrupted dual antiplatelet therapy-a prospective study.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prospective Studies; Treatment Outcome | 2021 |
Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study.
Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Coronary Artery Disease; Dual Anti-Platelet Therapy; Endarterectomy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2020 |
Efficacy assessment of ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention by data mining and machine-learning decision tree approaches.
Topics: Acute Coronary Syndrome; Aged; Algorithms; Asian People; Clopidogrel; Data Mining; Decision Trees; Female; Hemorrhage; Hospitalization; Humans; Machine Learning; Male; Middle Aged; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor | 2020 |
[Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation].
Topics: Acute Coronary Syndrome; Acute Disease; Aspirin; Atrial Fibrillation; Clopidogrel; Combined Modality Therapy; Cyclophosphamide; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stents; Stroke; Vitamin K | 2020 |
Comparison Between Clopidogrel and Prasugrel Associated With CYP2C19 Genotypes in Patients Receiving Percutaneous Coronary Intervention in a Japanese Population.
Topics: Aged; Aged, 80 and over; Alleles; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Female; Follow-Up Studies; Genotype; Hemorrhage; Humans; Japan; Loss of Function Mutation; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; Stroke; Treatment Outcome | 2020 |
Major bleeding risk and mortality associated with antiplatelet drugs in real-world clinical practice. A prospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Databases, Factual; Drug Therapy, Combination; Female; France; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Incidence; Intracranial Hemorrhages; Male; Middle Aged; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Young Adult | 2020 |
Efficacy and Safety of Ticagrelor vs. Clopidogrel in East Asian Patients with Acute Myocardial Infarction: A Nationwide Cohort Study.
Topics: Aged; Asian People; Clopidogrel; Cohort Studies; Data Management; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Propensity Score; Stroke; Taiwan; Ticagrelor; Treatment Outcome | 2021 |
Safety and Efficacy of Single Versus Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiovascular Diseases; Clopidogrel; Dual Anti-Platelet Therapy; Embolism; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prosthesis Implantation; Septal Occluder Device; Stroke; Thrombosis | 2020 |
Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Genotype; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenotype; Platelet Aggregation Inhibitors; Precision Medicine; Risk Assessment; Risk Factors; Thrombosis; Time Factors; Treatment Outcome; United States | 2021 |
In ACS, prasugrel reduces 30-day MACE and mortality vs. ticagrelor or clopidogrel; no differences for major bleeding.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
In older patients with NSTE-ACS, clopidogrel safely reduced bleeding compared with ticagrelor at 1 year.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Hemorrhage; Humans; Patients; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor | 2020 |
Effect of Gender on Clinical Outcomes in Patients Receiving
Topics: Aged; Alleles; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Hemorrhage; Humans; Loss of Function Mutation; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Sex Factors; Treatment Outcome | 2020 |
Factors Influencing Provider and Patient Choice of P2Y
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Patient Preference; Patient Selection; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2022 |
Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Algorithms; Aspirin; Case-Control Studies; Cause of Death; Clopidogrel; Databases, Factual; Dyspnea; Female; Hemorrhage; Humans; Ischemia; Male; Middle Aged; Myocardial Infarction; Network Meta-Analysis; Percutaneous Coronary Intervention; Propensity Score; Purinergic P2Y Receptor Antagonists; Recurrence; Republic of Korea; Retrospective Studies; Stroke; Ticagrelor; United States | 2020 |
Thoracentesis under clopidogrel is not associated with excessive bleeding events: a cohort study.
Topics: Aged; Aged, 80 and over; Clopidogrel; Cohort Studies; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pleural Effusion; Retrospective Studies; Thoracentesis | 2020 |
Predictors of Clopidogrel Hyper-Responsiveness in Neuro-Interventional Procedures.
Topics: Aged; Carotid Stenosis; Clopidogrel; Embolization, Therapeutic; Endovascular Procedures; Female; Hemorrhage; Humans; Intracranial Aneurysm; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Assessment; Risk Factors; Stents; Treatment Outcome | 2021 |
Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI.
Topics: Anticoagulants; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2022 |
Benefits and Risks of Prolonged Duration Dual Antiplatelet Therapy (Clopidogrel and Aspirin) After Percutaneous Coronary Intervention in High-Risk Patients With Diabetes Mellitus.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Dual Anti-Platelet Therapy; Duration of Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Mortality; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Proportional Hazards Models; Registries; Risk Assessment; Stroke | 2021 |
Comparison of Warfarin to Dual Antiplatelet Therapy Following Transcatheter Aortic Valve Replacement.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Thrombosis; Transcatheter Aortic Valve Replacement; Warfarin | 2021 |
A trial of antithrombotic therapy in patients with refractory migraine and antiphospholipid antibodies: A retrospective study of 75 patients.
Topics: Adolescent; Adult; Aged; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Child; Clopidogrel; Cyclooxygenase Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Migraine Disorders; Purinergic P2Y Receptor Antagonists; Pyrazoles; Pyridones; Retrospective Studies; Severity of Illness Index; Stroke; Treatment Outcome; Young Adult | 2021 |
Risk of postpolypectomy bleeding in patients taking direct oral anticoagulants or clopidogrel.
Topics: Administration, Oral; Aged; Anticoagulants; Clopidogrel; Colonic Polyps; Colonoscopy; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Thromboembolism; Ticlopidine; Warfarin | 2021 |
Outcomes of Individuals With and Without Heart Failure Presenting With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Case-Control Studies; Clopidogrel; Diabetes Mellitus; Dual Anti-Platelet Therapy; Female; Heart Failure; Hemorrhage; Hospitalization; Humans; Ischemic Attack, Transient; Ischemic Stroke; Kidney Failure, Chronic; Male; Middle Aged; Mortality; Multivariate Analysis; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; ST Elevation Myocardial Infarction; Stroke Volume; Ticagrelor; Treatment Outcome | 2021 |
Prasugrel versus ticagrelor in patients with myocardial infarction undergoing percutaneous coronary intervention.
Topics: Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Percutaneous Coronary Intervention; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Stroke; Sweden; Ticagrelor; Treatment Outcome | 2021 |
Bleeding associated with co-administration of clopidogrel and ACEi in patients undergoing PCI and DAPT.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2021 |
Risk of Major Bleeding With Potent Antiplatelet Agents After an Acute Coronary Event: A Comparison of Ticagrelor and Clopidogrel in 5116 Consecutive Patients in Clinical Practice.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cause of Death; Clopidogrel; England; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Survival Rate; Ticagrelor | 2021 |
Evaluation of serious bleeding signals during concomitant use of clopidogrel and hypnotic drugs.
Topics: Aged; Aged, 80 and over; Clopidogrel; Cohort Studies; Drug Interactions; Female; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypnotics and Sedatives; Male; Middle Aged; Platelet Aggregation Inhibitors; Pravastatin; Treatment Outcome | 2021 |
Bleeding risk stratification in coronary artery surgery: the should-not-bleed score.
Topics: Adult; Aged, 80 and over; Area Under Curve; Blood Transfusion; Cardiac Surgical Procedures; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Postoperative Hemorrhage; Retrospective Studies; Risk Assessment; Risk Factors; United States; Vascular Surgical Procedures | 2021 |
Comparison of effectiveness and safety between ticagrelor and clopidogrel in patients with acute coronary syndrome and on dialysis in Taiwan.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Renal Dialysis; Retrospective Studies; Taiwan; Ticagrelor; Treatment Outcome | 2022 |
Assessing the Efficacy and Safety of Tirofiban in Combination With Dual-antiplatelet Therapy in Progressive Ischemic Stroke Patients.
Topics: Aged; Aspirin; Clopidogrel; Disability Evaluation; Dual Anti-Platelet Therapy; Female; Functional Status; Hemorrhage; Humans; Infusions, Intravenous; Ischemic Stroke; Male; Middle Aged; Platelet Aggregation Inhibitors; Recovery of Function; Retrospective Studies; Time Factors; Tirofiban; Treatment Outcome | 2021 |
The impact of antiplatelet and antithrombotic regimen after TAVI: Data from the VIenna CardioThOracic Aortic Valve RegistrY (VICTORY).
Topics: Aged; Aged, 80 and over; Anticoagulants; Aortic Valve Stenosis; Aspirin; Austria; Clopidogrel; Dual Anti-Platelet Therapy; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Postoperative Care; Registries; Survival Rate; Transcatheter Aortic Valve Replacement; Vitamin K | 2021 |
Bleeding Risk and Mortality Associated With Uninterrupted Antithrombotic Therapy During Percutaneous Endoscopic Gastrostomy Tube Placement.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Female; Fibrinolytic Agents; Gastrostomy; Hemorrhage; Humans; Intubation, Gastrointestinal; Male; Middle Aged; Risk | 2021 |
The effects of polymorphisms in CYP2C19, ATP-binding cassette transporter B1, and paraoxonase-1 on clopidogrel treatment of Uygur patients following percutaneous coronary intervention.
Topics: Adult; Age Factors; Aged; Alleles; Aryldialkylphosphatase; Asian People; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Comorbidity; Cytochrome P-450 CYP2C19; Dual Anti-Platelet Therapy; Ethnicity; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Percutaneous Coronary Intervention; Polymorphism, Genetic; Risk Factors; Sex Factors; Sociodemographic Factors | 2021 |
Long-term complications after stent assist coiling dependent on clopidogrel response.
Topics: Blood Platelets; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Stents | 2021 |
Ticagrelor or Clopidogrel After an Acute Coronary Syndrome in the Elderly: A Propensity Score Matching Analysis from 16,653 Patients Treated with PCI Included in Two Large Multinational Registries.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Registries; Retrospective Studies; Ticagrelor | 2021 |
Safety and Efficacy of Triple Therapy With Ticagrelor or Prasugrel Versus Clopidogrel After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.
Topics: Aged; Aged, 80 and over; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Massachusetts; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; ST Elevation Myocardial Infarction; Stroke; Ticagrelor | 2021 |
Diffuse alveolar haemorrhage: a rare complication of clopidogrel use.
Topics: Aged, 80 and over; Bronchoalveolar Lavage; Bronchoscopy; Clopidogrel; Female; Hemorrhage; Humans; Lung Diseases | 2021 |
Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Body Mass Index; Case-Control Studies; China; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prodrugs; Retrospective Studies; Risk Factors; Treatment Outcome | 2021 |
Clopidogrel versus Ticagrelor in CYP2C19 Loss-of-Function Allele Noncarriers: A Real-World Study in China.
Topics: Acute Coronary Syndrome; Aged; Alleles; Angina, Unstable; Clopidogrel; Cytochrome P-450 CYP2C19; Hemorrhage; Humans; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Twelve-month outcome of patients with an established indication for oral anticoagulation undergoing coronary artery stenting and stratified by the baseline risk of bleeding: Insights from the Warfarin and Coronary Stenting (War-Stent) Registry.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Stents; Thrombolytic Therapy; Ticlopidine; Treatment Outcome; Warfarin; Young Adult | 2017 |
Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Incidence; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2017 |
Contemporary Trends and Outcomes Associated With the Preprocedural Use of Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
Topics: Adenosine; Aged; Blue Cross Blue Shield Insurance Plans; Clopidogrel; Drug Utilization Review; Ethnicity; Female; Graft Occlusion, Vascular; Hemorrhage; Hospital Mortality; Humans; Male; Michigan; Middle Aged; Outcome and Process Assessment, Health Care; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Preoperative Period; Purinergic P2Y Receptor Antagonists; Stents; Ticagrelor; Ticlopidine; Time Factors | 2017 |
Previous hypertensive hemorrhage increases the risk for bleeding and ischemia for PCI patients on dual antiplatelet therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Ischemia; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Ticlopidine | 2017 |
Comparative Effectiveness and Safety Analysis of Dual Antiplatelet Therapies Within an Integrated Delivery System.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Delivery of Health Care, Integrated; Female; Hemorrhage; Humans; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Retrospective Studies; Safety; Ticagrelor; Ticlopidine | 2017 |
Total Thrombus-formation Analysis System Predicts Periprocedural Bleeding Events in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Intraoperative Complications; Male; Microchip Analytical Procedures; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prasugrel Hydrochloride; Risk Assessment; Ticlopidine | 2017 |
Association of measured platelet reactivity with changes in P2Y
Topics: Aged; Blood Platelets; Brain Ischemia; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2017 |
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Streptokinase; Stroke; Ticagrelor; Ticlopidine; Tissue Plasminogen Activator | 2017 |
Outcome of Triple Antiplatelet Therapy Including Cilostazol in Elderly Patients with ST-Elevation Myocardial Infarction who Underwent Primary Percutaneous Coronary Intervention: Results from the INTERSTELLAR Registry.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Retrospective Studies; ST Elevation Myocardial Infarction; Tetrazoles; Ticlopidine | 2017 |
Gender-related differences in antiplatelet treatment patterns and outcome: Insights from the GReekAntiPlatElet Registry.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Female; Greece; Hemorrhage; Humans; Ischemia; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Registries; Risk Factors; Sex Characteristics; Stents; Ticlopidine; Treatment Outcome | 2017 |
Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM)
Topics: Aged; Aspirin; Catheterization, Peripheral; Clopidogrel; Coronary Angiography; Enoxaparin; Female; Femoral Artery; Fibrinolytic Agents; Heart Failure; Hemorrhage; Humans; Male; Middle Aged; Mortality; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Radial Artery; Recurrence; Shock; ST Elevation Myocardial Infarction; Tenecteplase; Thrombolytic Therapy; Ticlopidine; Tissue Plasminogen Activator | 2016 |
Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Fibrinolytic Agents; Hemorrhage; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prevalence; Proportional Hazards Models; Republic of Korea; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome; Warfarin | 2017 |
Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction | 2018 |
The impact of clinical and genetic factors on ticagrelor and clopidogrel antiplatelet therapy.
Topics: Adenosine; Aged; Clopidogrel; Cytochrome P450 Family 4; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Time Factors | 2017 |
Quantification of bleeding during dental extraction in patients on dual antiplatelet therapy.
Topics: Aspirin; Blood Loss, Surgical; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Dental Care for Chronically Ill; Female; Hemorrhage; Hemostasis, Surgical; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine; Tooth Extraction | 2017 |
Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Austria; Clopidogrel; Female; Hemorrhage; Hospital Mortality; Humans; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prescription Drugs; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine | 2017 |
Comparison of prasugrel versus clopidogrel in Korean patients with acute myocardial infarction undergoing successful revascularization.
Topics: Aged; Asian People; Calcium Channel Blockers; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine; Treatment Outcome | 2018 |
Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Computer Simulation; Coronary Thrombosis; Cost-Benefit Analysis; Decision Trees; Disease-Free Survival; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Middle Aged; Models, Economic; Monte Carlo Method; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
A retrospective comparison between delayed and early hip fracture surgery in patients taking clopidogrel: same total bleeding but different timing of blood transfusion.
Topics: Aged; Aged, 80 and over; Blood Transfusion; Clopidogrel; Female; Fracture Fixation, Internal; Hemiarthroplasty; Hemorrhage; Hip Fractures; Hip Joint; Hospital Mortality; Humans; Length of Stay; Male; Perioperative Period; Platelet Aggregation Inhibitors; Postoperative Complications; Retrospective Studies; Ticlopidine; Time Factors; Time-to-Treatment; Withholding Treatment | 2017 |
CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Drug Costs; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine | 2017 |
Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Databases, Factual; Hemorrhage; Humans; Kaplan-Meier Estimate; Kidney; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Renal Insufficiency, Chronic; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome; United States | 2017 |
Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Female; Germany; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Proportional Hazards Models; Prospective Studies; Registries; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome; United States | 2017 |
Platelet transfusion to reverse antiplatelet therapy before decompressive surgery in patients with intracranial haemorrhage.
Topics: Adult; Aged; Aged, 80 and over; Clopidogrel; Decompression, Surgical; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Transfusion; Preoperative Care; Stroke; Thrombosis; Ticlopidine | 2017 |
Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Case-Control Studies; Clopidogrel; Cohort Studies; Comorbidity; Diabetes Mellitus; Female; Greece; Hemorrhage; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Prospective Studies; Stroke; Ticagrelor; Ticlopidine | 2018 |
Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor?
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome; Withholding Treatment | 2017 |
Which is the best antiaggregant or anticoagulant therapy after TAVI? A propensity-matched analysis from the ITER registry. The management of DAPT after TAVI.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Propensity Score; Registries; Stroke; Ticlopidine; Transcatheter Aortic Valve Replacement | 2017 |
Dual Antiplatelet Therapy Is Associated With Coagulopathy Detectable by Thrombelastography in Acute Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Coagulation; Clopidogrel; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Stroke; Thrombelastography | 2020 |
Safety and Necessity of Antiplatelet Therapy on Patients Underwent Endovascular Aortic Repair with Both Stanford Type B Aortic Dissection and Coronary Heart Disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Ticlopidine | 2017 |
Discontinuation of Oral Antiplatelet Agents before Dental Extraction - Necessity or Myth?
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Bulgaria; Clopidogrel; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Patient Safety; Platelet Aggregation Inhibitors; Prospective Studies; Risk Assessment; Tooth Extraction; Treatment Outcome; Withholding Treatment; Young Adult | 2017 |
The safety and effectiveness of adenosine diphosphate receptor inhibitor pretreatment among acute myocardial infarction patients treated with percutaneous coronary intervention in community practice: Insights from the TRANSLATE-ACS study.
Topics: Aged; Clopidogrel; Community Health Services; Female; Hemorrhage; Humans; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Treatment Outcome; United States | 2018 |
Outcome of Transurethral Resection of Bladder Tumor: Does Antiplatelet Therapy Really Matter? Analysis of a Retrospective Series.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Carcinoma, Transitional Cell; Clopidogrel; Cystoscopy; Female; Hemorrhage; Humans; Intraoperative Complications; Length of Stay; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Ticlopidine; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 2017 |
Cardiovascular and Bleeding Risks in Acute Myocardial Infarction Newly Treated With Ticagrelor vs. Clopidogrel in Taiwan.
Topics: Aged; Asian People; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Ischemia; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Propensity Score; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk; Taiwan; Ticagrelor; Treatment Outcome | 2018 |
European guidelines on perioperative venous thromboembolism prophylaxis: Chronic treatments with antiplatelet agents.
Topics: Anesthesiology; Anticoagulants; Aspirin; Blood Coagulation; Clopidogrel; European Union; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Incidence; Intermittent Pneumatic Compression Devices; Long-Term Care; Nerve Block; Perioperative Care; Platelet Aggregation Inhibitors; Postoperative Complications; Risk Assessment; Risk Factors; Societies, Medical; Surgical Procedures, Operative; Time Factors; Venous Thromboembolism | 2018 |
Real-world clopidogrel utilization in acute coronary syndromes: patients selection and outcomes in a single-center experience.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Drug Prescriptions; Drug Therapy, Combination; Drug Utilization Review; Female; Hemorrhage; Hospital Mortality; Humans; Italy; Logistic Models; Male; Middle Aged; Multivariate Analysis; Non-ST Elevated Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2017 |
Anticoagulation strategies in patients with atrial fibrillation after PCI or with ACS : The end of triple therapy?
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Guideline Adherence; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Randomized Controlled Trials as Topic; Risk Factors; Stents; Stroke; Thrombosis; Vitamin K | 2018 |
Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Chi-Square Distribution; China; Clinical Decision-Making; Clopidogrel; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Female; Gene Frequency; Genetic Predisposition to Disease; Hemorrhage; Heterozygote; Homozygote; Humans; Hypertension; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Precision Medicine; Retrospective Studies; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2018 |
Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.
Topics: Aged; Chi-Square Distribution; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Predisposition to Disease; Haplotypes; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Retrospective Studies; Risk Factors; Serbia; ST Elevation Myocardial Infarction; Ticlopidine; Treatment Outcome | 2018 |
Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Angiography; Dabigatran; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Incidence; Ischemia; Kaplan-Meier Estimate; Male; Middle Aged; Outcome Assessment, Health Care; Patient Safety; Phenindione; Propensity Score; Proportional Hazards Models; Risk; Treatment Outcome; Vitamin K | 2018 |
Comparison of the effects of P2Y12 receptor antagonists on platelet function and clinical outcomes in patients undergoing Primary PCI: A substudy of the HEAT-PPCI trial.
Topics: Anticoagulants; Clopidogrel; Coronary Thrombosis; Hemorrhage; Humans; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
Dual antiplatelet therapy is safe and efficient after left atrial appendage closure.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Patient Safety; Platelet Aggregation Inhibitors; Stroke; Treatment Outcome | 2018 |
Antiplatelet drug selection in PCI to vein grafts in patients with acute coronary syndrome and adverse clinical outcomes: Insights from the British Cardiovascular Intervention Society database.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Bypass; Databases, Factual; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Risk Factors; Saphenous Vein; Ticagrelor; Time Factors; Treatment Outcome; United Kingdom | 2018 |
Short-term dual antiplatelet therapy after interventional left atrial appendage closure with different devices.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Catheterization; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Echocardiography, Transesophageal; Feasibility Studies; Female; Germany; Hemorrhage; Humans; Incidence; Kidney; Kidney Diseases; Male; Platelet Aggregation Inhibitors; Registries; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2018 |
Comparison of the 9-month intra-stent conditions and 2-year clinical outcomes after Resolute zotarolimus-eluting stent implantation between 3-month and standard dual antiplatelet therapy.
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Vessels; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Hemorrhage; Humans; Japan; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Sirolimus; Thrombosis; Tomography, Optical Coherence | 2018 |
Platelet function testing: dead or alive.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelets; Cardiovascular Diseases; Cell Adhesion Molecules; Clinical Decision-Making; Clopidogrel; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Microfilament Proteins; Patient Selection; Phosphoproteins; Phosphorylation; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Reproducibility of Results | 2018 |
Perioperative Use of Anticoagulant and Platelet-inhibiting Medications for Elective Spine Surgery: Results of a Nationwide Survey.
Topics: Anticoagulants; Clopidogrel; Elective Surgical Procedures; Fibrinolytic Agents; Health Care Surveys; Hemorrhage; Heparin; Humans; Neurosurgical Procedures; Orthopedic Procedures; Platelet Aggregation Inhibitors; Spine; Ticlopidine | 2018 |
Pretreatment with P2Y12 inhibitors and outcome in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
Topics: Aged; Belgium; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Preoperative Care; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Stents; Survival Analysis; Thrombosis; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
Clinical Outcomes of Plavix and Generic Clopidogrel for Patients Hospitalized With an Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Cost Savings; Cost-Benefit Analysis; Databases, Factual; Drug Costs; Drug Substitution; Drugs, Generic; Female; Hemorrhage; Humans; Male; Ontario; Patient Admission; Patient Readmission; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2018 |
Influence of CYP2C19 Phenotype on the Effect of Clopidogrel in Patients Undergoing a Percutaneous Neurointervention Procedure.
Topics: Aged; Aged, 80 and over; Angioplasty; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Hemorrhage; Humans; Male; Middle Aged; Phenotype; Platelet Aggregation Inhibitors; Retrospective Studies | 2019 |
Outcomes in patients treated with ticagrelor versus clopidogrel after acute myocardial infarction stratified by renal function.
Topics: Aged; Clopidogrel; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Registries; Risk Assessment; Stroke; Sweden; Ticagrelor | 2018 |
In-Hospital Outcomes of Dual Loading Antiplatelet Therapy in Patients 75 Years and Older With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Findings From the CCC-ACS (Improving Care for Cardiovascular Disease in China-Acute Corona
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Aspirin; China; Clopidogrel; Databases, Factual; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quality Improvement; Registries; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
Early P2Y12 Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry.
Topics: Aged; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Administration Schedule; Drug Substitution; Drug-Eluting Stents; Female; Hemorrhage; Humans; Italy; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Treatment Outcome | 2018 |
Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Count; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thrombocytopenia; Time Factors; Treatment Outcome | 2018 |
Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes: insights from the TRILOGY ACS trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Clopidogrel; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2018 |
Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice: Results From the Bern Percutaneous Coronary Intervention Registry.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Clopidogrel; Drug Administration Schedule; Drug Substitution; Dyspnea; Female; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Switzerland; Tertiary Care Centers; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
Utility of GRACE and ACUITY-HORIZONS risk scores to guide dual antiplatelet therapy in Korean patients with acute myocardial infarction undergoing drug-eluting stenting.
Topics: Aged; Clopidogrel; Decision Support Techniques; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Registries; Republic of Korea; Risk Assessment; Ticagrelor | 2018 |
Relationship between high platelet reactivity on clopidogrel and long-term clinical outcomes after drug-eluting stents implantation (PAINT-DES): a prospective, propensity score-matched cohort study.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Prospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2018 |
Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Female; Heart Diseases; Hemorrhage; Humans; Male; MicroRNAs; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Vascular Diseases | 2019 |
Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alleles; Aspirin; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Hemorrhage; Humans; Male; Phenotype; Pilot Projects; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prospective Studies; Risk; Thrombosis | 2018 |
Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Review Literature as Topic; Stroke; Ticlopidine | 2018 |
Adverse Effect of Antithrombotic Medications on Bleeding Events and Comparison of Antithrombotic Agents in Hemodialysis Patients.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Diabetic Nephropathies; Drug Monitoring; Female; Fibrinolytic Agents; Hemorrhage; Hospitalization; Humans; Japan; Male; Middle Aged; Renal Dialysis; Risk Assessment; Withholding Treatment | 2019 |
The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Stents; Stroke; Thrombelastography; Ticlopidine | 2019 |
Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome | 2018 |
A Case Report of Cangrelor Bridge Therapy for a Diagnostic Bronchoscopy With Biopsy.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Aspirin; Biopsy; Bronchoscopy; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
External Validation of the DAPT Score in a Nationwide Population.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Decision Support Techniques; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Assessment; Stents; Stroke; Sweden | 2018 |
Clinical Characteristics, Procedural Factors, and Outcomes of Percutaneous Coronary Intervention in Patients With Mechanical and Bioprosthetic Heart Valves.
Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Clopidogrel; Drug Therapy, Combination; Female; Heart Valve Prosthesis; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Vitamin K; Warfarin | 2018 |
Chronic Kidney Disease and Third-Generation P2Y
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Prognosis; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic | 2019 |
Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different P2Y
Topics: Acute Coronary Syndrome; Cause of Death; Clopidogrel; Drug Prescriptions; Follow-Up Studies; Hemorrhage; Humans; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Republic of Korea; Survival Rate; Ticagrelor | 2019 |
Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease.
Topics: Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Coronary Artery Disease; Denmark; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Outcome and Process Assessment, Health Care; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Risk Assessment; Stroke; Warfarin | 2018 |
Response to clopidogrel and of the cytochrome CYP2C19 gene polymorphism.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug-Related Side Effects and Adverse Reactions; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Genotyping Techniques; Hemorrhage; Heterozygote; Humans; Longitudinal Studies; Male; Middle Aged; Pharmacogenomic Testing; Polymorphism, Genetic; Tunisia | 2018 |
Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Decision Support Techniques; Drug Therapy, Combination; Drug-Eluting Stents; Female; Germany; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Registries; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States | 2018 |
Elevated Neutrophil and Presence of Intracranial Artery Stenosis Increase the Risk of Recurrent Stroke.
Topics: Aged; Cerebral Infarction; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Neutrophils; Platelet Aggregation Inhibitors; Recurrence; Risk Factors; Stroke | 2018 |
Comparative effectiveness and safety of antiplatelet drugs in patients with diabetes mellitus and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Comorbidity; Comparative Effectiveness Research; Diabetes Mellitus; Female; Hemorrhage; Hospital Mortality; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Ticagrelor; Treatment Outcome; United States | 2018 |
Impact of Cytochrome P450 2C19 Reduced-Function Polymorphism on Lesions and Clinical Outcome in Japanese Patients After Drug-eluting Stent Implantation.
Topics: Aged; Asian People; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Female; Genetic Association Studies; Hemorrhage; Humans; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prospective Studies; Treatment Outcome | 2018 |
Efficacy and Safety of Loading Doses With P2Y12-Receptor Antagonists in Patients Without Dual Antiplatelet Therapy Undergoing Elective Coronary Intervention.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
Association of potent P2Y12 blockers with ischemic and bleeding outcomes in non-ST-segment elevation myocardial infarction.
Topics: Aged; Clopidogrel; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Propensity Score; Purinergic P2Y Receptor Antagonists; Registries; Republic of Korea; Stroke; Ticagrelor | 2019 |
Performance of PRECISE-DAPT Score for Predicting Bleeding Complication During Dual Antiplatelet Therapy.
Topics: Aged; Aspirin; Clopidogrel; Decision Support Techniques; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Stents; Ticagrelor; Treatment Outcome | 2018 |
EBUS-TBNA on Patients Receiving Antiplatelet Therapy: Are We Throwing Caution to the Wind?
Topics: Aged; Biopsy, Fine-Needle; Bronchoscopy; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Hemorrhage; Humans; Image-Guided Biopsy; Incidence; Lung Neoplasms; Lymph Nodes; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prospective Studies; Withholding Treatment | 2019 |
Intravenous Antiplatelet Therapy Bridging in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Administration, Intravenous; Aged; Aspirin; Cardiac Surgical Procedures; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Perioperative Care; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Time Factors; Tirofiban; Treatment Outcome | 2019 |
Comparing the vascular thromboembolic events following arteriovenous fistula in Chinese population with end-stage renal diseases receiving Clopidogrel versus Beraprost sodium therapy: a retrospective cohort study.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; China; Clopidogrel; Constriction, Pathologic; Epoprostenol; Female; Hemorrhage; Humans; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Platelet Aggregation Inhibitors; Renal Dialysis; Retrospective Studies; Thrombosis; Time Factors; Young Adult | 2018 |
Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clinical Decision-Making; Clopidogrel; Coronary Thrombosis; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drug-Eluting Stents; Europe; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Registries; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; United States | 2019 |
Switching of Oral P2Y
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Aged, 80 and over; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prevalence; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; ST Elevation Myocardial Infarction; Ticagrelor | 2019 |
intravenous cangrelor (Kengrexal°) and coronary angioplasty: No advantage over first-line clopidogrel.
Topics: Adenosine Monophosphate; Administration, Intravenous; Clopidogrel; Coronary Artery Disease; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome | 2016 |
Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Black or African American; Cause of Death; Clopidogrel; Comorbidity; Female; Health Status Disparities; Healthcare Disparities; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prevalence; Prospective Studies; Race Factors; Registries; Risk Assessment; Risk Factors; Sex Factors; Stroke; Time Factors; Treatment Outcome; United States | 2019 |
Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database.
Topics: Acute Coronary Syndrome; Administrative Claims, Healthcare; Aged; Clopidogrel; Comparative Effectiveness Research; Databases, Factual; France; Hemorrhage; Humans; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Risk Factors; Secondary Prevention; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
Evaluation of adverse events involving bleeding associated with oral P2Y12 inhibitors use in the Food and Drug Administration adverse event reporting system.
Topics: Adverse Drug Reaction Reporting Systems; Clopidogrel; Hemorrhage; Humans; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticlopidine; United States; United States Food and Drug Administration | 2019 |
Efficacy and Safety of Ticagrelor Compared with Clopidogrel in Patients with End-Stage Renal Disease with Acute Myocardial Infarction.
Topics: Aged; Clopidogrel; Female; Hemorrhage; Humans; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Stroke; Ticagrelor; Treatment Outcome | 2019 |
Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention.
Topics: Aged; Aged, 80 and over; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug Resistance; Europe; Female; Genetic Association Studies; Genetic Predisposition to Disease; Hemorrhage; Homozygote; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Soluble Guanylyl Cyclase; Stents; Time Factors; Treatment Outcome | 2019 |
One-year clinical outcomes of ticagrelor compared with clopidogrel after percutaneous coronary intervention in patients with acute myocardial infarction: From Korean Health Insurance Review and Assessment Data.
Topics: Aged; Cause of Death; Clopidogrel; Combined Modality Therapy; Drug Substitution; Female; Hemorrhage; Humans; Incidence; Insurance, Health; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Republic of Korea; Stroke; Ticagrelor; Treatment Outcome | 2019 |
CYP2C19 Genotype-Guided Antiplatelet Therapy and 30-Day Outcomes After Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aged; Alleles; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Female; Genotype; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2019 |
Enhanced platelet inhibition by clopidogrel and risk of bleeding in patients requiring oral anticoagulation after drug-eluting stent implantation.
Topics: Anticoagulants; Clopidogrel; Drug-Eluting Stents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine; Treatment Outcome | 2019 |
Pretreatment with P2Y12 receptor antagonists in ST-elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry.
Topics: Aged; Aged, 80 and over; Angioplasty; Clopidogrel; Coronary Angiography; Female; Hemorrhage; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; ST Elevation Myocardial Infarction; Stents; Survival Rate; Sweden; Thrombosis; Ticagrelor | 2019 |
Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Stents; Time Factors; Treatment Outcome | 2019 |
Invited Commentary.
Topics: Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Ticagrelor | 2019 |
Effect of Selective Serotonin Reuptake Inhibitors on Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Retrospective Cohort Study.
Topics: Aged; Clopidogrel; Cohort Studies; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Stroke; Treatment Outcome | 2019 |
Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Cardiovascular Diseases; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Prasugrel Hydrochloride; Registries; Retrospective Studies; ST Elevation Myocardial Infarction; Treatment Outcome; United States | 2019 |
Multicenter research of bleeding risk between prasugrel and clopidogrel in Japanese patients with coronary artery disease undergoing percutaneous coronary intervention.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Retrospective Studies; Risk Factors; Stroke; Survival Rate; Time Factors; Treatment Outcome | 2019 |
[Percutaneous left atrial appendage closure in a patient with atrial fibrillation and Rendu-Osler-Weber disease].
Topics: Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Echocardiography; Female; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Stroke; Telangiectasia, Hereditary Hemorrhagic | 2019 |
Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Retrospective Studies; Stroke; Ticagrelor | 2019 |
Efficacy and safety of switching from ticagrelor to clopidogrel during the early and late phase in acute coronary syndrome patients after percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; China; Clopidogrel; Drug Substitution; Electrocardiography; Follow-Up Studies; Hemorrhage; Humans; Kaplan-Meier Estimate; Magnetic Resonance Angiography; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Under-prescription of novel antiplatelet drugs in patients with acute coronary syndrome and previous cardiovascular disease.
Topics: Acute Coronary Syndrome; Aftercare; Clopidogrel; Comorbidity; Coronary Disease; Drug Utilization; Female; Follow-Up Studies; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Metabolic Syndrome; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Prospective Studies; Smoking; Spain; Stroke; Tertiary Care Centers; Ticagrelor | 2019 |
A prospective interventional registry of short-term dual-antiplatelet treatment after implantation of drug-eluting stents in patients with atrial fibrillation requiring oral anticoagulation therapy.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Multivariate Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Registries | 2020 |
Discontinuation of Ticagrelor or Clopidogrel on Bleeding: Essential Role of Antifibrinolytic Agents.
Topics: Antifibrinolytic Agents; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Ticagrelor | 2020 |
Hot Polypectomy: A Cautionary Tale?
Topics: Clopidogrel; Colonic Polyps; Colonoscopy; Double-Blind Method; Hemorrhage; Humans | 2019 |
A Randomized Trial of Interrupted Clopidogrel in Patients Undergoing Polypectomy: More Questions Than Answers?
Topics: Clopidogrel; Double-Blind Method; Hemorrhage; Humans; Ticlopidine | 2019 |
RE: Risk of Postpolypectomy Bleeding With Uninterrupted Clopidogrel Therapy in an Industry-Independent, Double-Blind, Randomized, Trial.
Topics: Clopidogrel; Double-Blind Method; Hemorrhage; Humans; Ticlopidine | 2019 |
The impact of
Topics: Aged; Alleles; Aspirin; Clopidogrel; Cytochrome P450 Family 4; Female; Genotype; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Postoperative Complications; Stents; Ticagrelor | 2019 |
Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention.
Topics: Aged; Aryldialkylphosphatase; ATP Binding Cassette Transporter, Subfamily B; Carboxylic Ester Hydrolases; Cerebrovascular Disorders; Clopidogrel; Cytochrome P-450 Enzyme System; Female; Hemorrhage; Humans; Ischemia; Male; Middle Aged; Platelet Aggregation Inhibitors; Receptors, Purinergic P2Y12; Retrospective Studies | 2019 |
Tailored P2Y
Topics: Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk; Stroke; Thrombosis | 2019 |
Contemporary Antiplatelet Therapy and Clinical Outcomes of Japanese Patients With Acute Myocardial Infarction - Results From the Prospective Japan Acute Myocardial Infarction Registry (JAMIR).
Topics: Aged; Aged, 80 and over; Cause of Death; Clopidogrel; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Recurrence; Registries; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2019 |
Reply.
Topics: Clopidogrel; Double-Blind Method; Hemorrhage; Humans; Industry | 2019 |
The Safety of Ultrasound-Guided Thoracentesis in Patients on Novel Oral Anticoagulants and Clopidogrel: A Single-Center Experience.
Topics: Academic Medical Centers; Administration, Oral; Aged; Anticoagulants; Clopidogrel; Cohort Studies; Female; Follow-Up Studies; Hemorrhage; Hemothorax; Humans; Male; Middle Aged; Patient Safety; Pleural Effusion; Retrospective Studies; Risk Assessment; Surgery, Computer-Assisted; Survival Rate; Thoracentesis; Treatment Outcome; Ultrasonography, Interventional | 2019 |
Safety and Effectiveness of Contemporary P2Y
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Asian People; Cardiovascular Diseases; Cause of Death; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Recurrence; Republic of Korea; Stroke; Ticagrelor; Treatment Outcome | 2019 |
A case for genotype-guided de-escalation of antiplatelet therapy after percutaneous coronary angioplasty.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Labeling; Drug Monitoring; Dual Anti-Platelet Therapy; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Pharmacogenomic Testing; Platelet Aggregation Inhibitors; Platelet Function Tests; Practice Guidelines as Topic; Prasugrel Hydrochloride; Ticagrelor | 2019 |
Switching acute coronary syndrome patients from prasugrel to clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Chi-Square Distribution; Clopidogrel; Drug Resistance; Drug Substitution; Female; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Risk Assessment; Risk Factors; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
A Boolean view separates platelet activatory and inhibitory signalling as verified by phosphorylation monitoring including threshold behaviour and integrin modulation.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Iloprost; Integrins; Milrinone; Models, Biological; Molecular Dynamics Simulation; Phosphorylation; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Ticlopidine | 2013 |
[Effect of intracoronary and intravenous administration of tirofiban loading dose in patients underwent percutaneous coronary interventions because of acute coronary syndrome].
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Monitoring; Electrocardiography; Female; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Preoperative Care; Retrospective Studies; Survival Analysis; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Is discontinuation of clopidogrel necessary for intracapsular hip fracture surgery? Analysis of 102 hemiarthroplasties.
Topics: Aged; Aged, 80 and over; Blood Transfusion; Clopidogrel; Comorbidity; Databases, Factual; Female; Hemiarthroplasty; Hemorrhage; Hip Fractures; Humans; Male; Platelet Aggregation Inhibitors; Postoperative Complications; Retrospective Studies; Risk Factors; Ticlopidine; Treatment Outcome | 2013 |
Bleeding complications during percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Immunoglobulin Fab Fragments; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Ticlopidine | 2004 |
Operative treatment of hip fractures in patients on clopidogrel: a case-control study.
Topics: Aged; Aged, 80 and over; Blood Loss, Surgical; Blood Transfusion; Case-Control Studies; Clopidogrel; Female; Hemorrhage; Hip Fractures; Humans; Intraoperative Period; Male; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Retrospective Studies; Ticlopidine | 2012 |
Spontaneous haemorrhage in an eyelid hidrocystoma in a patient treated with clopidogrel.
Topics: Clopidogrel; Diagnosis, Differential; Eyelid Neoplasms; Female; Hemorrhage; Hidrocystoma; Humans; Middle Aged; Platelet Aggregation Inhibitors; Sweat Gland Neoplasms; Ticlopidine | 2013 |
Is platelet transfusion efficient to restore platelet reactivity in patients who are responders to aspirin and/or clopidogrel before emergency surgery?
Topics: Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Transfusion; Prospective Studies; Ticlopidine; Wounds and Injuries | 2013 |
Anti-thrombotic treatment in patients with a long-term indication for anticoagulant therapy undergoing coronary stenting.
Topics: Anticoagulants; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2013 |
Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Clopidogrel; Hemorrhage; Humans; Incidence; Male; Minimally Invasive Surgical Procedures; Prostatectomy; Prostatic Hyperplasia; Retrospective Studies; Thulium; Ticlopidine; Treatment Outcome; Urinary Tract Infections; Venous Thrombosis | 2014 |
Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarction.
Topics: Abciximab; Aged; Aged, 80 and over; Antibodies, Monoclonal; Clopidogrel; Coronary Thrombosis; Cost Savings; Cost-Benefit Analysis; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Infusions, Parenteral; Injections; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recurrence; Registries; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Effect of platelet inhibition on bleeding complications in trauma patients on preinjury clopidogrel.
Topics: Adult; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Platelet Function Tests; Receptors, Purinergic P2Y12; Retrospective Studies; Ticlopidine; Wounds and Injuries | 2013 |
ED administration of thienopyridines in non-ST-segment elevation myocardial infarction: results from the NCDR.
Topics: Aged; Clopidogrel; Drug Administration Schedule; Emergency Service, Hospital; Female; Hemorrhage; Hospital Mortality; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Registries; Retrospective Studies; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Is clopidogrel adequate in 2013?
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Predictors of bleeding in acute coronary syndromes with clopidogrel and prasugrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Follow-Up Studies; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine | 2013 |
Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Stroke; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Hidden implications: potential antiplatelet effects of adjuvant anaesthetic agents.
Topics: Adenosine Diphosphate; Adjuvants, Anesthesia; Aged; Aspirin; Cholecystectomy, Laparoscopic; Clopidogrel; Female; Hemorrhage; Humans; Intraoperative Complications; Platelet Aggregation; Platelet Aggregation Inhibitors; Thrombelastography; Ticlopidine | 2013 |
Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebrovascular Disorders; Clopidogrel; Comorbidity; Dabigatran; Drug Synergism; Female; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Hypertrophy, Left Ventricular; Logistic Models; Male; Middle Aged; Models, Cardiovascular; Myocardial Ischemia; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Risk; Ticlopidine; Treatment Outcome | 2013 |
The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Ischemia; China; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Resistance; Drug-Eluting Stents; Female; Genotype; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Proportional Hazards Models; Prospective Studies; Receptors, Purinergic P2Y12; Risk Factors; ROC Curve; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Use of clopidogrel and proton pump inhibitors after a serious acute coronary event: risk of coronary events and peptic ulcer bleeding.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Cohort Studies; Coronary Vessels; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk; Ticlopidine; United Kingdom | 2013 |
Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Australia; Clopidogrel; Coronary Artery Bypass; Cost-Benefit Analysis; Drug Costs; Hemorrhage; Humans; Markov Chains; Middle Aged; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial.
Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Drug; Hemorrhage; Humans; Incidence; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2013 |
Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary intervention.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Genetic Linkage; Genetic Variation; Genotype; Hemorrhage; Humans; Myocardial Infarction; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine | 2013 |
Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Area Under Curve; Biomarkers; Cell Adhesion Molecules; Clopidogrel; Coronary Thrombosis; Drug Resistance; Female; Hemorrhage; Humans; Logistic Models; Male; Microfilament Proteins; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Phosphoproteins; Phosphorylation; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Risk Assessment; Risk Factors; ROC Curve; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Bleeding and thrombosis risk matters: how long can we stick to the one-size-fits-all strategy of platelet inhibition?
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2013 |
Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Asian People; Aspirin; Atrial Fibrillation; Blood Coagulation; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Disease-Free Survival; Drug Monitoring; Drug Therapy, Combination; Female; Hemorrhage; Humans; International Normalized Ratio; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Republic of Korea; Retrospective Studies; Risk Factors; Stents; Stroke; Ticlopidine; Time Factors; Treatment Outcome; Warfarin | 2014 |
Withholding clopidogrel for 3 to 6 versus 7 days or more before surgery in hip fracture patients.
Topics: Aged; Aged, 80 and over; Blood Loss, Surgical; Clopidogrel; Female; Hemorrhage; Hip Fractures; Humans; Male; Middle Aged; Orthopedic Procedures; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors; Withholding Treatment | 2013 |
Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Registries; Renal Insufficiency, Chronic; Taiwan; Ticlopidine; Treatment Outcome | 2013 |
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Activation; Platelet Function Tests; Practice Guidelines as Topic; Prognosis; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticlopidine | 2014 |
Novel uses for platelet function testing in the clinical laboratory: where are we now?
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Drug Monitoring; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Randomized Controlled Trials as Topic; Risk; Ticlopidine | 2014 |
Sex differences in spontaneous reports on adverse bleeding events of antithrombotic treatment.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aspirin; Child; Child, Preschool; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Female; Fibrinolytic Agents; Hemorrhage; Humans; Infant; Infant, Newborn; Male; Middle Aged; Practice Patterns, Physicians'; Risk; Sex Factors; Sweden; Ticlopidine; Warfarin; Young Adult | 2014 |
[The CHAMPION PHOENIX study].
Topics: Adenosine Monophosphate; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Coronary Thrombosis; Double-Blind Method; Hemorrhage; Humans; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stents; Ticlopidine | 2013 |
Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Hospitalization; Humans; Male; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Risk Factors; Stents; Stroke; Ticlopidine; Treatment Outcome | 2014 |
Simultaneous intrahepatic and subgaleal hemorrhage in antiphospholipid syndrome following anticoagulation therapy.
Topics: Adolescent; Anticoagulants; Antiphospholipid Syndrome; Chemical and Drug Induced Liver Injury; Clopidogrel; Drug Substitution; Drug Therapy, Combination; Female; Flank Pain; Hemorrhage; Humans; Hydroxychloroquine; International Normalized Ratio; Magnetic Resonance Imaging; Platelet Aggregation Inhibitors; Recurrence; Risk Factors; Scalp; Skin Diseases; Ticlopidine; Tomography, X-Ray Computed; Treatment Outcome; Venous Thrombosis | 2013 |
Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis.
Topics: Aged; Angioplasty; Aspirin; Brain Ischemia; Carotid Stenosis; Cilostazol; Clopidogrel; Diffusion Magnetic Resonance Imaging; Drug Resistance; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Stents; Tetrazoles; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Stroke; Thienopyridines; Ticlopidine; Warfarin | 2014 |
The antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-enhanced platelet function.
Topics: Adenosine Diphosphate; Animals; Antidepressive Agents; Blotting, Western; Calcium; Carotid Artery Thrombosis; Clopidogrel; Cyproheptadine; Flow Cytometry; Hemorrhage; Humans; Immunoprecipitation; Indoles; Male; Mice; Mice, Inbred C57BL; Piperazines; Pizotyline; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Receptor, Serotonin, 5-HT2A; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Ticlopidine | 2014 |
Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies; Comorbidity; Coronary Artery Disease; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Phenprocoumon; Platelet Aggregation Inhibitors; Risk Factors; Stroke; Ticlopidine; Vitamin K; Warfarin | 2014 |
Warfarin: Impact on hemostasis after radial catheterization.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cardiac Catheterization; Catheterization, Peripheral; Clopidogrel; Databases, Factual; Drug Administration Schedule; Female; Hemorrhage; Hemostasis; Hemostatic Techniques; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Platelet Aggregation Inhibitors; Radial Artery; Retrospective Studies; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome; Warfarin | 2015 |
Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Combined Modality Therapy; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Risk Assessment; Severity of Illness Index; Stents; Stroke; Survival Rate; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2014 |
Dual antiplatelet therapy (clopidogrel and aspirin) is associated with increased all-cause mortality after carotid revascularization for asymptomatic carotid disease.
Topics: Aged; Alabama; Angioplasty; Aspirin; Asymptomatic Diseases; Carotid Stenosis; Clopidogrel; Drug Therapy, Combination; Endarterectomy, Carotid; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Patient Discharge; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Stents; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel.
Topics: Aged; Clopidogrel; Cohort Studies; Databases, Factual; Electronic Health Records; Female; Hemorrhage; Humans; Ischemia; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Product Surveillance, Postmarketing; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2014 |
Safety evaluation of substituting clopidogrel for ticlopidine in Japanese patients with ischemic stroke--Hiroshima ticlopidine, clopidogrel safe exchange trial.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Drug Substitution; Female; Fibrinolytic Agents; Hemorrhage; Humans; Japan; Male; Middle Aged; Prospective Studies; Stroke; Ticlopidine; Treatment Outcome | 2014 |
Estimating the effects of time-varying exposures in observational studies using Cox models with stabilized weights adjustment.
Topics: Clopidogrel; Confounding Factors, Epidemiologic; Drug-Eluting Stents; Electronic Health Records; Hemorrhage; Humans; Myocardial Infarction; Observational Studies as Topic; Pharmacoepidemiology; Platelet Aggregation Inhibitors; Proportional Hazards Models; Ticlopidine; Time Factors | 2014 |
Dual antiplatelet therapy over 6 months increases the risk of bleeding after biodegradable polymer-coated sirolimus eluting stents implantation: insights from the CREATE study.
Topics: Aspirin; Biodegradable Plastics; Clopidogrel; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine | 2014 |
Are we there yet? deciding when it is safe (and wise) to stop clopidogrel after stent implantation.
Topics: Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine; Time Factors | 2014 |
Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Logistic Models; Male; Middle Aged; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Proportional Hazards Models; Recombinant Proteins; Risk Factors; Stents; Ticlopidine | 2014 |
A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
Topics: Aged; Aged, 80 and over; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Thrombosis; Drug Resistance; Drug Substitution; Female; Germany; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Risk Factors; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Direct Service Costs; Drug Therapy, Combination; Drugs, Generic; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry.
Topics: Aged; Clopidogrel; Drug Administration Schedule; Drug Utilization Review; Female; Guideline Adherence; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome; United States | 2014 |
Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY).
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female; France; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Registries; Risk Factors; Stents; Ticlopidine; Treatment Outcome | 2014 |
Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies.
Topics: Anesthesiology; Aspirin; Cardiac Surgical Procedures; Cardiology; Clopidogrel; Eptifibatide; Hemorrhage; Humans; Italy; Myocardial Ischemia; Peptides; Perioperative Care; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Assessment; Societies, Medical; Stents; Surgical Procedures, Operative; Thoracic Surgery; Ticlopidine; Tirofiban; Tyrosine | 2014 |
Comparative effects of the anti-platelet drugs, clopidogrel, ticlopidine, and cilostazol on aspirin-induced gastric bleeding and damage in rats.
Topics: Animals; Aspirin; Cilostazol; Clopidogrel; Hemoglobins; Hemorrhage; Male; Peroxidase; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Stomach Diseases; Tetrazoles; Ticlopidine | 2014 |
Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; United States | 2014 |
Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk.
Topics: Adenosine Diphosphate; Animals; Apyrase; Clopidogrel; Coronary Circulation; Dogs; Fibrinolysis; Hemorrhage; Humans; Mice, Inbred C57BL; Myocardial Infarction; Myocardial Reperfusion Injury; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Tissue Plasminogen Activator; Treatment Outcome; Vascular Patency | 2014 |
Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Cohort Studies; Data Collection; Denmark; Female; Hemorrhage; Humans; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Recurrence; Renal Dialysis; Renal Insufficiency, Chronic; Ticlopidine; Treatment Outcome | 2014 |
Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry.
Topics: Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Thrombosis; Female; Germany; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Recurrence; Registries; Risk Factors; Shock, Cardiogenic; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: a proof-of-concept study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Biotransformation; Carboxylic Ester Hydrolases; Clopidogrel; Drug Interactions; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk; Ticlopidine | 2014 |
Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Sex Factors; Thrombosis; Ticlopidine | 2015 |
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Ischemia; Odds Ratio; Percutaneous Coronary Intervention; Perioperative Period; Platelet Aggregation Inhibitors; Prevalence; Registries; Regression Analysis; Retrospective Studies; Risk Factors; Stents; Ticlopidine; Treatment Outcome | 2015 |
Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Databases, Bibliographic; Drug Therapy, Combination; Drug-Eluting Stents; Follow-Up Studies; Hemorrhage; Prospective Studies; Registries; Ticlopidine; Treatment Outcome; Warfarin | 2014 |
Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome; Warfarin | 2015 |
Patterns of Antiplatelet Therapy in Patients Who Have Experienced an Acute Coronary Event: A Descriptive Study in UK Primary Care.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Primary Health Care; Proton Pump Inhibitors; Retrospective Studies; Secondary Prevention; Stroke; Ticlopidine; United Kingdom | 2015 |
A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI.
Topics: Adenosine; Aged; Blood Platelets; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Electrocardiography; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
From innovation to implementation: optimizing long-term outcomes after TAVR.
Topics: Aortic Valve Stenosis; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Ticlopidine; Transcatheter Aortic Valve Replacement | 2014 |
Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Decision Support Techniques; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Markov Chains; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Risk Adjustment; Risk Assessment; Thrombosis; Ticlopidine; Time; Treatment Outcome | 2015 |
Point-of-care platelet function testing predicts bleeding in patients exposed to clopidogrel undergoing coronary artery bypass grafting: Verify pre-op TIMI 45--a pilot study.
Topics: Aged; Area Under Curve; Blood Platelets; Clopidogrel; Coronary Artery Bypass; Drug Resistance; Female; Hemorrhage; Humans; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Predictive Value of Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; ROC Curve; Ticlopidine; Treatment Outcome; United States | 2015 |
Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy.
Topics: Aged; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Prosthesis Design; Registries; Risk Factors; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Dual Antiplatelet Therapy Duration Following Coronary Stenting. [Corrected].
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Ticlopidine | 2015 |
Stent selection and antiplatelet therapy duration: one size does not fit all.
Topics: Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Postoperative Complications; Sirolimus; Ticlopidine | 2015 |
[Triple anticoagulant therapy - now what can I give for pain?].
Topics: Aged; Analgesics; Anticoagulants; Aspirin; Back Pain; Benzimidazoles; beta-Alanine; Clopidogrel; Contraindications; Dabigatran; Drug Therapy, Combination; Germany; Hemorrhage; Humans; Male; Risk Factors; Stents; Ticlopidine | 2015 |
Effect of Active Smoking on Comparative Efficacy of Antithrombotic Therapy in Patients With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Case-Control Studies; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Proportional Hazards Models; Smoking; Stroke; Thromboembolism; Ticlopidine; Warfarin | 2015 |
Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist.
Topics: Animals; Aspirin; Bleeding Time; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Lactones; Macaca fascicularis; Platelet Aggregation Inhibitors; Platelet Transfusion; Pyridines; Receptors, Thrombin; Ticlopidine | 2015 |
Glanzmann's thrombasthenia: meeting the anticoagulation challenge.
Topics: Aminocaproic Acid; Aspirin; Clopidogrel; Factor VIIa; Hemorrhage; Humans; Isoantibodies; Male; Middle Aged; Platelet Transfusion; Recombinant Proteins; Thrombasthenia; Ticlopidine | 2015 |
Uninterrupted perioperative clopidogrel and bleeding-related events after total joint arthroplasty: a case series.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Perioperative Care; Platelet Aggregation Inhibitors; Postoperative Complications; Ticlopidine | 2015 |
Management and outcome of major bleeding in patients on triple therapy after coronary stenting. Clues from the WARfarin and coronary STENTing (WAR-STENT) registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Registries; Stents; Thrombosis; Ticlopidine; Treatment Outcome; Warfarin | 2015 |
Pre-procedural dual antiplatelet therapy and bleeding events following transcatheter aortic valve implantation (TAVI).
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Transcatheter Aortic Valve Replacement | 2015 |
Pre-treatment with dual antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Australia; Clopidogrel; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Registries; Ticlopidine; Treatment Outcome | 2015 |
Redesigning TRACER trial after TRITON.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Evaluation; Drug Therapy, Combination; Hemorrhage; Humans; Lactones; Neoplasms; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Research Design; Ticlopidine | 2015 |
Perioperative Management of Antiplatelets and Anticoagulants Among Patients Undergoing Elective Transurethral Resection of the Prostate--A Single Institution Experience.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Elective Surgical Procedures; Enoxaparin; Hemorrhage; Humans; Male; Middle Aged; Perioperative Care; Platelet Aggregation Inhibitors; Postoperative Complications; Prostate; Prostatic Hyperplasia; Retrospective Studies; Thromboembolism; Ticlopidine; Transurethral Resection of Prostate; Victoria; Warfarin; Withholding Treatment | 2015 |
Iatrogenic Endobronchial Bleeding: Speed Things Up or Cool It Down?
Topics: Biopsy; Bronchoscopy; Clopidogrel; Epinephrine; Hemorrhage; Humans; Iatrogenic Disease; Platelet Aggregation Inhibitors; Prognosis; Risk Factors; Sodium Chloride; Ticlopidine; Tranexamic Acid; Vasoconstrictor Agents | 2015 |
Prasugrel Versus Clopidogrel: A Comparative Examination of Local Bleeding After Dental Extraction in Patients Receiving Dual Antiplatelet Therapy.
Topics: Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine | 2015 |
Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
Topics: Aged; Clopidogrel; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk Assessment; Risk Factors; Switzerland; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Platelet reactivity in MitraClip patients.
Topics: Aspirin; Clopidogrel; Cohort Studies; Heart Valve Prosthesis Implantation; Hemorrhage; Ischemia; Mitral Valve Insufficiency; Platelet Aggregation; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine | 2016 |
Comparing prasugrel to twice daily clopidogrel post percutaneous coronary intervention in a Veterans Affairs population.
Topics: Aged; Cardiovascular Diseases; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; Stroke; Ticlopidine; United States; United States Department of Veterans Affairs | 2015 |
Platelet reactivity and hemorrhage risk in neurointerventional procedures under dual antiplatelet therapy.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Therapy, Combination; Embolization, Therapeutic; Female; Hemorrhage; Humans; Intracranial Aneurysm; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk; ROC Curve; Stents; Ticlopidine; Treatment Outcome | 2016 |
Ticagrelor shift from PLATO to PEGASUS: Vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Follow-Up Studies; Hemorrhage; Humans; Mortality; Neoplasms; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Sepsis; Ticagrelor; Ticlopidine | 2015 |
[Clopidogrel versus prasugrel in acute coronary syndrome treated with coronary angioplasty].
Topics: Acute Coronary Syndrome; Angioplasty; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; Stents; Ticlopidine; Treatment Outcome | 2015 |
Platelet function recovery following exposure to triple anti-platelet inhibitors using an in vitro transfusion model.
Topics: Apoptosis Regulatory Proteins; Arachidonic Acid; Aspirin; Blood Platelets; Blood Transfusion; Clopidogrel; Flow Cytometry; Hemorrhage; Humans; Lactones; P-Selectin; Peptide Fragments; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Transfusion; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Proteinase-Activated; Receptors, Purinergic P2Y12; Ticlopidine | 2015 |
Safety of prasugrel in real-world patients with ST-segment elevation myocardial infarction: 1-year results from a prospective observational study (Bleeding and Myocardial Infarction Study).
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Registries; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Endobronchial Ultrasound-guided Transbronchial Needle Aspiration while Receiving Aspirin and Clopidogrel: Is It Always Safe?
Topics: Aspirin; Clopidogrel; Contraindications; Echocardiography, Doppler, Color; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Female; Hemorrhage; Humans; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine | 2015 |
Antiplatelet effects of clopidogrel and aspirin after interventional patent foramen ovale/ atrium septum defect closure.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cardiac Surgical Procedures; Clopidogrel; Comorbidity; Female; Follow-Up Studies; Foramen Ovale, Patent; Hemorrhage; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Postoperative Care; Preoperative Care; Risk Factors; Ticlopidine; Treatment Outcome | 2016 |
Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction.
Topics: Aged; Alleles; Asian People; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Substitution; Female; Genotype; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticlopidine | 2016 |
Cochlear Implantation in the Setting of Perioperative Anticoagulation and Antiplatelet Therapy.
Topics: Aged; Anticoagulants; Aspirin; Blood Loss, Surgical; Clopidogrel; Cochlear Implantation; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Postoperative Complications; Ticlopidine; Treatment Outcome; Warfarin | 2016 |
[Impact of preoperative dual antiplatelet therapy on perioperative bleeding in patients undergoing off-pump coronary artery bypass grafting].
Topics: Aspirin; Blood Transfusion; Clopidogrel; Coronary Artery Bypass, Off-Pump; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2015 |
Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population.
Topics: Adenosine; Aged; Aged, 80 and over; Asian People; Biotransformation; Chi-Square Distribution; China; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Monitoring; Female; Genotype; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Pharmacogenomic Testing; Phenotype; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Female; Germany; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome; United States | 2015 |
Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications.
Topics: Adenosine; Chi-Square Distribution; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention. Results of the ACCEL-BLEED study.
Topics: Aged; Asia, Eastern; Asian People; Aspirin; Cell Adhesion Molecules; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Single Nucleotide; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticlopidine; Time Factors | 2016 |
Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study).
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Endovascular Procedures; Female; France; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Outcome and Process Assessment, Health Care; Outpatients; Platelet Aggregation Inhibitors; Prevalence; Prognosis; Registries; Stroke; Ticlopidine | 2016 |
Access-site bleeding and radial artery occlusion in transradial primary percutaneous coronary intervention: influence of adjunctive antiplatelet therapy.
Topics: Abciximab; Adenosine; Aged; Antibodies, Monoclonal; Catheterization, Peripheral; Clopidogrel; Female; Hematoma; Hemorrhage; Hemostatic Techniques; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Punctures; Purinergic P2Y Receptor Antagonists; Radial Artery; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Australia; Clopidogrel; Comorbidity; Female; Hemorrhage; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Comparison of Three Tests to Distinguish Platelet Reactivity in Patients with Renal Impairment during Dual Antiplatelet Therapy.
Topics: Aged; Aspirin; Clopidogrel; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney Diseases; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Thrombosis; Ticlopidine | 2016 |
Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Humans; Insurance, Health; Korea; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Succinates; Tetrazoles; Ticlopidine; Treatment Outcome | 2016 |
Dual antiplatelet therapy reduces stroke but increases bleeding at the time of carotid endarterectomy.
Topics: Aged; Aspirin; Asymptomatic Diseases; Carotid Artery Diseases; Chi-Square Distribution; Clopidogrel; Comorbidity; Drug Administration Schedule; Drug Therapy, Combination; Endarterectomy, Carotid; Female; Hemorrhage; Hospital Mortality; Humans; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Platelet Aggregation Inhibitors; Propensity Score; Protective Factors; Registries; Reoperation; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome; United States | 2016 |
Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Databases, Factual; Disease Management; Female; Health Resources; Hemorrhage; Hospital Costs; Humans; Length of Stay; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine; Treatment Outcome | 2016 |
Clinical Features and Outcomes of Diffuse Alveolar Hemorrhage During Antithrombotic Therapy: A Retrospective Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Connective Tissue Diseases; Female; Fibrinolytic Agents; Heart Failure; Hemorrhage; Humans; Infections; Lung Diseases; Male; Middle Aged; Neoplasms; Pneumonia; Pulmonary Alveoli; Retrospective Studies; Survival Rate; Tetrazoles; Ticlopidine; Vasculitis; Warfarin | 2016 |
Platelets are dispensable for antibody-mediated transfusion-related acute lung injury in the mouse.
Topics: Animals; Antibodies, Monoclonal; Aspirin; Blood Platelets; Blood Transfusion; Clopidogrel; Diphtheria Toxin; Edema; Hemorrhage; Histocompatibility Antigens Class I; Lung; Male; Megakaryocytes; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Neutrophils; Platelet Activation; Platelet Aggregation Inhibitors; Rats; Respiratory Distress Syndrome; Signal Transduction; Thrombocytopenia; Ticlopidine; Transfusion-Related Acute Lung Injury | 2016 |
Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Anemia; Aspirin; Body Mass Index; Clopidogrel; Cohort Studies; Coronary Thrombosis; Diabetes Mellitus; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Renal Insufficiency; Risk Assessment; Smoking; Ticlopidine; United States | 2016 |
One-year incidence and clinical impact of bleeding events in patients treated with prasugrel or clopidogrel after ST-segment elevation myocardial infarction.
Topics: Aged; Clopidogrel; Female; Follow-Up Studies; France; Hemorrhage; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Prospective Studies; Risk Factors; ST Elevation Myocardial Infarction; Ticlopidine; Time Factors | 2016 |
Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibition stu
Topics: Aged; Algorithms; Clinical Decision-Making; Clopidogrel; Hemorrhage; Humans; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Risk Assessment; Thienopyridines; Ticlopidine; Treatment Outcome | 2016 |
[Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Alleles; Angina Pectoris; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Genotype; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Tandem Mass Spectrometry; Ticlopidine | 2016 |
Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea Acute Myocardial Infarction Registry-National Institute of Health.
Topics: Adenosine; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Propensity Score; Registries; Republic of Korea; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
[Safety of implantation permanent pacemaker at different times in patients with dual antiplatelet therapy].
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hematoma; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Pacemaker, Artificial; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2016 |
Utility of the HAS-BLED Score in Risk Stratifying Patients on Dual Antiplatelet Therapy Post 12 Months After Drug-Eluting Stent Placement.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Georgia; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Period; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk Assessment; Ticlopidine; Time Factors | 2017 |
Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Ohio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Retrospective Studies; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome; Warfarin | 2017 |
A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction.
Topics: Aspirin; Cardiovascular System; Clopidogrel; Hemorrhage; Humans; Lactones; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Secondary Prevention; Stroke; Thrombosis; Ticlopidine; Treatment Outcome | 2016 |
[Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy].
Topics: Aspirin; Beijing; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Patient Readmission; Platelet Aggregation Inhibitors; Proportional Hazards Models; Recurrence; Retrospective Studies; Secondary Prevention; Stroke; Ticlopidine | 2016 |
The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Germany; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Registries; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome; United States | 2016 |
Safety and effectiveness of the new P2Y12r inhibitor agents vs clopidogrel in ACS patients according to the geographic area: East Asia vs Europe.
Topics: Acute Coronary Syndrome; Aged; Asia, Eastern; Clopidogrel; Europe; Female; Follow-Up Studies; Hemorrhage; Humans; Internationality; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Ticlopidine; Treatment Outcome | 2016 |
The Effect of Antiplatelet Agents on Bleeding-Related Complications After Ureteroscopy.
Topics: Adenosine; Adult; Aged; Anticoagulants; Aspirin; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk; Ticagrelor; Ticlopidine; Ureteroscopy | 2016 |
EBUS-TBNA and EUS-FNA: Risk Assessment for Patients Receiving Clopidogrel.
Topics: Age Factors; Aged; Biopsy, Fine-Needle; Clopidogrel; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Esophagus; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Assessment; Ticlopidine; Ultrasonography | 2016 |
Successful multivessel percutaneous coronary intervention for acute coronary syndrome in a HIV-positive severe haemophiliac.
Topics: Acute Coronary Syndrome; Clopidogrel; Hematuria; Hemophilia A; Hemorrhage; HIV Infections; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Risk Factors; Severity of Illness Index; Ticlopidine | 2016 |
Effect of Drugs Associated With Bleeding Tendency on the Complications and Outcomes of Transforaminal Epidural Steroid Injection.
Topics: Aged; alpha-Cyclodextrins; Alprostadil; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Injections, Epidural; Male; Middle Aged; Pain; Pain Measurement; Platelet Aggregation Inhibitors; Retrospective Studies; Steroids; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Influence of CYP2C19 genetic polymorphisms on clinical outcomes of intracranial aneurysms treated with stent-assisted coiling.
Topics: Adolescent; Adult; Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Follow-Up Studies; Hemorrhage; Humans; Intracranial Aneurysm; Middle Aged; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prospective Studies; Stents; Ticlopidine; Treatment Outcome; Young Adult | 2017 |
Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug Antagonism; Drug Therapy, Combination; Europe; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Proton Pump Inhibitors; Registries; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome; United States | 2017 |
Resuscitation experience in a patient with left ventricular assist device.
Topics: Anesthesia, General; Anticoagulants; Capnography; Cardiopulmonary Resuscitation; Clopidogrel; Defibrillators, Implantable; Epinephrine; Female; Heart Failure; Heart Ventricles; Heart-Assist Devices; Hemorrhage; Humans; Middle Aged; Monitoring, Intraoperative; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome; Warfarin | 2016 |
Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acu
Topics: Acute Coronary Syndrome; Aftercare; Aged; Cardiovascular Diseases; Clopidogrel; Comparative Effectiveness Research; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Recurrence; Stroke; Ticlopidine; Treatment Outcome | 2016 |
Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Proportional Hazards Models; Randomized Controlled Trials as Topic; Ticlopidine | 2016 |
Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (C
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Canada; Clopidogrel; Drug Substitution; Emergency Medical Services; Emergency Service, Hospital; Female; Hemorrhage; Hospitalization; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Young Adult | 2016 |
Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Databases, Factual; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Hospitals, Veterans; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Proportional Hazards Models; Prosthesis Design; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome; United States; United States Department of Veterans Affairs | 2017 |
Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Creatinine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Renal Insufficiency, Chronic; Risk Assessment; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Life-threatening Wunderlich's syndrome with concurrent clopidogrel use.
Topics: Acute Kidney Injury; Blood Transfusion; Clopidogrel; Embolization, Therapeutic; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Syndrome; Ticlopidine | 2016 |
Bleeding Complications following Image-Guided Percutaneous Biopsies in Patients Taking Clopidogrel-A Retrospective Review.
Topics: Aged; Aged, 80 and over; Biopsy, Large-Core Needle; Clopidogrel; Drug Administration Schedule; Female; Hemorrhage; Humans; Image-Guided Biopsy; Incidence; Male; Middle Aged; Minnesota; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Ticlopidine; Time Factors; Vascular System Injuries | 2017 |
Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Diabetes Mellitus; Female; Follow-Up Studies; Graft Occlusion, Vascular; Hemorrhage; Humans; Incidence; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Poland; Prospective Studies; Thrombosis; Ticlopidine | 2016 |
Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after
Topics: Adenosine; Adenosine Diphosphate; Aged; Cardiovascular Diseases; Clopidogrel; Drug Substitution; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Patient Preference; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P1 Receptor Antagonists; Ticagrelor; Ticlopidine | 2017 |
Platelet aggregation and the risk of stent thrombosis or bleeding in elective percutaneous coronary intervention patients.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Elective Surgical Procedures; Female; Hemorrhage; Humans; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk Factors; Stents; Ticlopidine | 2017 |
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Aged; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Antiplatelet Strategies and Outcomes in Patients with Noncardioembolic Ischemic Stroke from a Real-World Study with a Five-Year Follow-Up.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; China; Clopidogrel; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Secondary Prevention; Stroke; Ticlopidine; Treatment Outcome | 2017 |
Percutaneous left atrial appendage closure followed by single antiplatelet therapy: Short- and mid-term outcomes.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Catheterization; Clopidogrel; Drug Administration Schedule; Female; France; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Stroke; Thrombosis; Ticlopidine; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Real world insights on the initiation and treatment duration of oral antiplatelets in acute coronary syndromes: a retrospective cohort study.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Belgium; Cardiologists; Clopidogrel; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Retrospective Studies; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2017 |
Pulmonary alveolar hemorrhage mimicking a pneumopathy: a rare complication of dual antiplatelet therapy for ST elevation myocardial infarction.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Lung Diseases; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Pulmonary Alveoli; ST Elevation Myocardial Infarction; Ticlopidine; Tomography, X-Ray Computed | 2016 |
Dipeptidyl Peptidase-4 Inhibitor-Associated Risk of Bleeding: An Evaluation of Reported Adverse Events.
Topics: Adverse Drug Reaction Reporting Systems; Aspirin; Clopidogrel; Dipeptidyl-Peptidase IV Inhibitors; Hemorrhage; Humans; Hypoglycemic Agents; Metformin; Odds Ratio; Platelet Aggregation Inhibitors; Retrospective Studies; Risk; Ticlopidine | 2017 |
Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis.
Topics: Aged; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Propensity Score; Renal Dialysis; Retrospective Studies; Stroke; Survival Rate; Taiwan; Ticlopidine | 2017 |
Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Female; Germany; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Propensity Score; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Risk Factors; Sex Factors; Ticlopidine; Time Factors; Treatment Outcome; United States | 2017 |
Platelet turnover predicts outcome after coronary intervention.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Chi-Square Distribution; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Linear Models; Logistic Models; Male; Mean Platelet Volume; Microfilament Proteins; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Phosphoproteins; Phosphorylation; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Mortality and cancer after 12 versus 30 months dual antiplatelet therapy. The Korean Outcomes Registry Evaluating Antithrombotics (KOREA).
Topics: Aged; Aspirin; Cause of Death; Chi-Square Distribution; Clopidogrel; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Neoplasms; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Proportional Hazards Models; Registries; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery s
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Clopidogrel; Coronary Stenosis; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Mortality; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease.
Topics: Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Lactones; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Pyridines; Quality of Life; Quality-Adjusted Life Years; Secondary Prevention; Stroke; Thrombosis; Ticlopidine | 2017 |
Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Peripheral Arterial Disease; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Propensity Score; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Safety and efficacy of clopidogrel in children with heart disease.
Topics: Adolescent; Aspirin; Child; Child, Preschool; Clopidogrel; Female; Heart Diseases; Hemorrhage; Humans; Infant; Infant, Newborn; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Ticlopidine; Warfarin | 2008 |
Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Risk Factors; Stents; Ticlopidine; Warfarin | 2008 |
Haemorrhagic herpes zoster associated with clopidogrel treatment.
Topics: Clopidogrel; Female; Hemorrhage; Herpes Zoster; Humans; Middle Aged; Platelet Aggregation Inhibitors; Skin Diseases, Vesiculobullous; Ticlopidine | 2009 |
Stroke prevention--insights from incoherence.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk; Secondary Prevention; Stroke; Telmisartan; Ticlopidine | 2008 |
Cardiovascular outcomes after a change in prescription policy for clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Female; Health Policy; Hemorrhage; Humans; Insurance Benefits; Insurance, Health, Reimbursement; Insurance, Pharmaceutical Services; Male; Myocardial Infarction; National Health Programs; Ontario; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Recurrence; Stents; Ticlopidine | 2008 |
Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Assessment; Thrombosis; Ticlopidine; Warfarin | 2008 |
Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Assessment; Thrombosis; Ticlopidine; Warfarin | 2008 |
[Perioperative discontinuation of antiplatelet therapy of patients with coronary stents. Reevaluating the risks].
Topics: Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Decision Trees; Drug-Eluting Stents; Hemorrhage; Humans; Intraoperative Complications; Long-Term Care; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Substance Withdrawal Syndrome; Ticlopidine | 2009 |
A paradigm shift in anti-platelet therapy?
Topics: Clopidogrel; Dose-Response Relationship, Drug; Drug Monitoring; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2008 |
Clopidogrel under scrutiny.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Stents; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Europe; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Stents; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome; United States | 2008 |
Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Contusions; Coronary Angiography; Coronary Artery Disease; Drug-Eluting Stents; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Observation; Patient Compliance; Platelet Aggregation Inhibitors; Severity of Illness Index; Ticlopidine | 2008 |
Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease-Free Survival; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Mortality; Myocardial Infarction; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Prospective Studies; Stents; Stroke; Ticlopidine | 2008 |
Efficacy and safety of optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Evaluation; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Hospital Mortality; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Registries; Retrospective Studies; Ticlopidine; Treatment Outcome | 2009 |
Factors associated with bleeding in elderly hospitalized patients treated with enoxaparin sodium : a prospective, open-label, observational study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Body Weight; Clopidogrel; Creatinine; Dose-Response Relationship, Drug; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Inpatients; Length of Stay; Logistic Models; Male; Middle Aged; Odds Ratio; Prospective Studies; Risk Factors; Sex Factors; Ticlopidine; Treatment Outcome; Warfarin | 2009 |
Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clinical Trials, Phase III as Topic; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2009 |
Clopidogrel induces an acute hemostatic deficit and increases intra abdominal bleeding in rabbits.
Topics: Abdomen; Animals; Cell Adhesion Molecules; Clopidogrel; Dose-Response Relationship, Drug; Flow Cytometry; Hemorrhage; Hemostasis; In Vitro Techniques; Microfilament Proteins; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Rabbits; Ticlopidine | 2009 |
Another view on prasugrel.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Drug Administration Schedule; Drug Resistance; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Research Design; Risk Assessment; Stents; Thiophenes; Ticlopidine; Treatment Outcome | 2009 |
Improving outcomes with antiplatelet therapies in percutaneous coronary intervention and stenting.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug-Eluting Stents; Hemorrhage; Humans; Patient Selection; Platelet Aggregation Inhibitors; Platelet Function Tests; Practice Guidelines as Topic; Prosthesis Design; Risk Assessment; Stents; Thrombelastography; Ticlopidine; Treatment Outcome | 2009 |
Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.
Topics: Adenosine Diphosphate; Administration, Oral; Animals; Binding, Competitive; Bleeding Time; Clopidogrel; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolytic Agents; Hemorrhage; Hemostasis; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Rabbits; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thionucleotides; Thiophenes; Thrombosis; Ticlopidine | 2009 |
Bleeding risks with combination of oral anticoagulation plus antiplatelet therapy: is clopidogrel any safer than aspirin when combined with warfarin?
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Coagulation; Clopidogrel; Coumarins; Dipyridamole; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Hemorrhage; Hospitalization; Humans; Platelet Aggregation Inhibitors; Registries; Risk Assessment; Risk Factors; Ticlopidine; Warfarin | 2008 |
Effect of oral antiplatelet agents on major bleeding in users of coumarins.
Topics: Acenocoumarol; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Blood Coagulation; Case-Control Studies; Clopidogrel; Coumarins; Dipyridamole; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Hemorrhage; Hospitalization; Humans; Logistic Models; Male; Medical Records Systems, Computerized; Middle Aged; Netherlands; Odds Ratio; Phenprocoumon; Platelet Aggregation Inhibitors; Risk Assessment; Ticlopidine; Vitamin K | 2008 |
Safety issues of adjunctive clopidogrel in patients discharged after percutaneous coronary intervention with stent placement and requiring oral anticoagulation.
Topics: Administration, Oral; Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Patient Discharge; Stents; Ticlopidine | 2011 |
rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats.
Topics: Animals; Clopidogrel; Factor VII; Factor VIIa; Hemorrhage; Hemostasis; Platelet Count; Rats; Recombinant Proteins; Thrombin; Thrombocytopenia; Ticlopidine | 2009 |
Antagonists of the EP3 receptor for prostaglandin E2 are novel antiplatelet agents that do not prolong bleeding.
Topics: Acrylamides; Animals; Clopidogrel; Dinoprostone; Female; Hemorrhage; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Prostaglandin Antagonists; Purinergic P2 Receptor Antagonists; Rats; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP3 Subtype; Receptors, Purinergic P2Y12; Sulfones; Thrombosis; Ticlopidine | 2009 |
Ischaemia versus bleeding: the art of clinical decision-making.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Decision Making; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2009 |
Point-of-care platelet function analysis ready for prime time?
Topics: Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Hemorrhage; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Thrombosis; Ticlopidine | 2009 |
The ischaemia/bleeding balance in PCI.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Hemorrhage; Humans; Lactones; Platelet Aggregation Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Receptors, Thrombin; Severity of Illness Index; Thrombin; Ticlopidine | 2009 |
Summaries for patients. What aspirin dose is safest and most effective for preventing heart disease?
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Primary Prevention; Risk Factors; Thrombosis; Ticlopidine | 2009 |
Summaries for patients. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Primary Prevention; Risk Factors; Thrombosis; Ticlopidine | 2009 |
Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Observation; Platelet Aggregation Inhibitors; Primary Prevention; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Thrombosis; Ticlopidine | 2009 |
Does the combination of warfarin and aspirin have a place in secondary stroke prevention? Yes.
Topics: Anticoagulants; Aspirin; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk; Stroke; Ticlopidine; Warfarin | 2009 |
Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2009 |
[Do antiplatelet agents (aspirin and other antiplatelets such as clopidogrel) increase the risk of hemorrhagic complications after endoscopic polypectomy or endoscopic sphincterotomy and should these drugs therefore be withdrawn 7-10 days before these pro
Topics: Aspirin; Clopidogrel; Colonic Polyps; Colonoscopy; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Postoperative Complications; Practice Guidelines as Topic; Preoperative Care; Risk Factors; Sphincterotomy, Endoscopic; Ticlopidine; Time Factors | 2009 |
Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Female; Hemorrhage; Heparin; Humans; Incidence; Inpatients; Logistic Models; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Platelet Count; Prognosis; Registries; Risk Factors; Severity of Illness Index; Thrombocytopenia; Ticlopidine | 2009 |
[Introduction to the topic: drug eluting stents. An underestimated problem in surgery].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Hemorrhage; Humans; Intraoperative Complications; Long-Term Care; Platelet Aggregation Inhibitors; Risk Factors; Substance Withdrawal Syndrome; Ticlopidine | 2009 |
[Patients with coronary artery stents: when and how should operations be carried out?].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cooperative Behavior; Coronary Restenosis; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Interdisciplinary Communication; Intraoperative Complications; Long-Term Care; Patient Education as Topic; Platelet Aggregation Inhibitors; Reoperation; Risk Factors; Substance Withdrawal Syndrome; Ticlopidine | 2009 |
[Drug-eluting stents: implications for surgery patients].
Topics: Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cooperative Behavior; Coronary Restenosis; Decision Trees; Drug-Eluting Stents; Evidence-Based Medicine; Guideline Adherence; Hemorrhage; Humans; Interdisciplinary Communication; Intraoperative Complications; Long-Term Care; Patient Care Team; Platelet Aggregation Inhibitors; Risk Assessment; Substance Withdrawal Syndrome; Ticlopidine | 2009 |
Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Chronic Disease; Clopidogrel; Coronary Disease; Disease-Free Survival; Drug Therapy, Combination; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Male; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Stents; Thromboembolism; Ticlopidine; Treatment Outcome; Warfarin | 2009 |
Clopidogrel. Bleeding and resistance.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Resistance; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2009 |
External beam radiotherapy for prostate cancer patients on anticoagulation therapy: how significant is the bleeding toxicity?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anticoagulants; Clopidogrel; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Multivariate Analysis; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Rectum; Severity of Illness Index; Ticlopidine; Transurethral Resection of Prostate; Urologic Diseases; Warfarin | 2010 |
Future of oral antiplatelet therapy: four challenged hypotheses.
Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Prognosis; Purinergic P2 Receptor Antagonists; Pyridines; Risk Assessment; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2009 |
Clopidogrel in ESRD patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Kidney Failure, Chronic; Platelet Aggregation Inhibitors; Ticlopidine | 2009 |
Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Biomarkers; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Microfilament Proteins; Middle Aged; Patient Discharge; Phosphoproteins; Phosphorylation; Pilot Projects; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Risk Assessment; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Femoral artery complications after cardiac catheterization: a study of patient profile.
Topics: Aged; Anticoagulants; Cardiac Catheterization; Clopidogrel; Coronary Artery Disease; Female; Femoral Artery; Hematoma; Hemorrhage; Hemostatic Techniques; Heparin; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Platelet Aggregation Inhibitors; Punctures; Retrospective Studies; Risk Assessment; Risk Factors; Sex Factors; Ticlopidine | 2010 |
[Pulmonary haemorrhage and haemothorax after massive ingestion of clopidogrel as a suicide attempt].
Topics: Clopidogrel; Female; Hemorrhage; Hemothorax; Humans; Lung Diseases; Middle Aged; Platelet Aggregation Inhibitors; Suicide, Attempted; Ticlopidine | 2009 |
Antiplatelet agents used for early intervention in acute coronary syndrome: myocardial salvage versus bleeding complications.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticlopidine | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine; Vitamin K | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Incidence; Platelet Aggregation Inhibitors; Risk; Stroke; Ticlopidine; Vitamin K; Warfarin | 2009 |
Comparison of bleeding complications with omega-3 fatty acids + aspirin + clopidogrel--versus--aspirin + clopidogrel in patients with cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Ticlopidine; United States | 2009 |
Effect of clopidogrel on perioperative blood loss and transfusion in coronary artery bypass graft surgery.
Topics: Aged; Aspirin; Blood Transfusion; Cardiopulmonary Bypass; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Female; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Patient Selection; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Retrospective Studies; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications.
Topics: Aged; Blood Coagulation Tests; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2010 |
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Drug-Eluting Stents; Europe; Hemorrhage; Humans; Ischemic Attack, Transient; Myocardial Infarction; Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Recurrence; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2009 |
Pro: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation".
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel; Contraindications; Drug Therapy, Combination; Hemorrhage; Humans; International Normalized Ratio; Intracranial Embolism; Middle Aged; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Risk Factors; Severity of Illness Index; Thrombophilia; Ticlopidine; Warfarin | 2009 |
Contra: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation".
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel; Contraindications; Drug Therapy, Combination; Hemorrhage; Humans; Intracranial Embolism; Middle Aged; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Risk Factors; Severity of Illness Index; Thrombophilia; Ticlopidine; Vitamin K; Warfarin | 2009 |
Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us?
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome | 2009 |
Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Germany; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Risk Assessment; Risk Factors; ROC Curve; Severity of Illness Index; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding risk.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
There is no place like home after successful percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Evidence-Based Medicine; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Infusions, Parenteral; Injections; Length of Stay; Myocardial Infarction; Patient Discharge; Platelet Aggregation Inhibitors; Radial Artery; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Health Planning Guidelines; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Factors; Societies, Medical; Ticlopidine; Treatment Outcome | 2009 |
The right oral antithrombotics in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prognosis; Ticlopidine; Vitamin K | 2009 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Patient Admission; Proportional Hazards Models; Recurrence; Registries; Retrospective Studies; Risk Factors; Ticlopidine; Vitamin K | 2009 |
eComment: Controversies on the antiplatelet therapy before coronary artery bypass grafting surgery.
Topics: Aspirin; Blood Transfusion; Cardiopulmonary Bypass; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Hemorrhage; Humans; Patient Selection; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cost-Benefit Analysis; Databases, Factual; Drug Costs; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Life Expectancy; Multicenter Studies as Topic; Myocardial Infarction; Outcome and Process Assessment, Health Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Thiophenes; Thrombolytic Therapy; Ticlopidine; United States | 2010 |
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors | 2008 |
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should not be continued for more than 1 year and preferably indefinitely.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors | 2008 |
Improved clinical outcome after acute myocardial infarction in hospitals participating in a Swedish quality improvement initiative.
Topics: Aged; Clopidogrel; Female; Fibrinolytic Agents; Follow-Up Studies; Guideline Adherence; Hemorrhage; Hospital Mortality; Hospitals; Humans; Incidence; Male; Myocardial Infarction; Outcome Assessment, Health Care; Patient Readmission; Prevalence; Quality Assurance, Health Care; Quality of Health Care; Sweden; Ticlopidine | 2009 |
Ticagrelor versus clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine | 2009 |
Ticagrelor versus clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Research Design; Ticagrelor; Ticlopidine | 2009 |
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Female; Follow-Up Studies; Gene Frequency; Genotype; Hemorrhage; Heterozygote; Humans; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Risk Factors; Stents; Ticlopidine; Treatment Outcome | 2010 |
Safety of carotid endarterectomy while on clopidogrel (Plavix). Clinical article.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Clopidogrel; Cohort Studies; Edema; Endarterectomy, Carotid; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Partial Thromboplastin Time; Platelet Aggregation Inhibitors; Postoperative Complications; Prothrombin Time; Retrospective Studies; Risk; Stroke; Ticlopidine | 2010 |
Safety and efficacy of clopidogrel treatment in Japanese patients undergoing drug-eluting stent implantation.
Topics: Aged; Clopidogrel; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Ticlopidine | 2010 |
Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention.
Topics: Aged; Cardiovascular Surgical Procedures; Clopidogrel; Coronary Vessels; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Ticlopidine | 2010 |
In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Coagulants; Collagen; Coronary Artery Disease; Factor VIIa; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Recombinant Proteins; Thrombin; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Laser-Assisted; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Pyridines; Retrospective Studies; Risk Factors; Ticlopidine; Treatment Outcome | 2010 |
Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Prospective Studies; Risk Factors; Stroke; Thromboembolism; Ticlopidine; Treatment Outcome; Warfarin | 2010 |
Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database.
Topics: Aged; Clopidogrel; Cohort Studies; Databases, Factual; Drug Administration Schedule; Drug-Eluting Stents; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Propensity Score; Proportional Hazards Models; Retrospective Studies; Ticlopidine | 2010 |
Letter by Doraiswamy regarding article, "Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring
Topics: Anticoagulants; Aspirin; Clopidogrel; Confounding Factors, Epidemiologic; Double-Blind Method; Drug Resistance; Elective Surgical Procedures; Hemorrhage; Heparin; Humans; Myocardial Revascularization; Patient Selection; Platelet Aggregation Inhibitors; Postoperative Complications; Randomized Controlled Trials as Topic; Research Design; Thromboembolism; Ticlopidine; Tirofiban; Tyrosine | 2010 |
Delays of event adjudication in the TRITON trial.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cerebral Infarction; Clopidogrel; Coronary Restenosis; Data Collection; Disease-Free Survival; Hemorrhage; Myocardial Infarction; Observer Variation; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Stents; Thiophenes; Ticlopidine; Treatment Outcome; United States; United States Food and Drug Administration | 2010 |
[Multicentric study of thrombosis prevention in upper-extremity microsurgery. Survey at the Fesum centers].
Topics: Aspirin; Clopidogrel; Drug Monitoring; Evidence-Based Practice; Fibrinolytic Agents; France; Hemorrhage; Heparin; Humans; Microsurgery; Perioperative Care; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Pyrrolidines; Research Design; Risk Factors; Skin Transplantation; Surgical Flaps; Thrombosis; Ticlopidine; Upper Extremity | 2010 |
Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naïve patients in the acute phase after TIA or minor ischaemic stroke.
Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Ischemic Attack, Transient; Longitudinal Studies; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Stroke; Ticlopidine | 2010 |
[Balancing act in antithrombotic therapy. Between hemorrhage and embolism].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Coronary Restenosis; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Phenprocoumon; Proton Pump Inhibitors; Stents; Thromboembolism; Ticlopidine | 2010 |
Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Ticlopidine | 2010 |
Effect of 450-mg loading dose of clopidogrel on platelet function in Japanese patients undergoing coronary stent placement.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Asian People; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Melena; Middle Aged; Neoplasms; Patient Selection; Platelet Aggregation Inhibitors; Platelet Count; Platelet Transfusion; Risk Assessment; Stents; Thrombocytopenia; Ticlopidine; Treatment Outcome | 2010 |
Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: putting the CHARISMA trial into therapeutic perspective.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Retrospective Studies; Risk; Thrombosis; Ticlopidine; Time Factors; Vascular Diseases | 2010 |
[Dental management of patients using anti agregant drugs: background, risks and clinical guidelines].
Topics: Atherosclerosis; Clopidogrel; Dentistry; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Factors; Thrombosis; Ticlopidine; Tooth Extraction | 2009 |
High-dose fibrinogen concentrate for haemostatic therapy of a major trauma patient with recent clopidogrel and aspirin intake.
Topics: Aspirin; Clopidogrel; Drug Interactions; Fibrinogen; Glasgow Coma Scale; Hemorrhage; Hemostatics; Humans; Injections, Intravenous; Male; Middle Aged; Platelet Aggregation Inhibitors; Thrombelastography; Ticlopidine; Treatment Outcome; Wounds and Injuries | 2010 |
Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window.
Topics: Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Hemorrhage; Humans; Platelet Aggregation; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine; Time Factors | 2010 |
Letter by Aboyans et al regarding article, "Smoking, clopidogrel, and mortality in patients with established cardiovascular disease".
Topics: Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Factors; Smoking; Ticlopidine | 2010 |
[Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stroke; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2010 |
Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel.
Topics: Animals; Aspirin; Carotid Arteries; Clopidogrel; Disease Models, Animal; Drug Therapy, Combination; Factor VIIa; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Rabbits; Recombinant Proteins; Regional Blood Flow; Thrombosis; Ticlopidine | 2010 |
Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk.
Topics: Animals; Anticoagulants; Clopidogrel; Drug Combinations; Enoxaparin; Factor XI; Hemorrhage; Male; Mice; Mice, Inbred BALB C; Oligonucleotides, Antisense; Thrombosis; Ticlopidine | 2010 |
Fine-tuning therapy for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Angiography; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Comorbidity; Denmark; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Proportional Hazards Models; Registries; Risk; Stroke; Ticlopidine; Warfarin | 2010 |
Clopidogrel and cardiac operations.
Topics: Cardiac Surgical Procedures; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors | 2010 |
Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antithrombins; Chi-Square Distribution; Clopidogrel; Coronary Angiography; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart Diseases; Hemorrhage; Heparin; Hirudins; Hospital Mortality; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; New York City; Odds Ratio; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Propensity Score; Proportional Hazards Models; Recombinant Proteins; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
It is standard practice, but is it really best practice or clinical biocreep?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antithrombins; Clopidogrel; Coronary Angiography; Drug Administration Schedule; Drug Therapy, Combination; Heart Diseases; Hemorrhage; Heparin; Hirudins; Hospital Mortality; Humans; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Emerging oral antiplatelet therapies for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Cardiology; Clopidogrel; Drug Therapy, Combination; Emergency Medicine; Hemorrhage; Hospitalists; Humans; Imines; Lactones; Patient Selection; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Pyridines; Receptor, PAR-1; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: insights from the Global Registry of Acute Coronary Events.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Coronary Angiography; Electrocardiography; Female; Follow-Up Studies; Hemorrhage; Hospital Mortality; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Registries; Risk Factors; Smoking; Survival Rate; Ticlopidine; Time Factors | 2010 |
National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin.
Topics: Acute Disease; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Emergency Service, Hospital; Female; Health Care Surveys; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Sex Distribution; Ticlopidine; United States; Warfarin; Young Adult | 2010 |
An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Cardiac Catheterization; Clinical Protocols; Clinical Trials as Topic; Clopidogrel; Comparative Effectiveness Research; Guidelines as Topic; Hemorrhage; Humans; Myocardial Infarction; Patient Care Planning; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Standard of Care; Thiophenes; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2010 |
Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: balancing safety and efficacy.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Fibrinolytic Agents; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Safety; Secondary Prevention; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin | 2010 |
A new clopidogrel (Plavix) point-of-care assay: rapid determination of antiplatelet activity in trauma patients.
Topics: Aged; Clopidogrel; Female; Hemorrhage; Humans; Injury Severity Score; Male; Platelet Aggregation Inhibitors; Point-of-Care Systems; Retrospective Studies; Ticlopidine; Wounds and Injuries | 2011 |
Antiplatelet drugs in the elderly: prescriptions often inappropriate and reduced tolerance by associated diseases and drugs.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; France; Hemorrhage; Humans; Male; Off-Label Use; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prospective Studies; Risk Factors; Ticlopidine | 2012 |
Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding St
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hemorrhage; Humans; Long-Term Care; Male; Middle Aged; Multivariate Analysis; Myocardial Ischemia; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Predictive Value of Tests; Premedication; Prospective Studies; Receptors, Purinergic P2Y12; Stents; Ticlopidine | 2011 |
Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chronic Disease; Clopidogrel; Cohort Studies; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kidney Diseases; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Ticlopidine; Treatment Outcome | 2011 |
Clopidogrel loading dose and bleeding outcomes in patients undergoing urgent coronary artery bypass grafting.
Topics: Aged; Clopidogrel; Coronary Artery Bypass; Emergency Treatment; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Ticlopidine | 2011 |
Immortal person-time bias in observational studies in cardiac surgery.
Topics: Aspirin; Bias; Clopidogrel; Coronary Artery Bypass; Data Interpretation, Statistical; Drug Therapy, Combination; Hemorrhage; Hospital Mortality; Humans; Platelet Aggregation Inhibitors; Postoperative Complications; Research Design; Risk Assessment; Risk Factors; Ticlopidine; Treatment Outcome | 2011 |
Efficacy of post-operative clopidogrel treatment in patients revascularized with coronary artery bypass grafting after myocardial infarction.
Topics: Aged; Clopidogrel; Combined Modality Therapy; Comorbidity; Coronary Artery Bypass; Denmark; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Period; Propensity Score; Proportional Hazards Models; Registries; Secondary Prevention; Ticlopidine | 2011 |
The rate of post-polypectomy bleeding for patients on uninterrupted clopidogrel therapy during elective colonoscopy is acceptably low.
Topics: Case-Control Studies; Clopidogrel; Colonic Polyps; Colonoscopy; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Ticlopidine | 2011 |
Can endoscopists become more aggressive or have more options for patients with antithrombotic agents?
Topics: Clopidogrel; Colonic Polyps; Colonoscopy; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Ticlopidine | 2011 |
[Do genetic factors reduce the effects of clopidogrel?].
Topics: Adenosine; Clopidogrel; Cytochrome P-450 Enzyme System; Genetic Variation; Genotype; Hemorrhage; Humans; Isoenzymes; Pharmacogenetics; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Care Units; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Propensity Score; Proportional Hazards Models; Registries; Risk Assessment; Risk Factors; Stents; Sweden; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Dual antiplatelet therapy and the risk of bleeding.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Thrombosis; Ticlopidine; Warfarin | 2011 |
[The CURRENT-OASIS 7 study].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Confidence Intervals; Drug Administration Schedule; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Proportional Hazards Models; Randomized Controlled Trials as Topic; Salivary Ducts; Thrombosis; Ticlopidine | 2011 |
Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry).
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antithrombins; Clopidogrel; Female; Hemorrhage; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Premedication; Recombinant Proteins; Thrombosis; Ticlopidine | 2011 |
Standard- vs high-dose clopidogrel after percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Hemorrhage; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Reproducibility of Results; Risk; Thrombosis; Ticlopidine; Treatment Outcome | 2011 |
Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Propensity Score; Shock, Cardiogenic; Stents; Ticlopidine; Treatment Outcome | 2011 |
Comparison of efficacy and safety of a standard versus a loading dose of clopidogrel for acute myocardial infarction in patients ≥ 75 years of age (from the FAST-MI registry).
Topics: Aged; Aged, 80 and over; Analysis of Variance; Blood Transfusion; Clopidogrel; Female; France; Hemorrhage; Hospital Mortality; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Registries; Risk Factors; Survival Rate; Ticlopidine; Treatment Outcome | 2011 |
Commentary: recombinant activated factor VII: the controversial conundrum regarding its off-label use.
Topics: Clopidogrel; Factor VIIa; Hemorrhage; Hemostasis; Hemostatics; Humans; Male; Platelet Aggregation Inhibitors; Recombinant Proteins; Ticlopidine | 2011 |
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting.
Topics: Aspirin; Cerebrovascular Circulation; Clopidogrel; Coronary Artery Bypass; Coronary Vessels; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Thrombosis; Ticlopidine | 2011 |
Recent trends in Australian percutaneous coronary intervention practice: insights from the Melbourne Interventional Group registry.
Topics: Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Australia; Clopidogrel; Comorbidity; Coronary Occlusion; Coronary Restenosis; Coronary Thrombosis; Diabetes Mellitus; Drug Utilization; Drug-Eluting Stents; Emergencies; Female; Hemorrhage; Hospital Mortality; Humans; Logistic Models; Male; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Renal Insufficiency; Shock, Cardiogenic; Ticlopidine | 2011 |
Comparison of platelet reactivity and clopidogrel response in patients ≤ 75 Years Versus > 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Follow-Up Studies; Hemorrhage; Humans; Middle Aged; Myocardial Ischemia; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Stents; Ticlopidine | 2011 |
Safety of ultrasound-guided fine needle aspiration biopsy of neck lesions in patients taking antithrombotic/anticoagulant medications.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Biopsy, Fine-Needle; Chi-Square Distribution; Clopidogrel; Female; Head and Neck Neoplasms; Hematoma; Hemorrhage; Heparin; Humans; Male; Middle Aged; Retrospective Studies; Ticlopidine; Ultrasonography, Interventional; Warfarin | 2011 |
Comparison of characteristics, management practices, and outcomes of patients between the global registry and the gulf registry of acute coronary events.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Aspirin; Cardiac Catheterization; Clopidogrel; Diabetes Mellitus; Female; Fibrinolytic Agents; Heart Failure; Hemorrhage; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Mechanical Thrombolysis; Middle Aged; Middle East; Myocardial Revascularization; Platelet Aggregation Inhibitors; Registries; Sex Distribution; Shock, Cardiogenic; Smoking; Stroke; Ticlopidine | 2011 |
Normal chest radiograph and ground glass opacities on a thoracic computed tomographic scan in a patient with diffuse alveolar haemorrhage due to dual antiplatelet therapy prescribed after patent foramen ovale percutaneous device closure.
Topics: Adult; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Foramen Ovale, Patent; Hemoptysis; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Pulmonary Alveoli; Septal Occluder Device; Ticlopidine; Tomography, X-Ray Computed | 2011 |
Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Angioplasty; Anticoagulants; Antihypertensive Agents; Aspirin; Canada; Citalopram; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Female; Fluoxetine; Fluvoxamine; Heart Failure; Hemorrhage; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Neoplasms; Paroxetine; Peptic Ulcer; Platelet Aggregation Inhibitors; Renal Insufficiency; Retrospective Studies; Risk; Risk Factors; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Sertraline; Sex Factors; Ticlopidine | 2011 |
Correlation between point-of-care platelet function testing and bleeding after coronary artery surgery.
Topics: Aged; Aspirin; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Coronary Vessels; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Postoperative Care; Postoperative Hemorrhage; Ticlopidine | 2012 |
Carbon monoxide-releasing molecule-2 enhances coagulation in rabbit plasma and decreases bleeding time in clopidogrel/aspirin-treated rabbits.
Topics: Administration, Oral; Animals; Aspirin; Bleeding Time; Blood Coagulation; Carbon Monoxide; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Injections, Intravenous; Male; Organometallic Compounds; Plasma; Platelet Aggregation Inhibitors; Rabbits; Thrombelastography; Ticlopidine | 2011 |
Platelet inhibition and surgical bleeding. A plea for more science and evidence-based guidelines.
Topics: Blood Transfusion; Cardiac Surgical Procedures; Clopidogrel; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Preoperative Care; Ticlopidine | 2011 |
No free lunches: balancing bleeding and efficacy with ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Ticagrelor; Ticlopidine | 2011 |
Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Incidence; Italy; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prevalence; Prosthesis Design; Registries; Risk Assessment; Risk Factors; Severity of Illness Index; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Metals; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prosthesis Design; Risk Assessment; Risk Factors; Stents; Tetrazoles; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2011 |
Clopidogrel (plavix).
Topics: Clopidogrel; Dose-Response Relationship, Drug; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2011 |
Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial center.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Female; Fibrinolytic Agents; Gastrointestinal Hemorrhage; Hemorrhage; Hospital Mortality; Humans; Immunoglobulin Fab Fragments; Incidence; Internet; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Paris; Platelet Aggregation Inhibitors; Proportional Hazards Models; Radial Artery; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Pharmacogenomics and clopidogrel: irrational exuberance?
Topics: Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Hemorrhage; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2011 |
Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Austria; Blood Platelets; Cardiovascular Diseases; Cell Adhesion Molecules; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Gene Frequency; Genotype; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Microfilament Proteins; Middle Aged; Multivariate Analysis; Pharmacogenetics; Phenotype; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Predictive Value of Tests; Prospective Studies; Risk Assessment; Risk Factors; Sensitivity and Specificity; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Extension of Kaplan-Meier methods in observational studies with time-varying treatment.
Topics: Age Factors; Aged; Clopidogrel; Comorbidity; Confounding Factors, Epidemiologic; Coronary Artery Disease; Drug-Eluting Stents; Female; Health Behavior; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Sex Factors; Ticlopidine; Time Factors | 2012 |
Safety of endobronchial ultrasound-guided transbronchial needle aspiration for patients taking clopidogrel: a report of 12 consecutive cases.
Topics: Aged; Aged, 80 and over; Biopsy, Fine-Needle; Bronchoscopy; Clopidogrel; Endosonography; Female; Follow-Up Studies; Hemorrhage; Humans; Lung Neoplasms; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Assessment; Safety Management; Sampling Studies; Ticlopidine | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electric Countershock; Evidence-Based Medicine; Fibrinolytic Agents; Hemorrhage; Humans; International Normalized Ratio; Risk Factors; Societies, Medical; Stroke; Ticlopidine; Vitamin K | 2012 |
Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia.
Topics: Antibodies, Monoclonal, Murine-Derived; Anticoagulants; Aspirin; Clopidogrel; Drug Resistance; Hemorrhage; Humans; Immunization, Passive; Male; Metabolic Syndrome; Middle Aged; Myocardial Infarction; Prednisone; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Recombinant Fusion Proteins; Remission, Spontaneous; Rituximab; Stents; Thrombopoiesis; Thrombopoietin; Ticlopidine | 2012 |
Coronary artery bypass graft surgery in acute coronary syndrome: incidence, cost impact, and acute clopidogrel interruption.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Bypass; Female; Hemorrhage; Hospital Costs; Hospitalization; Humans; Incidence; Length of Stay; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Ticlopidine; United States | 2012 |
Clopidogrel increases bleeding complications in patients undergoing heart rhythm device procedures.
Topics: Cardiac Resynchronization Therapy; Case-Control Studies; Clopidogrel; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Female; France; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Assessment; Risk Factors; Thrombosis; Ticlopidine; Treatment Outcome | 2012 |
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Trees; Drugs, Generic; Genotype; Hemorrhage; Humans; Models, Economic; Models, Statistical; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine | 2012 |
Erratum for Fernandez et al. “Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE Study)” Am J Cardiol
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Elective Surgical Procedures; Hemorrhage; Humans; Incidence; Platelet Aggregation Inhibitors; Preoperative Care; Risk Factors; Thrombosis; Ticlopidine; United States | 2012 |
Triple antithrombotic therapy after coronary stenting in the elderly with atrial fibrillation: necessary or too hazardous?
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Stents; Ticlopidine; Warfarin | 2012 |
Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Medicare; Myocardial Infarction; Patient Readmission; Proportional Hazards Models; Registries; Ticlopidine; Treatment Outcome; United States; Warfarin | 2012 |
Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study.
Topics: Aged; Alabama; Antithrombins; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Elective Surgical Procedures; Female; Hemorrhage; Hirudins; Humans; Incidence; Infusions, Intravenous; Injections, Intravenous; Ischemia; Male; Middle Aged; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recombinant Proteins; Retrospective Studies; Severity of Illness Index; Thrombosis; Ticlopidine | 2012 |
Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Economics, Pharmaceutical; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; United States | 2012 |
Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Cohort Studies; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prosthesis Design; Pyridines; Registries; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Logistic Models; Male; Metals; Middle Aged; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation Inhibitors; Propensity Score; Proportional Hazards Models; Prosthesis Design; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome; United States; United States Department of Veterans Affairs | 2012 |
Adherence to guidelines for the prescribing of double and triple combinations of antithrombotic agents.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Attitude of Health Personnel; Clopidogrel; Community Pharmacy Services; Comorbidity; Drug Interactions; Drug Prescriptions; Drug Therapy, Combination; Drug Utilization Review; Female; Fibrinolytic Agents; Guideline Adherence; Health Care Surveys; Health Knowledge, Attitudes, Practice; Hemorrhage; Humans; Male; Middle Aged; Netherlands; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Retrospective Studies; Risk Assessment; Risk Factors; Surveys and Questionnaires; Ticlopidine; Vitamin K | 2014 |
Relationship between cytochrome P450 2C19*17 genotype distribution, platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Genotype; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation; Ticlopidine | 2012 |
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Risk Assessment; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin | 2012 |
Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study.
Topics: Adult; Aged; Clopidogrel; Denmark; Drug Administration Schedule; Epidemiologic Methods; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Failure; Recurrence; Stents; Thrombosis; Ticlopidine; Withholding Treatment | 2012 |
A potent alternative to clopidogrel emerges. Prasugrel appears to lower heart attack risk for patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Dosage Calculations; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2010 |
Practice observed.
Topics: Aged; Buttocks; Clopidogrel; Contusions; Drug Interactions; Female; Ginkgo biloba; Hematuria; Hemorrhage; Humans; Phytotherapy; Plant Preparations; Platelet Aggregation Inhibitors; Postmenopause; Self Medication; Thigh; Ticlopidine; Vaginal Diseases | 2012 |
Ticagrelor FDA approval issues revisited.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Approval; Hemorrhage; Humans; Multicenter Studies as Topic; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2012 |
[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Monitoring; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Stroke; Survival Rate; Ticlopidine; Treatment Outcome; Warfarin | 2012 |
[Removal of epidural catheter under dual antiplatelet therapy following acute coronary syndrome : scenario without special consideration to the current guidelines on epidural regional anesthesia].
Topics: Acute Coronary Syndrome; Analgesia, Epidural; Aspirin; Catheterization; Clopidogrel; Digestive System Surgical Procedures; Drug Interactions; Hemorrhage; Humans; Male; Middle Aged; Pain, Postoperative; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Risk; Thiophenes; Ticlopidine | 2012 |
Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS.
Topics: Adverse Drug Reaction Reporting Systems; Aspirin; Clopidogrel; Data Mining; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Ticlopidine; United States; United States Food and Drug Administration; Warfarin | 2012 |
Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies; Comorbidity; Denmark; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Registries; Risk Factors; Stroke; Ticlopidine; Vitamin K | 2012 |
Early and late outcome associated with bleeding events in the setting of dual antiplatelet therapy following stent placement.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine | 2012 |
[General antithrombotic therapy practice facing fundamental change].
Topics: Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stents; Survival Rate; Ticlopidine | 2012 |
Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: a potential ticagrelor-angiotensin receptor blocker interaction?
Topics: Adenosine; Angiotensin II Type 1 Receptor Blockers; Clopidogrel; Drug Interactions; Dyspnea; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney; Kidney Diseases; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2012 |
Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Comorbidity; Decision Support Techniques; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Predictive Value of Tests; Retrospective Studies; Risk Assessment; Risk Factors; Sweden; Ticlopidine; Treatment Outcome; Warfarin | 2012 |
Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices.
Topics: Blood Platelets; Clopidogrel; Embolization, Therapeutic; Female; Hemorrhage; Humans; Intracranial Aneurysm; Intracranial Thrombosis; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Ticlopidine; Treatment Outcome | 2012 |
[Platelet inhibition in clinical practice].
Topics: Aged; Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Aspirin; Cerebral Infarction; Clopidogrel; Coronary Artery Bypass; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Patient Compliance; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Transfusion; Risk Factors; Thrombosis; Ticlopidine | 2012 |
Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cerebrovascular Disorders; Clopidogrel; Computer Simulation; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Disease-Free Survival; Drug Costs; Gene Frequency; Genetic Predisposition to Disease; Genetic Testing; Health Care Costs; Hemorrhage; Humans; Insurance, Health, Reimbursement; Kaplan-Meier Estimate; Markov Chains; Medicare; Models, Economic; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Quality-Adjusted Life Years; Risk Assessment; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome; United States | 2013 |
Safety of endoscopic sphincterotomy in patients under dual antiplatelet therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cholangiopancreatography, Endoscopic Retrograde; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Safety; Platelet Aggregation Inhibitors; Retrospective Studies; Sphincterotomy, Endoscopic; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Effect of routine clopidogrel use on bleeding complications after ultrasound-guided thoracentesis.
Topics: Clopidogrel; Contraindications; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pleural Effusion; Prospective Studies; Respiratory Distress Syndrome; Thoracic Surgical Procedures; Ticlopidine; Ultrasonography, Interventional | 2012 |
Dual antiplatelet therapy in peripheral arterial disease and after peripheral percutaneous revascularization.
Topics: Aspirin; Clopidogrel; Endovascular Procedures; Hemorrhage; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Stents; Stroke; Ticlopidine; Treatment Outcome | 2012 |
Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Disease; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Prognosis; Stroke; Thrombosis; Ticlopidine; Treatment Outcome | 2013 |
[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation].
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Clopidogrel; Dabigatran; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Stroke; Thromboembolism; Ticlopidine; Warfarin | 2012 |
The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Case-Control Studies; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Regression Analysis; Risk Factors; Thrombosis; Ticlopidine; United Kingdom; Warfarin | 2013 |
Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.
Topics: Acute Coronary Syndrome; Alleles; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Variation; Genotype; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Phosphoproteins; Piperazines; Polymerase Chain Reaction; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
[Analysis of the risk factors of patients with acute coronary syndrome suffering hemorrhage during hospitalization].
Topics: Acute Coronary Syndrome; Age of Onset; Aged; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Incidence; Logistic Models; Male; Middle Aged; Platelet Glycoprotein GPIIb-IIIa Complex; Renal Insufficiency; Risk Factors; Ticlopidine | 2012 |
Life-threatening haemorrhage after extracorporeal shockwave lithotripsy in a patient taking clopidogrel.
Topics: Clopidogrel; Hematoma; Hemorrhage; Humans; Lithotripsy; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine; Ureteral Calculi | 2002 |
ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidel
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Biomarkers; Clopidogrel; Disease Management; Drug Therapy, Combination; Electrocardiography; Eptifibatide; Female; Health Behavior; Hemorrhage; Humans; Hypolipidemic Agents; Immunoglobulin Fab Fragments; Male; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Ticlopidine; Tirofiban; Tyrosine | 2002 |
Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Retrospective Studies; Secondary Prevention; Ticlopidine; Time Factors; United States | 2002 |
Clopidogrel plus aspirin for stroke prevention.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk; Secondary Prevention; Stroke; Ticlopidine; Treatment Outcome | 2002 |
[Anticoagulation and antiaggregation in cardiac patients].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Heart Valve Prosthesis; Hemorrhage; Humans; Myocardial Infarction; Placebos; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Primary Prevention; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Thromboembolism; Ticlopidine | 2003 |
[New antiaggregants and their importance for the practitioner].
Topics: Abciximab; Administration, Oral; Adult; Anesthesia, Spinal; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Contraindications; Drug Therapy, Combination; Eptifibatide; Female; Fibrinolytic Agents; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Peptides; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pregnancy; Ticlopidine; Tirofiban; Tyrosine | 2003 |
Massive hemorrhage during radiofrequency ablation of a pulmonary neoplasm.
Topics: Catheter Ablation; Clopidogrel; Hemorrhage; Humans; Intraoperative Complications; Lung Neoplasms; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2003 |
Spontaneous pharyngeal haemorrhage in the anticoagulated patient.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Clopidogrel; Hemorrhage; Humans; Male; Pharyngeal Diseases; Platelet Aggregation Inhibitors; Ticlopidine; Warfarin | 2003 |
Qualitative platelet defect and thrombohaemorrhagic complications in a patient with polycythaemia vera. Case 10.
Topics: Aged; Aspirin; Blood Platelet Disorders; Clopidogrel; Hemorrhage; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polycythemia Vera; Thrombosis; Ticlopidine | 2003 |
[Sudden edema and pain in the knee].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Edema; Hemorrhage; Humans; Knee Joint; Male; Pain; Platelet Aggregation Inhibitors; Radiography; Ticlopidine | 2003 |
By the way, doctor. A new television ad says I should ask my doctor about Plavix, a drug that reduces the risk of heart attack and stroke. I'm 65 years old and healthy. Should I be taking Plavix preventively?
Topics: Aged; Cardiovascular Diseases; Clopidogrel; Female; Health Status; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2003 |
When guidelines collide...
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Stents; Ticlopidine; Warfarin | 2004 |
Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Ticlopidine; Warfarin | 2004 |
Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes.
Topics: Analysis of Variance; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Cardiac Catheterization; Clopidogrel; Drug Administration Schedule; Enoxaparin; Hemorrhage; Humans; Injections, Subcutaneous; Logistic Models; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Premedication; Retrospective Studies; Risk Factors; Ticlopidine | 2004 |
Perioperative hemorrhage and combined clopidogrel and aspirin therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Combinations; Endarterectomy, Carotid; Female; Goiter, Nodular; Hemorrhage; Humans; Intraoperative Complications; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Thyroidectomy; Ticlopidine; Tomography, X-Ray Computed | 2004 |
[Secondary prevention of TIA and stroke. How much must thrombocytes not be inhibited?].
Topics: Aspirin; Cerebral Infarction; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggregation; Platelet Aggregation Inhibitors; Risk; Secondary Prevention; Ticlopidine | 2004 |
[Peridural injections during acetylsalicylic acid and clopidogrel therapy?].
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Injections, Epidural; Intervertebral Disc Displacement; Middle Aged; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2004 |
[Clopidogrel protection is not increased further by ASS!].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Middle Aged; Placebos; Platelet Aggregation Inhibitors; Recurrence; Risk Factors; Stroke; Ticlopidine | 2004 |
[Clopidogrel as basic therapy in high-risk stroke patients].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Hemorrhage; Humans; Life Style; Meta-Analysis as Topic; Multicenter Studies as Topic; Placebos; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Ticlopidine; Time Factors | 2004 |
Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Eptifibatide; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Stents; Ticlopidine | 2005 |
Summaries for patients. Is it cost-effective to treat high-risk cardiac patients with clopidogrel plus aspirin as opposed to aspirin alone?
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit Analysis; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Stroke; Ticlopidine | 2005 |
A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit Analysis; Electrocardiography; Hemorrhage; Humans; Markov Chains; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Recurrence; Risk Factors; Sensitivity and Specificity; Stroke; Ticlopidine | 2005 |
Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet thromboembolism and intimal thickening in mice.
Topics: Animals; Aspirin; Blood Coagulation Tests; Clopidogrel; Disease Models, Animal; Drug Therapy, Combination; Hemorrhage; Male; Mice; Mice, Inbred Strains; Platelet Aggregation; Platelet Aggregation Inhibitors; Pulmonary Embolism; Survival Rate; Thromboembolism; Ticlopidine; Tunica Intima | 2005 |
Dual antiplatelet therapy for coronary stenting: a clear path for a research agenda.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Eptifibatide; Hemorrhage; Length of Stay; Membrane Proteins; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Premedication; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Risk Factors; Stents; Thrombophilia; Ticlopidine | 2005 |
Effect of clopidogrel with and without aspirin on bleeding following transbronchial lung biopsy.
Topics: Animals; Aspirin; Biopsy, Needle; Bronchoscopy; Clopidogrel; Hemorrhage; Lung; Platelet Aggregation Inhibitors; Swine; Ticlopidine | 2005 |
Clopidogrel-related refractory bleeding after coronary artery bypass graft surgery: a rationale for the use of coagulation factor concentrates?
Topics: Clopidogrel; Coronary Artery Bypass; Coronary Restenosis; Drug Administration Schedule; Factor VIIa; Factor XIII; Fibrinogen; Hemorrhage; Hemostasis, Surgical; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Recombinant Proteins; Reoperation; Retreatment; Ticlopidine; Treatment Outcome | 2005 |
Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Case-Control Studies; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Assessment; Ticlopidine; Warfarin | 2005 |
[Antiplatelet agents and regional anaesthesia: experience in 130 patients].
Topics: Aged; Aspirin; Autonomic Nerve Block; Blood Loss, Surgical; Blood Vessel Prosthesis Implantation; Clopidogrel; Endarterectomy, Carotid; Hematoma; Hemorrhage; Humans; Middle Aged; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Prospective Studies; Punctures; Risk; Ticlopidine | 2005 |
Adverse reactions to anticoagulants and to antiplatelet drugs recorded by the German spontaneous reporting system.
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Anticoagulants; Aspirin; Association; Blood Cell Count; Cerebral Hemorrhage; Clopidogrel; Databases, Factual; Drug Information Services; Germany; Hemorrhage; Heparin; Humans; Phenprocoumon; Platelet Aggregation Inhibitors; Product Surveillance, Postmarketing; Thrombocytopenia; Ticlopidine; Time Factors; Treatment Outcome; Vitamin K | 2005 |
Molecular mechanism of Clopidogrel and Aspirin therapy-induced bleeding episodes.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Eicosanoids; Hemorrhage; Humans; Ticlopidine | 2006 |
[Cerebral secondary prevention--clopidogrel alone or in combination with ASS].
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticlopidine; Treatment Outcome | 2005 |
Bleeding complications in elderly patients following acute myocardial infarction.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Assessment; Ticlopidine; Warfarin | 2005 |
New modalities and aspects of antiplatelet therapy for stroke prevention.
Topics: Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Drug Design; Drug Resistance; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Tetrazoles; Ticlopidine | 2006 |
[Recommendations for peri-procedural thrombocyte aggregation inhibition].
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Factors; Surgical Procedures, Operative; Thrombosis; Ticlopidine; Time Factors | 2006 |
Effect of clopidogrel premedication in off-pump cardiac surgery: are we forfeiting the benefits of reduced hemorrhagic sequelae?
Topics: Aged; Blood Transfusion; Case-Control Studies; Clopidogrel; Coronary Artery Bypass, Off-Pump; Female; Hemorrhage; Hemostasis, Surgical; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Premedication; Reoperation; Retrospective Studies; Risk Factors; Ticlopidine; Treatment Outcome | 2006 |
Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Assessment; Severity of Illness Index; Stents; Ticlopidine; Warfarin | 2006 |
Good old warfarin for stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Factors; Stroke; Ticlopidine; Warfarin | 2006 |
Clopidogrel for the prevention of atherothrombotic events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Incidence; Platelet Aggregation Inhibitors; Ticlopidine | 2006 |
Clopidogrel for the prevention of atherothrombotic events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2006 |
Antiplatelet and anticoagulant therapy in patients with giant cell arteritis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Dose-Response Relationship, Drug; Female; Giant Cell Arteritis; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Stroke; Ticlopidine; Warfarin | 2006 |
[Bleeding complications after treatment with antithrombotic agents after acute coronary syndrome].
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Ticlopidine | 2006 |
[Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome].
Topics: Age Factors; Aged; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Female; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Stroke; Thrombolytic Therapy; Ticlopidine | 2006 |
Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Cross-Sectional Studies; Drug Therapy, Combination; Endpoint Determination; Female; Heart Conduction System; Hemorrhage; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Registries; Ticlopidine; Treatment Outcome; United States | 2006 |
Letter by van der Linden et al regarding article, "Effect of clopidogrel premedication in off-pump cardiac surgery: are we forfeiting the benefits of reduced hemorrhagic sequelae?".
Topics: Aprotinin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Hemorrhage; Hemostatics; Humans; Platelet Aggregation Inhibitors; Premedication; Ticlopidine | 2006 |
Letter by Poston regarding article, "Effect of clopidogrel premedication in off-pump cardiac surgery: are we forfeiting the benefits of reduced hemorrhagic sequelae?".
Topics: Clopidogrel; Coronary Artery Bypass, Off-Pump; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Premedication; Ticlopidine | 2006 |
[Safety of aspirin, clopidogrel, and acenocumarol combination in patients requiring anticoagulation].
Topics: Acenocoumarol; Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Ticlopidine | 2006 |
Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits.
Topics: Animals; Aspirin; Blood Coagulation; Clopidogrel; Disease Models, Animal; Drug Therapy, Combination; Factor Xa; Fibrinolytic Agents; Hemorrhage; Hemostasis; Isoxazoles; Male; Platelet Aggregation; Pyrazoles; Rabbits; Thrombosis; Ticlopidine | 2007 |
Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; International Normalized Ratio; Male; Middle Aged; Platelet Aggregation Inhibitors; Proportional Hazards Models; Retrospective Studies; Risk Factors; Ticlopidine; Warfarin | 2007 |
Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel.
Topics: Aged; Angiography; Anticoagulants; Blood Component Transfusion; Clopidogrel; Drug Interactions; Embolization, Therapeutic; Enoxaparin; Factor VII; Factor VIIa; Female; Hematoma; Hemoglobins; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recombinant Proteins; Renal Insufficiency; Retroperitoneal Space; Ticlopidine; Tomography, X-Ray Computed | 2007 |
The use of clopidogrel in carotid endarterectomy: an audit of current practice.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Endarterectomy, Carotid; Hemorrhage; Humans; Medical Audit; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Surveys and Questionnaires; Ticlopidine | 2007 |
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyridamole; Drug Combinations; Drug Therapy, Combination; Endarterectomy, Carotid; Female; Hemorrhage; Humans; Intracranial Embolism; Ischemic Attack, Transient; Male; Middle Aged; Middle Cerebral Artery; Pilot Projects; Platelet Aggregation Inhibitors; Postoperative Care; Randomized Controlled Trials as Topic; Research Design; Stroke; Ticlopidine; Treatment Outcome; Ultrasonography, Doppler, Transcranial | 2007 |
Clopidogrel: the good, the bad, and the ugly.
Topics: Acute Disease; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Assessment; Ticlopidine | 2007 |
[Anticoagulation in atrial fibrillation. ACTIVE Study (Arterial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events)].
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage; Humans; Intracranial Embolism; Irbesartan; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Tetrazoles; Thromboembolism; Ticlopidine | 2007 |
Admissions to a medical intensive care unit related to adverse drug reactions.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Female; Hemorrhage; Hospitalization; Hospitals, Teaching; Humans; Intensive Care Units; Male; Platelet Aggregation Inhibitors; Ticlopidine | 2007 |
A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis.
Topics: Administration, Oral; Animals; Aorta; Aspirin; Bleeding Time; Blood Coagulation; Clopidogrel; Disease Models, Animal; Fibrin; Fibrinogen; Fibrinolytic Agents; Hemorrhage; Naphthalenes; Platelet Activation; Platelet Aggregation Inhibitors; Propionates; Prosthesis Design; Receptors, Thromboxane A2, Prostaglandin H2; Stainless Steel; Stents; Swine; Thrombosis; Ticlopidine; Time Factors | 2007 |
Safety of the cardiac triple therapy: the experience of the Quebec Heart Institute.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Quebec; Retrospective Studies; Risk Factors; Ticlopidine; Warfarin | 2007 |
Temporal trends in antiplatelet/antithrombotic use in acute coronary syndromes and in-hospital major bleeding complications.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiac Catheterization; Clopidogrel; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Ticlopidine | 2007 |
Intensifying platelet inhibition--navigating between Scylla and Charybdis.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2007 |
Outcomes associated with combined antiplatelet and anticoagulant therapy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; Dipyridamole; Drug Therapy, Combination; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Thromboembolism; Ticlopidine; Treatment Outcome; Warfarin | 2008 |
Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cerebrovascular Disorders; Clopidogrel; Drug Therapy, Combination; Female; Heart Diseases; Hemorrhage; Hospital Mortality; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Research Design; Retrospective Studies; Risk Assessment; Risk Factors; Secondary Prevention; Stroke; Thrombolytic Therapy; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
Analysis of the upper gastrointestinal tract bleeding prevalence in patients treated due ischaemic heart disease.
Topics: Acenocoumarol; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Body Mass Index; Clopidogrel; Female; Gastrointestinal Tract; Hemorrhage; Humans; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Ticlopidine | 2007 |
A retrospective study of the management of retro-peritoneal bleeding after percutaneous coronary intervention in the era of combination anti-platelet therapy.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disease; Female; Femoral Artery; Follow-Up Studies; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Length of Stay; Male; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retroperitoneal Space; Retrospective Studies; Ticlopidine; Treatment Outcome | 2008 |
[Prasugrel versus clopidogrel. From the American Heart Association meeting, 2007].
Topics: Clopidogrel; Congresses as Topic; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2008 |
Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices.
Topics: Acute Coronary Syndrome; Atherectomy; Clopidogrel; Emergency Service, Hospital; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Preoperative Care; Randomized Controlled Trials as Topic; Ticlopidine; Troponin | 2009 |
Prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Stroke; Thiophenes; Ticlopidine | 2008 |
Prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk; Thiophenes; Ticlopidine | 2008 |
What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Heparin; Hirudins; Humans; Myocardial Infarction; Patient Selection; Peptide Fragments; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Recombinant Proteins; Research Design; Stents; Thrombin; Thrombosis; Ticlopidine; Treatment Outcome | 2008 |
Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Germany; Glomerular Filtration Rate; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Renal Insufficiency; Retrospective Studies; Surveys and Questionnaires; Survival Analysis; Ticlopidine | 2008 |
Bleeding risks with prasugrel in the TRITON trial: good news ... bad news.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Hematemesis; Hematuria; Hemorrhage; Humans; Intracranial Hemorrhages; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2008 |
Anti-platelet agents and surgical delay in elderly patients with hip fractures.
Topics: Aged; Aspirin; Bleeding Time; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hip Fractures; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2008 |
For better or for worse: the future of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Disease; Forecasting; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Thiophenes; Thrombolytic Therapy; Thrombosis; Ticlopidine | 2008 |
Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Carotid Stenosis; Clopidogrel; Comorbidity; Coronary Artery Bypass; Drug Therapy, Combination; Female; Fibrinogen; Graft Occlusion, Vascular; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Microspheres; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Risk; Stents; Ticlopidine | 2001 |
Diffuse alveolar hemorrhage after clopidogrel use.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Hemorrhage; Humans; Lung Diseases; Male; Middle Aged; Platelet Aggregation Inhibitors; Radiography; Ticlopidine | 2001 |
Haemorrhage associated with combined clopidogrel and aspirin therapy.
Topics: Aged; Aged, 80 and over; Aortic Aneurysm, Abdominal; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Ticlopidine | 2001 |
Treatment of acute coronary syndromes.
Topics: Acute Disease; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Meta-Analysis as Topic; Myocardial Ischemia; Platelet Aggregation Inhibitors; Risk; Ticlopidine | 2002 |
Treatment of acute coronary syndromes.
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Postoperative Complications; Ticlopidine | 2002 |
Guidelines for acute coronary syndrome without ST elevation.
Topics: Clopidogrel; Coronary Disease; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Ticlopidine | 2002 |